,id,ticker,title,category,content,date,provider,url,article_id
119461,340976,PKI,PerkinElmer Q4 2019 Earnings Preview,news,"PerkinElmer  NYSE PKI  is scheduled to announce Q4 earnings results on Monday  January 27th  after market close 
The consensus EPS Estimate is  1 33   12 7  Y Y  and the consensus Revenue Estimate is  801 14M   5 9  Y Y  
Over the last 2 years  PKI has beaten EPS estimates 75  of the time and has beaten revenue estimates 63  of the time 
Over the last 3 months  EPS estimates have seen 0 upward revisions and 8 downward  Revenue estimates have seen 0 upward revisions  and 8 downward ",2020-01-26,Seeking Alpha,https://invst.ly/pn3k-,2068027
119462,340977,PKI,PerkinElmer Q4 earnings down 10   soft guidance pressures shares  down 3  AH,news,"PerkinElmer  NYSE PKI  Q4 results 
Revenue   805 5M   6 5    Discovery   Analytical Solutions   495 5M   8 0    Diagnostics   309 0M   4 2   
Net income   64 5M   9 5    non GAAP net income   192 3M   17 0    EPS   0 58   9 4    non GAAP EPS   1 35   14 4   
2020 guidance  Revenue   3 05B   3 09B  consensus   3 08B   EPS   2 89   2 99  non GAAP EPS   4 50   4 60  consensus   4 63  
Shares down 3  after hours 
Previously  PerkinElmer EPS beats by  0 02  beats on revenue",2020-01-27,Seeking Alpha,https://invst.ly/pnkx1,2068849
119463,340978,PKI,Stocks making the biggest move after the bell  Whirlpool  F5 Networks  PerkinElmer and more,news,Take a look at the companies making headlines after the bell Whirlpool Corporation   Whirlpool stock briefly rose in extended trading on Monday before returning to the closing price of  148 23 after it reported strong fourth quarter earnings but missed on revenue  The home appliance company reported earnings of  4 91 per share excluding certain items on revenue of  5 38 billion  Analysts expected an EPS of  4 27 on revenue of  5 52 billion  according to Refinitiv F5 Networks   The software application company s stock dropped more than 3  in extended trading on Monday on weak second quarter guidance despite reporting a beat on the top and bottom line  The company expects to deliver an EPS of  2 14  2 17 in the second quarter  while analysts expected earnings of  2 44 per share  according to Refinitiv  The technology company reported first quarter earnings of  2 55 per share on revenue of  569 million  while analysts expected earnings of  2 43 per share on revenue of  566 million  according to Refinitiv Juniper Networks   Shares of the computer network company fell more than 2  in extended trading on Monday despite beating analysts  estimates on fourth quarter revenue and earnings per share  Juniper s first quarter revenue outlook was in line with analyst estimates  but the company expects to deliver earnings of 27 cents per share while analysts expected earnings of 31 cents per share  according to Refinitiv  The company reported fourth quarter earnings of 58 cents per share on revenue of  1 21 billion  while analysts expected earnings of 57 cents per share on revenue of  1 19 billion  according to Refinitiv PerkinElmer   Shares of the life sciences company slipped more than 2  in extended trading on Monday despite its strong fourth quarter results that beat analysts  expectations  The company sees first quarter earnings of 70 cents per share while analysts expected an EPS of 84 cents  For the fiscal year  the company expects to deliver an EPS of  4 50  4 60  which is lower than the  4 63 EPS that Wall Street expected  according to Refinitiv  The company reported earnings of  1 35 per share on revenue of  806 million  while analysts expected earnings of  1 33 per share on revenue of  801 million  according to Refinitiv ,2020-01-27,CNBC,https://invst.ly/pnls2,2068931
119464,340979,PKI,PerkinElmer Inc  PKI  Q4 2019 Earnings Call Transcript,news,"PerkinElmer Inc  NYSE PKI Q4 2019 Earnings CallJan 27  2020  5 00 p m  ETContents 

Prepared Remarks
Questions and Answers
Call Participants

Prepared Remarks 
OperatorLadies and gentlemen  thank you for standing by and welcome to the Fourth Quarter 2019 PerkinElmer s Earnings Conference Call  At this time  all participants are in a listen only mode   Operator Instructions I would now like to hand the conference over to your speaker today  Mr  Bryan Kipp  Vice President of Investor Relations  Please go ahead  sir Bryan Kipp    Investor RelationsThanks  Catherine  Good afternoon and welcome to the PerkinElmer fourth quarter and full year 2019 earnings conference call  With me on the call are Prahlad Singh  President and Chief Executive Officer and Jamey Mock  Senior Vice President and Chief Financial Officer If you have not received a copy of our earnings press release  you may get one from the Investors section of our website at   Please note this call is being webcast live and will be archived on our website until February 10  2020 Before we begin  we need to remind everyone of the Safe Harbor statements that we outlined in our earnings press release issued earlier this afternoon and also those in our SEC filings  Statements or comments made on this call may be forward looking statements  which may include but are not necessarily limited to financial projections or other statements of the Company s plans  objectives  expectations or intentions  These matters involve certain risks and uncertainties  The Company s actual results may differ significantly from those projected or suggested by any forward looking statements due to a variety of factors which are discussed in detail in our SEC filings  Any forward looking statements made today represent our views only as of today  We disclaim any obligation to update forward looking statements in the future  even if our estimates change  So you should not rely on any of today s forward looking statements as representing our views as of any date after today  During this call  we will be referring to certain non GAAP financial measures  A reconciliation of the non GAAP financial measures we plan to use during this call to the most directly comparable GAAP measures is available as an attachment to our earnings press release  To the extent we use non GAAP financial measures during this call that are not reconciled to GAAP in that attachment  we will provide reconciliations promptly I am now pleased to introduce the President and Chief Executive Officer of PerkinElmer Prahlad Singh  Prahlad Prahlad Singh    President and Chief Executive OfficerThank you  Bryan  and good evening everyone  I m pleased to report that PerkinElmer had a strong finish to 2019 with reported revenue in the fourth quarter increasing 6  year over year and adjusted earnings per share growing 14   beating both the top and bottom line of our previous guidance Our revenue in the fourth quarter was  806 million  representing organic growth of 5  and our adjusted earnings per share was  1 35  As I reflect on 2019  the rapid transformation we made as an organization has put us in an excellent position to accelerate profitable growth and advance outcomes around the world in 2020 and beyond  I have no doubt that these positive changes will become increasingly apparent to external stakeholders over the coming quarters and years From a financial perspective  we delivered strong performance in 2019 across our businesses despite evolving macro headwinds  We delivered organic growth of 5   170 basis points of margin expansion and 14  adjusted earnings per share growth  Jamey will discuss our financial results in greater detail As you are familiar  last summer we aligned our go to market approach and combined our R D teams  empowering our regional commercial leaders to make decisions closer to customers and encouraging our R D team to think differently and leverage the breadth of our capabilities across the end markets we serve to develop full workflow solutions that address evolving customer needs We entered 2020 as a new highly collaborative organization that has significant opportunity to leverage our differentiated capabilities to accelerate positive outcomes for the betterment of people and their environment  All in all  I am extremely proud of all of our 13 000 employees who come to work every day with enthusiasm around our mission of innovating for a healthier world  a relentless focus on transformative innovation and operational excellence and a strong commitment to meeting the ever changing needs of our customers I ll just share a few examples from the fourth quarter where we ve seen our transformation efforts pay off  Our targeted focus on solving critical issues impacting the future of science and healthcare enabled us to achieve new milestones by working with our customers and partners Within the Diagnostics business  the FDA approval of our GSP Neonatal Creatine Kinase  MM kit has resulted in first commercially available assay for screening newborns affected by Duchenne muscular dystrophy  PerkinElmer s kit is specifically designed for screening newborns and is a cost effective way to screen for DMD with a two tier testing approach using the CK MM assay and then DMD gene analysis  Screening newborns not only prevents DMD patients and their families from an unnecessary diagnostic odyssey but it also ensurers timely treatment for a disease that could otherwise go undetected for years Via our proprietary DMD kit  PerkinElmer is participating in Parent Project Muscular Dystrophy s consented pilot program to screen newborns in New York State for Duchenne  The program aims to screen 100 000 babies  about half of all those born each year in New York over a two year period Taking a step back for a moment  when we think about positive and accelerated outcomes  we are looking at the whole human care cycle  not just siloed points along the diagnostics and therapeutics spectrum  Our advancements in newborn screening  such as the DMD kit for example  play into a larger strategy focused on the full continuum from family planning to maternal fetal to newborn health  childhood and family health  To this end  we are excited about some of the truly novel solutions that we have in our pipeline today and hopefully we ll be discussing more in the months and years ahead Turning to DASH   Phonetic  our new go to market strategy is fundamentally shifting how we are approaching new analytical market opportunities  As I mentioned at a recent conference  cannabis is an early win example of this new go to market approach that we hope to replicate going forward  We have progressed from a relatively nascent business in early 2018 to  26 million in revenue from cannabis testing in 2019  Thanks to our efforts to really understand the voice of the customer and provide an end to end workflow solution  including sample prep  quality and safety testing and analytics capabilities To continue to show a strong commitment to this rapidly expanding market and to broaden our distribution reach  this past December at MJBizCon  we announced that Emerald Scientific  a leading cannabis and hemp lab technology player and testing standard leader will now offer a cannabis and hemp testing portfolio to their North American customers Our success in developing complete workflow solutions is also serving as a key differentiator across our life sciences portfolio  With the acquisition of Cisbio  for example  which is tracking ahead of our deal model  we now can provide end to end solutions in the discovery stage on target identification  lead generation and optimization in preclinical for both pharma and biotech research  During the fourth quarter alone  we introduced several new Cisbio kits for phosphor relate and total protein and biomarker detection  And with our reagent R D for all PerkinElmer technologies now consolidated at our site in Codolet  France  we expect an uptick in drug discovery screening reagent innovation in the future A final example of our new strategy coming to life is within the fast growing food market where we are already reverse integrating some PerkinElmer food assets into the Meizheng sales channel to take advantage of its commercial breadth customer intimacy and local domain expertise  One example of this in action is with our recently introduced PaddyCheck PC 6800 technology from Perten which automates analysis and increasing testing accuracy of paddy rice for key quality markers The new solution also eliminates the need for traditional labor intensive steps and delivers accurate results with 5 to 10 minutes  With rice serving as a key staple in people s diet  helping to ensure the quality of this mega grain is important for the increasing research and planting demands of the ever growing global food chain While Meizheng was only consolidated for part of the fourth quarter  we were pleased with its double digit growth and early synergies  As we look ahead  critical to our success will be our ability to execute across the Company on three key priorities we have laid out for our organization this year  ensuring a customer first mindset  innovating to address critical health and scientific challenges and evolving our employee experience  From the customers  standpoint providing exceptional experiences with PerkinElmer means that we are improving our tools  processes and responsiveness to deliver solutions when  where and how our customers need them On the innovation front  this year you will see us further our partnerships with customers and industry organizations to accelerate the visibility and development of new offerings across our end markets  And internally we will continue to work on creating a culture that drives greater cross company collaboration than ever before Before I hand it over to Jamey  I want to briefly provide an update on Vanadis  Earlier this month  our team hosted people from the investment community at our lab in Pittsburgh  Pennsylvania where we discussed Vanadis and the broader PerkinElmer genomic strategy  Specific to Vanadis the key messages that we try to drive home were Vanadis NIPT is a test for every woman due to its high precision and low no call rate  The system has clear workflow advantages over NGS  Customer feedback continues to remain positive and the NIPT market is sizable and growing rapidly We truly believe that Vanadis NIPT will play a pivotal role in helping to democratize noninvasive prenataltesting across the globe over the next few decades  In terms of placements in 2019  we achieved 28 systems and we continue to have a healthy funnel For 2020  our plan is to end the year between 50 to 55 installations in total  which would imply another 22 to 27 systems this year  up from 10 placements in 2018 and 18 placements in 2019  All told I m confident that we are on the right path as an organization  While there were a lot of internal changes in 2019  we are now well positioned as we turn the page to the next chapter of the PerkinElmer story  I look forward to sharing our continued progress throughout the year I ll now hand it over to Jamey to discuss our Q4 and 2019 financial Results in more detail as well as our 2020 guidance Jamey Mock    Senior Vice President and Chief Financial OfficerThanks  Prahlad and good evening everyone  Before I start  I want to point everyone s attention to our fourth quarter earnings call presentation  which has been posted on the Investors section of our website under financial information  The goal of this document is to drive additional transparency and simplicity around the Company and our quarterly performance  Today I plan to begin by highlighting the fourth quarter  Then I ll provide some additional color on our served end markets and financial metrics  Lastly  I ll finish by providing a look back on our 2019 performance and our financial outlook for 2020 Jumping in  we are pleased with our fourth quarter results and full year 2019 performance  Market conditions were in line with our expectations  entering the fourth quarter  As they have all year  our growth accelerators continued to perform well  lead by EUROIMMUN which grew at a double digit clip on broad based global demand and cannabis which more than doubled year over year  Our genomics testing business remains on track to complete the Branford to Pittsburgh consolidation by the end of the first quarter and Vanadis momentum continues to build As Prahlad mentioned  the recent granting of the Vanadis NIPT PLA code by the American Medical Association  was an important development in December that favorably positioned Vanadis Diagnostics for 2020  Our 2019 acquisitions of Cisbio  Meizheng and Solus all performed well during the quarter and concluded the year well positioned to be strong  incremental contributors in the years ahead From an operational standpoint  prior actions to reduce organizational complexity undoubtedly made us a nimbler organization  Our 50  organic incremental margin in 2019 is a direct product of the increased transparency and accountability across the organization Turning to the fourth quarter results  We achieved 5  organic revenue growth with broad based momentum across our portfolio  Adjusted reported revenue grew 6  to  806 million and included a 1  foreign exchange headwind and a 2  net acquisition tailwind  By business Diagnostics  representing 38  of total sales grew 5  organically driven by our immunodiagnostics and reproductive health business lines  Discovery   Analytical Solutions representing 62  of total sales also grew 5  organically due to continued strength in life sciences and a rebound in our core food business  I will provide some additional color on both businesses in a moment On a geographic basis  organic growth trends  largely paralleled what we experienced during the third quarter  Asia Pacific and Europe both grew mid single digits  While the Americas grew low single digits  Operationally  we are extremely pleased with our performance in the fourth quarter and we continue to see significant potential to improve our profitability moving forward Adjusted operating margins expanded 210 basis points in the fourth quarter to 23 9  driven by productivity  mix  cost out actions and some timing  As Prahlad mentioned  adjusted earnings per share of  1 35 was an increase of 14  versus the fourth quarter of 2018 and  0 03 ahead of our guidance  Looking further into the key drivers within our segments  let s start with our Diagnostics business  As mentioned in my earlier remarks  organic revenue grew 5  which was off a strong 14  organic growth comparison in 4Q  18  Immunodiagnostics grew low double digits  EUROIMMUN led the way with a mid teens growth rate which was broad based from both a geographic and product basis Geographically  the US and Western Europe both grew over 20  and China grew at a healthy mid teens clip  Reproductive health grew low single digits organically driven by expanded coverage in Asia Pacific  We highlighted expanded newborn screening in the Philippines on our last earnings call  Additionally  we also benefited from expanded screening programs in Japan and Vietnam in 2019  Paralleling the third quarter our applied genomics business remained soft  declining high single digits in the fourth quarter  Momentum in our NGS and nucleic acid extraction reagents was more than offset by softness in automated workstation and robotics products segments Turning to Discovery   Analytical Solutions  organic growth of 5  in the fourth quarter was driven by our life sciences and food franchises  By end market  we experienced high single digit organic revenue growth in pharma biotech propelled by our Discovery and Informatics product lines Our informatics business continues to perform well  growing double digits in the fourth quarter  PerkinElmer Signals solutions are increasingly gaining traction among the top pharma  biotech and contract research organizations as Signals helps drive increased collaboration  improve efficiencies and accelerate time to discovery for R D scientists  The applied markets were up mid single digits in the quarter  driven by an improvement in our core food business  continued strength in our cannabis solutions and a modest sequential improvement in Asia Pacific industrial and environmental safety demand  Overall industrial and environmental grew approximately 1   Food was up mid teens with core food up mid single digits and cannabis up over 150  year over year Shifting to below the line items  adjusted net interest and other expense for the fourth quarter was approximately  13 million and our adjusted tax rate was approximately 16  Turning to the balance sheet  we finished the year with approximately  2 1 billion of debt and  192 million of cash  Free cash flow in the quarter was  192 million and adjusted free cash flow in the quarter was  193 million  As a reminder  the difference between the reported and the adjusted number is due to cash payments associated with prior acquisitions For the year  we achieved an adjusted free cash flow conversion of 70  which was an improvement versus 2018  While this was short of our 80  estimate  we understand the fundamental levers of the shortfall and we feel confident that we have the right action plans in place to improve the conversion rate over the coming years Finally  we exited the quarter with a net debt to adjusted EBITDA ratio of approximately 2 8 times  Turning to the full year results  We are very pleased by our performance  the progress we made aligning our organization and the relentless focus of our entire organization displayed during times of internal change and external macro uncertainty For 2019 we posted 5  organic revenue growth and 14  adjusted earnings per share growth  Except for core food  end markets performance played out as we expected entering the year and conditions were consistent throughout the year  From an adjusted EPS standpoint we beat the midpoint of our initial guide by  0 07 due to our strong margin performance and improved tax benefits  which more than offset a slight organic shortfall  As we transition to 2020  we remain excited by the prospects for growth given the portfolio transformation over the past few years  including our recent acquisitions  the momentum of our growth accelerators and our new organizational structure Consequently  for 2020  we expect 5  to 6  organic growth and reported revenue to be between  3 05 billion and  3 09 billion  including  12 million from foreign exchange headwinds and approximately  35 million of contributions from acquisitions  We are forecasting full year adjusted EPS guidance of  4 50 to  4 60  up 10  to 12  and including a  0 02 headwind from foreign exchange  We expect to expand our operating margin    adjusted operating margin by 80 basis points Finally  we anticipate  54 million in adjusted interest and other expenses  a 16  tax rate and our share count to average  112 million for the year  Embedded in this full year guide is the impact from a 53rd fiscal week in 2020  As most of you know  PerkinElmer operates on a 364 day fiscal calendar  Therefore  similar to the year 2015 every fifth year includes a 53rd week  For 2020 we anticipate the impact of the 53rd week will be approximately  10 million to  15 million of revenue  However  given the extra week of expenses  the extra week will dilute our adjusted operating margin by 25 basis points to 30 basis points and adjusted EPS by a negative  0 03 to  0 05  For modeling purposes the extra week falls into the first quarter We anticipate adjusted free cash flow conversion of 75  to 80  during the 2020 fiscal year which would represent a 5  to 10  improvement year over year  We are acutely focused on improving our free cash flow conversion in a prudent way while balancing growth and profitability  It is going to be a two to three year process to get back to the 85  to 90  range Turning to the first quarter of 2020  we are forecasting reported revenue of  700 million  representing 6  organic revenue growth  including a foreign exchange headwind of approximately  8 million versus the comparable prior period  In terms of adjusted earnings per share guidance for the first quarter  we are forecasting  0 70  We expect the impact from the extra week to dilute our first quarter operating margin rate by 90 basis points to 110 basis points  Excluding the extra week  foreign exchange headwind and higher tax rate  earnings in the first quarter would be up 9  to 12   Again  all of this is noted in the last page of our fourth quarter earnings presentation  which I mentioned earlier Before I hand it back to the operator  the growing corona virus outbreak is a concern on multiple fronts  First  our thoughts and prayers go out to those impacted  Teams across PerkinElmer are actively working to develop solutions to control and hopefully help stop the spread of this infection  That said  we have not embedded any financial impact in our first quarter or full year guidance  If the epidemic continues to grow  it could negatively impact our EUROIMMUN and CIMBio franchises  given patients in China may avoid going to the hospital for immunology and infectious disease testing  There are currently a lot of unknowns  Therefore  we think it is prudent to highlight this risk going into the year This concludes my prepared remarks  Operator  at this time  we would like to open the call to questions Questions and Answers OperatorThank you   Operator Instructions  And our first question comes from Catherine Schulte with Baird  Your line is open Catherine Ramsey    Robert W  Baird    AnalystHey guys  Thanks for the questions  I just wanted to go back to that first quarter guide  If we back out that extra week  I think the first quarter comes in closer to 3 5  to 4   despite having a fairly easy comp with the government shutdown we saw last year  So can you just walk us through the pluses and minuses off of what you think a normalized growth rate should look like in that first quarter Jamey Mock    Senior Vice President and Chief Financial OfficerYeah  thanks  Catherine  I ll take this one  So I think if you back out the extra week  it s more like 4  to 4 5  in the first quarter  which is down versus every I think    every quarter in the year 2019 we reported 5  organic growth  So it s a similar comp throughout the year  I think there s two things largely that are affecting us in the first quarter First genomics testing  if you remember 2019 we started off very high  particularly in the sequencing part of that business  And so that had a great first half and a little bit softer second half due to the consolidation  We expect that to continue into the first quarter  So that s probably 0 5 point of organic growth by itself  what we re planning on in the first quarter here And the second area is applied genomics  Similarly  what I mentioned on robotics and automated workstations that had a stronger first half  weaker second half  We re expecting that to continue into the first half year  And so  those two things really are the only difference between our 5  organic run rate that we saw throughout the year  including the fourth quarter and walking into the first quarter here Catherine Ramsey    Robert W  Baird    AnalystOkay  And on that applied genomics business  we ve seen a number of data points suggesting that DTC microarray industry will continue to have some meaningful headwinds this year  Now you have some exposure there  So how do you think about that business returning to better growth Prahlad Singh    President and Chief Executive OfficerYeah  Catherine  this is Prahlad  So I think our exposure to the DTC market is not much  Most of our relationships there are pharma and on the newborn screening side  The thing that we are just going through is the consolidation piece that we    as we ve pointed out earlier  by the end of Q1 that should be resolved  So we don t    we  at this point  don t see that as our exposure to DTC is not too much Catherine Ramsey    Robert W  Baird    AnalystGreat  thank you Jamey Mock    Senior Vice President and Chief Financial OfficerThanks  Catherine OperatorThank you  Our next question comes from Dan Arias with Stifel  Your line is open Dan Arias    Stifel    AnalystGood afternoon  guys  Thanks Jamey Mock    Senior Vice President and Chief Financial OfficerHi  Dan Dan Arias    Stifel    AnalystMaybe just on    hey  Jamey    maybe just on Vanadis since Prahlad touched on it and we were just out there  what kind of revenues are you thinking that the placements in utilization will yield for 2020  And then along those lines  can you just sort of talk to the visibility that you have when you think about the labs that will get you there  Is there a volume trajectory that you feel confident about at this point or is it still kind of fluid in terms of what the ramp will look like Prahlad Singh    President and Chief Executive OfficerYeah  Dan  in fact as a matter of fact we have a very healthy funnel and we are actually in the    currently in the process of shipping and installing several systems  As we ve said earlier and I have  our focus right now continues to be that the earlier adopters have a flawless experience If you just look at what I pointed out earlier of 50 to 55 installations  Dan  We have placed 10 systems in 2018  18 systems in 2019 and the implied range between 22 to 27 in 2020  So from our perspective  we think installations are an important metric to track early on in the product s life cycle  But in the end  eventually as I ve said  our goal is to democratize Vanadis NIPT  So that s where we are focusing And also with the NIPT PLA code  that gives us several advantages in the US once that is issued  So from a priority perspective  we are looking at the number of installations  getting the clinical data out and working on the PLA code Dan Arias    Stifel    AnalystOkay  So it sounds like that s a TBD on a forecast for Vanadis Prahlad Singh    President and Chief Executive OfficerYeah  I think from a revenue perspective our guidance will be to continue to monitor the number of installations Dan Arias    Stifel    AnalystOkay  Okay and then just secondly  Jamey  if I just think about the top line guide and I take out the half  one  Phonetic  or so that you re getting from the extra week  that s 5  organic at the midpoint  which is in line with 2019  which is a year where you had some organizational issues and then either one off or maybe somewhat unlikely to repeat elements  And then I think at the end of this year you should also be getting a little bit of juice from Meizheng  So I guess how much of the outlook for 2020 on the organic side is conservatism to start the year versus maybe something that s under appreciated about either the DX ramp or the factors that are at play in DAS Jamey Mock    Senior Vice President and Chief Financial OfficerYeah  good question  So I mean maybe we just kind of talk through the end markets here  Dan  So I would say where we have a little bit of incremental caution is around life sciences and immunodiagnostics  I ll start with immunodiagnostics  Obviously EUROIMMUN leads the way there  They have been mid teens for quite some time  but I think we re pretty consistent in saying that we re going to model them at 12  organic growth  So I think we expect a little bit of down downtick there Life sciences  I don t think we ve seen anything  but funding levels have remained very strong  And so we re hopeful that it continues  but I d say there s probably more downside than there is the upside  So I d say that s where we re cautionary Conversely  if you look at food and applied genomics  food what we ve talked about in terms of some kind of rebound in the core  and we had at least one data point here in the fourth quarter  should provide some upside  Offsetting that  I don t anticipate cannabis being as large an incremental contributor this year  So those kind of offset a little bit there And then applied genomics  once we get through the first half we ll see how it s going  but hopefully that has a little bit of easier comp  Indecipherable     comp as well in the second half year  So overall  Dan  to answer your question probably a little bit cautious in life sciences and immunodiagnostics  maybe a little bit of upside in food and applied genomics  the others pretty steady Dan Arias    Stifel    AnalystOkay  thanks a lot Jamey Mock    Senior Vice President and Chief Financial OfficerYeah OperatorThank you  Our next question comes from Derik DeBruin with Bank of America  Your line is open Derik DeBruin    Bank of America Merrill Lynch    AnalystHey  thanks  So a couple of questions  I think the first one  did    I think some companies  but maybe you don t have as much exposure here  but I think some companies were flagging that they didn t expect a significant budget flush during the fourth quarter from some of their customers as in prior years  I m just wondering what you saw in terms of incremental spending and just sort of what was sort of like the year end budget activity Jamey Mock    Senior Vice President and Chief Financial OfficerYeah  it s always difficult to tell  Derik  but I don t think we saw much  In terms of life sciences  actually it was a little soft in the Americas in the fourth quarter  Applied market hung in there in the fourth quarter  So maybe there s a little bit off there  But I d say it s difficult to tell and overall  nothing out of the ordinary here Derik DeBruin    Bank of America Merrill Lynch    AnalystOkay  And just on the China  I appreciate the comments on the corona virus  I mean  we ve been getting some questions today just given that you do have an infectious disease testing business that you ve got  Just sort of  I think we were wondering  would you    are you testing for it  are you going to see potentially any incremental sales into your diagnostics products to potentially offset some of the headwinds you re referring to Prahlad Singh    President and Chief Executive OfficerYeah  And maybe I ll take that  So  Derik  we are in the process of developing a PCR and an antibody assay  PCR is generally a frontline assay during an outbreak and we are making strides  But we do have to take it through the CFDA which is now the NMPA approval process  And they are working with us and with several other entities to get a front line testing assay out Again  most of the focus right now is doing it more from a CSR perspective  just to make sure that we have an assay that we can use for testing  What s the commercial impact of that  I would say at this point is unknown Derik DeBruin    Bank of America Merrill Lynch    AnalystThanks  And Jamey if I can squeeze one more in  So if you    if you adjust for the extra week  about a 105 basis points  110 basis points of implied op margin expansion in 2020  I guess is that a    I mean  how sustainable is that through like 100 basis points number on a go forward basis  I mean  is there incremental    you re sort of at your 22  ish operating margin target that you put out there a few years ago  Is there an upside to that number Jamey Mock    Senior Vice President and Chief Financial OfficerYeah  I mean like we ve been saying  we see a lot of room for continued expansion and profitability here  And I don t think 22  was ever a stopping point  We see that ultimately over time getting up into the mid 20 s  How much can be done in the year 2020  we think 100 basis points ex the extra week is a pretty healthy clip coming off 170 basis point in 2019 To your point  I mean we guided in 2019 120 basis points to 250 basis points and ended up beating that at 170 basis points  So could there be upside to the 80 basis points that we re guiding  sure  But I think we re more focused on the long term and putting programs in place to get this to the mid 20 s OperatorThank you  And our next question comes from Vijay Kumar with Evercore ISI  Your line is open Vijay Kumar    Evercore ISI    AnalystHey guys  Thanks for taking my question  Jamey  if I could just touch on the margin question  Extra week incremental revenues  can you walk us like why margins would be down  I would have thought the extra revenues benefited margins Jamey Mock    Senior Vice President and Chief Financial OfficerYeah  You re talking for the quarter  Vijay  or for the year Vijay Kumar    Evercore ISI    AnalystQuarter and now for the year  I m just curious why incremental revenues have lower margins Jamey Mock    Senior Vice President and Chief Financial OfficerYeah  So if you look at it  Vijay  the    and then we tried to lay this out in our earnings presentation  the exact numbers  so we feel like the extra week will provide  10 million to  15 million of additional revenue  which is not what we experienced  if you just take our total year and divide by 52 weeks  But we think that that s the right amount of extra revenue coming in the year However  if you look at the expenses for an extra week that more than offsets that amount of gross margin  So if you take the  10 million to  15 million  you get a 50  roughly thereabouts gross margin then you add an extra week of operating expenses  and an extra week of interest expense  it s actually dilutive to the year  And like I said  we tried to lay that out both for the quarter and for the year on that last page in the earnings presentation Vijay Kumar    Evercore ISI    AnalystGot you  And then maybe just a follow up on that theme  the extra week  One on Vanadis  is there    are you guys in a position to compete for tenders in Europe  And related to that extra week that  10 million to  15 million is sub 50 basis points on the top line  Should it be just  if you did the one week or for 53  something higher than what the implied on the extra week is Jamey Mock    Senior Vice President and Chief Financial OfficerLet me start with the extra week  then Prahlad is going to jump in on Vanadis here  So we think most of our customers  and we actually saw this back in 2015  operate on a calendar year  so January 1st to December 31st  And if you look at where the extra days in this year fall  they fall on the fringes  So take this quarter for example  December 31st and 31st for 2019 actually fall in this fiscal year 2020  But we think that the revenue from that is mostly going to be spent in the 2019  And therefore  it was recorded in our 2019 revenue So once you back out a couple of those days  you get down to  let s say  three more days and a lot of that is capex  some of that is scheduled professional services  so not just a daily run rate  And so therefore you get down to some recurring revenues that are  we believe  in the 10  to 15  range  which ends up being a 1 5  to 2   which was very    in sort of the third quarter 2015  we actually said that it was 2  impact to our organic growth  So it s kind of a similar operating assumption here Prahlad Singh    President and Chief Executive OfficerAnd Vijay to your    for the first part of your question  yeah  we are    we can and are starting to participate in tenders in Europe Vijay Kumar    Evercore ISI    AnalystThat s helpful  Prahlad  And just to be clear  the guidance has no assumptions around any potential wins in Europe on Vanadis Prahlad Singh    President and Chief Executive OfficerWell  I think what we are assuming basically is 22 to 27 installations  So some of it is in Europe  some is in Asia and some is it in the    some in the US  We are not sort of focusing on which particular tender  Vijay  we could win or which we would win Jamey Mock    Senior Vice President and Chief Financial OfficerBut there will be some capex revenue in our   Prahlad Singh    President and Chief Executive OfficerThat will come from  Speech Overlap Jamey Mock    Senior Vice President and Chief Financial OfficerIn our year guidance as well as some sample ramp as well Vijay Kumar    Evercore ISI    AnalystGot you  Thank you  guys Prahlad Singh    President and Chief Executive OfficerYeah Jamey Mock    Senior Vice President and Chief Financial OfficerYeah OperatorThank you  Our next question comes from Steve Beuchaw with Wolfe Research  Your line is open Stephen Beuchaw    Wolfe Research    AnalystHi  good afternoon  Thanks for the time here  I was hopping first if you could help unpack your thought process around reproductive in the 2020 guidance  Birth rates  particularly in China  were a headwind there in 2019  What do you expect for broader growth in that category  And how are you thinking about the birth rate dynamic prospectively Jamey Mock    Senior Vice President and Chief Financial OfficerYes  So I think    hey  Steve  Overall we think reproductive health ticks up a little bit  So we ve got Vanadis that should kick in  some genomics testing that gets reported in there that should kick in and some    I don t anticipate    we re not anticipating any good news on birth rates  We think we ve continued to see significant issues particularly in China  We expect that to continue We have a lot of good APAC expansion that I mentioned earlier in my prepared remarks around the Philippines  in Japan and Vietnam  So that has a little pressure  So net net  there is probably a little bit of upside to reproductive health year over year  but we re definitely planning on birth rates impacting us and we ll see where geographic expansion gets us Stephen Beuchaw    Wolfe Research    AnalystOkay  And then    not just for 2020  but maybe even far out  Phonetic  with a medium term bent  I wonder if you could speak for a minute about cannabis  You mentioned that the growth in fact for cannabis in 2020  you expect to be somewhat smaller than it was in 2019  Can you put any numbers around that and is that a market that s just somewhat matured or is there a competitive dynamic  Why would that be slower growth after a big 2019  Thanks Jamey Mock    Senior Vice President and Chief Financial OfficerYeah  I mean in cannabis this year performed extremely well  We re thrilled with the team  the solution that we bring  Prahlad mentioned that it was  26 million in revenue  which was off a  10 million base  That kind of incremental contributor is difficult to predict and we are not banking on that in this guidance  We expect it to go up still at a double digit rate  But to go up another  16 million just feels like a significant planning assumption that we re not  It could happen  but that s not what we re banking on right now So the market still seems great  We ll see how states roll out  I think there s a couple more that will come online in 2020  But I don t think we re going to bank on that kind of incremental contributor this year Stephen Beuchaw    Wolfe Research    AnalystOkay  Thank you for all the color guys Jamey Mock    Senior Vice President and Chief Financial OfficerThanks  Steve OperatorThank you  Our next question comes from Tycho Peterson with JP Morgan  Your line is open Tycho Peterson    JP Morgan    AnalystHey  Thanks  Sorry to go back to the 1Q guide  but you mentioned backing out the extra week  EPS would have grown 9  to 12    0 75 to  0 77  That s still below consensus  I would have thought with the recent reorganization efforts you would have at least been able to guide to consensus  So can you just talk about if there are other offsets other than the extra week that are kind of weighing on the EPS in the first quarter Jamey Mock    Senior Vice President and Chief Financial OfficerYeah  I mean    hey  Tycho  So in general there s probably a little bit of mix difference in the gross margin line versus what we kind of exited the last end of the year on as well as on the operating margin line  There s a little bit of comp timing year over year as well as some investments we re making in our growth accelerators in terms of Vanadis and cannabis etc  that kind of set up the year  So overall we think we d be up about 40 basis points in the quarter excluding the extra week and that continues to uptick throughout the year here Tycho Peterson    JP Morgan    AnalystOkay  And then a couple of quick clean ups  It sounds like the Vanadis installed base went down  It was 19 last quarter  Now you re saying 18  Was there something    is it customer return or why did it go down Prahlad Singh    President and Chief Executive OfficerTycho  it s 28  So till the end of the third quarter we were 19 and that went to 28 Tycho Peterson    JP Morgan    AnalystOkay Maybe  Tycho  what we were saying was in 2018 we delivered 10 systems  In 2019  we added 18 systems to get to 28  Next year  we re guiding somewhere in the 22 to 27 Prahlad Singh    President and Chief Executive Officer27 Jamey Mock    Senior Vice President and Chief Financial OfficerSo we re taking a methodical approach to increase our placements every year and be prudent on how we roll out these systems Tycho Peterson    JP Morgan    AnalystAll right  And then on EUROIMMUN  mid teens in the fourth quarter  you made a comment that that s maybe not sustainable and we should be back to thinking 12   maybe 13   Was there something in the fourth quarter that allowed it to overshoot to the upside Jamey Mock    Senior Vice President and Chief Financial OfficerNo  no  I mean  look  we hope that it s mid teens  I think we ve been consistent in saying that we re going to budget a year at 12  going forward  That s what we plan in the initial deal model throughout the first two years of having EUROIMMUN in the PerkinElmer family  it s grown mid teens both years  maybe it does again  But we ve always been consistent in saying we d like to plan this at about 12  based upon terrific product introductions  geographic expansion  including the US and we just think 12  is a good operating assumption Tycho Peterson    JP Morgan    AnalystOkay  And then just one last quick one on the genomics  the automation  it sounds like you re going to recapture half of it in the first quarter  Was that in line with your original expectation or were you expecting to recapture most of that in the fourth quarter Jamey Mock    Senior Vice President and Chief Financial OfficerNo  not as much  Actually  Tycho  we re expecting that to persist into the first quarter  So some of the pressure we saw in the second half of 2019 we re expecting to persist  We keep seeing things pushed to the right here from a demand perspective and we re not banking on that that will change in the first half year Naturally when you get to the second half  you get a different comp  If it s better than that  we re happy  But right now our operating assumption is that we re going to continue on with the growth rates we saw in the second half of 2019 into the first half of 2020 Tycho Peterson    JP Morgan    AnalystGot it  Okay  Thanks Jamey Mock    Senior Vice President and Chief Financial OfficerThanks OperatorThank you  And our next question comes from Patrick Donnelly with Citi  Your line is open Patrick Donnelly    Citi    AnalystGreat  thanks  Maybe just building on Tycho s question on EUROIMMUN  Can you just talk through how sensitive that business is to the China hospital volume  And then maybe just give us some color on what the volume per day looks like on the gross there Prahlad Singh    President and Chief Executive OfficerYeah  Patrick  I think it will be difficult to give a volume per day  I think as Jamey pointed out in his remarks  given the evolving situation right now  all we are doing is highlighting the corona virus thing  We don t know what the impact of that will be  It all depends on how it plays out over the next few days or weeks  I think the point that Jamey made to Tycho s earlier question is that EUROIMMUN has done better than what we have forecasted in the deal model  which has been 12  over the past couple of years and we hope that it continues to do that way  From our forecasting perspective  we have modeled it at 12  Patrick Donnelly    Citi    AnalystOkay  And then maybe Jamey just on the cash flow  appreciate the 75  to 80  conversion guidance  Can you just talk about some internal initiatives you guys are focused on there  I know you had some headwinds around receivables and inventory kind of extended out some agreement terms  Can you just talk about the trends you re expecting in 2020 there  the focus points Jamey Mock    Senior Vice President and Chief Financial OfficerYes  sure  Thanks  Patrick  So I mean we ve learned a lot about cash flow over the last year here and we ve made some progress  not where we wanted it to go to  but definitely some uptick  The 2020 operating assumption is that working capital turns are basically static  Unlike the last couple of years where we ve actually been reducing our working capital turns and it s been a headwind  So there is internal processes around things like billing and invoicing accuracy and timeliness and collection efforts  etc  But really  when you look at receivables it s in three or four different business models And we expect some of that to somewhat plateau in 2020  We ve seen terms changing  particularly in China and some of the emerging markets that are much more developed now  Informatics  we ve started to sell subscriptions on a three year basis a couple of years ago  So we should expect some more cash from that  Cannabis  we ve been leaning into a little bit here  So the fundamental embedded in the 75  to 80  is basically static from an efficiency standpoint  which will be great  Hopefully  there s upside and certainly over the next couple of years we will drive that The second thing I d say is around capital expenditures  So capital expenditures downtick I think about 20  this year  We didn t repeat some of the investments in genomics and we ve been kind of monitoring EUROIMMUN  I would say over the next couple of years  there are two remaining areas that require capital expansion  That s EUROIMMUN in China  we re building out a facility there  and then our Tulip business in India  growing extremely well  And we got to increase some of the facility space there  But after that  I don t think we see a lot of capital expansion  So we ve kind of reduced it a little bit here  It will be static for a little while and then hopefully that downticks over time Patrick Donnelly    Citi    AnalystAppreciate it OperatorThank you  And our next question comes from Doug Schenkel with Cowen  Your line is open Doug Schenkel    Cowen and Co     AnalystHey  good afternoon guys  I m just going to ask three quick ones and then get back into the queue  Just getting on the train and I don t want to have too much of background noise  So first  following up on Patrick s question  has there been or is there any formal change  plan for incentive comp as it relates to free cash flow conversion  And the second  what assumptions for growth by geography are embedded into revenue growth guidance for the year  And three  what are your capital deployment priorities for the year  Do you have a target in terms of capital you intend to deploy and what s the mix you d expect between share repurchases and M A  Thank you Jamey Mock    Senior Vice President and Chief Financial OfficerYeah  sure  So I didn t catch the second one  But I ll answer the other two and then I ll ask you to repeat that one  Doug  So  incentive comp is now in all of our financial plans  Free cash    or sorry  free cash flow is now in our incentive comp plans  So that answers that question From a capital deployment perspective  we continue to remain acquisition first from a priority standpoint  And so  I think if you look at the last couple of years we did four acquisitions in  18  four acquisitions in  19  We always look at a healthy pipeline  I think you can expect us to be active there  The dollar amount may fluctuate  But I think that s still our priority here from a capital deployment We ended leverage a little bit down versus the end of last year and our liquidity is much stronger after the refinancing  And then in terms of where  it s always been pretty consistent  I think we re primarily focused on diagnostics and life sciences  And I think that s it  And you cut out on the second question there  Doug  What was the second question Doug Schenkel    Cowen and Co     AnalystYeah  Sorry about that  Jamey  What are your assumptions for growth by geography in terms of what you ve embedded into your revenue growth guidance for the year Jamey Mock    Senior Vice President and Chief Financial OfficerYeah  good question  So basically we re pretty much mid single digit across the board  If you look at Americas and APAC  that s been mid single digits all of 2019  Europe was low single digits  We expect the Vanadis kind of revenue to clip that over into maybe the mid single digit train  Phonetic   I call it a weaker mid single digit  So  pretty consistent across the board and pretty consistent with what we saw in 2019 Doug Schenkel    Cowen and Co     AnalystOkay  thank you Jamey Mock    Senior Vice President and Chief Financial OfficerThank you OperatorOur next question comes from Jack Meehan with Barclays  Your line is open Jack Meehan    Barclays    AnalystThanks  good afternoon  I wanted to start maybe move back to DAS  I was curious what you re seeing from your industrial customers  what that grew in the fourth quarter and just given the current state of the macro what the 2020 guidance assumes there in terms of progression Prahlad Singh    President and Chief Executive OfficerSo I think we ll talk about 4Q to start with  Jamey Jamey Mock    Senior Vice President and Chief Financial OfficerYeah  4Q was flat  consistent with where it s been most of the year  Jack Jack Meehan    Barclays    AnalystAnd then for 2020 Jamey Mock    Senior Vice President and Chief Financial OfficerWe expect no change  Industrial environmental has been remarkably consistent for us  pretty flat throughout the entire year  And I think that s our operating assumption going into 2020 Jack Meehan    Barclays    AnalystGreat  Okay  And then back on the Diagnostics business  I wanted to follow up on the genetic testing lab  Just marking to market  what was the final contribution for 2019  What does the guidance assume for 2020 contribution  And given the pace of the transition  is there any additional timing dynamic there assuming for the first quarter as well Jamey Mock    Senior Vice President and Chief Financial OfficerYeah  so 2019 genomics testing did extremely well  Obviously  it was much stronger in the first half  Then the second half  it was probably a little under  20 million in total  In terms of 2020  I think we d rather not give the specific guidance here  but you can expect that it s going to grow substantially  And in terms of the cadence through the year  I mentioned in my earlier remarks that the first quarter will continue to be challenged  because the consolidation is not supposed to happen until the    well  it s happening right now an the real roadblock there is hiring  We feel good about it  but sometimes it can take two to three months to on board people in that space  And so we feel like the second quarter is when we ll start to ramp back up again  And so overall  we expect another healthy incremental growth driver from genomics testing in 2020 Jack Meehan    Barclays    AnalystGreat  If I could squeeze in one more  What were the individual contributions from Meizheng and Cisbio  The acquired growth in DAS was a little bit higher than what you were looking for  Just was there anything outside that contributed in the quarter Jamey Mock    Senior Vice President and Chief Financial OfficerNo  not really  no  Cisbio and Meizheng both continued to do well  I think we said Meizheng had been growing into the 20  plus range and continues to perform well  We got I think 11 out of 13 weeks or something in the quarter from them  And Cisbio has been double digit all year Jack Meehan    Barclays    AnalystGreat  Thanks  Jamey Jamey Mock    Senior Vice President and Chief Financial OfficerThanks  Jack OperatorThank you  Our next question comes from Brandon Couillard with Jefferies  Your line is open Brandon Couillard    Jefferies    AnalystHey  thanks  Good afternoon  Hey  Prahlad  curious if you could just touch on the services business for a minute  I know you did some restructuring there in the third quarter  I m just curious what your outlook is for the OneSource business  specifically enterprise services as you look into  20 Prahlad Singh    President and Chief Executive OfficerYeah  Brandon  I think in terms of the services business we did some restructuring as you said  And this was again innovate the implementation of ServiceMax  We continue to sort of see productivity coming out of there  I think as we look forward  we are in a good position for 2020 and we expect to win some tenders  And I think as we ve said it will continue to be a high single digit growth business for us Brandon Couillard    Jefferies    AnalystThanks  Then one just for Jamey on the tax rate ticking up a little bit this year  Is there anything specific behind that or just an added level of conservatism just sort of embedded for the tax rate  Thanks Jamey Mock    Senior Vice President and Chief Financial OfficerNo  Yeah  I mean it s a good question  Brandon  It had gotten down to about 14  in 2018  We guided 16  for the year and came in at 15   So there is a little natural uptick in tax  I think if you look at where we are growing  you look at EUROIMMUN  you look at informatics  enterprise  a lot of those areas are higher tax jurisdictions  So therefore  we do anticipate that to go up a little  And then the offset to that  which is difficult to forecast  are some of the discrete items  We always have tax planning items  We had a lot in 2019 which basically brought us from the 16  down to 15   But there is a little natural upward pressure there that makes us think that 16  is the right number Brandon Couillard    Jefferies    AnalystVery good  Thank you Jamey Mock    Senior Vice President and Chief Financial OfficerThank you OperatorThank you  Our next question comes from Dan Leonard with Wells Fargo  Your line is open Dan Leonard    Wells Fargo    AnalystThank you  A couple of things  One  Prahlad you teased us with some potential proof points coming in 2020 as a result of the combined efforts of the organization  Are these    whether they d be new product introductions or service efforts or what have you  are these things that would have an impact in 2020 or are these things that would build and have a further impact in 2021 and beyond Prahlad Singh    President and Chief Executive OfficerI think we started seeing some of the benefits already  as I pointed out  the whole cannabis workflow solutions that we have seen  There have been other examples of where we ve combined our sample prep business from the applied genomics side with reagents from oure life sciences business  So we ve started seeing proof points of this and I don t think it s going to be a discrete 2020 item  It will continue to be ongoing and we expect to see more synergistic opportunities coming out of this Dan Leonard    Wells Fargo    AnalystOkay  And then secondly  can you walk me through your strategy to go from    you mentioned the PLA code    can you walk through your strategy to go from that PLA code to getting that code included in medical coverage policies for NIPT Prahlad Singh    President and Chief Executive OfficerI think just getting the code offers us the advantage that as a manufacturer we can devote negotiated reimbursement rates directly with payers and direct billing on a methodology that would be specific to Vanadis NIPT  And that hopefully offers better reimbursement rate for the laboratories  And also additionally we can bill insurance without any risk of incorrect coding So I think that s the level I want to share just given the competitive situations and for commercial reasons  But at this point really what I would say is that we are really excited what AMA s acceptance of our PLA code that came in at the end of December  And right now we are all hands on to ensure that the submissions get in time and we get the code in hand Dan Leonard    Wells Fargo    AnalystOkay  thank you  And then just final cleanup for Jamey  Jamey  what was the China growth rate in Q4  Was it consistent with the mid single digits of APAC or was it higher or lower than that Jamey Mock    Senior Vice President and Chief Financial OfficerConsistent with APAC  Dan Dan Leonard    Wells Fargo    AnalystThank you Jamey Mock    Senior Vice President and Chief Financial OfficerNo problem OperatorThank you  And we have a question from Paul Knight with Janney Montgomery  Your line is open Paul Knight    Janney Montgomery Scott    AnalystThanks for the time  The    I know the product portfolio has clearly benefited from cannabis and food safety testing  Is there any goal you would have or point out on the R D that you want to spend this year  Is it increasing faster than revenue  And what are the    some of the areas you would like to develop further Jamey Mock    Senior Vice President and Chief Financial OfficerYeah  Paul  overall R D  if you look at it in 2019  we actually saw a little bit of efficiency and that was related to some of the organizational restructuring  We want that to be ticking up a little bit over time  And so what s embedded in this guidance is kind of a constant R D as a percent of sales  if anything  maybe a little bit of uptick  You mentioned cannabis and food  that s one of the areas that we re increasing some of our budget  And I think in general  we re putting a little bit more resources between    behind life sciences  diagnostics and food  And I think you can expect that R D as a percent of revenue will be at least flat if not up a little bit this year Paul Knight    Janney Montgomery Scott    AnalystOkay  thank you Jamey Mock    Senior Vice President and Chief Financial OfficerYeah OperatorThank you  Our next question comes from Dan Brennan with UBS  Your line is open Daniel Brennan    UBS Equities    AnalystGreat  Thanks for the questions  So Jamey or Prahlad  just wondering for DAS  I don t know if you guys broke out exactly what s baked in for 2020 guidance overall  And then maybe within that  I know you touched on applied and environmental book  Can you break down a little bit food and biopharma  Both were solid in the quarter  kind of what s baked in going forward and what s    kind of  what is the outlook Jamey Mock    Senior Vice President and Chief Financial OfficerYeah  I think we re optimistic to have  Phonetic  upticks here  And maybe it s a point or point and a half  Phonetic   If you look at food  I mentioned it earlier  I mean we expect some kind of rebound in core food  Fourth quarter was a good data point  If nothing else  there is some good comp here  Obviously it s difficult to predict weather and climate change  And if that impacts us then that will be different than what we re planning on  But core food should rebound  I mentioned that cannabis will have a slight offset to that though that we re not expecting as much incremental contributors  But net net I think food ticks up a little bit Life sciences  I think ticked up a little bit  We talked about    Prahlad talked about some of our enterprise business going well and some extra tenders and an extra week here  I think Cisbio and informatics continues to be extremely strong  both were double digit this year  We re planning them more in the high single digit range  So we haven t seen anything  but I just don t think we re going to plan them at double digit  So net net  that probably upticks a little bit And then industrial and environmental  we are planning flat  So no change from 2019  So if you mix a little bit of improvement in the life sciences and food  you probably uptick a little bit in DAS year over year Daniel Brennan    UBS Equities    AnalystGreat  thank you  And then if you kind of pull this go back a little bit  I know like a year or so ago the conversation was maybe kind of high single digit growth type of portfolio which obviously you guys still sound very constructive on the momentum that you have with all the business changes  But when you think about 2020 guidance  you ve given a lot of color on the different businesses  but how would you characterize the 5  balance or is there a conservatism in it  And if you had to call out a swing factor on the upside or downside what would that be  Thank you Prahlad Singh    President and Chief Executive OfficerYeah  And I think    look  again we continue to be very excited about the portfolio and the prospects that we have for accelerating profitable growth  You ve got a lot of fans in the fire  I think entering the year  we are trying to be balanced  given there are some uncertainties that we see  And again example that Jamey talked about just coming in  is with the corona virus  You don t know how that plays out  but essentially the growth accelerators that we have are inherently the swing factors that will play a very important role as we look forward Daniel Brennan    UBS Equities    AnalystOkay  great  Thank you OperatorThank you  We have a question from Bill Quirk with Piper Sandler  Your line is open William Quirk    Piper Sandler    AnalystGreat  thanks  Good evening  everybody  So a couple of questions for me  First off  Prahlad  really do appreciate all the Vanadis commentary  Is there any    just I guess last question maybe on that    any particular geography or customer type where you re seeing an outsized interest and success in terms of placements  And then secondly  just staying in diagnostics for a moment  with respect to the corona virus assay development  the CDC has some emergency procedures in place to be able to rapidly disseminate tests from a regulatory standpoint  Are you familiar  are you aware of a similar type of program in any of the other affected countries  Thanks Prahlad Singh    President and Chief Executive OfficerYeah  and just starting with your first question around Vanadis  I think from an interest perspective  we are seeing interest in all the three    all the three regions  In APAC ex China given that we don t have approval in China yet  we are going through the clinical  In Europe and of course with the recent launch that we did in the US  we continue to see broad spread interest on it In regards to your second question  yes  similar to the CPC the CFDA    the MMPA and CFDA in China also has accelerated emergency processes that they have in place and we are working with them to get a test out hopefully in a few weeks William Quirk    Piper Sandler    AnalystGreat  thank you very much Prahlad Singh    President and Chief Executive OfficerYeah OperatorThank you  And we have a question from Derik DeBruin with Bank of America  Your line is open Derik DeBruin    Bank of America Merrill Lynch    AnalystHey  great  Thanks for taking the follow up  Just one question  I just wanted to clarify some since I got a bunch of questions from investors  So typically the rule of thumb  what do you look at extra days is about 0 5  organic revenue growth is a contribution for consumable heavy  Phonetic  companies  So the  10 million to  15 million seems a little bit light in terms of revenue contribution on the extra week  Did I hear you correctly in saying you thought some of that was pull forward into the fourth quarter  I m just trying to say to make sure that is because it just seems like it s a lower number than I would have thought  given your business mix Jamey Mock    Senior Vice President and Chief Financial OfficerYeah  overall  it s 1 5  to 2   So the rule of thumb of 0 5  times 5 we re only really I guess 0 5  to 1  off here  I don t think it s too different than what we saw in 3Q  15 or the rule of thumb overall  I did say that    yeah  I mean if you look at December 30th and 31st  I think most customers operate on a calendar budget in that our sales force  probably much like every other year looks at the capex spending and says  let s execute those before December 29th and I don t think that s any different than what we ve done in most years  So I think it s pretty much noise around the    around the fringes here Derik DeBruin    Bank of America Merrill Lynch    AnalystOkay  great  thanks  Just want to clarify  Thank you OperatorThank you  There are no other question in the queue  I would like to turn the call back to Prahlad Singh for any closing remarks Prahlad Singh    President and Chief Executive OfficerThank you all for your questions  As we ve shared today  we have a number of exciting opportunities on the horizon as we continue to drive toward our mission and accelerate outcomes for the betterment of people and the environment  I look forward to updating you on our continued progress in 2020  Thank you Operator Operator Closing Remarks Duration  68 minutesCall participants Bryan Kipp    Investor RelationsPrahlad Singh    President and Chief Executive OfficerJamey Mock    Senior Vice President and Chief Financial OfficerCatherine Ramsey    Robert W  Baird    AnalystDan Arias    Stifel    AnalystDerik DeBruin    Bank of America Merrill Lynch    AnalystVijay Kumar    Evercore ISI    AnalystStephen Beuchaw    Wolfe Research    AnalystTycho Peterson    JP Morgan    AnalystPatrick Donnelly    Citi    AnalystDoug Schenkel    Cowen and Co     AnalystJack Meehan    Barclays    AnalystBrandon Couillard    Jefferies    AnalystDan Leonard    Wells Fargo    AnalystPaul Knight    Janney Montgomery Scott    AnalystDaniel Brennan    UBS Equities    AnalystWilliam Quirk    Piper Sandler    Analyst
More PKI analysis
All earnings call transcripts",2020-01-27,The Motley Fool,https://invst.ly/pno3u,2069000
119465,340980,PKI,What Investors Liked and Didn t Like About PerkinElmer s Q4 Earnings Results,news,"PerkinElmer  NYSE PKI  entered 2020 with a pretty good head of steam  The global healthcare company saw its shares jump 24  last year  But there hasn t been a lot of news from PerkinElmer so far in January to move the stock either up or down    until yesterday 
The company announced its fiscal 2019 fourth quarter and full year results after the market closed on Monday  Here are the highlights from PerkinElmer s quarterly update 

By the numbers
PerkinElmer reported revenue in the fourth quarter of  805 5 million  This reflected a 6  increase from the prior year period revenue total of  756 3 million  It also topped the consensus Wall Street revenue estimate of  800 9 million 
The company announced net income of  64 5 million  or  0 58 per share  based on generally accepted accounting principles  GAAP   In the prior year period  PerkinElmer posted GAAP net income of  71 3 million  or  0 64 per share 
PerkinElmer s adjusted earnings in Q4 came in at  1 35 per share  This was a 14  jump from the  1 18 per share reported in the fourth quarter of 2018  It was also a little better than the average analysts  adjusted earnings estimate of  1 33 per share 
Behind the numbers
The company s discovery and analytical solutions segment was its biggest winner in the fourth quarter  Sales for the segment increased by 8  year over year to  496 5 million 
PerkinElmer s diagnostics segment increased by 4  year over year to  309 million  The segment s organic growth  which excludes the impact of currency fluctuations  acquisitions  and divestitures  was slightly higher at 5  
While the company s year over year GAAP earnings decline might cause some eyebrows to raise  there s more to the story  This negative comparison was primarily due to debt extinguishment costs of  32 1 million in the fourth quarter of 2019  The adjusted earnings figure gives a better picture of the company s bottom line status 
CEO Prahlad Singh said   We are pleased with our strong finish to 2019   However  investors weren t quite as pleased  PerkinElmer shares fell by nearly 3  in after hours trading on Monday  spurred more by the company s outlook than its performance in the fourth quarter 
Looking ahead
The company expects that revenue for full year 2020 will be between  3 05 billion and  3 09 billion  The company anticipates GAAP earnings per share  EPS  of  2 89 to  2 99  with adjusted non GAAP EPS between  4 50 and  4 60 
For the first quarter of 2020  PerkinElmer is looking for revenue of  700 million  It also projects Q1 GAAP EPS from continuing operations of  0 33 with adjusted EPS of  0 70    lower than the consensus Wall Street adjusted EPS estimate of  0 84 
This year could be more volatile for healthcare stocks like PerkinElmer than in recent years because of the U S  presidential election  However  Singh stated that PerkinElmer s  rapid transformation we made as an organization over the past few years and in particular 2019 has put us in an excellent position to accelerate profitable growth and advance outcomes around the world in 2020 and beyond  ",2020-01-28,The Motley Fool,https://invst.ly/pnuxt,2069225
119466,340981,PKI,Sell siders weigh in on PerkinElmer after Q4 report,news,"PerkinElmer  PKI  2 7   is down on below average volume after reporting Q4 and full year results after the close yesterday  Earnings and revenue topped expectations  but soft 2020 guidance has dampened investor enthusiasm 
Jefferies  Brandon Couillard  Hold  105   Q1 and 2020 outlook appears achievable  Too early to tell if the coronavirus outbreak will trim the top line  China accounts for  20  of revenues  
Stifel s Daniel Arias  Buy  102   2020 guidance appears conservative 
JPMorgan s Tycho Peterson  Neutral  95   2020 guidance conservative  Coronavirus outbreak could be a risk to sales 
UBS s Daniel Brennan  Neutral  100   2020 guidance realistic instead of conservative ",2020-01-28,Seeking Alpha,https://invst.ly/pnyiv,2069528
119489,341004,PKI,PerkinElmer beats by  0 01  beats on revenue,news,PerkinElmer  NYSE PKI   Q3 EPS of  0 73 beats by  0 01 Revenue of  554 28M   7 7  Y Y  beats by  1 84M Shares  0 17  Press ReleaseNow read ,2017-11-02,Seeking Alpha,https://www.investing.com/news/stock-market-news/perkinelmer-beats-by-001-beats-on-revenue-763136,763136
119490,341005,PKI,PerkinElmer to acquire Aussie biotech RHS Limited,news,PerkinElmer  NYSE PKI  has agreed to acquire Adelaide  Australia based RHS Limited for   25 1M   0 28 per share  representing a 100  premium over RHS  February 23 closing price RHS develops single cell genomic technologies  One of its leading products is EmbryoCellect  a microarray used to detect whole chromosome aneuploidy  abnormal number of chromosomes  Now read ,2018-02-26,Seeking Alpha,https://www.investing.com/news/stock-market-news/perkinelmer-to-acquire-aussie-biotech-rhs-limited-1311193,1311193
119515,341030,PKI,U S  futures extend losses after jobless claims  Dow sheds 0 5 ,news,Investing com   U S  stock futures pointed to a lower open on Thursday  extending losses after official data showed that U S  jobless claims rose unexpectedly last week  while markets awaited speeches from Federal Reserve Chairman Ben Bernanke and President Barack Obama  Ahead of the open  the Dow Jones Industrial Average futures pointed to a loss of 0 5   the S P 500 futures indicated a decline of 0 6   while the Nasdaq 100 futures pointed to a 0 45  drop   Stock futures added to losses after official data showed that first time jobless claims rose by 2 000 to 414 000 last week  confounding expectations for a decline to 405 000  A separate report showed that the U S  trade deficit narrowed to USD44 8 billion in July  compared to expectations of USD51 0 billion deficit  Meanwhile  markets were awaiting a speech from Fed Chief Bernanke later in the day for any hints regarding further easing measures Later in the day  President Obama was to address a joint session of Congress  where he was expected to announce a USD300 billion stimulus package to bolster the U S  economy and spur job growth In earnings news  shares in the world s largest pork producer and processor Smithfield Foods jumped 2 9  after reporting a 7 6  increase in fiscal first quarter net income on 6 6  higher revenue   On the downside  shares in Pall Corporation  the world s largest manufacturer of filtration  separation  and purification products  dropped 2 5  after it lowered its earnings outlook for the fourth quarter  due to weakness in its industrial segment  Meanwhile  shares in diagnostics technologies company Caliper Life Sciences soared 41 5  after it agreed to be acquired by PerkinElmer in a deal valued at USD600 million    Other stocks in focus include technology bellwether Microsoft  which said it will unveil an early version of its Windows 8 operating system at its annual shareholder conference next Tuesday  Across the Atlantic  European stock markets pared gains after the European Central Bank kept its benchmark interest rate unchanged at 1 50   The EURO STOXX 50 rose 0 25   France s CAC 40 edged 0 1  higher  Germany s DAX dipped 0 1   while Britain s FTSE 100 was 0 05  lower                Also Thursday  the Bank of England left its benchmark interest rate on hold at 0 5  and kept its asset buying program unchanged at GBP200 billion Later in the day  the U S  was to release government data on crude oil inventories  natural gas stockpiles as well as a report on consumer credit ,2011-09-08,Investing.com,https://www.investing.com/news/stock-market-news/u.s.-futures-extend-losses-after-jobless-claims;-dow-sheds-0.5-223473,223473
119516,341031,PKI,US STOCKS Wall St dips after trade  jobless data,news,"  Initial jobless claims rise
   Obama  Bernanke speeches eyed
   Indexes off  S P 0 5 pct  Dow 0 2 pct  Nasdaq 0 3 pct
   For up to the minute market news see  STXNEWS US 
   Updates to early morning 
 By Chuck Mikolajczak
 NEW YORK  Sept 8  Reuters    U S  stocks slipped on
Thursday after data showed continued softness in the labor
market but a shrinking trade gap  ahead of a speech by U S 
President Barack Obama detailing his plan for jobs growth 
 Applications for unemployment benefits rose to 414 000 in
the week ended Sept  3 from an upwardly revised 412 000 in the
prior week  the Labor Department said 
 A separate report showed the trade deficit narrowed
considerably in July  a positive signal for growth in the third
quarter after a sluggish first half  For details  see
 ID nN1E7870A9 
  The trade balance was better than expected despite worse
jobless claims  so that could move up  gross domestic product 
estimates  and that is why we probably didn t go down more than
what we should have on the number   said Sam Ginzburg  head of
capital markets at First New York in New York 
 The Dow Jones industrial average  dropped 27 81
points  or 0 24 percent  to 11 387 05  The Standard   Poor s
500 Index  fell 5 46 points  or 0 46 percent  to
1 193 16  The Nasdaq Composite Index  shed 8 18 points 
or 0 32 percent  to 2 540 76 
 On the heels of the jobless data and last Friday s payrolls
report showing no jobs were created in August  Obama is
expected to propose tax cuts for the middle class and
businesses and new spending to repair roads  bridges and other
infrastructure  For details  see  ID nN1E786157 
 Federal Reserve Chairman Ben Bernanke will deliver a speech
on the U S  economic outlook to the Economic Club of Minnesota
at 1 30 p m  EDT  1730 GMT   but he is unlikely to outline new
measures to boost the economy   ID nN1E7860OB 
  I want to hear what Bernanke has to say  I want to hear
what Obama has to say  which in turn is going to make Friday 
for our market  a very interesting day   said Ginzburg 
 The European Central Bank signaled that its interest rate
rise cycle had been halted  saying euro zone inflation risks
were no longer skewed to the upside and economic growth would
be slow at best  European stocks were little changed  For ECB
story   ID nL5E7K80SP   for European stocks    EU 
 Caliper Life Sciences Inc  surged 41 4 percent to
 10 43 after a deal to be bought by PerkinElmer Inc  
PerkinElmer fell 3 2 percent to  21 35 
   Reporting by Chuck Mikolajczak  editing by Jeffrey Benkoe ",2011-09-08,Reuters,"https://www.investing.com/news/stock-market-news/us-stocks-wall-st-dips-after-trade,-jobless-data-223482",223482
119563,341078,PKI,PerkinElmer  PKI  Tops Q3 Earnings Estimates,opinion,"PerkinElmer  NYSE PKI  came out with quarterly earnings of  1 06 per share  beating the Zacks Consensus Estimate of  1 01 per share  This compares to earnings of  0 90 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 4 95   A quarter ago  it was expected that this maker of scientific instruments would post earnings of  1 01 per share when it actually produced earnings of  1  delivering a surprise of  0 99  
Over the last four quarters  the company has surpassed consensus EPS estimates three times 
PerkinElmer  which belongs to the Zacks Instruments   Scientific industry  posted revenues of  706 92 million for the quarter ended September 2019  missing the Zacks Consensus Estimate by 2 16   This compares to year ago revenues of  674 31 million  The company has topped consensus revenue estimates two times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
PerkinElmer shares have added about 12  since the beginning of the year versus the S P 500 s gain of 21 1  
What s Next for PerkinElmer 
While PerkinElmer has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for PerkinElmer was unfavorable  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  4  Sell  for the stock  So  the shares are expected to underperform the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  1 35 on  818 50 million in revenues for the coming quarter and  4 04 on  2 91 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Instruments   Scientific is currently in the bottom 30  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-10-30,Zacks Investment Research,https://www.investing.com/analysis/perkinelmer-pki-tops-q3-earnings-estimates-200480436,200480436
119565,341080,PKI,PerkinElmer  PKI  Q3 Earnings Beat Estimates  Revenues Miss,opinion,PerkinElmer  Inc    NYSE PKI   reported third quarter 2019 adjusted earnings per share  EPS  of  1 06  which beat the Zacks Consensus Estimate of  1 01 per share by 4 9   Moreover  the bottom line improved 17 8  from the year ago quarter Based in Waltham  MA  this leading MedTech company reported revenues of  706 9 million  up 4 8  from the year ago quarter and improved 5  organically  Adjusted revenues in the reported quarter came in at  707 1 million  up 4 8  year over year  However  the top line lagged the Zacks Consensus Estimate of   722 5 million by 2 2  Segment DetailsDASAt this segment  revenues totaled  426 9 million  reflecting an improvement of 5 1  from the year ago quarter  Organically  the segment grew 4  in the quarter under review  Per management  the third quarter performance was affected by soft performance in applied markets  However  solid show by life sciences contributed to organic revenues Coming to profits at the DAS segment  the company reported third quarter 2019 adjusted operating income of  86 2 million  up 26 8  from the year ago quarter Diagnostics segmentRevenues at this segment amounted to  280 million  up 4 4  on a year over year basis  Adjusted revenues in the segment totaled  280 2 million  up 4 4  from the prior year quarter  Organically  the segment improved 6  in the third quarter  Per management  the upside can be attributed to strength across reproductive health and immunodiagnostics business lines Adjusted operating income in the segment totaled  79 7 million  up 4 6  from the year ago quarter Geographical DetailsPer management  the major geographies witnessed a mixed third quarter  with low single digit organic revenue growth in the United States and mid single digit organic revenue growth in Asia Pacific  APAC  and Europe PerkinElmer  Inc  Price  Consensus and EPS Surprise    Margin AnalysisGross profit in the quarter came in at  342 3 million  up 3  year over year  Adjusted gross margin  as a percentage of revenues  was 51 7   up 70 bps year over year Adjusted operating income was  152 5 million  up 18 6  year over year Adjusted operating margin  as a percentage of revenues  was 21 6  in the quarter  up 250 bps Financial UpdateIn the third quarter  cash and cash equivalents came in at  392 9 million  which increased a whopping 161 9  sequentially During the reported quarter  net cash provided by operating activities came in at  106 7 million  up 14 5  from the year ago quarter 2019 Guidance RaisedPerkinElmer now expects 2019 adjusted EPS of  4 07 Acquisition UpdateThe company announced the buyout of Meizheng Group   a leading food safety testing company in China  The buyout is likely to strengthen PerkinElmer s food safety abilities in attractive markets  which includes pathogen  toxin and drug residue testing  Further  the acquisition is likely to bolster PerkinElmer s assay capabilities ConclusionPerkinElmer exited the third quarter on a mixed note  with EPS surpassing the consensus mark  while revenues missing the same  The company witnessed strong performances by its core Discover   Analytics Solutions and Diagnostics units in the quarter under review  Strength in reproductive health and immunodiagnostics business lines led to the impressive performance  Modest growth in international markets is also encouraging Further  expansion in operating margins buoys optimism  Solid show by Tulip and EUROIMMUN also paints a bright picture However  negative currency movements impacted the company s top line in the quarter under review  Furthermore  PerkinElmer continues to make acquisitions  which increases integration risks Zacks RankCurrently  PerkinElmer carries a Zacks Rank  3  Hold  Earnings of Other MedTech Majors at a GlanceSome better ranked stocks which reported solid results this earning season are Edwards Lifesciences   NYSE EW    Thermo Fisher Scientific Inc    NYSE TMO   and ResMed Inc    NYSE RMD    each carrying a Zacks Rank  2  Buy   You can see  Edwards Lifesciences delivered third quarter 2019 adjusted EPS of  1 41  outpacing the Zacks Consensus Estimate by 15 6   Third quarter net sales of  1 09 billion surpassed the Zacks Consensus Estimate by 5 5  Thermo Fisher delivered third quarter 2019 adjusted EPS of  2 94  which surpassed the Zacks Consensus Estimate by 2 1   Revenues of  6 27 billion outpaced the Zacks Consensus Estimate by 1 3  ResMed reported third quarter 2019 adjusted EPS of 93 cents  which beat the Zacks Consensus Estimate of 87 cents by 6 9   Revenues were  681 1 million  surpassing the Zacks Consensus Estimate by 3 6  Free  Zacks  Single Best Stock Set to Double Today you are invited to download our just released Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  Sheraz Mian hand picks one to have the most explosive upside of all This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible  Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain ,2019-10-30,Zacks Investment Research,https://www.investing.com/analysis/perkinelmer-pki-q3-earnings-beat-estimates-revenues-miss-200480691,200480691
119566,341081,PKI,PerkinElmer  PKI  Tops Q4 Earnings And Revenue Estimates,opinion,"PerkinElmer  NYSE PKI  came out with quarterly earnings of  1 35 per share  beating the Zacks Consensus Estimate of  1 32 per share  This compares to earnings of  1 18 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 2 27   A quarter ago  it was expected that this maker of scientific instruments would post earnings of  1 01 per share when it actually produced earnings of  1 06  delivering a surprise of 4 95  
Over the last four quarters  the company has surpassed consensus EPS estimates three times 
PerkinElmer  which belongs to the Zacks Instruments   Scientific industry  posted revenues of  805 50 million for the quarter ended December 2019  surpassing the Zacks Consensus Estimate by 0 44   This compares to year ago revenues of  756 35 million  The company has topped consensus revenue estimates two times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
PerkinElmer shares have added about 2 8  since the beginning of the year versus the S P 500 s gain of 2  
What s Next for PerkinElmer 
While PerkinElmer has outperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for PerkinElmer was favorable  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  2  Buy  for the stock  So  the shares are expected to outperform the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  0 88 on  702 27 million in revenues for the coming quarter and  4 63 on  3 08 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Instruments   Scientific is currently in the top 6  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2020-01-27,Zacks Investment Research,https://www.investing.com/analysis/perkinelmer-pki-tops-q4-earnings-and-revenue-estimates-200501959,200501959
119606,341121,PKI,PerkinElmer  PKI  Down 9 2  Since Last Earnings Report  Can It Rebound ,opinion,"A month has gone by since the last earnings report for PerkinElmer  NYSE PKI   Shares have lost about 9 2  in that time frame  underperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is PerkinElmer due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important drivers  PerkinElmer Beats on Q1 Earnings  Hikes  19 GuidancePerkinElmer  Inc  reported first quarter 2019 adjusted earnings per share  EPS  of 69 cents which outpaced the Zacks Consensus Estimate by 4 5   The bottom line rose 9 5  from the year ago quarter Based in Waltham  MA  this leading MedTech company reported revenues of  648 7 million  up 0 7  from the year ago quarter and improved 5  organically  Adjusted revenues in the quarter came in at  648 9 million  up 0 7  year over year  Notably  the top line beat the Zacks Consensus Estimate of  644 million Segment DetailsDASAt this segment  revenues totaled  388 8 million  reflecting a decrease of 1 9  from the year ago quarter  Organically  the segment grew 2  in the quarter under review  Per management  the first quarter performance was impacted by several unique timing items  However  solid show by pharma biotech end market contributed to organic revenue growth Coming to profits at the DAS segment  the company reported first quarter 2019 adjusted operating income of  54 3 million  down 6 1  from the year ago quarter Diagnostics segmentRevenues at this segment amounted to  259 9 million  up 5 1  on a year over year basis  Adjusted revenues in the segment totaled  260 1 million  up 5  from the prior year quarter  Organically  the segment grew 9  in the first quarter Adjusted operating income in the segment totaled  66 million  up significantly by 25 2  year over year  Per management  the upside can be attributed to strength across reproductive health  applied genomics and immunodiagnostics business Geographical DetailsPer management s expectations  the major geographies witnessed a mixed first quarter  with high single digit organic revenue growth in the United States and mid single digit organic revenue growth in Asia Pacific  APAC   This was partially offset by a low single digit organic revenue decrease in Europe  Organic revenue growth in China came in high single digits  excluding the impact of lost revenues due to the U S  Government shutdown  Margin AnalysisGross profit in the quarter came in at  323 1 million  up 3 1  year over year  Adjusted gross margin  as a percentage of revenues  was 49 8   up 120 bps year over year Adjusted operating margin was  105 2 million  up 9 7  year over year  Adjusted operating margin  as a percentage of revenues  was 16 2  in the quarter  up 130 bps 2019 Guidance RaisedPerkinElmer expects 2019 adjusted EPS in the range of  4 02  4 07  up from the previously guided range of  4 00  4 05  Notably  the Zacks Consensus Estimate of  4 03 lies within the guided range Acquisition UpdateIn the first quarter  the company announced the buyout of Cisbio Bioassays   a leading custom assay service provider  The addition of Cisbio strengthens PerkinElmer s position in life sciences and diagnostics markets 
How Have Estimates Been Moving Since Then 
Fresh estimates followed a downward path over the past two months 
VGM Scores
At this time  PerkinElmer has a poor Growth Score of F  however its Momentum Score is doing a lot better with a B  However  the stock was allocated a grade of D on the value side  putting it in the bottom 40  for this investment strategy 
Overall  the stock has an aggregate VGM Score of D  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
PerkinElmer has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-05-24,Zacks Investment Research,https://www.investing.com/analysis/perkinelmer-pki-down-92-since-last-earnings-report-can-it-rebound-200425117,200425117
119607,341122,PKI,PerkinElmer  PKI  Misses Q2 Earnings And Revenue Estimates,opinion,"PerkinElmer  NYSE PKI  came out with quarterly earnings of  1 per share  missing the Zacks Consensus Estimate of  1 01 per share  This compares to earnings of  0 91 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of  0 99   A quarter ago  it was expected that this maker of scientific instruments would post earnings of  0 66 per share when it actually produced earnings of  0 69  delivering a surprise of 4 55  
Over the last four quarters  the company has surpassed consensus EPS estimates two times 
PerkinElmer  which belongs to the Zacks Instruments   Scientific industry  posted revenues of  722 52 million for the quarter ended June 2019  missing the Zacks Consensus Estimate by 1 06   This compares to year ago revenues of  703 36 million  The company has topped consensus revenue estimates two times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
PerkinElmer shares have added about 21  since the beginning of the year versus the S P 500 s gain of 20 7  
What s Next for PerkinElmer 
While PerkinElmer has outperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for PerkinElmer was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  1 02 on  724 38 million in revenues for the coming quarter and  4 05 on  2 92 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Instruments   Scientific is currently in the top 14  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-07-29,Zacks Investment Research,https://www.investing.com/analysis/perkinelmer-pki-misses-q2-earnings-and-revenue-estimates-200446672,200446672
119608,341123,PKI,Why Is PerkinElmer  PKI  Down 8 4  Since Last Earnings Report ,opinion,"It has been about a month since the last earnings report for PerkinElmer  NYSE PKI   Shares have lost about 8 4  in that time frame  underperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is PerkinElmer due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important catalysts  PerkinElmer Q2 Earnings and Revenues Miss EstimatesPerkinElmer reported second quarter 2019 adjusted earnings per share  EPS  of  1  which missed the Zacks Consensus Estimate of  1 01 per share by 0 9   However  the bottom line improved 9 9  from the year ago quarter Based in Waltham  MA  this leading MedTech company reported revenues of  722 5 million  up 2 7  from the year ago quarter and improved 5  organically  Adjusted revenues in the quarter came in at  722 7 million  up 2 7  year over year  However  the top line lagged the Zacks Consensus Estimate of   730 3 million by 1 1  Segment DetailsDASAt this segment  revenues totaled  434 million  reflecting an improvement of 0 8  from the year ago quarter  Organically  the segment grew 2  in the quarter under review  Per management  the second quarter performance was affected by soft performance in applied markets  However  solid show by life sciences contributed to organic revenue growth Coming to profits at the DAS segment  the company reported second quarter 2019 adjusted operating income of  81 5 million  up 6 7  from the year ago quarter Diagnostics segmentRevenues at this segment amounted to  288 6 million  up 5 8  on a year over year basis  Adjusted revenues in the segment totaled  288 7 million  up 5 8  from the prior year quarter  Organically  the segment grew 9  in the second quarter  Per management  the upside can be attributed to strength across reproductive health  and immunodiagnostics business lines Adjusted operating income in the segment totaled  79 7 million  up 3 2  from the year ago quarter Geographical DetailsPer management  the major geographies witnessed a mixed second quarter  with high single digit organic revenue growth in the United States  mid single digit organic revenue growth in Asia Pacific  APAC  and low single digit organic revenue growth in Europe Margin AnalysisGross profit in the quarter came in at  347 8 million  up 2 2  year over year  Adjusted gross margin  as a percentage of revenues  was 51   down 30 bps year over year Adjusted operating margin was  146 million  up 5 6  year over year  Adjusted operating margin  as a percentage of revenues  was 20 2  in the quarter  up 50 bps Financial UpdateIn the second quarter  cash and cash equivalents came in at  150 million  down 8  from that of 2018 end level During the reported quarter  net cash provided by operating activities stood at  46 9 million  down 35 8  from the year ago quarter 2019 Guidance ReiteratedPerkinElmer continues to expect 2019 adjusted EPS in the range of  4 02  4 07  Notably  the Zacks Consensus Estimate of  4 05 lies within the guided range 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in estimates review 
VGM Scores
Currently  PerkinElmer has an average Growth Score of C  a grade with the same score on the momentum front  Following the exact same course  the stock was allocated a grade of C on the value side  putting it in the middle 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of C  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of these revisions indicates a downward shift  Notably  PerkinElmer has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-08-27,Zacks Investment Research,https://www.investing.com/analysis/why-is-perkinelmer-pki-down-84-since-last-earnings-report-200459356,200459356
119646,341161,PKI,PerkinElmer  PKI  Reports Next Week  Wall Street Expects Earnings Growth,opinion,"The market expects PerkinElmer  NYSE PKI  to deliver a year over year increase in earnings on higher revenues when it reports results for the quarter ended March 2019  This widely known consensus outlook is important in assessing the company s earnings picture  but a powerful factor that might influence its near term stock price is how the actual results compare to these estimates 
The earnings report  which is expected to be released on April 25  2019  might help the stock move higher if these key numbers are better than expectations  On the other hand  if they miss  the stock may move lower 
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management s discussion of business conditions on the earnings call  it s worth handicapping the probability of a positive EPS surprise 
Zacks Consensus Estimate
This maker of scientific instruments is expected to post quarterly earnings of  0 66 per share in its upcoming report  which represents a year over year change of  4 8  
Revenues are expected to be  644 45 million  up 0 1  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  Our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction     has this insight at its core 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for PerkinElmer 
For PerkinElmer  the Most Accurate Estimate is higher than the Zacks Consensus Estimate  suggesting that analysts have recently become bullish on the company s earnings prospects  This has resulted in an Earnings ESP of  2 64  
On the other hand  the stock currently carries a Zacks Rank of  3 
So  this combination indicates that PerkinElmer will most likely beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
While calculating estimates for a company s future earnings  analysts often consider to what extent it has been able to match past consensus estimates  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that PerkinElmer would post earnings of  1 16 per share when it actually produced earnings of  1 18  delivering a surprise of  1 72  
Over the last four quarters  the company has beaten consensus EPS estimates three times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
PerkinElmer appears a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-04-17,Zacks Investment Research,https://www.investing.com/analysis/perkinelmer-pki-reports-next-week-wall-street-expects-earnings-growth-200408385,200408385
119647,341162,PKI,Can Diagnostic Revenues Fuel PerkinElmer s  PKI  Q1 Earnings ,opinion,"PerkinElmer  Inc    NYSE PKI   is expected to release first quarter 2019 results on Apr 25  after market close  The quarterly results are expected to reflect steady growth in the core Diagnostics business  Foreign exchange headwinds are also likely to show on results PerkinElmer has an average positive earnings surprise of 2 2  for the last four quarters Which Way Are Estimates Treading For the quarter to be reported  the Zacks Consensus Estimate for earnings per share is pegged at 66 cents  suggesting a 4 8  improvement year over year  The same for revenues stands at  644 5 million  indicating growth of 0 1  Let s see how things are shaping up before the earnings results PerkinElmer  Inc  Price and EPS Surprise
    Diagnostics Revenues  A Key CatalystWe expect PerkinElmer s Diagnostics segment to be a major driver for first quarter 2019 results  Notably  the company s immunodiagnostics and applied genomics business lines are key contributors to Diagnostics revenues Per management  the acquisitions of Tulip  Bioo Scientific  RHS and EUROIMMUN have broadened the segment s services  PerkinElmer is now providing services in reproductive health  emerging infectious diseases  autoimmune diseases and applied genomics which are expected to show on the quarter to be reported results Additionally  the CE IVD marking of the Vanadis product in the recent past is likely to widen accessibility to noninvasive prenatal screening for more women in the upcoming quarter Reflective of these  the Zacks Consensus Estimate for the segment s first quarter revenues stands at  258 million  indicating a rise of 4 5  year over year Other Factors at PlayManagement at PerkinElmer is optimistic about product introductions in the areas of imaging  reagents and software  which might contribute to the results for the quarter to be reported  The company continues to expand its value added services and IT offerings through the addition of new tools  solutions and capabilities  This expanded product portfolio is expected to aid results in the quarter to be reported Apart from acquisitions in the Diagnostics business  PerkinElmer is optimistic about the buyouts of Dani Analitica and China based Spectrum Instruments  These acquisitions are expected to expand PerkinElmer s footprint and technical capabilities in the core gas chromatography market  Additionally  PerkinElmer s EUROIMMUN buyout has continued to be accretive and management foresees bigger opportunities ahead However  PerkinElmer expects a headwind of  1 million or less in the coming quarters from China  Tariffs in the Discovery   Analytical Solutions unit are likely to be at the high end since the company exports products from the United States to China In fact  the Zacks Consensus Estimate for the segment s first quarter revenues stands at  387 million  down 2 5  year over year Additionally  PerkinElmer expects foreign exchange to affect first quarter 2019 results by approximately  27 million Despite the headwinds  PerkinElmer is well positioned on strength in Diagnostics business and acquisitions for the quarterly results What Does Our Model Say Per our proven model  a stock needs to have a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to deliver a positive earnings surprise  This is precisely the case here Earnings ESP  PerkinElmer has an Earnings ESP of  2 64   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  PerkinElmer carries a Zacks Rank  3 Please note that we caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into the earnings announcement  especially when the company is seeing negative estimate revision Other Stocks Worth a LookHere are a few other medical stocks worth considering as they also have the right combination of elements to post an earnings beat this quarter Cardinal Health   NYSE CAH   has an Earnings ESP of  1 13  and a Zacks Rank  3 Stryker Corporation   NYSE SYK   has an Earnings ESP of  0 63  and a Zacks Rank  3 Medidata Solutions   NASDAQ MDSO   has an Earnings ESP of  12 31  and a Zacks Rank  3 Is Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ",2019-04-22,Zacks Investment Research,https://www.investing.com/analysis/can-diagnostic-revenues-fuel-perkinelmers-pki-q1-earnings-200409023,200409023
119672,341187,PKI,PerkinElmer  PKI  Earnings Expected To Grow  What To Know Ahead Of Next Week s Release,opinion,"Wall Street expects a year over year increase in earnings on higher revenues when PerkinElmer  NYSE PKI  reports results for the quarter ended December 2018  While this widely known consensus outlook is important in gauging the company s earnings picture  a powerful factor that could impact its near term stock price is how the actual results compare to these estimates 
The stock might move higher if these key numbers top expectations in the upcoming earnings report  which is expected to be released on January 31  On the other hand  if they miss  the stock may move lower 
While management s discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations  it s worth having a handicapping insight into the odds of a positive EPS surprise 
Zacks Consensus Estimate
This maker of scientific instruments is expected to post quarterly earnings of  1 16 per share in its upcoming report  which represents a year over year change of  19 6  
Revenues are expected to be  746 15 million  up 16 3  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 0 55  lower over the last 30 days to the current level  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  This insight is at the core of our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction  
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is subject to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for PerkinElmer 
For PerkinElmer  the Most Accurate Estimate is higher than the Zacks Consensus Estimate  suggesting that analysts have recently become bullish on the company s earnings prospects  This has resulted in an Earnings ESP of  0 77  
On the other hand  the stock currently carries a Zacks Rank of  3 
So  this combination indicates that PerkinElmer will most likely beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that PerkinElmer would post earnings of  0 92 per share when it actually produced earnings of  0 90  delivering a surprise of  2 17  
Over the last four quarters  the company has beaten consensus EPS estimates three times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
PerkinElmer appears a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-01-23,Zacks Investment Research,https://www.investing.com/analysis/perkinelmer-pki-earnings-expected-to-grow-what-to-know-ahead-of-next-weeks-release-200378931,200378931
119701,341216,PKI,Can Diagnostic Revenues Drive PerkinElmer  PKI  Q1 Earnings ,opinion,"PerkinElmer  Inc  s   NYSE PKI   first quarter 2018 results  expected to release on Apr 30 after market close  are likely to show steady growth in the core Diagnostics business  While this might prove to be a major driver  declining revenues in all other segments might mar overall results In the fourth quarter of fiscal 2017  the company reported adjusted earnings of 97 cents per share  beating the Zacks Consensus Estimate of 94 cents  Meanwhile  revenues were approximately  641 6 million  which beat the Zacks Consensus Estimate of  617 million  Revenues also surpassed the year ago quarter s  567 million Notably  for the first quarter  the Zacks Consensus Estimate for earnings is pegged at 61 cents  reflecting year over year growth of 10 9   The same for revenues is pinned at  615 86 million  indicating 19 8  growth PerkinElmer delivered an average positive earnings surprise of 1 6  for the trailing four quarters PerkinElmer  Inc  Price and EPS Surprise
    Let s dig deeper Diagnostics Revenues in FocusDiagnostic revenues accounted for 30 1  of total revenues in the last quarter  Revenues in the segment rose to  193 4 million  up 23 3  from  193 4 million a year ago  This also reflects an improvement of 6  organically  The segment has been fortifying the company s market position in terms of exclusiveness of services in the respective markets For the Diagnostics market  the company offers products that are used to detect genetic disorders  PerkinElmer also provides digital x ray flat panel detectors and infectious disease testing solutions in its Diagnostics portfolio  The first quarter results are likely to indicate strong growth in the Diagnostic revenues In the last reported quarter  operating profit margin for the segment  as a percentage of revenues  was 30 8   up 20 basis points  bps  year over year It is also encouraging to note that the Zacks Consensus Estimate for the Diagnostics segment is at  235 million  up 21 5  sequentially Other Factors at PlayEUROIMMUN Buyout  A PositiveThe divestment of medical imaging business and the acquisition of EUROIMMUN Medical Laboratory Diagnostics AG have been major drivers for the segment  PerkinElmer announced the completion of the EUROIMMUN buyout for approximately  1 3 billion in cash in December 2017  EUROIMMUN is an autoimmune testing company and an emerging player in the infectious disease and allergy testing space Per management  the EUROIMMUN buyout has expanded PerkinElmer s capabilities and helped it gain considerable traction  It has led to an increase in Diagnostics employees by more than 3000  strengthening the company s R D platform  The company is optimistic about increasing its R D spending by 30  in 2018 from 2017 which is likely to account for 8 7  of product revenues In the fourth quarter  EUROIMMUN contributed revenues of approximately  360 million  representing growth of 13 15   It is also likely to add 100 bps to PerkinElmer s organic growth Discovery   Analytical Solutions  DAS Revenues from DAS totaled  448 2 million in the fourth quarter  up 9 3  from  409 9 million in the year ago quarter  PerkinElmer has been focusing on finalizing the organizational changes associated with the life sciences business under DAS Lately  the company has collaborated with Helix to develop and commercialize exome sequencing based tests that will help consumers take proactive health management decisions However  the Zacks Consensus Estimate for revenues is at  381 million  down 15  sequentially Guidance SolidThe company issued adjusted earnings guidance for 2018  Adjusted earnings are expected at  3 50 a share  Further  it expects reported revenues in the range of  2 72  2 74 billion  which includes approximately  25 million in foreign exchange tailwinds and around  360 million from EUROIMMUN  PerkinElmer projects 5 6  organic revenue growth for 2018 Thus  PerkinElmer is confident about improving growth trajectory in the first quarter Our quantitative model shows an earnings beat for PerkinElmer this quarter  This is because a stock needs to have a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to be able to beat estimates Zacks ESP  Earnings ESP for PerkinElmer is  0 52   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  PerkinElmer carries a Zacks Rank  3  A favorable Zacks Rank increases the predictive power of ESP Stocks Worth a LookHere are a few medical stocks worth considering as they have the right combination of elements to post earnings beats this quarter Stryker Corporation   NYSE SYK   has an Earnings ESP of  0 13  and a Zacks Rank  2  You can see  Hologic  Inc    NASDAQ HOLX   has an Earnings ESP of  0 94  and a Zacks Rank  3 Edwards Lifesciences   NYSE EW   has an Earnings ESP of  0 99  and a Zacks Rank  3 The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-04-18,Zacks Investment Research,https://www.investing.com/analysis/can-diagnostic-revenues-drive-perkinelmer-pki-q1-earnings-200306866,200306866
119702,341217,PKI,5 Trade Ideas For Monday  GDOT  OXY  PKI  PYPL  USM,opinion,"Green Dot Corporation  NYSE GDOT 
Green Dot   GDOT  had been moving steadily higher until the end of September  Since the calendar turned to October it has fallen back and comes into the week near the 200 day SMA  The RSI is oversold and started to turn up Friday while the MACD is falling  A bounce Monday gives a reason to participate to the upside   
Occidental Petroleum Corporation  NYSE OXY 
Occidental Petroleum   OXY  rose up from a March low and ran to a high in May  It consolidated there for over 3 months before pulling back into august  More consolidation was followed by a push back higher into the end of September  But that failed at a lower high and it is now back at support and the 200 day SMA  The RSI is turning back up and the MACD falling and now negative  Look for a push back higher to participate to the upside   
PerkinElmer Inc  NYSE PKI 
PerkinElmer   PKI  started higher in July out of consolidation  It continued to a top at the end of September before pulling back  Friday it showed signs of a reversal as it reached the August low and neared the 100 day SMA  The RSI has turned back up after being oversold and the MACD is falling and negative  Look for continuation to participate higher   
PayPal Holdings Inc  NASDAQ PYPL 
PayPal   PYPL  made a top in September and then started to roll lower  It continued through the 200 day SMA last week  finally finding support Thursday and bouncing  The RSI also bounced out of oversold territory with the MACD starting to level  Look for continuation to the upside to participate higher   
United States Cellular Corporation  NYSE USM 
United States Cellular   USM  rose from a low in July  into consolidation through August and September  It then started higher again and is consolidating again  The RSI is rising and bullish with the MACD moving higher  Look for continuation to participate to the upside   
Up Next  Bonus Idea
Elsewhere look for Gold to rise in the short term while Crude Oil pulls back in its uptrend  The US Dollar Index continues to mark time sideways while US Treasuries are bouncing in their downtrend  The Shanghai Composite looks weak as it makes 4 year lows and Emerging Markets may be ready to reverse their downtrend 
Volatility looks to remain elevated keeping the bias lower for the equity index ETF s SPY  NYSE SPY   IWM and QQQ  Their charts show short term trend changes to the downside and are close to longer term trend changes as well  The IWM is now over 11  off its high and looking the worst  while the QQQ has bounced after dropping more than 10   The SPY also bounced  after a smaller 8  pullback  Use this information as you prepare for the coming week and trad em well 
The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my Disclaimer page for my full disclaimer 
Original post",2018-10-15,Gregory W. Harmon,https://www.investing.com/analysis/5-trade-ideas-for-monday-green-dot-occidental-petroleum-perkinelmer-paypal-200348358,200348358
119703,341218,PKI,What s In Store For Cardinal Health s  CAH  Q1 Earnings ,opinion,"Cardinal Health  Inc  s   NYSE CAH   first quarter fiscal 2019 results are scheduled for release on Nov 8  before market opens  While results are likely to show impressive growth in the core Pharmaceutical segment  headwinds in the Medical Gloves sub segment are likely to mar prospects Fiscal Q4 Results at a GlanceIn the last reported quarter  Cardinal Health reported adjusted earnings of  1 01 per share  beating the Zacks Consensus Estimate of 93 cents  Adjusted earnings declined 22 9  year over year Revenues increased 7 2  on a year over year basis to  35 35 billion and beat the Zacks Consensus Estimate of  34 55 billion Cardinal Health has an average positive earnings surprise of 5 9  for the trailing four quarters Which Way Are Estimates Treading For the quarter to be reported  the Zacks Consensus Estimate for earnings is pegged at  1 06 per share  reflecting a decline of 2 8  year over year  The same for revenues is pinned at  33 54 billion  indicating growth of 2 8  from the year ago quarter Cardinal Health  Inc  Price and EPS Surprise
    Let s see how things are shaping up prior to the earnings release Pharmaceutical to Drive Fiscal Q1Cardinal Health s Pharmaceutical segment is the second largest pharmaceutical distributor in the United States and the largest nuclear pharmacy  Its products and services include pharmaceutical distribution  manufacturer and specialty services  and nuclear and pharmacy services In the last reported quarter  the segment accounted for 89  of net sales  Revenues at the segment increased 6 4  to  31 46 billion on a year over year basis  However  Pharmaceutical witnessed an 18  decline in profits to  416 million  thanks to generic pharmaceutical pricing However  it is encouraging to note that  for the quarter to be reported  the Zacks Consensus Estimate for the unit s revenues stands at  29 85 billion  reflecting a year over year rise of 3 2  Other Factors at PlayCardinal Health expects to see notable contributions from its Medical unit  For investors  notice  the segment manufactures products such as single use surgical drapes  gowns and apparel  exam and surgical gloves  etc  In the last reported quarter  the unit contributed 11  to net sales  Sales at the segment improved 14 1  year over year to  3 90 billion For the quarter to be reported  the Zacks Consensus Estimate is pinned at  3 98 billion  showing a year over year improvement of 6 9  However  the company has been facing challenges in the exam glove sub segment  In the last reported quarter  commodity pricing and supply disruptions created headwinds in the exam glove unit  For fiscal 2019  management has lower expectations for the Medical segment due to headwinds in the exam gloves segment  which is concerning What Does Our Model Say Per our proven model  a stock needs to have a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to deliver a positive earnings surprise in the quarter  However  this is not the case here Earnings ESP  Cardinal Health has an Earnings ESP of  0 63   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Cardinal Health carries a Zacks Rank  4  Sell  Please note that we caution against stocks with a Zacks Rank  4 or 5  Strong Sell  going into the earnings announcement  especially when the company is seeing negative estimate revision Stocks Worth a LookHere are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter PerkinElmer   NYSE PKI   has an Earnings ESP of  1 45  and a Zacks Rank  3 Quidel Corporation   NASDAQ QDEL   has an Earnings ESP of  10 55  and a Zacks Rank  3  You can see  Weight Watchers International   NASDAQ WTW   has an Earnings ESP of  3 29  and a Zacks Rank  3 3 Medical Stocks to Buy NowThe greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ",2018-10-30,Zacks Investment Research,https://www.investing.com/analysis/whats-in-store-for-cardinal-healths-cah-q1-earnings-200352476,200352476
119704,341219,PKI,PerkinElmer  PKI  Lags Q3 Earnings And Revenue Estimates,opinion,"PerkinElmer  NYSE PKI  came out with quarterly earnings of  0 90 per share  missing the Zacks Consensus Estimate of  0 92 per share  This compares to earnings of  0 73 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of  2 17   A quarter ago  it was expected that this maker of scientific instruments would post earnings of  0 86 per share when it actually produced earnings of  0 91  delivering a surprise of 5 81  
Over the last four quarters  the company has surpassed consensus EPS estimates three times 
PerkinElmer  which belongs to the Zacks Instruments   Scientific industry  posted revenues of  674 31 million for the quarter ended September 2018  missing the Zacks Consensus Estimate by 0 02   This compares to year ago revenues of  554 28 million  The company has topped consensus revenue estimates three times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
PerkinElmer shares have added about 17 2  since the beginning of the year versus the S P 500 s gain of 0 3  
What s Next for PerkinElmer 
While PerkinElmer has outperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for PerkinElmer was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  1 19 on  759 31 million in revenues for the coming quarter and  3 65 on  2 78 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Instruments   Scientific is currently in the top 44  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2018-10-31,Zacks Investment Research,https://www.investing.com/analysis/perkinelmer-pki-lags-q3-earnings-and-revenue-estimates-200352692,200352692
119705,341220,PKI,PerkinElmer s Vanadis NIPT CE Mark Boosts Prenatal Prospects,opinion,PerkinElmer  Inc    NYSE PKI   recently announced CE IVD mark for commercialization and distribution of its Vanadis NIPT  non invasive prenatal testing  system throughout Europe and countries that recognize the marking  However  Vanadis NIPT is not available for clinical use in the United States yet The latest development is likely to fortify PerkinElmer s hold in the global non invasive prenatal testing market Following the announcement  shares of PerkinElmer rose 0 3  to  82 76 at close  Over the past year  shares of PerkinElmer have rallied 12 6  against the  s 5 7  decline  The current level is also higher than the S P 500 index s 1  rise The stock carries a Zacks Rank  3  Hold  More on Vanadis NIPTVanadis NIPT enables pregnant women to receive reliable and accurate cell free DNA based screenings through a cost efficient method  The non invasive system provides screening results for trisomy 21  trisomy 18 and trisomy 13 The company has also collaborated with Women   Infants Hospital of Rhode Island to evaluate an innovative test method using Vanadis NIPT For investors  notice  Sweden based Vanadis Diagnostics was acquired by PerkinElmer in 2016  with a view to improve maternal and fetal health offerings A Peek Into NIPT MarketMarketsandMarkets opines that the global NIPT market is expected to reach  2 88 billion by 2021 at a CAGR of 16 4   Growing preference for non invasive techniques over invasive methods  rising focus on reimbursement for NIPT and launch of advanced NIPT products are fueling growth Hence the regulatory approval has been a well timed one for the Massachusetts based provider of scientific instruments Some key players in the space who deserve mention are Illumina   NASDAQ ILMN   and Natera   NASDAQ NTRA    Notably  Illumina s VeriSeq NIPT Solution and Natera s Panorama next generation NIPT are currently much in demand A Key PickA better ranked stock in the broader medical space is Veeva Systems   NYSE VEEV   Veeva Systems  long term earnings growth rate is estimated at 19 3   The stock carries a Zacks Rank  2  Buy   You can see  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-11-26,Zacks Investment Research,https://www.investing.com/analysis/perkinelmers-vanadis-nipt-ce-mark-boosts-prenatal-prospects-200362644,200362644
119706,341221,PKI,PerkinElmer  PKI  Up 5 9  Since Last Earnings Report  Can It Continue ,opinion,"A month has gone by since the last earnings report for PerkinElmer  NYSE PKI   Shares have added about 5 9  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is PerkinElmer due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important drivers  PerkinElmer Misses Q3 Earnings Estimates  Gains from EUROIMMUNPerkinElmer reported third quarter 2018 adjusted earnings per share of 90 cents  missing the Zacks Consensus Estimate by 2 2   However  earnings per share rose 23 3  from the year ago quarter The company reported revenues of  674 3 million  which also missed the Zacks Consensus Estimate by 0 02   Revenues grew 21 7  on a year over year basis Adjusted revenues came in at  674 5 million  which saw a year over year rise of 21 6  Segment DetailsDiscovery   Analytical Solutions  DAS Revenues in the segment totaled  406 2 million  reflecting a 5 4  rise from the year ago quarter  Per management  the segment saw organic growth of 7  in the reported quarter The growth reflects strength in both life sciences and applied end markets  Life sciences strength was driven by continued performance in the pharma biotech end market  Notably  PerkinElmer s new in vivo imaging products launched in late 2017 has been a key driver of DAS Coming to profits at the DAS segment  the company reported third quarter 2018 adjusted operating income of  68 million  up from 10 1  from the year ago quarter Diagnostics segmentRevenues were  268 1 million  up a whopping 58 8  on a year over year basis  Adjusted revenues in the segment totaled  268 3 million  up 58 7  from the prior year quarter  On an organic basis  revenues shot up 8  Per management  growth was mainly driven by the company s immunodiagnostics and applied genomics business lines  Acquisitions of Tulip and Haoyuan have also been key driving factors Adjusted operating income in the segment totaled  76 2 million  up 36  from the third quarter of 2017 Geographical DetailsIn the quarter under review  PerkinElmer s revenues saw healthy growth in all geographies with double digit organic revenue growth in Asia  high single digit organic revenue growth in the United States and low single digit organic revenue growth in Europe In Asia  the company saw strong organic growth in China and India  For EUROIMMUN  high incidence rates and incremental global customer wins helped China as well as Germany experience organic revenue growth of low double digits Margin AnalysisAdjusted gross profit in the quarter came in at  344 1 million  up 24 5  year over year  Adjusted gross margin  as a percentage of revenues  was 51  in the quarter  up 120 basis points  bps  year over year Adjusted operating income came in at  128 6 million  up 22 2  year over year  Adjusted operating margin  as a percentage of revenues  was 19 1  in the quarter  up 10 bps GuidanceFor 2018  PekinElmer expects adjusted EPS at  3 60  down from the previously guided figure of  3 65  Notably  the Zacks Consensus Estimate is pegged at  3 65  above the projected figure However  management expects core organic revenue growth of 6 5   This includes EUROIMMUN sales of approximately  364 million  The Zacks Consensus Estimate stands at  2 78 billion Notably  management continues to expect approximately 15  organic revenue growth from EUROIMMUN in 2018 For the fourth quarter of 2018  management forecasts reported revenues of  745 million  representing 16  year over year growth  The Zacks Consensus Estimate is pegged at  759 3 million  above the guided figure The guidance assumes approximately 5  core organic revenue growth   102 million in sales from EUROIMMUN EPS in the fourth quarter is predicted at  1 16 for the fourth quarter  which represents a 20  year over year rise  The Zacks Consensus Estimate is pinned at  1 19  above the projected figure This forecast includes an additional 4 cent headwind from foreign exchange 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates 
VGM Scores
At this time  PerkinElmer has an average Growth Score of C  though it is lagging a bit on the Momentum Score front with a D  Following the exact same course  the stock was allocated a grade of D on the value side  putting it in the bottom 40  for this investment strategy 
Overall  the stock has an aggregate VGM Score of D  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of these revisions indicates a downward shift  Notably  PerkinElmer has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2018-11-29,Zacks Investment Research,https://www.investing.com/analysis/perkinelmer-pki-up-59-since-last-earnings-report-can-it-continue-200363997,200363997
119731,341246,PKI,Orthofix To Buy Spinal Kinetics  Widens Spine Fixation Suite,opinion,Orthofix International N V    NASDAQ OFIX   recently inked a definitive agreement to buy Spinal Kinetics Inc  The buyout is in line with the company s aim to strengthen foothold in the  5 4 billion U S  spine hardware market Spinal Kinetics is a privately held developer and manufacturer of artificial cervical and lumbar discs Post the completion of the deal  Orthofix will expand its Spine Fixation portfolio through the addition of Spinal Kinetics  CE Marked M6 artificial discs  Notably  the M6 artificial disc is capable of mirroring the natural motion of the spine and is  therefore  preferred by many surgeons However  the M6 artificial discs are yet to receive FDA approvals  Notably  Spinal Kinetics has already filed for a Pre Market Approval  PMA  with the FDA for treating single level cervical degenerative disc disease  DDD  using the M6 C cervical disc Financial DetailsOn fulfillment of certain customary conditions  the deal is expected to be closed in second quarter 2018  Per the terms of the agreement  Orthofix is liable to pay  45 million in cash closing consideration along with certain contingent milestone payments  In this regard  the company will pay up to  60 million to Spinal Kinetics on achieving targets like FDA approval for the M6 C cervical disc along with reaching  30 million and  50 million of trailing 12 month sales targets Moreover  the buyout is likely to contribute to the top line in 2018  For 2019  the company projects organic revenue growth rate to rise  courtesy of the deal  Further  within 12 months of the PMA approval receipt in the United States  Orthofix expects the acquisition to be accretive to the adjusted earnings per share and EBITDA   Spine Fixation SBU at a GlanceOrthofix s Spine Fixation strategic business unit  SBU  manufactures and distributes a wide range of implant products used in surgical procedures  The company continues to witness impressive top line contributions from the unit  In the last quarter  the segment saw 13 5   up 13 2  at constant exchange rate  growth over the year ago quarter  This uptick can be attributed to new product launches and the adopted strategic initiatives In February 2018  Orthofix announced the 510 k  clearance receipt and the limited launch of the FORZA XP Expandable Spacer System in the United States  Continuing with these developments  the company is satisfied with the progress in IDE clinical trials focused on using pulse electromagnetic field technology for treating osteoarthritis of the knee and lowering repair failures after rotator cuff surgery  Market PotentialPer a report by P S Market research  the global artificial disc market revenues are estimated to reach  3 3 billion by 2024  Rising instances of DDD  improving technology  higher awareness about treatment procedures followed by increased healthcare spending and aging population are expected to stimulate demand in the market Furthermore  Orthofix expects a double digit growth in the global artificial disc market in the upcoming  Thus  the latest development has come at the opportune time for the company to cash in on the bountiful opportunities in the high potential niche market Price PerformanceOver the past three months  Orthofix s shares have outperformed the  it belongs to  The stock has gained 8 9  compared with the industry s 5 2  rise Zacks Rank   Key PicksOrthofix carries a Zacks Rank  3  Hold  A few other better ranked stocks in the broader medical sector are Bio Rad Laboratories   NYSE BIO    athenahealth  Inc    NASDAQ ATHN   and PerkinElmer   NYSE PKI   Bio Rad Laboratories sports a Zacks Rank of 1  Strong Buy   You can see  The company has a long term expected earnings growth rate of 20  athenahealth is a Zacks  1 Ranked player  The company has a long term expected earnings growth rate of 21 5  PerkinElmer has a long term expected earnings growth rate of 12 3   The stock carries a Zacks Rank  2  Buy  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-03-15,Zacks Investment Research,https://www.investing.com/analysis/orthofix-to-buy-spinal-kinetics-widens-spine-fixation-suite-200298715,200298715
119732,341247,PKI,BioScrip s Dull 2017 Earnings A Woe  Core Business Robust,opinion,On Mar 14  we issued an updated research report on BioScrip  Inc    NYSE BIO    Although the company struggles with reimbursement challenges  its core business continues to grow  The stock has a Zacks Rank  4  Sell  BioScrip exited the fourth quarter of 2017 on a dismal note with lower than expected earnings performance  Although  revenues were above the consensus mark  the huge year over year decline was a disappointment  This downside was due to a shift in the company s strategy to solely focus on growing core revenue mix including contract changes with United Healthcare  which were completed as of September 30  2017 Also  external challenges like reimbursement cuts persisting throughout 2017 pertaining to the 21st century Cures Act hampered growth  Full year result was thus discouraging as a result of the catastrophic disruption from hurricanes Irma and Harvey in the third quarter besides the Cures Act reimbursement cuts In the past three months  shares of BioScrip have underperformed the broader   The stock has gained 2 6  compared with the 9 1  rise of the broader industry The healthcare industry also wades through a highly competitive scenario  In fact BioScrip s rivals include large and well established companies equipped with higher financial  marketing and technological resources BioScrip  Inc  Price    On a positive note  this Denver  CO based leading Infusion Service provider has continued to progress with its new multi faceted CORE plan to improve the financial position  The scheme involves identifying and executing strategies to accelerate core revenue growth  build a favorable product mix  drive operational efficiency  raise revenue collection as well as increase employee effectiveness Additionally  in the fourth quarter  the company made a significant advancement by implementing its single repeatable model  which enforces operating cost reduction on the back of solid synergies drawn  supply chain rationalization  growth in nursing productivity  enhanced shipping utilization and improving patient on boarding times Key PicksSome better ranked stocks in the broader medical sector are Bio Rad Laboratories   NYSE BIO    athenahealth  Inc    NASDAQ ATHN   and PerkinElmer   NYSE PKI   Bio Rad Laboratories sports a Zacks Rank  1  Strong Buy   You can see  The company has a long term expected earnings growth rate of 20  athenahealth is a Zacks  1 Ranked player  The company has a long term expected earnings growth rate of 21 5  PerkinElmer has a long term expected earnings growth rate of 12 3   The stock carries a Zacks Rank  2  Buy  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-03-15,Zacks Investment Research,https://www.investing.com/analysis/bioscrips-dull-2017-earnings-a-woe-core-business-robust-200298710,200298710
119733,341248,PKI,Favorable Market Trend   Core Business Expansion Aid STERIS,opinion,On Mar 20  we issued an updated research report on STERIS plc   NYSE STE    The company has been actively trying to expand into the adjacent markets and strengthen its core business through acquisitions and dilutions  However  the company operates in a tough competitive landscape  raising a concern  The stock carries a Zacks Rank  3  Hold  Shares of the company have outperformed the over the past year  The stock has surged 38 5  compared with the industry s 25 9  rally  STERIS exited third quarter fiscal 2018 on a mixed note with earnings beating the Zacks Consensus Estimate but revenues missing the same  However  we are encouraged by the favorable underlying market trends along with new product and service offerings  The company s organic growth was strong across specialty services  life sciences and applied sterilization segments We are particularly upbeat about STERIS  series of six acquisitions in the first nine months of fiscal 2018  Through these buyouts  the company aims to strengthen the Healthcare Products  Healthcare Specialty Services and the Applied Sterilization Technologies businesses  Furthermore  financed by both cash in hand and credit facility borrowings  the company had to incur acquisition cost of around  51 6 million  net of cash acquired  including a contingent consideration of  5 3 million We think this developer  manufacturer and marketer of infection prevention  decontamination  microbial reduction and surgical and gastrointestinal support products and services can pursue back to back acquisitions in the long run to expand business and customer base  courtesy of its strong financial position We are also impressed by the company s recent organizational changes to serve customers in a better way  Additionally  we expect this move to enhance the company s cost structure  Further  growth in free cash flow reserve is indicative of the company s strong cash balance  Meanwhile  STERIS competes for pharmaceutical  research and industrial customers against several large companies boasting extensive product portfolios and a wide global reach as well as several small companies with limited product offerings and operations in one or a few countries The company expects to confront intense competition as new infection prevention  sterile processing  contamination control  gastrointestinal and surgical support products and services enter the market  This might hamper STERIS  growth considerably Moreover  many STERIS  customers are undergoing consolidation  partly owing to healthcare cost reduction measures initiated by peer pressure as well as legislators  regulators and third party payors  We believe  if the company fails to check the customer consolidation rate right now  then it might affect its business as well as the financial standing Key PicksA few better ranked stocks in the broader medical sector are Bio Rad Laboratories   NYSE BIO    athenahealth  Inc    NASDAQ ATHN   and PerkinElmer   NYSE PKI   Bio Rad Laboratories sports a Zacks Rank  1  Strong Buy   You can see The company has a long term expected earnings growth rate of 20  athenahealth is a Zacks  1 Ranked player  The company has a long term expected earnings growth rate of 21 5  PerkinElmer has a long term expected earnings growth rate of 12 3   The stock carries a Zacks Rank  2  Buy  Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2018-03-20,Zacks Investment Research,https://www.investing.com/analysis/favorable-market-trend--core-business-expansion-aid-steris-200299709,200299709
119734,341249,PKI,Luminex  LMNX  Product Portfolio Solid  Competition Rife ,opinion,On Mar 23  we issued an updated research report on Luminex Corporation   NASDAQ LMNX    The company has a broad product portfolio  which comprises advanced xMAP  xTAG and MultiCode technology  However  the company operates in the highly competitive life sciences industry Luminex carries a Zacks Rank  3  Hold  Portfolio Strength Buoys OptimismLuminex s large installed instrument base consists of the Luminex 100  LX100   Luminex 200  LX200   FlexMap 3D systems and the MAGPIX technology  The company widened and accelerated market acceptance of its xMAP technology through development  marketing and distribution partnerships with leading companies in the life sciences markets Luminex s molecular portfolio will soon include the next gen VERIGENE 2 system  The company will continue to target clinical trial commencement for the system and expects a GI panel by the end of the second quarter of fiscal 2018 A comprehensive format incorporating many additional clinical studies on VERIGENE and other molecular platforms will follow in 2018 and beyond  Additionally  management expects its license technology group to continue to generate LT mid single digit annual revenue growth  while contributing to profits Further  Luminex is making noteworthy progress with another major product   the ARIES system   which represents a major revenue opportunity  The company is focused on fortifying market leadership in infectious disease with the ARIES system  which is a sample to answer platform Luminex Corporation Price and Consensus    In the fourth quarter  increasing volumes of VERIGENE  ARIES and internal manufacturing process improvements led to a significant improvemnet in gross margin  Further  net revenues from these two platforms were  47 million in 2017  Management expects it to grow at a high rate  consequently making it feasible to achieve its goal of exiting 2019 on  100 million a year rate HeadwindsOn the flip side  Luminex faces cutthroat competition in the niche space at the moment  The industry is characterized by rapid and continuous technological innovation Adding to the woes  Luminex s prospects are likely to be marred by future changes in the reimbursement landscape  Per the new molecular diagnostic code system established by the Centers for Medicare and Medicaid Services   CMS   recently  the Protecting Access to Medicare Act  PAMA  will require clinical laboratories to report to CMS the volume of each laboratory test and the price paid by private payors  This has led to a drop in Luminex s customer base Unfavorable Price Movement Luminex has underperformed its  in the past year Notably  the stock has gained 6 7   comparing unfavorably with the industry s growth of 68 4  Further  the current level is significantly lower than S P 500 Index s rally of 101 7   Decline in consumable revenues and stiff competition continue to dampen the stock s performance Key PicksA few better ranked stocks in the broader medical sector are Bio Rad Laboratories   NYSE BIO    athenahealth  Inc    NASDAQ ATHN   and PerkinElmer   NYSE PKI   Bio Rad Laboratories sports a Zacks Rank of  1  Strong Buy   You can see   The company has a long term expected earnings growth rate of 20  athenahealth is a Zacks  1 Ranked player  The company has a long term expected earnings growth rate of 21 5  PerkinElmer has a long term expected earnings growth rate of 12 3   The stock carries a Zacks Rank  2 5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ,2018-03-25,Zacks Investment Research,https://www.investing.com/analysis/luminex-lmnx-product-portfolio-solid-competition-rife-200300701,200300701
119735,341250,PKI,DENTSPLY To Acquire OraMetrix  Boost CAD CAM Dental Unit,opinion,In a bid to strengthen its CAD CAM based dental unit  DENTSPLY SIRONA Inc    NASDAQ XRAY    recently announced a definitive agreement to acquire OraMetrix   a leading industry provider of innovative 3 D technology solutions The company also offers an advanced  CAD platform developed for dental professionals to deliver consistently predictable orthodontic outcomes The transaction is expected to be completed by the second quarter of 2018 What is CAD CAM DENTSPLY s CAD CAM is a dental imaging platform and a major foundation in global dental  is a field of dental supplies and prosthodontics using computer aided design and computer aided manufacturing technologies In fact  the dental supplies market looks promising at the moment  Over the last 10 years  the market has gained 119 8  compared with the S P 500 Index s rally of 101 4  DENTSPLY SIRONA Inc  Price and Consensus     Deal in DetailFinancial terms of the deal have been kept under wraps by DENTSPLY Post the acquisition  the company will be able to provide an end to end digital workflow to dental professionals and address the increasing demands for aesthetics  The acquisition of OraMetrix is likely to strengthen DENTSPLY s footprint in the global dental industry Notably  the company announced its plans to broaden OraMetrix  technologies and services post the buyout  For this  DENTSPLY is likely to incur additional investments and expenses which will be dilutive to overall earnings per share in 2018 and 2019  Meanwhile  OraMetrix posted revenues of approximately  20 million in 2017 The acquisition is likely to bolster the company s Technologies   Equipment segment  This segment consists of dental implants  CAD CAM systems  imaging systems  treatment centers and orthodontic products  In the fourth quarter of 2017  sales improved 10 4  to  630 2 million in the segment and 5 8  at cc In fact  the acquisition will introduce a comprehensive orthodontic offering that will include a  full arch clear aligner  solution for DENTSPLY ConclusionDENTSPLY has been one of the underperforming companies in the MedTech space  Lackluster margin trends  declining earnings and foreign exchange headwinds have been plaguing the company  However  per a research report by Technavio  the global dental CAD CAM market will witness a CAGR of more than 8  by 2021  We believe that DENTSPLY is striving to overcome these problems with such deals The company s price performance has been dull as well  DENTSPLY s shares have lost 15 2  compared with the  s decline of 0 3  in a year s time  Interestingly  an uptick in its share price was witnessed post the announcement of OraMetrix s buyout  Notably  shares of DENTSPLY have inched up 0 8  to close at  51 10 following the press release Further  the company s agreements with MedTech bigwigs like Patterson Companies  NASDAQ PDCO  in Canada are likely to drive sales  Recently  DENTSPLY witnessed a rebound in sales in Asia  particularly Japan  and strong growth in Russia Zacks Rank   Key PicksDENTSPLY has a Zacks Rank  4  Sell  A few better ranked stocks in the broader medical sector are Bio Rad Laboratories   NYSE BIO    athenahealth  Inc    NASDAQ ATHN   and PerkinElmer   NYSE PKI   Bio Rad Laboratories sports a Zacks Rank of  1  Strong Buy   You can see   The company has a long term expected earnings growth rate of 20  athenahealth is a Zacks  1 Ranked player  The company has a long term expected earnings growth rate of 21 5  PerkinElmer has a long term expected earnings growth rate of 12 3   The stock carries a Zacks Rank  2  Buy  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-03-26,Zacks Investment Research,https://www.investing.com/analysis/dentsply-to-acquire-orametrix-boost-cadcam-dental-unit-200301067,200301067
119756,341271,PKI,Medtronic s Positive Study Results May Boost CSH Business,opinion,Medtronic plc   NYSE MDT   recently presented encouraging outcome from the U S  Pivotal Extreme Risk Study and the real world NOTION trial  Nordic Aortic Valve Intervention Trial  on the CoreValve TAVR system  The data was presented at the American College of Cardiology s   ACC   67th Annual Scientific Session This development remains part of the company s consistent effort to strengthen its position in the high potential transcatheter aortic valve replacement   TAVR   market which is projected to reach around  6 5 billion by 2022  data by Cision  Study Results in DetailThe NOTION trial enrolled around 280 patients  aging at least 70 years  and was subjected to surgical aortic valve replacement   SAVR   or TAVR with the CoreValve System  Notably  the studies evaluated patients at five years post implant with the CoreValve TAVR system The results demonstrated patients to experience an enhanced quality of lifealong with strong hemodynamic performance within five years  We believe  these results may boost the uptake of the CoreValve TAVR system Developments in CoreValve TAVR PlatformThe CoreValve Evolut platform comprises CoreValve  CoreValve Evolut R and the CoreValve Evolut PRO system  Notably  in July 2017  Medtronic received FDA approval for the extended use of its self expanding CoreValve Evolut TAVR system  With this approval  patients with symptomatic severe aortic stenosis and at an intermediate risk for open heart surgery became eligible for treatment using the technology  Again  in March  CoreValve Evolut PRO system received FDA approval to be used on symptomatic patients who are at high or extreme risks for open heart surgery Continuing with the slew of developments  last September  Medtronic announced initiating a post market FORWARD PRO Clinical Study to measure the performance of CoreValve Evolut PRO transcatheter aortic valve implantation   TAVI   system in regular clinical treatments Thus  we believe  a clinical study data displaying the efficiency of the product will help the company gain traction in the Coronary   Structural Heart   CSH   space Interestingly  Medtronic s CSH third quarter fiscal 2018 revenues were up 18   14  at constant exchange rate  to  886 million on the back of low constant currency growth in transcatheter aortic valves  as a result of strong customer uptake of the CoreValve Evolut PRO platform and expanded FDA approval  to include patients at intermediate risk Market ProspectsPer a report by Medgadget  the global heart valve repair and replacement market is expected to grow from  2 281 2 million in 2014 to  3 767 0 million in 2020  at a CAGR of 8 7  We believe that unhealthy lifestyle and a rise in ageing population will continue to result in a high incidence of cardiovascular diseases  This is further supported by data provided by GBI Research  Per the report  the global cardiovascular diseases market will see a CAGR of 4 1  by 2019  and within this space  the U S  market is expected to witness the highest momentum at a CAGR of 4 7   Thus  the release of positive study data will help Medtronic cash in the abundant opportunities in the pancreatic cancer therapeutics market Share Price MovementOver the past six months  the company s share price has underperformed the broader   The stock has gained 1 7  in comparison with the broader industry s 8 8  gain  We believe that the latest development will help the stock rebound Zacks Rank   Key PicksMedtronic carries a Zacks Rank  3  Hold  Some better ranked stocks in the broader medical sector are Bio Rad Laboratories   NYSE BIO    athenahealth  Inc    NASDAQ ATHN   and PerkinElmer   NYSE PKI   Bio Rad Laboratories sports a Zacks Rank of 1  Strong Buy   You can see  The company has a long term expected earnings growth rate of 20  athenahealth is a Zacks  1 Ranked player  The company has a long term expected earnings growth rate of 21 5  PerkinElmer has a long term expected earnings growth rate of 12 3   The stock carries a Zacks Rank  2  Buy  Breaking News  Cryptocurrencies Now Bigger than VisaThe total market cap of all cryptos recently surpassed  700 billion   more than a 3 800  increase in the previous 12 months  They re now bigger than Morgan Stanley  NYSE MS   Goldman Sachs  NYSE GS  and even Visa  The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved Zacks has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market ,2018-03-13,Zacks Investment Research,https://www.investing.com/analysis/medtronics-positive-study-results-may-boost-csh-business-200297961,200297961
119757,341272,PKI,Cooper Companies Banks On Specialty Lenses  Competition Rife,opinion,On Mar 13  we issued an updated research report on The Cooper Companies   NYSE COO    The company carries a Zacks Rank  3  Hold   Cooper Companies maintained its leading position in the specialty lens market  supported by exclusive products like Biofinity and Clariti  However  intense competition in the contact lens space will continue to build pressure on pricing The company s flagship silicone hydrogel lenses are expected to see strong sales in the coming quarters  In the first quarter of fiscal 2018  revenues increased on the back of silicone hydrogel lenses  led by the Clariti and MyDay in the dailies space and Biofinity in the monthly space The company is also focusing on expanding geographically  The launch of MyDay Toric daily disposable contact lenses in the United States is in line with this  Management believes that the Toric market will grow faster than the overall market and the company can cash in on the opportunity with its strong portfolio and the recent addition of MyDay Toric  Moreover  Cooper Companies  CooperVision segment is one of the key drivers  The segment gains from silicone hydrogel lenses  led by solid prospects in MyDay  Clariti and Biofinity platforms  The outlook for the contact lens industry is favorable  We are encouraged to note that the Cooper Companies is progressing well with respect to inorganic expansion  In a bid to boost inorganic growth  Cooper Companies announced that CooperVision has completed the buyout of Paragon Vision Sciences in the fourth quarter of 2017 Shares of Cooper Companies have gained 21 7  in the past year  outperforming the  s gain of 13 3  On the flip side  Cooper Companies operates in a highly competitive market  Both of the company s business segments face considerable competition which continues to exert pressure on pricing Also  the company s extensive international presence makes it highly vulnerable to fluctuations in exchange rates Key PicksSome better ranked stocks in the broader medical sector are Bio Rad Laboratories   NYSE BIO    athenahealth  Inc    NASDAQ ATHN   and PerkinElmer   NYSE PKI   Bio Rad Laboratories sports a Zacks Rank of 1  Strong Buy   You can see  The company has a long term expected earnings growth rate of 20  athenahealth is a Zacks  1 Ranked player  The company has a long term expected earnings growth rate of 21 5  PerkinElmer has a long term expected earnings growth rate of 12 3   The stock carries a Zacks Rank  2  Buy  Breaking News  Cryptocurrencies Now Bigger than VisaThe total market cap of all cryptos recently surpassed  700 billion   more than a 3 800  increase in the previous 12 months  They re now bigger than Morgan Stanley  NYSE MS   Goldman Sachs  NYSE GS  and even Visa  The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved Zacks has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market ,2018-03-13,Zacks Investment Research,https://www.investing.com/analysis/cooper-companies-banks-on-specialty-lenses-competition-rife-200297960,200297960
119760,341275,PKI,Medtronic s  MDT  Guardian Connect CGM System Wins FDA Nod ,opinion,Medtronic plc   NYSE MDT   announced the receipt of FDA approval for the Guardian Connect continuous glucose monitoring  CGM  system for diabetes patients between the ages of 14 to 75 years Notably  the system will be available in the first quarter of Medtronic s fiscal year 2019  May July 2018  Guardian Connect CGM The Guardian Connect is the first and only standalone CGM system to help diabetes patients be aware of potential high or low glucose events up to 60 minutes in advance Notably  the Guardian Connect will enable patients to use multiple daily injections  MDI  and manage the disease proactively  Patients and their relatives will stay informed  track glucose in real time and even receive text alerts through the system   The system s users will have exclusive access to the Sugar IQ smart diabetes assistant  This helps them deal with regular complications related to diabetes  The Sugar IQ assistant consistently studies the response of an individual s glucose levels to their food intake  insulin dosages  daily routines and other factors The Sugar IQ assistant  combined with the Guardian Connect can transform difficult to determine patterns into personalized as well as actionable insights  This will enable patients to keep glucose levels within the target range  Per the press release  latest sensors along withintelligent algorithms allow users to predict and understand glucose excursions  particularly hypoglycemia  This is likely to make diabetes more comprehensible for people who inject insulin  Using the CGM will help diabetes patients to achieve more glycemic time in range and reduce the risk of hypoglycemia Diabetes Business in FocusMedtronicis consistently trying to enhance the Diabetes business  Medtronic witnessed a 13  rise at constant exchange rate in the Diabetes business  revenues during third quarter fiscal 2018  The company benefited from a positive uptake of new sensor augmented insulin pump systems in the United States and the international markets along with enhanced production capacity for the same Recently  the company announced that FDA has approved a new arm indication for the Guardian Sensor 3 continuous glucose monitor  CGM   which is used with the MiniMed 670G insulin pump Notably  Medtronic expects double digit growth in the segment in fourth quarter fiscal 2018  courtesy of a consistent performance of MiniMed 670G system in the United States along with enhanced sensor supply capacity Additionally  Medtronic has been gearing up for the international introduction of the MiniMed 670G and the U S  launch of new professional CGM iPro 3 in 2019 Market PotentialAn ageing population  unhealthy lifestyle  a rising awareness and higher expenditure in healthcare are likely to drive growth in the highly competitive diabetes market Per a report by Mordor Intelligence  the global market for diabetes care devices is projected to reach a value of  30 25 billion by 2021  at a CAGR of 5 93   Considering the bullish market sentiments  we believe that the latest development has arrived at an opportune moment Stock Performance   Estimate RevisionOver the past month  shares of Medtronic have underperformed the   The stock has returned 0 6  compared with the industry s 3 9  rally and the S P 500 index s 1 9  gain Also  the estimate revision trend for the current year is unfavorable with 10 estimates moving south over the last two months compared with two in the opposite direction  Earnings estimates fell around 0 4  to  4 75 per share Zacks Rank   Key PicksMedtronic carries a Zacks Rank  3  Hold  Some better ranked stocks in the broader medical sector are Bio Rad Laboratories   NYSE BIO    athenahealth  Inc    NASDAQ ATHN   and PerkinElmer   NYSE PKI   Bio Rad Laboratories sports a Zacks Rank of 1  Strong Buy   You can see The company has a long term expected earnings growth rate of 20  athenahealth is a Zacks  1 Ranked player  The company has a long term expected earnings growth rate of 21 5  PerkinElmer has a long term expected earnings growth rate of 12 3   The stock carries a Zacks Rank  2 Breaking News  Cryptocurrencies Now Bigger than VisaThe total market cap of all cryptos recently surpassed  700 billion   more than a 3 800  increase in the previous 12 months  They re now bigger than Morgan Stanley  NYSE MS   Goldman Sachs  NYSE GS  and even Visa  The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved Zacks has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market ,2018-03-13,Zacks Investment Research,https://www.investing.com/analysis/medtronics-mdt-guardian-connect-cgm-system-wins-fda-nod-200298159,200298159
119761,341276,PKI,Laborie Medical Technologies To Acquire Cogentix Medical ,opinion,Cogentix Medical  Inc    NASDAQ CGNT   recently announced that it has entered a definitive merger agreement with Laborie Medical Technologies  Per the deal  Laborie Medical Technologies will buy all of the outstanding shares of Cogentix Medical for a net worth of  239 million  The company is a leading player in the Urology  Gynecology  and Colorectal fieldsCogentix Medical expects the transaction to close in the first half of the second quarter of 2018  Once completed  Cogentix Medical will become a wholly owned subsidiary of Laborie Medical Technologies  Price PerformanceCogentix Medical s shares have returned 92 7  in the past year  compared with the S P 500 Index s rally of 16 2  The stock has also outperformed its  s gain of 25 4   Cogentix Medical has a market cap of  177 24 million Cogentix Medical has a Zacks Rank  3  Hold  The Agreement in DetailPer the terms of the agreement  Laborie Medical technologies will initiate a tender offer for all outstanding shares of Cogentix Medical s common stock for  3 85 per share in cash  The company will execute the deal through its wholly owned subsidiaries of LM US Parent  Inc  and Camden Merger Sub  Inc Following the successful completion of the tender offer  there will be a  second step merger  in which all the outstanding shares of Cogentix Medical s common stock  which are not tendered  will be converted into the right to receive  3 85 per share of common stock  in cash  The transaction is subject to other customary closing conditions Notably  Cogentix Medical is a leading player in the global urology markets  The company s recent initiative to sign a licensing agreement that will allow it to launch an Endo Urology product line in the United States is noteworthy  This product is focused on minimally invasive treatment of kidney stones  Initial response of physicians to the product has been positive Per management  this latest transaction is also a great financial opportunity  which will deliver strong margin expansion over the long haul Market PotentialPer Markets   Markets  the urology devices market is estimated to reach a worth of  44 37 billion by 2022  at a CAGR of 7 1   Considering the prospects in the niche space  we expect Cogentix Medical to gain solid prominence in the days to come However  the company faces stiff competition from MedTech giant Medtronic plc   NYSE MDT   Key PicksA few better ranked stocks in the broader medical sector are PerkinElmer   NYSE PKI   and Bio Rad Laboratories   NYSE BIO   PerkinElmer has a long term expected earnings growth rate of 12 3   The stock carries a Zacks Rank  2  Buy  Bio Rad Laboratories sports a Zacks Rank of 1  Strong Buy   You can see The company has a long term expected earnings growth rate of 20  Breaking News  Cryptocurrencies Now Bigger than VisaThe total market cap of all cryptos recently surpassed  700 billion   more than a 3 800  increase in the previous 12 months  They re now bigger than Morgan Stanley  NYSE MS   Goldman Sachs  NYSE GS  and even Visa  The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved Zacks has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market ,2018-03-14,Zacks Investment Research,https://www.investing.com/analysis/laborie-medical-technologies-to-acquire-cogentix-medical-200298008,200298008
119783,341298,PKI,CryoLife  CRY  Beats Earnings And Revenue Estimates In Q4,opinion,"CryoLife  Inc    NYSE CRY   reported adjusted earnings per share  EPS  of 11 cents in the fourth quarter of 2017  down 8 3  year over year  Adjusted EPS however managed to surpass the Zacks Consensus Estimate of 9 cents Full year adjusted earnings came in at 40 cents  reflecting a decline of 16 7  from the year ago figure  The figure surpassed the Zacks Consensus Estimate of 26 cents Revenues in DetailRevenues in the quarter increased 17 3  year over year to  52 8 million  Moreover  the figure beat the Zacks Consensus Estimate by 10 9   Revenues were primarily driven by double digit revenue growth in BioGlue  On X and tissue processing  Moreover  revenues included  4 1 million contribution from the recently completed acquisition of JOTEC Full year revenues came in at  189 7 million  up 5 2  from the year ago period and beating the Zacks Consensus Estimate of  184 4 million
CryoLife  Inc  Price  Consensus and EPS Surprise
    On a segmental basis  Product revenues increased 21 5  year over year in the fourth quarter to  35 1 million  Within the segment  50 7  of the revenues came from BioGlue and BioFoam followed by 28 2  from On X Preservation Services revenues increased 9 9  in the quarter under review from the year ago quarter to  17 7 million  Within the segment  the company witnessed solid growth in Cardiac and Vascular tissues revenues On a geographical basis  the company s revenues in the United States rose 5 2  to  34 6 million  International revenues increased 50 4  to  18 2 million Operational UpdateCryoLife s gross profit in the reported quarter climbed 16 7  year over year to  36 4 million  However  gross margin contracted 40 basis points  bps  to 68 9  General  administrative  and marketing expenses in the fourth quarter rose 36  year over year to  30 2 million  Research and development expenses shot up 68 4  year over year to  6 4 million  Operating expenses totaled  36 6 million in the fourth quarter  up 40 2  year over year Adjusted operating loss in the quarter was  0 2 million  comparing unfavorably to operating profit of  5 1 million in the year ago quarter Financial UpdateCryoLife exited 2017 with cash and cash equivalents and restricted securities of  40 8 million  compared with  57 3 million at the end of 2016 2018 GuidanceFor 2018  CryoLife expects revenues in the band of  250 0  256 0 million  The Zacks Consensus Estimate for full year revenues stands at  263 4 million  above the guided range The company also expects adjusted earnings per share in the range of 29 32 cents  The Zacks Consensus Estimate for full year earnings is pegged at 28 cents  below the company s guided range Our TakeCryoLife exited fourth quarter 2017 on a promising note  We are encouraged to note that the company has been witnessing growth in all the product lines along with strong performance in all geographies  Moreover  the company has been gaining from directly selling the products to end users  We are also optimistic about the company s focus on product innovation through R D and completion of the JOTEC buyout However  escalating operating expenses seem to be discouraging  Also  a tough competitive landscape acts as a dampener Zacks Rank   Key PicksCryoLife has a Zacks Rank  3  Hold  A few better ranked stocks that reported solid results this earnings season are PetMed Express   NASDAQ PETS    PerkinElmer   NYSE PKI   and athenahealth  Inc    NASDAQ ATHN    While PetMed and athenahealth sport a Zacks Rank  1  Strong Buy  and PerkinElmer carry a Zacks Rank  2  Buy   You can see   PetMed reported third quarter fiscal 2018 results  Adjusted EPS of 44 cents were up 88 3  from the prior year quarter  Revenues rose 13 7  to  60 1 million PerkinElmer reported fourth quarter 2017 adjusted EPS of 97 cents  Adjusted revenues were approximately  641 6 million  up from  567 million in the year ago quarter athenahealth reported adjusted EPS of  1 11 in the fourth quarter of 2017  up 79  on a year over year basis  Revenues totaled  329 million  up 14 2  on a year over year basis The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-03-07,Zacks Investment Research,https://www.investing.com/analysis/cryolife-cry-beats-earnings-and-revenue-estimates-in-q4-200296694,200296694
119785,341300,PKI,Quest Diagnostics Long Term View Solid  Reimbursement A Woe,opinion,On Mar 7  we issued an updated research report on Quest Diagnostics  Inc    NYSE DGX    Amid huge reimbursement concerns  the company focuses on potentially strong areas  The stock carries a Zacks Rank  3  Hold  Shares of Quest Diagnostics have outperformed the  over the past year  The stock has gained 6 6  against the broader industry s 2 2  decline  We are encouraged to note that in recent times  Quest Diagnostics has witnessed significant growth through infectious disease testing  prescription drug monitoring and wellness business  The company lends attention to core diagnostic information services business as well as disciplined capital deployment Its several new collaborations with hospitals and integrated delivery networks continue to act as major growth drivers  We are looking forward to the company s recently closed buyout of Mobile Medical Examination Service  a national provider of home based health risk assessments and related services  This apart  the 2018 guidance issued promises this bullish trend to continue Later in 2016  Quest Diagnostics provided an upgraded long term growth outlook  beyond 2017  based on its new and extended two point strategy to generate shareholder value  accelerate growth and drive operational excellence This major commercial laboratory services provider expects 3 5  revenue growth for the period from 2017 to 2020  However  the bottom line rise is expected to better the top line at a faster rate in mid to high single digit range  Per the company  its increasing partnership strength with other health care leaders is creating ample opportunities for earnings and revenue boost while simultaneously  improving the patient experience as well as reducing the overall cost of care After enduring several quarters of dull volumes  the company has finally noticed improvement in terms of both volume and pricing  However  sustainability of this progress is still doubted  Further  reimbursement woes remain Also  Quest Diagnostics is highly disappointed with the recent CMS  Centers for Medicare   Medicaid Services  proposal related to the Protecting Access to Medicare Act  In December 2017  the company as a key member of the American Clinical Laboratory Association supported a lawsuit slapped on the acting secretary of the US Department of Health and Human Services  The complaint filed against CMS  operating under the HHS purview   charged it with its failure to follow a congressional directive to implement a market based laboratory payment system Stocks to ConsiderSome better ranked stocks in the broader medical sector are Bio Rad Laboratories   NYSE BIO    PetMed Express   NASDAQ PETS   and PerkinElmer   NYSE PKI   Bio Rad Laboratories sports a Zacks Rank  1  Strong Buy   You can see  The company has a long term expected earnings growth rate of 20  PetMed has a long term expected earnings growth rate of 10  and a Zacks Rank of 1 PerkinElmer has a long term expected earnings growth rate of 12 3   The stock carries a Zacks Rank  2  Buy  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-03-07,Zacks Investment Research,https://www.investing.com/analysis/quest-diagnostics-longterm-view-solid-reimbursement-a-woe-200296682,200296682
119786,341301,PKI,Pacific Biosciences Unveils New Version Of Sequel Software ,opinion,In a bid to make genomic research cost effective Pacific Biosciences of California  Inc    NASDAQ PACB   recently announced a new version of Sequel Software  V5 1  and a new polymerase Pacific Biosciences  flagship platform   the Sequel System   has been fortifying the company s footprint worldwide With the latest development  the Sequel System can now achieve up to 10 Gb per Single Molecule  Real Time  SMRT  Cell for genomic libraries  doubling the throughput when using ultra long inserts   40 kb  for de novo genome assembly These enhancements increase throughput and the overall performance of SMRT Sequencing for key applications  Notably  Pacific Biosciences has increased the throughput per SMRT Cell 1000 fold since the SMRT Sequencing technology was first commercialized in 2011  This throughput increases cost effectiveness for sequencing projects in the human  plant and animal markets  enabling researchers to increase the size and scope of their projects Sequel System at a GlanceSequel System is a nucleic acid sequencing platform based on SMRT technology that was developed in partnership with Roche  Though Pacific Bioscience s agreement with Roche was terminated in 2016  the Sequel System is still a significant contributor to Pacific Bioscience s top line We believe that the Sequel System s higher throughput  scalability  lower upfront capital investment as well as smaller size and weight will attract cost sensitive customers In the fourth quarter of 2017  consumable revenue growth was driven by higher sequel instrument utilization  The average annualized pull through revenues on sequel instruments was more than  180 000 and is nearing  200 000 Recent DevelopmentsIn January 2018  Pacific Biosciences announced an agreement with BGI Genomics to purchase an additional 10 Sequel Systems  This will significantly expand the capacity for SMRT Sequencing for BGI s global sequencing service business  which currently operates two Sequel Systems and a PacBio RS II Sequencing System In October 2017  Pacific Biosciences of California formed an alliance with genomic data driven medicine company  Bluebee  to develop an advanced de novo assembly pipeline that integrates both the company s technologies The company is alsocontinuing to work on the new version of the eight million ZMW SMRT Cell  The company has also expressed its plans to complete the developmental chip by the end of this year Notably  the company has received an order for 10 sequel systems from BGI in China  which is expected to further strengthen its foothold in the country Also  by the end of 2017  Pacific Biosciences confirmed that it is on track to perform beta testing on new enzyme and software for the Sequel Systems Industry ProspectsPer Markets And Markets  the global Genomics market is expected to grow at a CAGR of 10 2  to reach a worth of  23 88 Billion by 2022   Consequently  the prospects of long read sequencing market  a niche space in the genomics industry  is also growing in leaps and bounds  We believe  Pacific Biosciences  slew of latest developments to be well timed within this industry Further  per a recent report by Decisive Bio Insights  the Next Generation Sequencing manufacturer market size will reach  3 2 billion in 2017 and grow at 12  per annum rate to touch  4 6 billion by 2020  primarily driven by adoption from worldwide clinical customers Price Performance Over the past month  the stock has gained than 9 9   outperforming the  s gain of roughly 7 6  Zacks Rank   Key PicksPacific Biosciences has a Zacks Rank  3  Hold   A few better ranked stocks in the broader medical sector are PerkinElmer   NYSE PKI    Bio Rad Laboratories   NYSE BIO   and athenahealth  Inc    NASDAQ ATHN   PerkinElmer has a long term expected earnings growth rate of 12 3   The stock carries a Zacks Rank  2  Buy  Bio Rad Laboratories sports a Zacks Rank of 1  Strong Buy   You can see The company has a long term expected earnings growth rate of 20  athenahealth is a Zacks  1 Ranked player  The company has a long term expected earnings growth rate of 21 5  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-03-07,Zacks Investment Research,https://www.investing.com/analysis/pacific-biosciences-unveils-new-version-of-sequel-software-200296666,200296666
119789,341304,PKI,Orthofix PhysioStim s FDA Nod And CE Mark Boosts Prospects,opinion,As a major breakthrough in the field of PhysioStim  Orthofix International N V    NASDAQ OFIX   has secured approvals from the U S  FDA as well as the European CE Mark for its next generation PhysioStim Per the company  the PhysioStim bone growth stimulators provide a non surgical treatment option  particularly to patients with nonunion fracture beyond repair  In fact  such extremely critical conditions show no visible signs of healing The aforementioned Class III medical devices are built on Orthofix s proprietary pulsed electromagnetic field  PEMF  technology platform   According to the company  PEMF signal creates a low level electrical field at the fracture site  stimulating bone healing           Orthofix sounds highly positive about PhysioStim  claiming the devices to have occupied a leading position as prescribed bone growth stimulators in the United States combined with spinal fusion stimulators  The company also stated that the PhysioStim devices will be accompanied by STIM onTrack  a new application for mobile devices  This app uses a first to market feature enabling physicians to remotely track and view patient adherence to their prescription Huge Market ProspectWe are certainly looking forward to this path breaking achievement by the musculoskeletal healing device company in bone growth stimulation space  showing all indications to grow in leaps and bounds Going by a Grand View research report  the bone growth stimulator market size was valued at  1 billion in 2016 with more than 50 million Americans suffering arthritis  With arthritic problems rapidly rising due to aging and obesity factors  the patient population is likely to increasingly reach 78 4 million by 2040  Needless to add that this endemic arthritis is driving demand for bone growth stimulation products Taking global data into consideration  a Markets and Markets report states that the global bone growth stimulator market is estimated at  1 41 billion by 2022  witnessing a CAGR of 5 4   The major growth propellers are growing patient preference for non invasive and minimally invasive surgical treatments  increasing target patient population and procedural benefits offered by bone stimulation devices in bone fracture treatments In view of the above  we expect Orthofix to achieve a huge customer adoption rate for PhysioStim post the product launch in the United States and Europe Price Performance Over the past three months  shares of Orthofix have outperformed the  it belongs to  The stock has gained 11  compared with the industry s 5 5  rise Zacks Rank   Key PicksOrthofix carries a Zacks Rank  3  Hold   Some better ranked stocks in the broader medical sector are Bio Rad Laboratories   NYSE BIO    PetMed Express   NASDAQ PETS   and PerkinElmer   NYSE PKI   Bio Rad Laboratories sports a Zacks Rank  1  Strong Buy   You can see  The company has a long term expected earnings growth rate of 20  PetMed has a long term expected earnings growth rate of 10  and a Zacks Rank of 1 PerkinElmer has a long term expected earnings growth rate of 12 3   The stock carries a Zacks Rank  2  Buy  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-03-07,Zacks Investment Research,https://www.investing.com/analysis/orthofix-physiostims-fda-nod-and-ce-mark-boosts-prospects-200296662,200296662
119790,341305,PKI,Genomic Health  GHDX  Q4 Earnings   Revenues Miss Estimates,opinion,"Genomic Health  Inc    NASDAQ GHDX   reported fourth quarter 2017 adjusted earnings per share  EPS  of 8 cents  reflecting an improvement from the year ago quarter s 4 cents  Adjusted EPS however missed the Zacks Consensus Estimate of 9 cents Reported EPS came in at 5 cents  improving from the year ago figure by a penny Full year 2017 adjusted EPS came in at a penny  comparing favorably with the Zacks Consensus Estimate of a loss of 9 cents and the year ago number of a loss of 42 cents Revenues in DetailTotal revenues in the quarter rose 5 8  year over year to  87 5 million  missing the Zacks Consensus Estimate of  89 1 million  Growth in the United States and international markets drove the top line  Moreover  during the quarter  Genomic Health witnessed solid U S  invasive breast cancer growth Net revenues in 2017 totaled  340 8 million  missing the Zacks Consensus Estimate of  343 1 million  The figure however improved 3 9  from the year ago number 
Genomic Health  Inc  Price  Consensus and EPS Surprise
    Geographically  fourth quarter product revenues in the United States rose 5  to  73 5 million  The U S  product revenue growth was fueled by a 38 9  rise in Prostate test revenues to  5 million and a 3 6  hike in invasive breast cancer revenues to  66 2 million  International product revenues totaled  13 7 million in the reported quarter  up 14 2  During the quarter  the company delivered more than 31 990 Oncotype DX test results  up 6 6  year over year Margin TrendIn the quarter under review  Genomic Health s gross margin expanded 80 basis points  bps  year over year to 84 2  The company also witnessed a 5 6  rise in operating expenses to  71 4 million owing to a 0 61  rise in research and development expenses to  14 9 million  11 1  uptick in general and administrative expenses to  20 million and 5 2  increase in selling and marketing expenses to  36 5 million In the reported quarter  Genomic Health reported an operating income of  2 2 million  showing a year over year improvement from  1 5 million a year ago  Accordingly  the operating margin expanded 70 bps to 2 5  Financial UpdateGenomic Health exited 2017 with cash and cash equivalents and short term marketable securities  including a corporate equity investment  of  129 6 million  reflecting an improvement from  97 million recorded at the end of 2016 2018 GuidanceThe company issued guidance for 2018  Genomic Health expects full year 2018 revenues in the range of  366  382 million  reflecting growth of 10 15   The Zacks Consensus Estimate of  384 1 million is above the guided range The company expects adjusted basic EPS in the band of 39 56 cents  The Zacks Consensus Estimate is pegged at 34 cents Our TakeGenomic Health exited fourth quarter 2017 on a disappointing note Nevertheless  we are encouraged by the year over year rise in revenues  driven by solid performances in United States and internationally  Within prostate cancer  the Oncotype DX Genomic Prostate Score test witnessed expanded private coverage  We are also upbeat about the company s signing of an exclusive licensing agreement with Cleveland Diagnostics and research collaboration agreement with Janssen Pharmaceuticals  Also  the launch of Oncotype DX AR V7 Nucleus Detect buoys optimism  The company also witnessed positive developments for its Oncotype DX Breast Recurrence Score tests Genomic Health s sole reliance on the Breast Oncotype DX test is a concern  Moreover  the company s rising operating expenses pose a challenge Zacks Rank   Key PicksGenomic Health carries a Zacks Rank  5  Strong Sell  A few better ranked stocks that reported solid results this earnings season are PetMed Express   NASDAQ PETS    PerkinElmer   NYSE PKI   and athenahealth  Inc    NASDAQ ATHN    While PetMed and athenahealth sport a Zacks Rank  1  Strong Buy   PerkinElmer carries a Zacks Rank  2  Buy   You can see   PetMed reported third quarter fiscal 2018 results  Adjusted EPS of 44 cents was up 88 3  from the prior year quarter  Revenues rose 13 7  to  60 1 million PerkinElmer posted fourth quarter 2017 adjusted EPS of 97 cents  Adjusted revenues were approximately  641 6 million  up from  567 million a year ago athenahealthreported adjusted EPS of  1 11 in the fourth quarter of 2017  up 79  on a year over year basis Revenues totaled  329 million  up 14 2  Don t Even Think About Buying Bitcoin Until You Read ThisThe most popular cryptocurrency skyrocketed last year  giving some investors the chance to bank 20X returns or even more  Those gains  however  came with serious volatility and risk  Bitcoin sank 25  or more 3 times in 2017 Zacks has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly ",2018-03-08,Zacks Investment Research,https://www.investing.com/analysis/genomic-health-ghdx-q4-earnings--revenues-miss-estimates-200296893,200296893
119795,341310,PKI,4 Factors Driving Edwards Lifesciences To A New 52 Week High,opinion,Shares of Edwards Lifesciences Corporation   NYSE EW   scaled a new 52 week high of  138 82 on Mar 8  closing the session lower at  138 25  The company has outperformed the over the last three months  The stock has gained 16 9   compared with the S P 500 s 3  gain and the industry s 9 2  The stock has a market cap of  29 04 billion  The company has a positive earnings surprise of 9 9  for the last four quarters  Also  it has a long term expected earnings growth rate of 15 1  Further  the company s estimate revision trend for the current year is favorable  In the past couple of months  11 analysts moved north  with no movement in the opposite direction  Earnings estimates rose around 8 2  to  4 49 per share  The company s five year historical growth rate is also favorable at 23 4  as compared with the industry s 10 6  and the S P 500 s 2 8  Edwards Lifesciences carries a Zacks Rank  2  Buy   The company has an impressive Growth  of B as well  Our Growth Style Score highlights all the vital metrics of a company s financials to obtain a clearer picture of the quality and sustainability of its growth  Our research shows that stocks with Style Scores of A or B when combined with a Zacks Rank  1  Strong Buy   2 or 3  Hold  offer the best investment opportunities Taking the stable stock performance into consideration  we expect Edwards Lifesciences to scale higher in the coming quarters based on several growth drivers Strong Fourth Quarter Performance Edwards Lifesciences  fourth quarter 2017 performance was quite promising with revenues and earnings beating the Zacks Consensus Estimate  We are also encouraged by the strong performance by all three of the company s product lines  The company also performed well with respect to gross and adjusted operating margin  The company is focusing on product innovation through research and development Solid Guidance Edwards Lifesciences has raised its 2018 sales expectations to the high end of the previously projected range of  3 5  3 9 billion  The Zacks Consensus Estimate for full year revenues is  3 71 billion  well within the guided range  Adjusted earnings per share expectation has also been raised to  4 43  4 63 from the previous  4 10  4 30  The Zacks Consensus Estimate for full year adjusted earnings stands at  4 16  near the low end of the company s guided range CE Mark for CENTERA Valve The market is upbeat about Edwards Lifesciences  recent CE Mark for its self expanding CENTERA valve  The regulatory approval is likely to boost the company s Transcatheter Heart Valves segment Acquisition of Harpoon Medical Edwards Lifesciences recently acquired Harpoon Medical  Inc    a privately held medical technology company focused on beating heart repair for degenerative mitral regurgitation  Per the agreement  Harpoon Medical s flagship beating heart repair procedure for mitral valve patients   HARPOON system   will be added to Edward Lifesciences  Surgical Heart Valve Therapy portfolio for treating structural heart diseases Other Key PicksOther top ranked stocks in the broader medical sector are PerkinElmer   NYSE PKI    Bio Rad Laboratories   NYSE BIO   and athenahealth  Inc    NASDAQ ATHN   PerkinElmer has a long term expected earnings growth rate of 12 3   The stock carries a Zacks Rank  2 Bio Rad Laboratories sports a Zacks Rank of 1  You can see  The company has a long term expected earnings growth rate of 20  athenahealth is a Zacks  1 Ranked player  The company has a long term expected earnings growth rate of 21 5  Don t Even Think About Buying Bitcoin Until You Read ThisThe most popular cryptocurrency skyrocketed last year  giving some investors the chance to bank 20X returns or even more  Those gains  however  came with serious volatility and risk  Bitcoin sank 25  or more 3 times in 2017 Zacks has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly ,2018-03-08,Zacks Investment Research,https://www.investing.com/analysis/4-factors-driving-edwards-lifesciences-to-a-new-52week-high-200296889,200296889
119800,341315,PKI,Cooper Companies  COO  Tops Q1 Earnings   Revenue Estimates,opinion,Cooper Companies Inc    NYSE COO   reported adjusted earnings of  2 79 in first quarter fiscal 2018  beating the Zacks Consensus Estimate by 10 7  and increasing 44 6  year over year  We believe the upside was driven by robust revenue growth  The stock has a Zacks Rank  3  Hold  Revenues increased 4  at constant currency exchange rate  CER  on a year over year basis to  590 million  The figure also outpaced the Zacks Consensus Estimate of  582 1 million  The stellar top line performance was driven by silicone hydrogel lenses  led by the Clariti and MyDay in the dailies space and Biofinity in the monthly space Segmental AnalysisThe company has two business segments   CooperVision  CVI  and CooperSurgical  CSI  The Cooper Companies  Inc  Price  Consensus and EPS Surprise    CVIRevenues at CooperVision Segment increased 8  at constant currency  cc  to  444 8 million on a year over year basis  The segment continues to gain from the company s silicone hydrogel lenses led by solid prospects in the MyDay  Clariti and Biofinity platforms  Coming to the major catalysts within the CVI segment  robust performance by Toric  31  of CVI revenues   Multifocal  11    single use sphere lenses  26   and non single use sphere lenses  32   propelled solid growth Multifocal revenues rose 5  year over year at cc to  46 9 million  while Toric revenues increased 9  to  137 8 million  Single use sphere lenses sales climbed 11  at cc to  116 3 million  while sales of non single use sphere lenses rose 4  to  143 8 million Geographically  CVI revenues inched up 3  in the Americas and a respective 15  and 9  in the Asia Pacific and EMEA  at cc CSIRevenues at CooperSurgical Segment declined 6  at cc to  145 2 million on a year over year basis  However  the company witnessed 32  increase in this segment on a reported basis on the back of the PARAGARD acquisition  The fertility category  39  of CSI revenues  saw a 5  drop in sales at cc to  57 million  Also  the office and surgical products category declined 6  at cc to  88 2 million Margin DetailsAs a percentage of revenues  adjusted gross margin at the CSI segment was 69  in the reported quarter  up 700 basis points  bps  year over year  The margin was negatively impacted by the inventory step up associated with the PARAGARD buyout As a percentage of revenues  adjusted gross margin at the CVI segment was 67  in the reported quarter  higher than 63  of revenues in the year ago quarter  This reflects an increase of 400 bps on f avorable currency and product mix Hence  adjusted gross margin as a whole for Cooper Companies was 68  of revenues  up 500 bps year over year Adjusted operating margin  as a percentage of revenues  was 28  of net revenues in the fiscal first quarter  up 500 bps on a year over year basis GuidanceFor fiscal 2018  total revenues are now expected in the band of  2 510  2 560 million compared with the previous  2 480  2 530 million  The Zacks Consensus Estimate for fiscal 2018 revenues is pegged at  2 52 billion  within the guided range Revenues at the CVI segment are now estimated in the band of  1 865  1 900 million  higher than  1 830  1 865 million  Meanwhile  CSI revenue range has been slashed to  645  660 million from the prior  650  665 million Adjusted earnings per share are now anticipated in the band of  11 70  11 90 versus  11 35  11 65 earlier  The Zacks Consensus Estimate for fiscal 2018 adjusted earnings stands at  11 57  below the guided range Our TakeCooper Companies ended first quarter fiscal 2018 on a solid note  The company s CooperVision business has always been posting impressive results  The company s raised guidance for fiscal 2018 is promising  However  intense competition in the contact lens space will continue to increase pricing pressure for the company Notably  Cooper Companies has completed the acquisition of Paragon Vision Sciences  This added a leading ortho k technology to the company s lens portfolio  Considering the outstanding performance of the stock  we expect Cooper Companies to scale higher in the coming quarters  In this regard  positive long term growth of 10 8  holds promise Key PicksA few better ranked stocks that reported solid results this earnings season are PetMed Express   NASDAQ PETS    PerkinElmer   NYSE PKI   and athenahealth  Inc    NASDAQ ATHN    While PetMed and athenahealth sport a Zacks Rank  1  Strong Buy   PerkinElmer carries a Zacks Rank  2  Buy   You can see  PetMed reported third quarter fiscal 2018 results  Adjusted earnings per share of 44 cents were up 88 3  from the prior year quarter  Revenues rose 13 7  to  60 1 million PerkinElmer reported fourth quarter 2017 adjusted earnings per share of 97 cents  Adjusted revenues were approximately  641 6 million  up from  567 million a year ago athenahealth reported adjusted earnings per share of  1 11 in the fourth quarter of 2017  up 79  year over year  Revenues totaled  329 million  up 14 2  Don t Even Think About Buying Bitcoin Until You Read ThisThe most popular cryptocurrency skyrocketed last year  giving some investors the chance to bank 20X returns or even more  Those gains  however  came with serious volatility and risk  Bitcoin sank 25  or more 3 times in 2017 Zacks has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly ,2018-03-08,Zacks Investment Research,https://www.investing.com/analysis/cooper-companies-coo-tops-q1-earnings--revenue-estimates-200296879,200296879
119801,341316,PKI,GNC Holdings Expands In India  Boosts International Business,opinion,Keeping in line with the strategy to fortify its hold on high potential geographical regions  GNC Holdings  Inc    NYSE GNC   recently announced plans to expand presence in India  In India  the company operates in collaboration with the master franchise partner   Guardian Healthcare Services Pvt  Ltd Per the latest announcement  Guardian will add GNC Holdings  products to 4000 plus stores across India by 2020  In this regard  1000 new stores are expected to shelf GNC products in 2018 compared with approximately 50 retail locations at present  This apart  GNC Holdings has been targeting other channels like retailing  e commerce and distribution for expansion International Business   A Key Growth DriverGNC Holdings  international business has been a key growth driver for the company in recent years  Revenues at this segment increased 14 1  on higher cross border e commerce sales in China last quarter Of late  the company has been experiencing solid growth in China  In this regard  GNC Holdings recently announced plans of entering into a strategic partnership and joint venture agreement with Harbin Pharmaceutical Group Holding Co   Ltd  Meanwhile  the company has witnessed improvement in trends in Mexico  South Korea and Hong Kong Market PotentialPer a report by the Associated Chambers of Commerce and Industry in India  ASSOCHAM   India s nutraceutical market is estimated to value  10 billion by 2022  seeing a CAGR of approximately 20   during the forecast period of 2017 2022   Thus  in view of such data  we believe GNC Holdings  aggressive expansion plans in India are strategic Share Price PerformanceIn the past three months  GNC Holdings has been underperformed its   The stock has lost 14 6  compared with the industry s decline of 1 1   We believe this latest development will help the stock to rebound Zacks Rank   Key PicksGNC Holdings carries a Zacks Rank  3  Hold  Some better ranked stocks in the broader medical sector are PerkinElmer   NYSE PKI    Bio Rad Laboratories   NYSE BIO   and athenahealth  Inc    NASDAQ ATHN   Bio Rad Laboratories sports a Zacks Rank  1  Strong Buy   You can see  The company has a long term expected earnings growth rate of 20  athenahealth is a Zacks  1 Ranked player  The company has a long term expected earnings growth rate of 21 5  PerkinElmer has a long term expected earnings growth rate of 12 3   The stock carries a Zacks Rank  2  Buy  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-03-11,Zacks Investment Research,https://www.investing.com/analysis/gnc-holdings-expands-in-india-boosts-international-business-200297405,200297405
119803,341318,PKI,BioScrip  BIOS  Loss Widens In Q4   18 View Holds Promise,opinion,BioScrip  Inc    NYSE BIO   reported adjusted net loss from continuing operations of 15 cents per share in the fourth quarter of 2017  wider than both the Zacks Consensus Estimate and the year ago loss of 8 cents each Reported net loss from continuing operations for the period came in at 58 cents a share  wider than the year earlier loss of 46 cents RevenuesWith the completion of non core PBM business divestment  BioScrip now has a simplified business structure focused on core Infusion Services Net revenues for the quarter under review were  182 6 million  a 23 9  decline year over year  This huge downside resulted from the company s shift in strategy to focus on growing its core revenue mix  This apart  the impact of the Cures Act and contract modifications with UnitedHealthcare  completed as of Sep 30  2017  were major deterrents   However  the top line exceeded the Zacks Consensus Estimate of  172 million BioScrip  Inc  Price  Consensus and EPS Surprise    Notably  net revenues in the fourth quarter included core product mix of 75 7   an improvement from 69 6  in the prior year period Gross margin for the reported time frame expanded 740 basis points  bps  year over year to 38 5  This significant upside was driven by seasonal revenue strength leveraging the company s infrastructure and reduced product cost  Operating expenses were  53 5 million  an 18  reduction from the tally in fourth quarter 2016 FinancialsBioScrip exited 2017 with cash and cash equivalents of  39 5 million compared with  9 6 million at the end of 2016 2018 Guidance For 2018  the company has provided revenue view in the range of  710  720 million  The Zacks Consensus Estimate of  722 13 million for the metric lies above the company s guided range Additionally  BioScrip expects to incur restructuring expenses in the band of  5  6 million in 2018  primarily reflecting costs related to redesigning and optimizing its revenue cycle management process  The company also expects 2018 capital expenditures between  12 million and  14 million Our TakeBioScrip exited the fourth quarter on a dismal note with lower than expected earnings performances  Although  revenues were above the consensus mark  the huge year over year decline was a disappointment Nonetheless  we are encouraged by the company s progress in the fourth quarter  courtesy of its new multi faceted CORE plan to improve the financial position  The company also expects core revenues at Home Solutions and continued core growth to be accretive to its portfolio  Moreover  we are upbeat about BioScrip s completion of the UnitedHealthcare contract transition and projections of core revenue rise  Besides  management s outlook for 2018 sounds promising Zacks Rank   Key PicksBioScrip has a Zacks Rank  3  Hold   A few better ranked stocks in the broader medical sector are PerkinElmer   NYSE PKI    Bio Rad Laboratories   NYSE BIO   and athenahealth  Inc    NASDAQ ATHN   PerkinElmer has a long term expected earnings growth rate of 12 3   The stock carries a Zacks Rank  2  Buy  Bio Rad Laboratories sports a Zacks Rank  1  Strong Buy   You can see The company has a long term expected earnings growth rate of 20  athenahealth is a Zacks  1 Ranked player  The company has a long term expected earnings growth rate of 21 5  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-03-11,Zacks Investment Research,https://www.investing.com/analysis/bioscrip-bios-loss-widens-in-q4-18-view-holds-promise-200297404,200297404
119810,341325,PKI,IDEXX Laboratories Gains On Solid Prospects   CAG Business,opinion,On Mar 9  we issued an updated research report on IDEXX Laboratories  Inc    NASDAQ IDXX    The company witnesses strong organic revenue growth in the international business  Additionally  its companion animal market fundamentals remain solid with tremendous global runway for growth  The stock carries a Zacks Rank  2  Buy  Also  this leading molecular diagnostic company has been outperforming its  in the past three months  The stock has rallied 28 4  compared with 11  gain of the industry Meanwhile  IDEXX continues to demonstrate solid growth globally with strong international expansion  In fourth quarter 2017  the company witnessed double digit organic revenue growth in the international business  This upside was owing to continued consumable revenue gains supported by Catalyst instrument base and average testing utilization In international markets  the company witnessed considerable organic lab revenue gains supported by positive customer response to SDMA as well as significant growth in rapid assay sales  In addition  management experienced steady growth in reference labs led by consistent gains in Europe  Furthermore  CAG organic revenue growth in low double digits on strong VetLab consumables and CAG Diagnostics recurring organic revenue growth is impressive  We are also optimistic about the company s expanding premium instrument base in the United States and international markets  including growth in competitive instrument placements  increasing utilization and continued customer retention Moving ahead  we expect the company to gain from the commercial launch of Catalyst SDMA Test in North America in January  IDEXX too entered into a global agreement with a diagnostic company   Applied BioCode    in the same month Moreover  IDEXX has a strong cash balance that allows it to carry out share repurchases  Nevertheless  its high dependence on third party distributors and intense competition continue to pose threats  Other Stocks to ConsiderSome other top ranked stocks in the broader medical sector are PerkinElmer   NYSE PKI    Bio Rad Laboratories   NYSE BIO   and athenahealth  Inc    NASDAQ ATHN   PerkinElmer has a long term expected earnings growth rate of 12 3   The stock carries a Zacks Rank  2 Bio Rad Laboratories sports a Zacks Rank  1  Strong Buy   You can see  The company has a long term expected earnings growth rate of 20  athenahealth is a Zacks  1 Ranked player  The company has a long term expected earnings growth rate of 21 5   The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-03-11,Zacks Investment Research,https://www.investing.com/analysis/idexx-laboratories-gains-on-solid-prospects--cag-business-200297367,200297367
119820,341335,PKI,Medtronic s Guardian Sensor 3 With MiniMed 670G Wins FDA Nod,opinion,Medtronic plc   NYSE MDT   announced that the FDA has approved a new arm indication for the Guardian Sensor 3 continuous glucose monitor  CGM  used with the MiniMed 670G insulin pump  Notably  the Guardian Sensor 3 is the company s latest and most accurate CGM  Per Medtronic  this is the only sensor to have received an FDA nod for controlling automated insulin delivery via a hybrid closed loop system  the MiniMed 670G It is important to note that Medtronic commercially launched the MiniMed 670G system in June 2017  The system is a Hybrid Closed Loop insulin delivery system for Type I diabetic patients aged 14 years or older The MiniMed 670G system features Medtronic s Guardian Sensor 3  a glucose sensor with increased accuracy and enhanced performance  This new arm indication for the Guardian Sensor 3 now offers more convenience and flexibility for patients  It is available in the United States for use with the MiniMed 670G system Progress in MiniMed PortfolioMedtronic has been forging ahead with initiatives to boost the performance of its MiniMed portfolio  Recently  the company expanded its product portfolio with the unveiling of MiniMed Mio Advance infusion set  The recent offering from the Diabetes business will be commercially available in Canada  Hong Kong and certain countries across Europe in fourth quarter fiscal 2018  However  the company plans an extensive launch of the same in 2018 Also  the company reported positive data from an at home pediatric study on patients aged between seven and 13 years  The outcome is based on MiniMed 670G system and was demonstrated at the Advanced Technologies   Treatments for Diabetes  11th International Conference in Vienna  Austria Developments in Diabetes BusinessMedtronic witnessed a 13  rise at constant exchange rate in the Diabetes business revenues during third quarter fiscal 2018  The company benefited from a positive uptake of new sensor augmented insulin pump systems in the United States as well as in the international markets along with enhanced production capacity for the same Notably  Medtronic expects double digit growth in the segment in fourth quarter fiscal 2018  courtesy of a consistent performance of MiniMed 670G system in the United States along with enhanced sensor supply capacity Additionally  Medtronic has been gearing up for the international introduction of the MiniMed 670G and the U S  launch of CGM system Guardian Connect with sugar IQ in late 2018 and its new professional CGM iPro 3 in 2019  In this regard  the company had earlier announced favorable results supporting the use of CGM on patients with type 2 diabetes in October 2017 Market PotentialAn ageing population  unhealthy lifestyle  a rising awareness as well as expenditure in healthcare are likely to drive growth in the diabetes market  Per a report by Mordor Intelligence  the global market for diabetes care devices is projected to reach a value of  30 25 billion by 2021 at a CAGR of 5 93   Considering the bullish market sentiments  we believe the latest development has arrived at an opportune moment Stock Performance   Estimate RevisionOver the last three months  shares of Medtronic have underperformed the   The stock hasdipped 1 9  against the industry s 4 2  growth and the S P 500 index s 2 6  gain Also  the estimate revision trend for the current year remains unfavorable with nine estimates moving south over the last two months compared with a couple in the opposite direction  Earnings estimates inched up around 0 4  to  4 75 per share over the same time frame Zacks Rank   Key PicksMedtronic carries a Zacks Rank  3  Hold   A few better ranked stocks in the broader medical sector are PerkinElmer   NYSE PKI    Bio Rad Laboratories   NYSE BIO   and Becton  Dickinson and Company   NYSE BDX   PerkinElmer has a long term expected earnings growth rate of 12 3   The stock carries a Zacks Rank  2  Buy  Bio Rad Laboratories sports a Zacks Rank  1  Strong Buy   You can see   The company has a long term expected earnings growth rate of 25  Becton  Dickinson and Company is a Zacks  2 Ranked player  The company has a long term expected earnings growth rate of 13 3   Don t Even Think About Buying Bitcoin Until You Read ThisThe most popular cryptocurrency skyrocketed last year  giving some investors the chance to bank 20X returns or even more  Those gains  however  came with serious volatility and risk  Bitcoin sank 25  or more 3 times in 2017 Zacks  has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly ,2018-03-01,Zacks Investment Research,https://www.investing.com/analysis/medtronics-guardian-sensor-3-with-minimed-670g-wins-fda-nod-200295642,200295642
119823,341338,PKI,Hologic s Alliance With Philips To Boost Breast Health Unit,opinion,In a bid to enhance the breast health portfolio  Hologic  Inc    NASDAQ HOLX   recently announced a worldwide collaboration deal with Royal Philips   NYSE PHG    a leading health technology company  The global partnership agreement will provide integrated imaging solutions for women s health Notably  the financial details of this multi year  non exclusive global partnership agreement have not been disclosed The agreement has been signed to offer integrated solutions to care professionals  These solutions will include diagnostic imaging modalities  advanced informatics  and services for screening  diagnosis and treatment of women across the world  The deal  coupled with Hologic s innovative mammography technologies and Philips  leading portfolio of ultrasound  MRI  CT  X ray systems  advanced informatics and broad range of services  is anticipated to boost the Breast and Skeletal Health Solutions segment of the former With this partnership  Hologic and Philips will work on projects which  previously  could not be undertaken by the companies  Per the press release  as part of the multi modality deals for hospitals and health systems  Philips will now be able to offer select products from Hologic s breast health portfolio  including the latter s new 3Dimensions mammography system Breast Health Unit in FocusSolid GrowthWe are upbeat about Hologic s consistent efforts to gain traction in the Breast Health business that has contributed 36  to the company s overall top line growth in first quarter fiscal 2018  This segment has recorded 4 2  growth at constant currency in the quarter The company s unique direct to consumer initiatives in the segment have provided it with a competitive edge in the niche space Recent Developments in the SegmentIn November 2017  the company announced a development and distribution agreement with Clarius Mobile Health for its portable ultrasound scanner system  The company also announced the receipt of the 510 k  clearance from the FDA for its Quantra 2 2 Breast Density Assessment Software later in the month  Notably  the software can be used with Hologic 3D Mammography systems Within this segment  the company has redesigned its R D strategy toward continued innovation around its leadership position in 3D mammography   Also  in November  the company announced plans to make all of its mammography systems available for the Dutch Breast Cancer Screening Program in collaboration with Tromp Medical  Hologic s distributor in the Netherlands In line with this  starting 2018  Hologic s latest 3Dimensions mammography systems will be installed in mobile and stationary screening facilities in the Netherlands  In September 2017  Hologic announced the commercial launch of the 3Dimensions mammography system in Europe Notably  in conjunction with enhanced 3D image quality for radiologists  this system provides improved workflow for technologists  Moreover  it aims to provide a more comfortable mammography experience with low dose options  The company is optimistic about the recent addition to its suite of breast cancer screening  diagnostic and interventional solutions under the Breast Health business Market Trends Buoy OptimismPer a report by DPI Research on Medium  the breast cancer screening market in the United States is expected to reach a value of roughly  5 8 billion by 2022 Also  per a report by GBI Research  the global breast cancer treatment market will reach a value of  17 2 billion by 2021  at a CAGR of 7 3  Thus  the company clearly has solid prospects in this market Share Price PerformanceOver the past month  Hologic has declined 5 4   underperforming the  s gain of 0 8   However  the company s estimate revision trend for the current year has been encouraging  In the past couple of months  11 analysts moved north versus one movement in the south  Earnings estimates have been raised around 5 6  to  2 25 per share during the same time frame Zacks Rank   Key PicksHologic carries a Zacks Rank  2  Buy  Couple of top ranked stocks in the broader medical sector are Bio Rad Laboratories   NYSE BIO   and PerkinElmer   NYSE PKI   Bio Rad Laboratories sports a Zacks Rank of 1  Strong Buy   You can see The company has a long term expected earnings growth rate of 20  PerkinElmer has a long term expected earnings growth rate of 12 3   The stock carries a Zacks Rank  2 The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-03-04,Zacks Investment Research,https://www.investing.com/analysis/hologics-alliance-with-philips-to-boost-breast-health-unit-200295924,200295924
119829,341344,PKI,Bio Rad  BIO  Q4 Earnings Improve Y Y  Revenues Top Mark,opinion,Bio Rad Laboratories  Inc    NYSE BIO   reported fourth quarter 2017 earnings of  2 32 per share against the year ago loss of 70 cents  thus making a huge improvement  The Zacks Consensus Estimate is pegged at earnings of  1 28 per share  Notably  net income in the quarter was favorably impacted by a substantial benefit from the 2017 Tax Cuts and Jobs Act  Net sales came in at  620 4 million  up 8 6  year over year  up 5 4  at constant exchange rate or CER   The top line closely beat the Zacks Consensus Estimate of  619 million  The year over year rise in sales was largely driven by strong sales in Life Science products including continued sturdy sales of Droplet Digital PCR instruments and consumables plus cell biology products Quarter in DetailOn a segmental basis  the Life Science s net sales came in at  237 9 million  up 15  year over year  up 12 3  at CER   Also  sales at Droplet Digital PCR  ddPCR   cell biology product lines and process media rose on the back of a strong performance at CER  Geographically  North America  Europe and Asia Pacific demonstrated a sturdy flourish Bio Rad Laboratories  Inc  Price  Consensus and EPS Surprise    Within Clinical Diagnostics  the company registered sales of  378 4 million  up 4 9  year over year  up 1 5  at CER   This upside resulted from an increase in blood typing  immunology  diabetes and quality control product lines Gross margin of 54 7  during the reported quarter contracted 28 basis points  bps  year over year despite an 8  climb in gross profits  Adjusted operating margin however  expanded 300 basis points to 9 4  with a 59 1  surge in adjusted operating profit The company exited the year 2017 with cash and cash equivalents plus short term investments of  760 5 million compared with  844 million at the end of 2016  Full year net cash provided by operating activities was  103 9 million compared with  216 4 million a year ago 2018 Guidance For 2018  Bio Rad expects currency neutral revenue growth of approximately 3 5 4   This outlook anticipates continued strong sales in Life Science segment and increased growth for Diagnostics  The Zacks Consensus Estimate for 2018 is pegged at  2 30 billion  Operating margin at constant exchange rate is targeted at 10  of revenues Bottom LineBio Rad posted a strong quarterly performance with both earnings and sales showing a sharp year over year improvement  Sales growth was majorly driven by the company s many Life Science product lines  Within Diagnostics  instrument placement was solid throughout 2017  A promising 2018 guidance further instills confidence on the stock  However  contraction in gross margin in the quarter under review was due toescalated warranty and service costs  largely associated with higher instrument placements Zacks Rank   Key PicksBio Rad has a Zacks Rank  3  Hold   A few better ranked medical stocks are PetMed Express   NASDAQ PETS    PerkinElmer   NYSE PKI   and Becton  Dickinson and Company   NYSE BDX    While PetMed and PerkinElmer sport a Zacks Rank  1  Strong Buy   Becton  Dickinson and Company carries a Zacks Rank  2  Buy   You can see PetMed reported third quarter fiscal 2018 results  Adjusted EPS of 44 cents soared 88 3  from the prior year quarter  Revenues rose 13 7  to  60 1 million PerkinElmer reported fourth quarter 2017 adjusted EPS of 97 cents  Adjusted revenues were approximately  641 6 million  up from  567 million in the year earlier quarter Becton  Dickinson reported first quarter 2018 adjusted EPS of  2 48  up 3 9  at constant currency  Revenues totaled  3 08 billion  up 3 7  on constant currency basis The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-03-04,Zacks Investment Research,https://www.investing.com/analysis/biorad-bio-q4-earnings-improve-yy-revenues-top-mark-200295907,200295907
119830,341345,PKI,Here s Why Teleflex Has Been Losing Ground Since Q4 Earnings,opinion,Teleflex Incorporated s   NYSE TFX   shares lost 7 6  to close at  250 51 after it announced earnings results on Mar 5  The company reported adjusted earnings per share of  2 44 in fourth quarter 2017  beating the Zacks Consensus Estimate of  2 40  Earnings improved 14 6  from the year ago figure of  2 13 Revenues in DetailAdjusted revenues in the fourth quarter increased 15 8  year over year to  595 1 million  12 6  at constant exchange rate or CER  but missed the Zacks Consensus Estimate of  602 million owing to some temporary softness On a segmental basis  Vascular North America revenues increased 0 5   0 3  at CER  year over year in the fourth quarter to  80 7 million Teleflex Incorporated Price  Consensus and EPS Surprise     Interventional North America revenues increased 177 6  in the fourth quarter from the year ago quarter  177 2  at CER  to  61 7 million Anesthesia North America revenues were down 9 2  from the year ago quarter  down 9 4  at CER  to  49 9 million Surgical North America revenues in the fourth quarter were down 9 4  from the year ago quarter  9 8  at CER  to  43 7 million EMEA revenues increased 5 8  from the year ago quarter but fell 2  at CER to  143 6 million  Asia revenues rose 8  in the quarter from the year ago quarter  4 5  at CER  to  78 8 million  OEM revenues climbed 1 3  from the year ago quarter but declined 0 1  at CER to  46 million  All other revenues increased 67   67 6  at CER  to  90 7 million in the quarter under review Operational UpdateTeleflex s gross profit during the reported quarter increased 21 1  year over year to  330 7 million  Gross margin expanded 245 basis points  bps  to 55 6  SG A expenses in the fourth quarter rose 47 9  year over year to  213 3 million  Research and development expenses rose 62 4  year over year to  25 5 million  Operating expenses totaled  238 8 million in the fourth quarter  up 49 3  year over year Adjusted operating margin in the quarter was 15 5   down 657 bps from the year ago quarter Financial UpdateTeleflex exited 2017 with cash and cash equivalents of  333 6 million  compared with  543 8 million at the end of 2016 2017 at a GlanceFull year adjusted earnings came in at  8 40 compared with the year ago figure of  7 34  reflecting an increase of 14 4  Full year adjusted revenues came in at  2146 3 million  up 14 9  from the year ago period 2018 GuidanceFor 2018  Teleflex expects adjusted revenues growth at CER in the band of 12 13   The company also expects adjusted earnings per share in the band of  9 55  9 75  The Zacks Consensus Estimate for full year earnings per share is pegged at  9 68  within the company s guided range  The Zacks Consensus Estimate for full year revenues stands at  2 46 billion Our TakeTeleflex exitedfourth quarter 2017 on a mixed note  We are encouraged to note that the company is working on product innovation through R D  However  the contraction in operating margin is discouraging  Also  a tough competitive landscape acts as a dampener Zacks Rank   Key PicksTeleflex has a Zacks Rank  3  Hold  A few better ranked stocks that reported solid results this earnings season are PetMed Express   NASDAQ PETS    PerkinElmer   NYSE PKI   and ResMed   NYSE RMD    While PetMed sports a Zacks Rank  1  Strong Buy   PerkinElmer and ResMed carry a Zacks Rank  2  Buy   You can see PetMed reported third quarter fiscal 2018 results  Adjusted earnings per share were 44 cents  up 88 3  from the prior year quarter  Revenues rose 13 7  on a year over year basis to  60 1 million PerkinElmer reported fourth quarter 2017 adjusted earnings per share of 97 cents  Adjusted revenues were approximately  641 6 million  up from  567 million in the year ago quarter ResMed posted second quarter fiscal 2018 adjusted earnings per share of  1  up 36 9  from the prior year quarter  Revenues in the reported quarter increased 13 4  year over year  up 11  at constant exchange rate or CER  to  601 3 million Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-03-05,Zacks Investment Research,https://www.investing.com/analysis/heres-why-teleflex-has-been-losing-ground-since-q4-earnings-200296112,200296112
119831,341346,PKI,Integra LifeSciences Banks On CSS Segment  Competition Rife,opinion,On Mar 3  we issued an updated research report on Integra LifeSciences Holdings Corporation   NASDAQ IART    The stock carries a Zacks Rank  3  Hold  Integra LifeSciences exited the fourth quarter of 2017 on a solid note  The strong year over year increase in revenues on the back of the company s recently acquired business   Johnson   Johnson  NYSE JNJ  Codman Neurosurgery business and Derma Sciences  buoys optimism  However  a tough competitive landscape adds to the company s woes Over the past year  Integra LifeSciences has outperformed the   The stock has gained 25 9   compared with 2 7  decline of the industry Coming to the quarterly results  Integra LifeSciences saw 2 3  organic growth in the Codman Specialty Surgical  CSS  segment in fourth quarter  Reported revenues in the quarter grew 46 2  on the back of revenues from Codman Neurosurgery  This can be attributed to the sequential double digit growth registered by Tissue ablation business owing to strong capital sales of the newly launched CUSA Clarity  This apart  Dural Repair business performed well with 5  year over year organic growth on strength in DuraGen and DuraSeal product lines   We are also encouraged to note that the segments saw year over year revenue growth in the period  Nonetheless  we believe the company is trying to execute its growth plan through an efficient management team  Moreover  the rise in year over year investments in research and development is encouraging  Also  the company s promising guidance instills investor confidence in the stock However  Integra LifeSciences faces intense competition in the surgical implants and medical instruments market  The company needs to be innovative on the product front to fend off competition  Moreover  consolidation in the industry could lead to intense pricing pressure Also  significant margin contractions caused by escalating costs and expenses raise concerns Further  the company generates significant revenues from the international business  which increases its vulnerability to adverse currency movements Key PicksA few better ranked stocks in the broader medical sector are PerkinElmer   NYSE PKI    Bio Rad Laboratories   NYSE BIO   and athenahealth  Inc    NASDAQ ATHN   Bio Rad Laboratories sports a Zacks Rank of 1  Strong Buy   You can see  The company has a long term expected earnings growth rate of 20  PerkinElmer has a long term expected earnings growth rate of 12 3   The stock carries a Zacks Rank  2 athenahealth is a Zacks  1 Ranked player  The company has a long term expected earnings growth rate of 21 5  Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-03-05,Zacks Investment Research,https://www.investing.com/analysis/integra-lifesciences-banks-on-css-segment-competition-rife-200296111,200296111
119832,341347,PKI,Abaxis Banks On Strong Veterinary Business Amid Margin Woes,opinion,On Mar 5  we issued an updated research report on Abaxis  Inc    NASDAQ ABAX    The company has been witnessing strength in the Veterinary business based on encouraging consumable segment s growth  However  rising expenses along with a bleak gross and operating margin scenario have been raising concern  The stock carries a Zacks Rank  3  Hold  This manufacturer of portable Medical  human  and Veterinary  animal  blood analysis systems  providing clinicians with rapid blood constituent measurements in medical and veterinarian markets globally  has outperformed its  in the past three months  The stock has gained 44 2  compared with the industry s 4 1  We are upbeat about Abaxis  double digit consumable growth within the Veterinary business  Within the consumable product lines  total rotor revenues grew double digits  This apart  other veterinary consumable  which includes hematology reagents  rapid assays  i STAT cartridges  coagulation cartridges and urine analysis strips drove veterinary consumable revenues   Moreover  Abaxis has been emphasizing on product innovation through research and development  In this regard  in January  the company received approval from USDA  Center for Veterinary Biologics  for VetScan FLEX4 Rapid Test Solid global sales of Piccolo instruments are encouraging  Per management  as healthcare delivery consolidates across the United States into these groups  networks and healthcare conglomerates  Abaxis  Piccolo is positioned to capture the lion s share of the diagnostic tests market Meanwhile  escalating operating expenses have been exerting pressure on the bottom line  Moreover  Abaxis faces intense competition in both the Medical and Veterinary markets  In this regard  the company competes against firms that have substantially greater resources on all fronts   financial  research and development  R D  plus operations and marketing  Key PicksA few better ranked stocks in the broader medical sector are Bio Rad Laboratories   NYSE BIO    PetMed Express   NASDAQ PETS   and PerkinElmer   NYSE PKI   Bio Rad Laboratories sports a Zacks Rank of 1  Strong Buy   You can see The company has a long term expected earnings growth rate of 20  PetMed has a long term expected earnings growth rate of 10  and boasts a Zacks Rank  1 PerkinElmer has a long term expected earnings growth rate of 12 3   The stock carries a Zacks Rank  2  Buy  Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-03-05,Zacks Investment Research,https://www.investing.com/analysis/abaxis-banks-on-strong-veterinary-business-amid-margin-woes-200296100,200296100
119838,341353,PKI,Boston Scientific Acquires EMcision  Boosts Endoscopy Unit,opinion,Boston Scientific   NYSE BSX   recently broadened its Endoscopy portfolio with the buyout of a privately held company   EMcision  Limited   with presence in the U K  and Canada  Although the financial terms of the deal have been kept under wraps  the company expects the deal to prove accretive to earnings post 2018 Post acquisition  Boston Scientific s Endoscopy portfolio will include EMcision s FDA approved and CE Marked Habib EndoHPB probe  Notably  Habib EndoHPB probe is an innovative endoscopic bipolar radiofrequency device that coagulates tissue in the gastrointestinal  GI  tract  Moreover  the Habib EndoHPB probe aids in the treatment and palliative care of patients diagnosed with pancreaticobiliary cancer A Glimpse of the Endoscopy BusinessBoston Scientific s Endoscopy division develops and manufactures devices to treat a variety of digestive diseases  including those affecting the oesophagus  stomach  liver  pancreas  duodenum and colon  Revenues at this division rose 14 8  year over year to  436 million in the last reported quarter The upside was driven by strength in the biliary  hemostasis and EndoChoice ambulatory surgery center portfolio  The company also witnessed organic revenue growth of 10  at the segment   Last November  Boston Scientific completed the integration of EndoChoice into the Endoscopy business  Acquired in 2016  EndoChoice Holdings  focuses on the development and commercialization of pathology services  infection control products and single use devices for treating a variety of gastrointestinal conditions  Thus  we believe the latest buyout will help Boston Scientific boost top line contributions from the Endoscopy business Market ProspectsPer a Market Data Forecast report  the global pancreatic cancer therapeutics market is projected to reach a value of  2 99 billion by 2021  at a CAGR of 7 5   during the 2016 2021 period  The upbeat prospects of the market are primarily based on rising consumption of tobacco  unhealthy lifestyle practices like smoking  an aging population and obesity Per the company  around one million deaths annually can be attributed to pancreaticobiliary cancer globally  Thus  the addition of Habib EndoHPB probe will help Boston Scientific cash in on the abundant opportunities in the pancreatic cancer therapeutics market Share Price MovementOver the past three months  Boston Scientific has been outperforming its   The stock has gained 8 6  compared with the industry s 4  gain Zacks Rank   Key PicksBoston Scientific carries a Zacks Rank  3  Hold  Some better ranked stocks in the broader medical sector are Bio Rad Laboratories   NYSE BIO    PetMed Express   NASDAQ PETS   and PerkinElmer   NYSE PKI   Bio Rad Laboratories sports a Zacks Rank of 1  Strong Buy   You can see  The company has a long term expected earnings growth rate of 20  PetMed has a long term expected earnings growth rate of 10  and a Zacks Rank  1 PerkinElmer has a long term expected earnings growth rate of 12 3   The stock carries a Zacks Rank  2  Buy  Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-03-05,Zacks Investment Research,https://www.investing.com/analysis/boston-scientific-acquires-emcision-boosts-endoscopy-unit-200296086,200296086
119841,341356,PKI,Chimerix Q4 Loss Narrower Than Expected  Revenues Exceed,opinion,Chimerix  Inc    NASDAQ CMRX   reported net loss from continuing operations of 41 cents per share in the fourth quarter of 2017  wider than net loss of 32 cents a year ago  However  the same was narrower than the Zacks Consensus Estimate of a loss of 48 cents  For the full year  net loss came in at  1 51 per share  narrower than  1 65 a year ago RevenuesIn the fourth quarter  Chimerix reported Contract revenues of  1 8 million  down 7 1  year over year  The top line however  exceeded the Zacks Consensus Estimate of  1 million  The year over year decline resulted from a fall in reimbursable expenses related to the company s BARDA developmental contract Full year Contract revenues came in at  4 49 million  a 21 2  drop from the year ago period s level Research and development expenses totaled  12 9 million  up 10 3  year over year in the reported quarter  This downside was primarily due to the ongoing AdVance trial and the initiation of the AdAPT trial  General and administrative expenses amounted to  7 6 million  a 34 9  surge year over year  primarily on an increase in market education and launch readiness Chimerix  Inc  Price  Consensus and EPS Surprise    Consequently  loss from operations came in at  18 7 million  wider than  15 4 million in the prior year quarter  This operating loss may be attributed to significantly lower revenues year over year and escalating costs plus expenses FinancialsChimerix exited 2017 with cash and cash equivalents and short term investments of  151 5 million compared with  232 1 million recorded at the end of 2016 Our TakeChimerix exited the fourth quarter of 2017 on a positive note with narrower than estimated loss and revenues surpassing the Zacks Consensus Estimate  However  a year over year decrease in the top line was a concern Nonetheless  we are encouraged by the company s progress in the fourth quarter  courtesy of its advancement with lead product candidate  brincidofovir  The company witnessed impressive enrollments in its multiple ascending dose study of IV BCV In the quarter under review  the company commenced AdAPT study in both the United States and the EU  The study is designed to provide comparative data on brincidofovir for patients with life threatening adenovirus infection  The company is also progressing well with its ongoing first time in human study on CMX521 Zacks Rank   Key PicksChimerix has a Zacks Rank  3  Hold   A few better ranked stocks that have already reported solid earnings results are PetMed Express   NASDAQ PETS    PerkinElmer   NYSE PKI   and Becton  Dickinson and Company   NYSE BDX    While PetMed sports a Zacks Rank  1  Strong Buy   PerkinElmer and Becton  Dickinson carry a Zacks Rank  2  Buy   You can see   PetMed reported third quarter fiscal 2018 results  Adjusted earnings per share of 44 cents were up 88 3  from the prior year quarter  Revenues rose 13 7  on a year over year basis to  60 1 million PerkinElmer reported fourth quarter 2017 adjusted earnings per share of 97 cents  Adjusted revenues were approximately  641 6 million  up from  567 million in the year ago quarter Becton  Dickinson reported first quarter fiscal 2018 adjusted earnings per share of  2 48  up 3 9  at constant currency  Revenues totaled  3 08 billion  up 3 7  on constant currency basis Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-03-05,Zacks Investment Research,https://www.investing.com/analysis/chimerix-q4-loss-narrower-than-expected-revenues-exceed-200296070,200296070
119844,341359,PKI,NuVasive Gains From International Business Amid Pricing Woes,opinion,On Mar 5  we issued an updated research report on NuVasive  Inc    NASDAQ NUVA    While a strong Spine market spells huge scope for this Zacks Rank  3  Hold  stock  pricing and payer pressure come as major headwinds Notably  NuVasive exited the fourth quarter of 2017 on a dismal note with its top line missing the Zacks Consensus Estimate  The U S  business also delivered a dull performance with softness in both U S  Spinal Hardware and U S  Surgical Support businesses On a positive note  the company s solid international business registered more than 20  growth for the fifth consecutive quarter  buoying optimism on the stock among investors  Per management  the International region holds a tremendous growth opportunity for NuVasive Also  NuVasive s U S  surgical support business has performed robustly in the recent times  This segment s flourish is attributed to Biotronic  acquired in July 2016  With its integration still on track pertaining to a large scale buyout  the company anticipates benefits of building an up scale service business Management believes that the addition of Biotronic to NuVasive s profile has enhanced the company s service offerings and is delivering a greater consolidation across its procedurally integrated portfolio Currency volatility  reimbursement issues and a competitive landscape have been continuously posing challenges to the stock  Also  pricing pressure persists as a big concern for NuVasive with the company facing declining product prices due to stiff competition in the spine market  In the past three months  NuVasive has underperformed the  it belongs to  The stock has declined 12 3  against the industry s 4 7  gain  Key PicksSome better ranked stocks in the broader medical sector are Bio Rad Laboratories   NYSE BIO    PetMed Express   NASDAQ PETS   and PerkinElmer   NYSE PKI   Bio Rad Laboratories sports a Zacks Rank  1  Strong Buy   You can see  The company has a long term expected earnings growth rate of 20  PetMed has a long term expected earnings growth rate of 10  and a Zacks Rank of 1 PerkinElmer has a long term expected earnings growth rate of 12 3  and a Zacks Rank  2  Buy  Breaking News  Cryptocurrencies Now Bigger than VisaThe total market cap of all cryptos recently surpassed  700 billion   more than a 3 800  increase in the previous 12 months  They re now bigger than Morgan Stanley  NYSE MS   Goldman Sachs  NYSE GS  and even Visa  The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved Zacks has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market ,2018-03-06,Zacks Investment Research,https://www.investing.com/analysis/nuvasive-gains-from-international-business-amid-pricing-woes-200296416,200296416
119879,341394,PKI,Penumbra  PEN  Posts Earnings In Q4  Revenues Top Estimates,opinion,"Penumbra  Inc    NYSE PEN   reported fourth quarter 2017 earnings per share of 10 cents  comparing favorably with a loss of 9 cents in the year ago quarter  The figure is also better than the Zacks Consensus Estimate of a loss of a penny The company reported full year 2017 adjusted loss of a penny  narrower than the Zacks Consensus Estimate of a loss of 14 cents  The figure also compares favorably with the year ago loss of 7 cents Revenues in the reported quarter rose 31 4  year over year  up 29 7  at constant exchange rate or CER  to  96 1 million  exceeding the Zacks Consensus Estimate of  87 7 million Net revenues in 2017 totaled  333 8 million  outpacing the Zacks Consensus Estimate of  325 4 million  The figure also improved 26 8   up 26 4  at CER  from the year ago level On a geographic basis  fourth quarter revenues in the United States  representing 64 1  of total sales  grossed  61 6 million  up 26 7  from the year ago quarter  same at CER   Meanwhile  international sales  35 9  of total sales  advanced 40 6  year over year  up 35 6  at CER  to  34 4 million 
Penumbra  Inc  Price  Consensus and EPS Surprise
     Going by product category  revenues from neuro products grew 31 1   up 29 2  at CER  to  67 3 million in the quarter under review  Revenues from peripheral vascular product business rose to  28 7 million in the fourth quarter  reflecting an increase of 32 1   up 30 9  at CER  year over year Operational UpdatePenumbra s fourth quarter gross margin was 66 3   reflecting a 260 basis point  bps  expansion year over year  Gross profit rose 36 7  Research and development expenses totaled  8 4 million  up 37 7   while sales  general and administrative expenses amounted to  51 5 million  up 23 8  year over year  Operating profit in the reported quarter came in at  3 9 million  comparing favorably with the operating loss of  1 2 million in the prior year quarter Financial UpdatePenumbra exited 2017 with cash and cash equivalents of  50 6 million as compared with  13 2 million at the end of 2016 OutlookPenumbra has provided guidance for 2018 revenues  The company expects total revenues in the range of  400  405 million  The Zacks Consensus Estimate of  389 8 million lags the guided range Our TakePenumbra exited fourth quarter 2017 with better than expected results  The year over year comparison of earnings was favorable  Moreover  the company witnessed strong growth across all geographies and product lines  The company is focusing on product innovation through research and development Penumbra is an active player in the fast growing interventional therapies space  In fact  the company s products primarily cater to the unmet clinical needs in two major markets   neuro and peripheral vascular Zacks Rank   Key PicksPenumbra has a Zacks Rank  3  Hold  A few better ranked stocks that reported solid results this earnings season are PetMed Express   NASDAQ PETS    PerkinElmer   NYSE PKI   and Becton  Dickinson and Company   NYSE BDX    While PetMed sports a Zacks Rank  1  Strong Buy   PerkinElmer and Becton  Dickinson carry a Zacks Rank  2  Buy   You can see   PetMed reported third quarter fiscal 2018 results  Adjusted earnings per share of 44 cents were up 88 3  from the prior year quarter  Revenues rose 13 7  on a year over year basis to  60 1 million PerkinElmer reported fourth quarter 2017 adjusted earnings per share of 97 cents  Adjusted revenues were approximately  641 6 million  up from  567 million in the year ago quarter Becton  Dickinson reported first quarter 2018 adjusted earnings per share of  2 48  up 3 9  at constant currency  Revenues totaled  3 08 billion  up 3 7  at constant currency Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2018-02-27,Zacks Investment Research,https://www.investing.com/analysis/penumbra-pen-posts-earnings-in-q4-revenues-top-estimates-200295127,200295127
119880,341395,PKI,Express Scripts  ESRX  Q4 Earnings Top  Long Term View Solid,opinion,Express Scripts Holding Company   NASDAQ ESRX   posted fourth quarter 2017 adjusted earnings of  2 16 per share  which beat the Zacks Consensus Estimate of  2 08  Further  adjusted earnings improved from  1 88 per share in the year ago quarter Revenues of  25 38 billion also beat the Zacks Consensus Estimate of  25 12 billion and increased from  25 12 billion in the year ago quarter  Q4 Patient Claim Volume DetailsExpress Scripts  fourth quarter 2017 results benefited from a rise in patient claims and strong customer retention Adjusted network claims were 270 3 million  up 1 54  year over year Adjusted home delivery and specialty claims were 85 5 million in the fourth quarter  down 3 6  year over year As a result  net adjusted claims in the fourth quarter were 355 8 million  flat on a year over year basis Notably  adjusted EBITDA  earnings before interest  tax  depreciation and amortization  per adjusted patient claim in the fourth quarter was  6 04  higher than  5 79 reported in the year ago quarter  Express Scripts Holding Company Price and Consensus     Margin DetailsAdjusted gross profit in the fourth quarter was  2 55 billion  up 6 5  year over year  As a percentage of revenues  adjusted gross margin expanded 42 basis points  bps  to 10  of net revenues Adjusted selling  general and administrative expenses were  483 2 million  up 16 3  from the prior year quarter The upside in margins was driven by operational cost improvement backed by focus on technology  digital tools  home delivery and specialty services Balance SheetNet cash flow provided by operating activities was down 39  year over year The company exited the quarter with cash and cash equivalents of  2 31 billion  down from  3 07 billion in the year ago quarter Total debt  at the end of the quarter  was  1 03 billion  up from  722 3 million at the end of 2016  In fact  the company is striving to reduce debt level Guidance Adjusted claims for the first quarter of 2018 are expected in the range of 335 345 million Adjusted earnings per share for the first quarter of 2018 are estimated in the range of  1 73  1 78  This represents growth of 30 34  on a year over year basis For the full year  adjusted earnings are estimated in the band of  9 27 to  9 47  reflecting growth of 31 33  year over year  Revenues are expected in the band of  99 000 million to  102 000 million  Adjusted EBITDA is expected between  7 600 million and  7 800 million Coming to guidance for Express Scripts  core business  total adjusted claims are expected in the range of 280 290 million for the first quarter of 2018  For 2018  total adjusted claims from core business are expected between 1 125 and 1 165  Net revenues are estimated in the range of  80 500  83 000 million Long term ViewBuoyed by strong results in the quarter  Express Scripts  enterprise value initiative is estimated to cost  600  650 million  Notably  management expects cumulative savings of nearly  1 2 billion by 2021 Further  the company s targeted compounded annual adjusted EBITDA growth rate for the core business from 2017 2020 of between 2  and 4  is a positive Zacks Rank   Other Key PicksExpress Scripts has a Zacks Rank  2  Buy  A few other top ranked stocks in the broader medical sector are PerkinElmer   NYSE PKI    Bio Rad Laboratories   NYSE BIO   and Becton  Dickinson and Company   NYSE BDX   Bio Rad Laboratories sports a Zacks Rank of  1  Strong Buy   You can see The company has a long term expected earnings growth rate of 25  PerkinElmer has a long term expected earnings growth rate of 12 3   The stock carries a Zacks Rank  2 Becton  Dickinson and Company is a Zacks  2 Ranked player  The company has a long term expected earnings growth rate of 13 3  Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-02-27,Zacks Investment Research,https://www.investing.com/analysis/express-scripts-esrx-q4-earnings-top-longterm-view-solid-200295089,200295089
119881,341396,PKI,Masimo  MASI  Beats On Q4 Earnings   Revenues  View Positive,opinion,Masimo Corp    NASDAQ MASI   reported earnings of 72 cents per share in the fourth quarter of 2017  outperforming the Zacks Consensus Estimate of 61 cents  The bottom line improved from the year ago quarter s figure of 51 cents Revenues improved 22 9  to  225 2 million from  183 2 million in the year ago quarter and beat the Zacks Consensus Estimate of  202 million Segmental AnalysisProduct Revenues Product revenues delivered another strong quarter of double digit growth  In the fourth quarter  Masimo acquired significant renewals from renowned hospitals and hospital systems   U S  revenue growth in the segment was in double digits  Product revenues also witnessed impressive growth in overseas markets  New products  including NomoLine capnography  SedLine Brain Function Monitoring and O3 organ oximetry contributed to the result  Revenues in the segment were  199 2 million  up 13 4  year over year The company s worldwide direct product revenues increased 13 5  to  173 4 million on a year over year basis  Direct product revenues were 87 1  of total product revenues OEM sales increased 12 6  on a year over year basis to  25 8 million in the fourth quarter  This accounted for 12 9  of total product revenues Revenues from sales of Masimo rainbow products surged 42 5  to  24 0 million in the fourth quarter of 2017 compared with  16 9 million in the year ago quarter Royalty and Other RevenuesRevenues in this segment were  26 million for the quarter  up from  7 5 million in the year ago quarter  Per management  Royalty revenues from Medtronic   NYSE MDT   declined  0 5 million to  7 million Margin AnalysisTotal gross profit in the fourth quarter was  153 9 million  up 23 8  year over year  Gross margin was 68 3  of net revenues  up 40 basis points  bps  year over year Product gross margin for the fourth quarter was 65 3  of net revenues  compared with 66 5  in the year ago quarter Balance SheetAt the end of fourth quarter  total cash and cash equivalents were  315 3 million compared with  306 0 million in the year ago quarter During 2017  Masimo repurchased approximately 0 8 million shares of common stock at a total cost of  68 3 million GuidanceFor 2018  revenues are estimated at  836 million Total 2018 product revenues are estimated at  808 million Royalty and other revenues are estimated at around  28 million Adjusted earnings per share for 2018 ar expected at  2 80  reflecting an increase of approximately 14  year over year Other Companies with Solid Earnings ResultsOther MedTech companies that reported impressive results this earnings season are PetMed Express   NASDAQ PETS   and PerkinElmer   NYSE PKI  PetMed reported third quarter fiscal 2018 results on Jan 22  Adjusted earnings per share were 44 cents  up 88 3  from the prior year quarter  Revenues rose 13 7  on a year over year basis to  60 1 million PerkinElmer reported fourth quarter 2017 adjusted earnings per share of 97 cents on Jan 25  Adjusted revenues were approximately  641 6 million  up from  567 million in the year ago quarter The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ,2018-02-28,Zacks Investment Research,https://www.investing.com/analysis/masimo-masi-beats-on-q4-earnings--revenues-view-positive-200295321,200295321
119882,341397,PKI,Patterson Companies  PDCO  Misses On Q3 Earnings  Cuts View,opinion,"Patterson Companies Inc    NASDAQ PDCO   reported adjusted earnings of 43 cents per share in third quarter fiscal 2018  missing the Zacks Consensus Estimate of 51 cents  Earnings fell 25 9  year over year Net sales dipped 1 6  from the year ago quarter to  1 375 billion  which beat the Zacks Consensus Estimate of  1 382 billion Adjusting the effects of foreign currency exchange  sales declined 2 7  on a year over year basis Decreased sales and gross margin compression marred the company s results in the reported quarter Patterson Companies  Inc  Price and Consensus     
Patterson Companies has a Zacks Rank  2  Buy  Segmental AnalysisThe company currently distributes its products mainly through two subsidiaries   Patterson Dental and Patterson Animal Health Dental SegmentThis segment provides a virtually complete range of consumable dental products  equipment  software  turnkey digital solutions and value added services to dentists and dental laboratories throughout North America In the third quarter  dental sales  42  of total sales  declined 8 1  at cc year over year to approximately  577 9 million  Changes in sales force  disruptions from enterprise resource planning implementation and the expansion of the company s digital equipment portfolio marred revenues in the segmentDental ConsumableSales in the segment were  302 3 million  down 7 4  year over year Dental Equipment   SoftwareSales at the segment declined 10 6  on a year over year basis to  207 million Other Services and ProductsThis segment is primarily composed of technical service  parts and labor  software support services and office supplies decreased 3 4  on a year over year basis to  65 6 million Animal Health SegmentThis segment is a leading distributor of products  services and technologies to the production and companion animal health markets in North America and the U K Coming to the third quarter performance of the platform  58  of total sales   sales increased almost 4 2  at cc on a year over year basis to  794 9 million Global companion animal sales inched up 0 4   Production animal sales increased 8 8   reflecting strong performance across swine and beef cattle segment Margin AnalysisGross profit in the reported quarter was  294 7 million  down 10 6  year over year  As a percentage of revenues  gross margin contracted 200 basis points  bps  to 21 4  in the quarter Operating income in the third quarter was  50 04 million  up 7 5  year over year    As a percentage of revenues  operating margin expanded 31 bps to 21 4  in the quarter Share Repurchase UpdatePatterson Companies repurchased approximately 0 4 million shares of outstanding common stock for  13 5 million in the reported quarter  The company also paid  24 7 million in cash dividends to shareholders Guidance DownbeatThe company expects adjusted earnings per share for fiscal 2018 in the range of  1 65  1 70 per share  much lower than the previously issued range of  2 00  2 10 Patterson Companies expects deal amortization expenses of  26 9 million or 29 cents per share The company estimates integration and business restructuring expenses at  5 7 million or 6 cents per share Our TakeLackluster sales and earnings performance dampened Patterson Companies  fourth quarter results  However  we are upbeat about the company s Animal Health segment that has been performing well lately  The company provides a wide range of consumable supplies  equipment  software and value added services  The company s broad spectrum of products cushions it against economic downturns in the MedTech space  We believe a diversified product portfolio  strong veterinary business prospects  accretive acquisitions and strategic partnerships are key growth catalysts On the flip side  a downbeat guidance indicates looming concerns ahead   Decreasing revenues in the dental segment is another headwind  The recent decline in the segment is driven by decreased sales of CEREC and digital technology products  Management expects headwinds in the technology based equipment business to persist through fiscal 2018 Key PicksOther top ranked stocks that reported solid results this earnings season are PetMed Express   NASDAQ PETS    PerkinElmer   NYSE PKI   and Becton  Dickinson and Company   NYSE BDX    While PetMed sports a Zacks Rank  1  Strong Buy   PerkinElmer and Becton  Dickinson carry a Zacks Rank  2  You can see   PetMed reported third quarter fiscal 2018 adjusted earnings per share of 44 cents  up 88 3  from the prior year quarter  Revenues rose 13 7  to  60 1 million PerkinElmer posted fourth quarter 2017 adjusted earnings per share of 97 cents  Adjusted revenues were approximately  641 6 million  up from  567 million a year ago Becton  Dickinson reported first quarter 2018 adjusted earnings per share of  2 48  up 3 9  at constant currency  Revenues totaled  3 08 billion  up 3 7  at constant currency Don t Even Think About Buying Bitcoin Until You Read ThisThe most popular cryptocurrency skyrocketed last year  giving some investors the chance to bank 20X returns or even more  Those gains  however  came with serious volatility and risk  Bitcoin sank 25  or more 3 times in 2017 Zacks has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly ",2018-03-01,Zacks Investment Research,https://www.investing.com/analysis/patterson-companies-pdco-misses-on-q3-earnings-cuts-view-200295616,200295616
119883,341398,PKI,DENTSPLY  XRAY  Earnings And Revenues Beat Estimates In Q4,opinion,DENTSPLY SIRONA Inc    NASDAQ XRAY   announced preliminary fourth quarter 2017 results The company reported adjusted earnings per share  EPS  of 82 cents  beating the Zacks Consensus Estimate by a penny  However  per the preliminary results  the metric decreased 22 4  year over year Preliminary net sales increased to  1 091 million from  996 5 million a year ago  Also  the figure surpassed the Zacks Consensus Estimate of  1056 0 million and rose 5 3  at constant currency  cc  exchange rate The top line was favorably impacted by approximately  21 million as a result of inventory build in the distribution channels  The stock carries a Zacks Rank  4  Sell  DENTSPLY SIRONA Inc  Price and EPS Surprise    Net sales  Excluding Precious Metal Impact Net sales of the company s precious metal dental alloy products  which are used by third parties to construct crown and bridge materials  are subject to risks from fluctuations of precious metal prices To avoid the impact of fluctuating prices  DENTSPLY reports net sales with and without precious metal content to show actual performance  independent of precious metal price volatility Preliminary net sales at the segment were  1080 7 million  up 10  year over year Segmental DetailsThe business is organized into two reporting segments  Dental   Healthcare Consumables and Technologies Dental   Healthcare ConsumablesThe segment comprises preventive  restorative  instruments  endodontic and laboratory dental products as well as consumable medical device products Per the preliminary results  sales improved 9 1  to  460 8 million in the segment  up 4 6  at cc Technologies   Equipment segmentTechnologies consist of dental implants  CAD CAM systems  imaging systems  treatment centers and orthodontic products The metric increased 10 4  to  630 2 million in the segment and 5 8  at cc  Geographic DetailsIn the quarter  sales in the United States grew 11 2  to  365 7 million  up 11 2  year over year and 9 7  in the country at cc Net sales in Europe increased 10 6  to  445 1 million and 2 6  at cc Net sales in Rest of World climbed 5 7  to  280 2 million and  3 7  at cc Margin AnalysisGross profit in the reported quarter was  593 3million  up 9 6  year over year  As a percentage of revenues  gross margin expanded 10 basis points  bps  to 54 4  2017 at a GlanceThe company reported preliminary net sales of  3 993 4 million  up 6 6  year over year  The Consumables segment increased 5 8  to  1 792 6 million  44 9  of net sales  in 2017 while net sales for the Technologies   Equipment segment jumped 7 3  to  2 200 8 million  55 1   However  sales of the combined businesses for Technologies   Equipment slipped 0 1  at cc year over year The company registered adjusted earnings per share of  2 66 in 2017 GuidanceManagement expects adjusted EPS for 2018 in the range of  2 70  2 80  reflecting a 16 cent adverse impact on tax expense related to tax reform Revenues are projected to rise 3  at cc Key PicksA few better ranked stocks that reported solid results this earnings season are PetMed Express   NASDAQ PETS    PerkinElmer   NYSE PKI   and Becton  Dickinson and Company   NYSE BDX    While PetMed sports a Zacks Rank  1  Strong Buy   PerkinElmer and Becton  Dickinson carry a Zacks Rank  2  Buy   You can see   PetMed reported third quarter fiscal 2018 adjusted earnings per share of 44 cents  up 88 3  from the prior year quarter  Revenues rose 13 7  to  60 1 million PerkinElmer posted fourth quarter 2017 adjusted earnings per share of 97 cents  Adjusted revenues were approximately  641 6 million  up from  567 million a year ago Becton  Dickinson reported first quarter 2018 adjusted earnings per share of  2 48  up 3 9  at constant currency  Revenues totaled  3 08 billion  up 3 7  at cc Don t Even Think About Buying Bitcoin Until You Read ThisThe most popular cryptocurrency skyrocketed last year  giving some investors the chance to bank 20X returns or even more  Those gains  however  came with serious volatility and risk  Bitcoin sank 25  or more 3 times in 2017 Zacks  has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly ,2018-03-01,Zacks Investment Research,https://www.investing.com/analysis/dentsply-xray-earnings-and-revenues-beat-estimates-in-q4-200295660,200295660
119914,341429,PKI,PerkinElmer  PKI  Down 6 9  Since Earnings Report  Can It Rebound ,opinion,"A month has gone by since the last earnings report for PerkinElmer  Inc    NYSE PKI    Shares have lost about 6 9  in the past month  underperforming the market 
Will the recent negative trend continue leading up to its next earnings release  or is PKI due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important catalysts 
Recent EarningsPerkinElmer reported fourth quarter 2017 adjusted earnings of 97 cents per share  beating the Zacks Consensus Estimate of 94 cents The company  based in Waltham  MA  reported adjusted revenues of approximately  641 6 million  which beat the Zacks Consensus Estimate of  617 million  Revenues also surpassed the year ago figure of  567 million Segment DetailsDiscovery   Analytical Solutions  DAS Revenues from DAS totaled  448 2 million in the fourth quarter  up 9 3  from  409 9 million in the year ago quarter  PerkinElmer has been focusing on finalizing the organizational changes associated with the life sciences business in the DAS unit Coming to the profits at the DAS segment  the company reported fourth quarter 2017 adjusted operating income of  93 7 million  up from  82 9 million in the year ago quarter  As a percentage of revenues  adjusted operating profit margin was 20 9   UP 70 basis points  bps  year over year Diagnostics segmentRevenues were  193 4 million compared with  156 8 million in the year ago quarter  This reflects an improvement of 6  organically The divestment of medical imaging business and the acquisition of EUROIMMUN Medical Laboratory Diagnostics AG has been the major driver for the segment  PerkinElmer announced the completion of the buyout of EUROIMMUN for approximately  1 3 billion in cash in December 2017  EUROIMMUN is an autoimmune testing company and an emerging player in infectious disease and allergy testing Meanwhile  operating profit margin in the segment  as a percentage of revenues  was 30 8   up 20 bps year over year Financial DetailsAt the end of the quarter  operating cash flow from continuing operations was approximately  292 million  which includes  17 million of EUROIMMUN deal related cost and prepaid royalties  The company ended the year with approximately  2 billion of debt and  202 million of cash GuidanceThe company issued adjusted earnings guidance for 2018  PerkinElmer expects adjusted earnings of  3 50 per share  Further  it expects reported revenues in the range of  2 72  2 74 billion  which includes approximately  25 million in foreign exchange tailwinds and approximately  360 million reported revenues from EUROIMMUN  PerkinElmer projects 5 6  organic revenue growth in 2018 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates  There has been one revision lower for the current quarter PerkinElmer  Inc  Price and Consensus     
VGM Scores
At this time  PKI has a subpar Growth Score of D  however its Momentum is doing a bit better with a C  Charting a somewhat similar path  the stock was also allocated a grade of D on the value side  putting it in the bottom 40  for this investment strategy 
Overall  the stock has an aggregate VGM Score of D  If you aren t focused on one strategy  this score is the one you should be interested in 
The stock is suitable solely for momentum based on our style scores 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of this revision indicates a downward shift  Interestingly  PKI has a Zacks Rank  2  Buy   We expect an above average return from the stock in the next few months ",2018-02-26,Zacks Investment Research,https://www.investing.com/analysis/perkinelmer-pki-down-69-since-earnings-report-can-it-rebound-200294028,200294028
119944,341459,PKI,Myriad Genetics  Positive Study Data May Expand Customer Base,opinion,Myriad Genetics  Inc    NASDAQ MYGN   has been dominating the headlines on favorable results from a large study of the myRisk Hereditary Cancer test  Notably  the results were featured during the poster presentation at the 2018 Genitourinary Cancer Symposium in San Francisco  CA Results from the 1 162 patient study confirmed that more than 12  of men with prostate cancer had an inherited  i e  hereditary  mutation in a cancer causing gene  Per management  going by the results from the study  it is important to expand the use of genetic testing in men  diagnosed with prostate cancer consistent  with existing professional medical guidelines Management further added that the study results prove that the percentage of women with breast cancer and carrying hereditary cancer causing mutations are the same as that of percentage of men with prostate cancer and carrying mutations Per the company  prostate cancer is the most commonly diagnosed and second leading cause of cancer death among American men  Going by the Cancer Facts   Figures 2018 report by the American Cancer Society  164 690 men will be diagnosed with prostate cancer in 2018  The report also states that roughly 2 9 million American men are presently suffering from prostate cancer Myriad Genetics also stated that the global market for myRisk Hereditary Cancer along with other types of hereditary cancer tests is worth roughly  5 billion annually  In view of such data  we believe favorable results may boost the company s customer base and top line to a great extent Furthermore  the company has been leaving no stone unturned to strengthen its hold in the same  In this regard  last December  Myriad Genetics presented favorable riskScore test data at the 2017 San Antonio Breast Cancer Symposium  SABCS  in Texas  In September 2017  the company introduced riskScore under its myRisk Hereditary Cancer testing portfolio and also presented encouraging riskScore test data  It also announced favorable study results for its myRisk Hereditary Cancer suite Moreover  the recently reported second quarter of fiscal 2018 marked the fourth consecutive quarter with year over year Hereditary cancer volume growth led by encouraging response to the latest riskScore test under its myRisk Hereditary Cancer testing portfolio  Thus  we believe encouraging data from the study may drive the uptake of myRisk Hereditary Cancer test Price PerformanceMyriad Genetics has been gaining investor confidence on consistently positive results  Over the past six months  the company s share price has outperformed the   The stock has gained 19 2   as against the industry s 6 2  decline   Zacks Rank   Key PicksMyriad Genetics carries a Zacks Rank  3  Hold  Some better ranked stocks in the broader medical sector are PerkinElmer   NYSE PKI    Bio Rad Laboratories   NYSE BIO   and Becton  Dickinson and Company   NYSE BDX   Bio Rad Laboratories has a Zacks Rank  2  Buy   You can see The company has a long term expected earnings growth rate of 25  PerkinElmer has a long term expected earnings growth rate of 12 3   The stock carries a Zacks Rank  2 Becton  Dickinson and Company has a Zacks Rank  2  The company has a long term expected earnings growth rate of 13 3  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-02-12,Zacks Investment Research,https://www.investing.com/analysis/myriad-genetics-positive-study-data-may-expand-customer-base-200289909,200289909
119945,341460,PKI,GNC Holdings To Boost International Business With New Deals,opinion,GNC Holdings  Inc    NYSE GNC   has been dominating the headlines on announcements of plans to strike a couple of deals with China s leading pharmaceutical company   Harbin Pharmaceutical Group Holding Co   Ltd   Hayao    Notably  the company intends to enter a strategic partnership and China joint venture agreement with Hayao Under the terms of the equity investment agreement  Hayao will invest in around  300 million in cash or in kind in GNC Holdings Following the closing of the transaction  Hayao will own around 40  of GNC Holdings on a converted basis  The investment is anticipated to strengthen GNC Holdings  capital position  However  subject to certain customary closing conditions in the United States and China  the transaction is expected to close in the second half of 2018 At the same time  GNC Holdings will enter into a joint venture agreement with Hayao  Notably  leveraging on the latter s expertise in operational and manufacturing areas as well as broad pharmaceutical distribution network in China  GNC Holdings plans to strengthen its presence in China s booming supplements market However  closure of the Hayao transaction is dependent on the successful completion of GNC Holdings  plans to amend and extend its term loan facility  Interestingly  GNC Holdings aims to extend the maturity date of the term loan facility by two years  to March 2021 and issue a  275 million ABL Term Loan as part of the planned maturity extension International Business   A Key Growth DriverNotably  GNC Holdings  international business has been a key growth driver for the company in recent years  Of late  the company has been seeing solid growth in China   Furthermore  over the recent past  the company has witnessed improvement in trends in Mexico  South Korea and Hong Kong  We believe successful completion and execution of these agreements will significantly drive top line contributions from China Market PotentialPer a report by Grand View Research  the global market for dietary supplements is expected to see a CAGR of 9 5  between 2016 and 2024  The report further states that usage of the supplements in treating cardiovascular diseases and malnutrition will continue to boost demand  Thus  in view of such data  we believe GNC Holdings  joint venture plan with Hayao is strategic Share Price PerformanceGNC Holdings has been gaining investor confidence on consistently positive results  Over the past month  the company s share price has outperformed the   The stock has gained 33   as against the industry s 9 8  decline   Zacks Rank   Key PicksGNC Holdings carries a Zacks Rank  3  Hold  Some better ranked stocks in the broader medical sector are PerkinElmer   NYSE PKI    Bio Rad Laboratories   NYSE BIO   and Becton  Dickinson and Company   NYSE BDX   Bio Rad Laboratories has a Zacks Rank  2  Buy   You can see  The company has a long term expected earnings growth rate of 25  PerkinElmer has a long term expected earnings growth rate of 12 3   The stock carries a Zacks Rank  2 Becton  Dickinson and Company has a Zacks Rank  2  The company has a long term expected earnings growth rate of 13 3  Don t Even Think About Buying Bitcoin Until You Read ThisThe most popular cryptocurrency skyrocketed last year  giving some investors the chance to bank 20X returns or even more  Those gains  however  came with serious volatility and risk  Bitcoin sank 25  or more 3 times in 2017 Zacks  has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly ,2018-02-13,Zacks Investment Research,https://www.investing.com/analysis/gnc-holdings-to-boost-international-business-with-new-deals-200290369,200290369
119946,341461,PKI,Chemed  CHE  Beats On Q4 Earnings   Revenues  Issues View,opinion,"Chemed Corporation s   NYSE CHE   fourth quarter 2017 adjusted earnings per share  EPS  were  2 32  as compared with the year ago figure of  2 10  The figure also surpassed the Zacks Consensus Estimate of  2 28 Full year 2017 adjusted EPS came in at  8 43  beating the Zacks Consensus Estimate of  8 38  Moreover  the figure improved from the year ago number of  7 24 Quarter in DetailsRevenues in the quarter increased 6 2  year over year to  428 4 million  beating the Zacks Consensus Estimate of  422 million Net revenues in 2017 totaled  1 67 billion  outpacing the Zacks Consensus Estimate of  1 66 billion  The figure also improved from the year ago number of  1 58 billion Chemed currently operates through two wholly owned subsidiaries  namely  VITAS Healthcare Corporation  a major provider of end of life care  and Roto Rooter  a leading commercial and residential plumbing and drain cleaning service provider  In the fourth quarter  net revenues at VITAS Healthcare totaled  292 3 million  reflecting an increase of 2 8  year over year  Revenues were driven by a 0 8  increase in the average net Medicare reimbursement rate and a 4 7  rise in average daily census  However  this was partially offset by acuity mix shift which impacted revenues by 1 7  and 0 9  adverse impact on revenues due to Medicare Cap 
Chemed Corp  Price  Consensus and EPS Surprise
     Roto Rooter reported sales of  136 1 million in the fourth quarter  up 14 1  year over year  According to the company  revenues from water restoration increased 61 7  year over year to  22 1 million Gross margin expanded 110 basis points  bps  year over year to 31 9   Adjusted operating margin contracted a nominal 10 bps to 15 2  in the quarter on a 14 6  rise in selling  general and administrative expenses to  71 6 million Chemed exited 2017 with total cash and cash equivalents of  11 1 million  down from  15 3 million at the end of 2016  The company had total debt of  91 2 million at the end of 2017  compared with  100 million a year ago  As of Dec 31  2017  the company had approximately  288 million in undrawn borrowing capacity under its existing five year credit agreement During the fourth quarter  the company did not repurchase shares  As of Dec 31  2017  the company had  55 5 million of remaining shares under its repurchase authorization 2018 OutlookThe company projects VITAS Healthcare revenue growth for 2018 in the range of 2 5  to 3 5   prior to the Medicare Cap  Also  the admissions and Average Daily Census in 2018 are expected to increase 3  to 4   Medicare Cap billing limitations are expected at around  5 million in 2018 The Roto Rooter business is likely to grow 4  to 5  in the full year  The guidance was backed by a 2  increase in job pricing and water restoration services growth Full year adjusted EPS is expected to grow in the band of  10 60 to  10 85 as compared with  8 43 reported in 2017 Our TakeChemed exited the fourth quarter on a solid note  Also  the company witnessed year over year growth in both the fronts  Moreover  we are encouraged to note that the company s subsidiaries saw year over year revenue growth in the quarter  The expansion in gross margin and strong bottom line projections also buoy optimism Further  reimbursement related issues  seasonality in business  a competitive landscape and dependence on government mandates continue to pose challenges  Key PicksA few top ranked stocks that reported solid results this earnings season are PetMed Express   NASDAQ PETS    PerkinElmer   NYSE PKI   and Becton  Dickinson and Company   NYSE BDX    While PetMed sports a Zacks Rank  1  Strong Buy   PerkinElmer and Becton  Dickinson carry a Zacks Rank  2  Buy   You can see   PetMed reported third quarter fiscal 2018 adjusted earnings per share of 44 cents  up 88 3  from the prior year quarter  Revenues rose 13 7  to  60 1 million PerkinElmer posted fourth quarter 2017 adjusted earnings per share of 97 cents  Adjusted revenues were approximately  641 6 million  up from  567 million in the year ago quarter Becton  Dickinson reported first quarter fiscal 2018 adjusted earnings per share of  2 48  up 3 9  at constant currency  Revenues totaled  3 08 billion  up 3 7  at constant currency The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-02-14,Zacks Investment Research,https://www.investing.com/analysis/chemed-che-beats-on-q4-earnings--revenues-issues-view-200290865,200290865
119947,341462,PKI,Medtronic s Positive Study Results May Expand Customer Base,opinion,Medtronic plc   NYSE MDT   has presented positive data from an at home pediatric study on patients aged between seven and 13 years  Notably  the data is based on MiniMed 670G system and was demonstrated at the Advanced Technologies   Treatments for Diabetes  11th International Conference in Vienna  Austria Study Results in DetailThe multi center study had enrolled 105 participants within the 7 13 years  age group  The trial consisted of a two week run in phase along with a study phase of three months  97  of the participants chose to continue using the system as part of a Continued Access Program  Moreover  the study results demonstrated data from the pivotal trial of MiniMed 670G system on patients aged 14 years and above Using the study results  the company has applied for an expanded FDA approval to include the patients ranging from seven to 13 years as eligible for using the MiniMed 670G system  At the same time  the company is working to expand the usage of the product on children aged between two and six years  Hopes are harbored on the effectiveness of this system  which should get greater customer adoptability over time MiniMed 670G at a GlancePost the receipt of the FDA approval in 2016  Medtronic had commercially launched the MiniMed 670G system in June 2017  It is a Hybrid Closed Loop insulin delivery system for Type I diabetic patients aged 14 years or older  The MiniMed 670G system features Medtronic s latest Guardian Sensor 3  a glucose sensor with increased accuracy and enhanced performance  This is the only FDA approved sensor to control a hybrid closed loop system including diagnostic technology that continuously checks sensor health  The system also carries Medtronic s most advanced algorithm known as  SmartGuard HCL technology Developments in Diabetes BusinessMedtronic witnessed sluggish growth in Diabetes business last quarter  However  the company gained on a strong uptake of new sensor augmented insulin pump systems in the United States as well as in the international markets  This growth was temporarily offset by a limited supply of continuous glucose monitor  CGM  sensors  Moreover  a strong customer enrollment under the Priority Access Program briefly affected revenues Per management  the diabetes business should witness revenue growth in the third quarter of fiscal 2018 as the company has finished shipping pumps for the Priority Access Program  Also  the company is moving steadily with its sensor capacity expansion plans  scheduled to be completed in fourth quarter fiscal 2018 Additionally  Medtronic geared up for the international launch of the MiniMed 670G and the U S  launch of CGM system Guardian Connect with sugar IQ in late 2018 and its new professional CGM iPro 3 in 2019  In this regard  the company also announced favorable results supporting the use of CGM on people with type 2 diabetes in October 2017 This apart  we are upbeat about Animas Corporation s  one of the Johnson   Johnson  NYSE JNJ  Diabetes Care Companies  exit from the insulin pump business with Medtronic as partner to support a smooth transition for patients  caregivers and healthcare providers  Notably  patients using an Animas insulin pump will be offered the choice to switch to a Medtronic pump Market PotentialAn ageing population  unhealthy lifestyle and a rising awareness and expenditure in healthcare are likely to drive growth in the diabetes market  Per a report by Mordor Intelligence  the global market for diabetes care devices is projected to reach a value of  30 25 billion by 2021 at a CAGR of 5 93   Given the bullish market sentiments  we believe the latest positive study results have come at an opportune moment Share Price MovementMedtronic has been gaining investor confidence on consistently positive results  Over the past three months  the company s share price has outperformed the broader   The stock has gained 4 7  in comparison to the broader industry s 1 8  increase Zacks Rank   Key PicksMedtronic carries a Zacks Rank  3  Hold   Some better ranked stocks in the broader medical sector are PerkinElmer   NYSE PKI    Bio Rad Laboratories   NYSE BIO   and Becton  Dickinson and Company   NYSE BDX   PerkinElmer has a long term expected earnings growth rate of 12 3   The stock carries a Zacks Rank  2  Buy  Bio Rad Laboratories has a Zacks Rank of 2  You can see The company has a long term expected earnings growth rate of 25  Becton  Dickinson and Company is a Zacks  2 Ranked player  The company has a long term expected earnings growth rate of 13 3  Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-02-15,Zacks Investment Research,https://www.investing.com/analysis/medtronics-positive-study-results-may-expand-customer-base-200291300,200291300
119948,341463,PKI,Edwards Lifesciences  CE Mark For CENTERA Boosts THVT Arm,opinion,Edwards Lifesciences Corporation   NYSE EW   announced the receipt of CE Mark for its self expanding CENTERA valve  The valve is used for severe  symptomatic aortic stenosis patients at high risk of open heart surgery  However  the CENTERA valve is not approved for commercial sale in the United States Per the company  the Edwards CENTERA valve is repositionable and retrievable and can be delivered through a low profile  14 French  motorized delivery system The CE Mark was based on the CENTERA EU Trial results  which were presented at EuroPCR 2017  This study enrolled 203 high risk patients at 23 centers in Europe  Australia and New Zealand  The outcome of the trial demonstrated high survival rates  99   and low rates of disabling stroke  2 5   and new permanent pacemaker  4 9   at 30 days   The regulatory approval is likely to boost the company s Transcatheter Heart Valves  THV  segment precisely THV in FocusTHV segment includes technologies designed to treat heart valve diseases using catheter based approaches as opposed to open surgical techniques  In the fourth quarter  the company reported THV sales growth of 20 2  over the prior year quarter  with double digit procedure growth in Europe  The latest development is likely to further enhance the company s prospects in Europe Outside the United States  the underlying growth rate was 22  with contributions from all regions  Of late  Edward Lifesciences has witnessed multiple developments in its THV segment  Edwards Lifesciences announced the receipt of FDA approval for aortic and mitral valve in valve procedures  using SAPIEN 3 transcatheter heart valve in June  Management released positive patient outcomes of SAPIEN 3 valve  including high survival rates and low rates of stroke and paravalvular leak Market PotentialTaking into consideration the huge growth potential of the THV market  the recent CE Mark for CENTERA valveis strategic  As per Persistence Market Research report  the global heart valve repair and replacement market is projected to reach a worth  3 767 0 million in 2020  at a CAGR of 8 7  Share Price   Estimate Revision TrendEdwards Lifesciences has been gaining investor confidence on consistently positive results  Over the last year  the company s share price has outperformed the   The stock has gained 50 1  compared with the industry s 22 8  The current estimate revision trend is favorable  For the current year  11 estimates moved north compared with no movement in the opposite direction over the last month  As a result  the Zacks Consensus Estimate for the full year has risen 7 9  to  4 49 per share Zacks Rank and Other Key PicksEdwards Lifesciences carries a Zacks Rank  2  Buy  A few other top ranked stocks in the broader medical sector are PerkinElmer   NYSE PKI    Bio Rad Laboratories   NYSE BIO   and Becton  Dickinson and Company  NYSE BDX   Bio Rad Laboratories has a Zacks Rank  2  You can see The company has a long term expected earnings growth rate of 25  PerkinElmer has a long term expected earnings growth rate of 12 3   The stock carries a Zacks Rank  2 Becton  Dickinson and Company has a Zacks Rank  2  The company has a long term expected earnings growth rate of 13 3  Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-02-15,Zacks Investment Research,https://www.investing.com/analysis/edwards-lifesciences-ce-mark-for-centera-boosts-thvt-arm-200291476,200291476
119949,341464,PKI,Myriad Genetics Banks On Product Launches  Competition Rife,opinion,On Feb 16  we issued an updated research report on Myriad Genetics  Inc    NASDAQ MYGN    The stock carries a Zacks Rank  3  Hold  This Salt Lake City  UT based molecular diagnostics provider has been outperforming the broader over the past six months  The company has rallied 13 3   against the industry s 1  decline  Myriad Genetics exited the second quarter of fiscal 2018 on a promising note  The company particularly observed strong growth in GeneSight testing revenues   The company s molecular diagnostics portfolio has been gaining prominence in the MedTech space of late  We are particularly upbeat about the newly launched range of products  Myriad Genetics has been recording strong volumes of EndoPredict and GeneSight tests  In the Prolaris testing space  volumes continued to grow double digits in the fiscal second quarter In particular  Myriad Genetics was focused on driving revenues by commercializing its innovative products  including Vectra DA  Prolaris  myPath Melanoma  Myriad Genetics s Companion Diagnostics  EndoPredict and myPlan Lung Cancer Test  Earlier  management expected each of the products to generate revenues of more than  50 million by fiscal 2020 Moreover  Myriad Genetics has been consistently gaining reimbursement approvals  During the reported quarter  the company announced the finalization of LCD from Noridian for EndoPredict  thereby expanding the total coverage to around 90  of the U S  market  Also  the Prolaris test is under evaluation for revised NCCN guidelines and has been covered by Medicare for patients at intermediate risk   Also  in order to gain reimbursement coverage in Vectra DA and GeneSight testing platforms  the company has been undertaking certain measures Furthermore  the raised FY18 guidance instills confidence  We are upbeat about growth in new product volumes  an expanded reimbursement for new products and an increase in international RNA kit revenues  Meanwhile  Myriad Genetics faces competition in the key BRACAnalysis market  The company expects competition to intensify owing to advancement of technology  We believe competitive headwinds might reduce prices of expensive tests provided by the company  This might impede margin improvement as well Moreover  as the company receives a considerable portion of its revenues and pays a portion of its expenses in foreign currencies  it is at risk of exchange rate fluctuations between foreign currencies and the U S  dollar Key PicksSome better ranked stocks in the broader medical sector are PerkinElmer   NYSE PKI    Bio Rad Laboratories   NYSE BIO   and Becton  Dickinson and Company   NYSE BDX   Bio Rad Laboratories has a Zacks Rank  2  Buy   You can see The company has a long term expected earnings growth rate of 25  PerkinElmer has a long term expected earnings growth rate of 12 3   The stock carries a Zacks Rank  2 Becton  Dickinson and Company has a Zacks Rank  2  The company has a long term expected earnings growth rate of 13 3  Breaking News  Cryptocurrencies Now Bigger than VisaThe total market cap of all cryptos recently surpassed  700 billion   more than a 3 800  increase in the previous 12 months  They re now bigger than Morgan Stanley  NYSE MS   Goldman Sachs  NYSE GS  and even Visa  The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved Zacks has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market ,2018-02-18,Zacks Investment Research,https://www.investing.com/analysis/myriad-genetics-banks-on-product-launches-competition-rife-200291817,200291817
119950,341465,PKI,Discover Financial  Graco  Kansas City Southern  Packaging Corporation Of America,opinion,"Discover Financial Services  NYSE DFS 
Discover Financial   DFS  rose from a bottom in September  It crossed the 200 day SMA in October and consolidated there until it bounced off of the 50 day SMA and started higher again following a Golden Cross  That move topped in January and pulled back slightly before retesting the top and reversing  a Double Top  The pullback filled a gap and reversed last week  The RSI is rising and bullish with the MACD crossing up  Look for continuation to participate higher   
Graco Inc   NYSE GGG 
Graco   GGG  moved steadily higher after leaving consolidation at the end of July  It paused for consolidation in November and then started back higher in December  reaching a top in January  It pulled back from there with the market  touching the 200 day SMA and then reversing  Now it is back at the 100 day SMA with the RSI rising to the mid line and the MACD turning up towards a bullish cross  Look for continuation to participate higher   
Kansas City Southern  NYSE KSU 
Kansas City Southern   KSU  started higher in March  and then plateauing for 5 months beginning in June  It tried to move to a higher range then and topped at the end of November  A pullback to a higher low and then it reversed to form a Double Top and dropped with the market  After hitting the 200 day SMA it found support and rode it until turning back higher last week  Now it is breaking short term resistance with a RSI moving up over the mid line and the MACD about to cross up  Look for continuation to participate higher   
Packaging Corporation Of America  NYSE PKG 
Packaging Corporation of America   PKG  started higher in April and ran until consolidation began in July  It moved out of that to a higher high in September before pulling back to a higher low in November  It made another higher high in January then before pulling back to the 200 day SMA  but another higher low  Now it is rising again with the RSI rising and the MACD about to cross up  Look for continuation to participate higher   
PerkinElmer  NYSE PKI 
PerkinElmer   PKI  started to move higher in August  slowing as it moved toward year end  and then accelerating into a peak in late January  It pulled back from there to the 100 day SMA  the third time it has acted as support  and reversed last week  The RSI is trending higher at the mid line with the MACD about to cross up  Look for a push over short term resistance to participate higher   
Up Next  Bonus Idea
After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad  picture reviewed Friday  which with February Options Expiration behind  sees the equity markets recovered substantially from their first correction in 2 years 
Elsewhere look for Gold to continue higher in its new uptrend while Crude Oil also resumes the path higher  The US Dollar Index looks better to the downside and US Treasuries are biased lower  Both are entering major trend change territory  The Shanghai Composite and Emerging Markets have reversed their moves lower with the Chinese market still a bit weak 
Volatility continues to drift lower easing the pressure on the equity markets  The equity index ETF s SPY  NYSE SPY   iShares Russell 2000  NYSE IWM  and PowerShares QQQ Trust Series 1  NASDAQ QQQ   all had strong moves higher on the week  retracing at least 61 8  of the moves lower  All three ended the weak with possible reversal candles on the shorter timeframe though  but with strong charts on the longer timeframe  Perhaps some short term weakness remains  Use this information as you prepare for the coming week and trad em well 
The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ",2018-02-20,Gregory W. Harmon,https://www.investing.com/analysis/discover-financial-graco-kansas-city-southern-packaging-corporation-of-america-200291883,200291883
119985,341500,PKI,CVS Health  CVS  Q4 Earnings Beat Estimates   18 View Upbeat,opinion,"CVS Health Corporation s   NYSE CVS   fourth quarter 2017 adjusted earnings per share  EPS  of  1 92 were up 12 3  year over year  The adjusted EPS also beat the Zacks Consensus Estimate by 3 cents  This one time adjustment excludes the impact of a  1 5 billion income tax benefit resulting from the latest tax reform 
Reported EPS from continuing operations came in at  3 22 per share  a 102 5  surge from the year ago period 
Full year 2017 adjusted EPS came in at  5 90  a 1  improvement from the year ago adjusted number 
Net revenues in the fourth quarter increased 5 3  year over year to  48 39 billion  exceeding the Zacks Consensus Estimate by 1 8  CVS Health Corporation Price  Consensus and EPS Surprise

   Revenues for the year 2017 were  184 77 billion  a 4 1  improvement from 2016  Revenues also beat the Zacks Consensus Estimate of  183 88 billion 
Quarter in Details
Pharmacy Services revenues increased 9 3  to  34 2 billion in the reported quarter  driven by growth in specialty pharmacy volumes  higher pharmacy network volumes as well as brand inflation  This was  however  partially offset by increased generic dispensing and continued price compression 
Pharmacy network claims processed during the quarter climbed 8 2  to 389 7 million on a 30 day equivalent basis  backed by net new business growth  Also  the Mail Choice processed claim count was 69 million  up 5 9  on a 30 day equivalent basis on continued adoption of Maintenance Choice offerings and a rise in specialty pharmacy claims 
Revenues from CVS Health s Retail LTC were up by a marginal 0 3  year over year to  20 9 billion  According to the company  a 2 5  increase in same store prescriptions on a 30 day equivalent basis and brand inflation were partially offset by continued reimbursement pressure and an increase in the generic dispensing rate 
Front end same store sales were down 0 7  year over year but were positively impacted 80 basis points by seasonal cough and cold  Front store sales were adversely affected by soft customer traffic and efforts to rationalize promotional strategies  which were partially offset by an increase in basket size 
Pharmacy same store sales increased 0 4  in the reported quarter  Sales were adversely affected by approximately 340 basis points  bps  due to recent generic drug introductions  This apart  marketplace changes that restricted CVS Pharmacy from participating in certain networks had a 320 bps negative impact on same store prescription volumes in the reported quarter 
The generic dispensing rate  the proportion of all generic prescriptions to total number of prescriptions dispensed  increased approximately 80 bps to 86 9  at the Pharmacy Services segment and around 160 bps to 86 8  at the Retail LTC segment 
Gross profit improved 3 9  to  7 9 billion  However  gross margin contracted 21 bps to 16 3   Total operating margin in the quarter declined 10 bps to 6 4  
CVS Health exited the year 2017 with cash and cash equivalents and short term investments of  1 81 billion compared with  3 45 billion at the end of 2016  Full year  net cash provided by operating activities was  8 billion  down 21  from the year ago period 
During the fourth quarter  CVS Health opened 65 new retail stores and closed 13 and relocated five retail locations  As of Dec 31  2017  CVS Health operated 9 803 retail stores  including pharmacies in Target stores across 49 states as well as the District of Columbia  Puerto Rico and Brazil 
Outlook
The company has revised its outlook for 2018  The revision reflects the effects of the tax reform achieved through the Tax Cuts and Jobs Act  TCJA  
Management noted that  with  1 2 billion in cash benefits from the TCJA  the company will be able to make strategic investments in 2018 to stimulate greater growth over the longer term 
Accordingly  the company has increased its 2018 adjusted operating profit growth guidance to a range of 1  to 4  from the earlier stated range of  1 5   to 1 5  
Earlier  while providing its 2018 initial outlook  CVS Health noted that  it expects to deliver net revenue growth of 0 75  to 2 5  in the year  The current Zacks Consensus Estimate for the full year revenues is pegged at  188 04 billion 
For the first quarter of 2018  the company expects to register adjusted operating profit growth in the range of 0 5  to 4 5  
Our Take
CVS Health ended the year 2017 on a solid note with a better than expected fourth quarter performance  The year over year growth in the top line was driven by a strong Pharmacy Services segment  benefiting from the upside in the specialty services  However  year over year Retail LTC comparisons were dull 
Zacks Rank   Key Picks
CVS Health has a Zacks Rank  3  Hold  
A few better ranked stocks that reported solid results this earnings season are PetMed Express   NASDAQ PETS    PerkinElmer   NYSE PKI   and Becton  Dickinson and Company   NYSE BDX    While PetMed sports a Zacks Rank  1  Strong Buy   PerkinElmer and Becton  Dickinson carry a Zacks Rank  2  Buy   You can see   
PetMed recently reported third quarter fiscal 2018 results  Adjusted earnings per share of 44 cents were up 88 3  from the prior year quarter  Revenues rose 13 7  on a year over year basis to  60 1 million 
PerkinElmer reported fourth quarter 2017 adjusted earnings per share of 97 cents  Adjusted revenues were approximately  641 6 million  up from  567 million in the year ago quarter 
Becton  Dickinson reported first quarter 2018 adjusted earnings per share of  2 48  up 3 9  at constant currency  Revenues are  3 08 billion  up 3 7  at constant currency 
Will You Make a Fortune on the Shift to Electric Cars 
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge 
With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research 
It s not the one you think ",2018-02-08,Zacks Investment Research,https://www.investing.com/analysis/cvs-health-cvs-q4-earnings-beat-estimates-18-view-upbeat-200288590,200288590
119986,341501,PKI,Surmodics  SRDX  Beats On Earnings In Q1  Guidance Solid,opinion,"Surmodics  Inc    NASDAQ SRDX   reported adjusted earnings of 10 cents per share in first quarter fiscal 2018  lower than the year ago figure of 19 cents  The Zacks Consensus Estimate was a loss of 5 cents Revenues in the quarter fell 4 2  to  17 million  missing the Zacks Consensus Estimate of  18 million The stock has a Zacks Rank  3  Hold  Segment AnalysisSurmodics reports revenues under two segments   Medical Device and In Vitro Diagnostics  IVD  Medical DeviceIn the reported quarter  sales declined 7 2  to  12 8 million due to lower hydrophilic royalty revenues  Royalty and license fee revenues totaled  7 1 million  down  0 9 million year over year Per management  the decline in royalty and license fee revenues was caused by lower royalties resulting from expirations of patents in the third generation hydrophilic coatings This unit generated a  0 4 million operating loss in the reported quarter  comparing unfavorably with operating income of  3 7 million in the year ago quarter  Operating income in the segment was affected by planned increased investments related to Surmodics  whole product solution strategy  reductions in royalty revenues as well as a  0 7 million increase in contingent consideration expense 
IVDIn the quarter under review  sales increased 5 9  to  4 2 million  The upside came on the back of strong growth and stabilization across BioFX  microarray and antigen product sales IVD operating income was  1 7 million in the current quarter compared with  1 5 million in the first quarter of fiscal 2017 Surmodics  Inc  Price  Consensus and EPS Surprise     
Margin DetailsProduct gross margins contracted 160 basis points  bps  in the first quarter to 64 3  of product sales compared with 65 9  in the year ago period  Margins in the quarter suffered from expenses in the Irish facility infrastructure and lower Medical Device product gross margins First quarter of fiscal 2018 R D expenses were 46  of net sales  higher than 33 6  of net sales in the year ago quarter  The company anticipates R D expense to increase in fiscal 2018  thanks to the company s whole product solution strategy investments  advancing the TRANSCEND drug coater balloon human clinical trial  preclinical work on below the knee platform and AV fistula drug coated balloon projects SG A expenses in the first quarter of fiscal 2018 were 30 5  of revenues  expanding 310 bps year over year Balance Sheet and Cash FlowAt the end of the first quarter  the company had  46 7 million in cash and investments  Surmodics generated cash from operating activities of  0 6 million  The company invested  1 3 million in plant and equipment GuidanceSurmodics continues to expect fiscal year 2018 revenues in the range of  72  75 million The company expects fiscal 2018 earnings per share between negative 20 cents and 5 cents  compared with the previous estimate of a adjusted loss of 16 41 cents Bottom LineSurmodics ended first quarter fiscal 2018 on a favorable note  courtesy of solid performance in the In Vitro Diagnostics segment  The segment has been gaining grounds on the back of strong growth and stabilization across BioFX  microarray and antigen product sales  Surmodics issued a solid guidance for fiscal 2018  The company s solid initiatives to strengthen research and development programs hold promise The company witnessed significantly high operating losses  specifically in Ireland  Product sales declined substantially owing to shipment issues  particularly in the Medical Device segment  Further  foreign exchange woes related to the Creagh Medical buyout have been a major dampener  Surmodics  drug coated balloons face stiff competition in niche space  The company s margins are expected to be under pressure  thanks to expenses in the Irish facility infrastructure and lower Medical Device product gross margins Key PicksA few better ranked stocks that reported solid results this earnings season are PetMed Express   NASDAQ PETS    PerkinElmer   NYSE PKI   and Becton  Dickinson and Company   NYSE BDX    While PetMed sports a Zacks Rank  1  Strong Buy   PerkinElmer and Becton  Dickinson carry a Zacks Rank  2  Buy   You can see  PetMed  reported third quarter fiscal 2018 results  Adjusted earnings per share were 44 cents  up 88 3  from the prior year quarter  Revenues rose 13 7  on a year over year basis to  60 1 million PerkinElmer reported fourth quarter 2017 adjusted earnings per share of 97 cents  Adjusted revenues were approximately  641 6 million  up from  567 million in the year ago quarter Becton  Dickinson reported first quarter 2018 adjusted earnings per share of  2 48  up 3 9  at constant currency  Revenues totaled  3 08 billion  up 3 7  at constant currency The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ",2018-02-08,Zacks Investment Research,https://www.investing.com/analysis/surmodics-srdx-beats-on-earnings-in-q1-guidance-solid-200288918,200288918
119987,341502,PKI,Hologic  HOLX  Q1 Earnings   Revenues Top  Margins Down,opinion,"Hologic  Inc    NASDAQ HOLX   reported first quarter fiscal 2018 adjusted earnings per share  EPS  of 55 cents  up 5 8  year over year  Moreover  adjusted EPS beat the Zacks Consensus Estimate by 12 2  and surpassed the company s guidance of 48 50 cents On a reported basis  the company recorded EPS of  1 45  compared to 30 cents in first quarter fiscal 2017  Notably  the reported figure includes a one time tax provision net benefit of  329 2 million  courtesy of the U S  tax reform Revenues in DetailRevenues grossed  791 1 million in the quarter  up 7 7  year over year  up 6 7  at constant exchange rate or CER   The top line also exceeded the Zacks Consensus Estimate of  787 7 million and the company s guidance of  775  790 million Solid contributions from Hologic s Molecular Diagnostics  Breast Health and international business drove the top line Geographically  revenues in the United States grew 4 1  year over year to  597 2 million  Excluding blood screening and medical aesthetics  U S  revenues declined 0 8   International revenues were up 20 6   up 15 8  at CER  to  193 9 million  banking on strong contribution from Cynosure  Excluding blood screening and medical aesthetics  international revenues increased 17 6  or 11 6  at constant currency 
Hologic  Inc  Price  Consensus and EPS Surprise   Segments in DetailRevenues at the Diagnostics segment  35 9  of total revenues  declined 12 5  year over year  down 13 5  at CER  to  284 6 million in the first quarter  Under this segment  Molecular Diagnostics revenues of  148 6 million increased 6 2   5 3  at CER   The global growth at Molecular Diagnostics was primarily driven by an increasing market share and utilization of fully automated Panther system along with continued solid uptake of Aptima women s health products Cytology and Perinatal revenues of  123 4 million also showed a rise of 2 6   up 0 9  at CER  Revenues at the Breast Health segment  36 4   inched up 5 4   up 4 2  at CER  to  288 million  Revenues in the United States slipped 1   In the reported quarter  changes in product mix were partially offset by increases in service and new product revenues  International revenues however climbed 29 2  year over year at CER Revenues from the GYN Surgical business  13 6   were down 6 4   down 7 1  at CER  to  107 5 million  Medical Aesthetic business in the quarter reported revenues of  91 3 million  determining 11 5  of total revenues  Revenues at Skeletal Health  accounting for the rest  decreased 6   down 7 3  at CER  to  19 7 million Operational UpdateIn the fiscal first quarter  Hologic s gross margin contracted 140 basis points  bps  to 53 7   Adjusted gross margin also decreased 140 bps to 63 8  due to the divestiture of blood screening business and revenues from low margin Cynosure products Hologic s adjusted operating expenses amounted to  271 8 million  up 17 6  year over year  Adjusted operating margin contracted a massive 430 bps to 29 4  Financial UpdateHologic exited first quarter fiscal 2018 with cash and cash equivalents of  664 4 million  up from  646 million reported at the end of first quarter fiscal 2017  Total long term debt was  2 76 billion at the end of the reported quarter compared with  2 62 billion a year ago During the quarter  the company generated operating cash flow of  169 1 million  compared with the year ago cash flow of  169 6 million  GuidanceHologic has updated its fiscal 2018 financial guidance  The company currently expects adjusted revenues of  3 2  3 28 billion  growing in the range of 3 9 6 5  compared with the previously provided range of 4 6 6  at CER  The current Zacks Consensus Estimate is  3 25 billion  within the guided range Adjusted EPS is expected to grow 9 4 11 8  to  2 22  2 27 from the previously stated range of 3 4 5 9  to  2 10  2 15  The current Zacks Consensus Estimate for adjusted EPS is pegged at  2 18  below the guided range For second quarter fiscal 2018  Hologic expects adjusted revenues of  770  785 million  representing annualized growth of 6 5 8 6  at CER  The current Zacks Consensus Estimate for revenues is pegged at  791 7 million  above the projected range Adjusted EPS is projected at 53 54 cents  reflecting an annualized growth of 6 8   The current Zacks Consensus Estimate for second quarter adjusted EPS is pegged at 52 cents  below the company s guidance Our TakeHologic posted better than expected results in first quarter fiscal 2018 in terms of both earnings and revenues  Growth across all geographical regions buoys optimism  However  we are disappointed with the decline in revenues at the company s Diagnostics segment  The blood screening divestiture is also likely to impede growth momentum for the company Zacks Rank   Key PicksHologic carries a Zacks Rank  3  Hold  A few better ranked stocks that reported solid results this earnings season are PetMed Express   NASDAQ PETS    PerkinElmer   NYSE PKI   and Becton  Dickinson and Company   NYSE BDX    While PetMed sports a Zacks Rank  1  Strong Buy   PerkinElmer and Becton  Dickinson carry a Zacks Rank  2  Buy   You can see   PetMed recently reported third quarter fiscal 2018 results  Adjusted earnings per share of 44 cents were up 88 3  from the prior year quarter  Revenues rose 13 7  on a year over year basis to  60 1 million PerkinElmer reported fourth quarter 2017 adjusted earnings per share of 97 cents  Adjusted revenues were approximately  641 6 million  up from  567 million in the year ago quarter Becton  Dickinson reported first quarter 2018 adjusted earnings per share of  2 48  up 3 9  at constant currency  Revenues are  3 08 billion  up 3 7  at constant currency The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-02-08,Zacks Investment Research,https://www.investing.com/analysis/hologic-holx-q1-earnings--revenues-top-margins-down-200289013,200289013
119988,341503,PKI,Bruker  BRKR  Beats On Q4 Earnings   Revenues  Issues View,opinion,Bruker Corporation   NASDAQ BRKR   reported adjusted earnings per share  EPS  of 51 cents in the fourth quarter of 2017  up 10 9  from the year ago figure  Also  adjusted EPS beat the Zacks Consensus Estimate by a couple of cents Revenues in DetailBruker reported revenues of  530 5 million in the fourth quarter  up 12 8  year over year  The top line surpassed the Zacks Consensus Estimate of  507 million Excluding a 3 6  positive effect from acquisitions and a 5 2  favorable impact from changes in foreign currency rates  Bruker reported year over year organic revenue growth of 4  Bruker Corporation Price  Consensus and EPS Surprise   Geographically and currency adjusted  European revenues improved in high single digits year over year in the fourth quarter  North America revenues declined mid single digits  In Asia Pacific  organic revenues increased double digits  China revenues rose mid single digits in the fourth quarter Per management  the company registered organic revenue growth on strength in NANO and BEST Bruker s BioSpin Group revenues declined low single digits on an organic basis due to customer push outs into to 2018 Revenues in the NANO group increased low teens on an organic basis with significant growth in semiconductor metrology business and in the X ray and nano analysis products for material research  industrial and academic research applications CALID revenues were up low single digits on an organic basis with strong performance in the mass spec and optics product line  This was partially offset by a year over year decline in CALID detection business  BEST revenues rose 11 6  organically Margin TrendAs a percentage of revenues  gross margin in the reported quarter expanded 124 basis points  bps  to 48 1   Selling  general   administrative expenses increased 12  to  112 1 million  Research and development expenses rose 13 9  year over year to  43 5 million  Overall  adjusted operating margin expanded 132 bps to 18 8   The other charges rose 13 5  year over year to  5 9 million  Financial PositionBruker exited 2017 with cash and cash equivalents and short term investments of  439 2 million  down from  500 3 million at the end of the preceding year  Full year 2017 net cash used in operating activities was  30 2 million compared with  21 8 million in the year ago period 2017 at a GlanceIn 2017  Bruker s revenues rose 9 6  to  1 77 billion from  1 61 billion in 2016  The figure beat the Zacks Consensus Estimate of  1 74 billion  In fiscal 2017  Bruker s year over year organic revenue growth was 3 6   while growth from acquisitions was 4 8   The favorable effect from changes in foreign currency rates was 1 2  Adjusted EPS for 2017 was  1 21 compared with  1 19 in 2016  The figure surpassed the Zacks Consensus Estimate of  1 19 2018 GuidanceBruker issued guidance for 2018  For 2018  the company expects revenue growth of approximately 7   including organic revenue growth of approximately 3   The company expects a year over year increase in adjusted operating margin in the range of 50 80 bps For fiscal 2018  Bruker expects adjusted EPS in the range of  1 34  1 38  up 11 14  from the previous range  The Zacks Consensus Estimate of  1 34 is at the lower end of the company s guidance Our TakeBruker exited the fourth quarter on a solid note with year over year increase in revenues and earnings  The expansion in gross and operating margin buoys optimism  The company s strategic acquisition activity has been encouraging  We are also upbeat about the company s current focus on product development through higher R D  On the flip side  competitive landscape and macroeconomic headwinds continue to pose challenges for the company Zacks Rank   Key PicksBruker carries a Zacks Rank  3  Hold  A few better ranked stocks that reported solid results this earnings season are PetMed Express   NASDAQ PETS    PerkinElmer   NYSE PKI   and Becton  Dickinson and Company   NYSE BDX    While PetMed sports a Zacks Rank  1  Strong Buy   PerkinElmer and Becton  Dickinson carry a Zacks Rank  2  Buy   You can see  PetMed recently reported third quarter fiscal 2018 results  Adjusted earnings per share of 44 cents were up 88 3  from the prior year quarter  Revenues rose 13 7  on a year over year basis to  60 1 million PerkinElmer reported fourth quarter 2017 adjusted earnings per share of 97 cents  Adjusted revenues were approximately  641 6 million  up from  567 million in the year ago quarter Becton  Dickinson reported first quarter 2018 adjusted earnings per share of  2 48  up 3 9  at constant currency  Revenues are  3 08 billion  up 3 7  at constant currency The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-02-08,Zacks Investment Research,https://www.investing.com/analysis/bruker-brkr-beats-on-q4-earnings--revenues-issues-view-200289009,200289009
119989,341504,PKI,QIAGEN Strong On Molecular Diagnostics  Competition Rife,opinion,On Feb 6  we issued an updated research report on QIAGEN N V    NYSE QGEN    The stock carries a Zacks Rank  3  Hold  This Netherlands based molecular diagnostics provider offers innovative technologies and products for pre analytical sample preparation and molecular diagnostics solutions  The stock has been trading above the broader over the past six months  As per the latest share price  it has lost 2 1  compared with 3 9  decline of the broader industry The company ended the fourth quarter on a solid note with earnings and revenues beating the Zacks Consensus Estimate  During the quarter  QIAGEN s Molecular diagnostics sales increased significantly on dynamic growth in the QuantiFERON latent TB test  Also  double digit CER growth in revenues from the company s companion diagnostics partnerships and sustained double digit CER growth in consumables related to the QIAsymphony automation system contributed to the top line Moreover  during the reported quarter  the company surpassed its goal of 2 000 QIAsymphony placements in 2017  reflecting strong demand for the system  Management now aims to surpass 2 300 cumulative QIAsymphony placements by the end of 2018  Also  the company s focus to drive growth through Sample to Insight offerings buoys optimism   We are also upbeat about QIAGEN s solid progress with the test menu expansion strategy  In this regard  in January  the company s ipsogen JAK2 RGQ PCR Kit  ipsogen JAK2 assay  received FDA approval for additional use in the diagnosis of all myeloproliferative neoplasms  MPNs  We also look forward to the implementation of the recently drawn strategies to boost top line contributions from the NGS portfolio Meanwhile  QIAGEN is exposed to stiff competition  The company is facing intensifying competition from firms that provide competitive pre analytical solutions and other products used by QIAGEN s customers  The markets for some of the company s products are very competitive and price sensitive  which adds to the concerns  Also  strong reliance on collaborations and declining HPV sales in the United States are other negatives Key PicksSome better ranked stocks in the broader medical sector are PerkinElmer   NYSE PKI    Bio Rad Laboratories   NYSE BIO   and Becton  Dickinson and Company   NYSE BDX   Bio Rad Laboratories has a Zacks Rank  2  Buy   You can see The company has a long term expected earnings growth rate of 25  PerkinElmer has a long term expected earnings growth rate of 12 3   The stock carries a Zacks Rank  2 Becton  Dickinson and Company has a Zacks Rank  2  The company has a long term expected earnings growth rate of 12 8  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-02-08,Zacks Investment Research,https://www.investing.com/analysis/qiagen-strong-on-molecular-diagnostics-competition-rife-200289007,200289007
119990,341505,PKI,QIAGEN s QFT Plus Approval In Japan To Expand Customer Base,opinion,QIAGEN N V    NYSE QGEN   recently announced the receipt of Japan s Ministry of Health Labor and Welfare approval for QuantiFERON TB Gold Plus  QFT Plus  as an in vitro diagnostic to detect tuberculosis  TB  infection  Notably  built on the QuantiFERON TB Gold  QFT  platform  QFT Plus provides enhanced analysis of TB infection  This advanced kit makes TB testing with innovative antigens possible as it measures the cell mediated immune response from both CD4  and CD8  T cells  We believe this approval will help QIAGEN expand its customer base and drive the uptake of QFT Plus test  thereby boosting the top line QuantiFERON TB Diagnostic Test DevelopmentsThe QuantiFERON TB diagnostic test kit falls under QIAGEN s Molecular Diagnostics segment  which was the highest revenue grosser in the last reported quarter  Notably  the segment contributed 49  to total revenues on substantial growth in QuantiFERON latent TB tests  QIAsymphony automation system consumables portfolio and solid performance of companion diagnostic pharma collaborations In this regard  post the receipt of FDA approval in June 2017  QIAGEN had announced the complete launch of the fourth generation blood test for TB infection   QuantiFERON TB Gold Plus  QFT Plus    in the United States Furthermore  continuing with the slew of developments  QIAGEN announced the signing of a collaboration agreement with DiaSorin in January 2017  Post collaboration  QIAGEN s QuantiFERON TB diagnostic test will be available under DiaSorin s LIAISON portfolio of fully automated analyzers This is not the first time QIAGEN is partnering with this renowned in vitro diagnostics  IVD  player  In June  the companies had partnered to develop tests based on a review and selection process involving QIAGEN s assay technologies tests for DiaSorin s LIAISON family of analyzers As per the latest announcement  QFT Plus stands to be the first assay from QIAGEN s QuantiFERON portfolio that will be available for use on the LIAISON family systems  Moreover  per the agreement  the companies will be working on developing a completely automated version of the QuantiFERON test read out components for use with the QuantiFERON TB Plus test along with future QuantiFERON based tests that will be adopted for use on LIAISON In this regard  the companies plan to launch the CE marked QuantiFERON read out components for use on LIAISON XL in the third quarter of 2018  Moreover  a 2019 launch in the United States along with a 2020 launch in China are planned for the same Market ProspectsQIAGEN has been witnessing substantial demand for theQuantiFERON TB diagnostic test kit  Notably  the company announced a milestone of conducting 40 million QuantiFERON TB tests globally since its initial launch by the end of 2017 According to Research and Markets data published on Business Wire  the global TB diagnostics market is expected to see a CAGR of 4 5  between 2017 and 2025 Share Price PerformanceQIAGEN has been gaining investor confidence on consistently encouraging results  Over the past six months  the company s share price has outperformed the broader   The stock has gained 0 6   in contrast to the broader industry s 6  decline   Zacks Rank   Key PicksQIAGEN carries a Zacks Rank  3  Hold  Some better ranked stocks in the broader medical sector are PerkinElmer   NYSE PKI    Bio Rad Laboratories   NYSE BIO   and Becton  Dickinson and Company   NYSE BDX   Bio Rad Laboratories has a Zacks Rank  2  Buy   You can see  The company has a long term expected earnings growth rate of 25  PerkinElmer has a long term expected earnings growth rate of 12 3   The stock carries a Zacks Rank  2 Becton  Dickinson and Company has a Zacks Rank  2  The company has a long term expected earnings growth rate of 13 3  Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-02-11,Zacks Investment Research,https://www.investing.com/analysis/qiagens-qftplus-approval-in-japan-to-expand-customer-base-200289486,200289486
119991,341506,PKI,Abbott s FreeStyle LibreLink App Now Available In Europe,opinion,Abbott   NYSE ABT   announced the availability of FreeStyle LibreLink app in Europe for use in smartphones both iPhone and Android   Notably  diabetes patients using the FreeStyleLibre system in Europe will no longer need to carry the FreeStyle Libre readerseparately to get glucose result  Diabetes patients will now be able to check glucose results directly from their smartphones Per company  the FreeStyle LibreLink app allows users to hold their smartphone near their FreeStyle Libre sensor to capture and view real time glucose levels  Also  it shows eight hour glucose history and how the glucose levels are changing FreeStyle LibreLink app customers will have access to several updates and new features when compared to the FreeStyle Libre reader  The company also said that the app can replace the reader and also be used in combination with each other   FreeStyle LibreLink customers will have the option to share information with their physicians through LibreView and LibreLinkUp  These are other digital health tools that are part of the FreeStyle Libre platform The FreeStyle LibreLink app is free of cost for both iPhone and Android users  and will initially be available in 12 European countries  Also  Abbott is planning for a mobile app solution for FreeStyle Libre users outside Europe  based on in country regulatory approvals Developments in FreeStyle LibreFreeStyle Libre System is the flagship  sensor based continuous glucose monitoring  CGM  system  The company has been witnessing solid growth in the global Diabetes Care business  Notably  Diabetes Care sales rose 27 6  on a comparable operational basis in the last reported fourth quarter  buoyed by double digit international sales growth  led by continued consumer uptake of FreeStyle Libre  Accordingly  it is leaving no stone unturned to cash in on the growing popularity of this system that eliminates the need for daily finger sticks Following the FDA approval in September 2017 for the FreeStyle Libre Flash glucose monitoring system  Abbott recently achieved another major milestone after U S  Centers for Medicare   Medicaid Services  CMS  granted FreeStyle Libre approval for Medicare coverage Meanwhile  Abbott has been steadily progressing with the development of its Diabetes Care segment  Last September  the company announced the receipt of national reimbursement for FreeStyle Libre in the U K   marking another milestone for the company  Notably  the FreeStyle Libre system is partially or fully covered in 21 countries  including France  Germany and Japan Moreover  the company announced receipt of Health Canada License for FreeStyle Libre Flash Glucose Monitoring System in June 2017  This drove the Diabetes Care segment  which saw revenue growth of 37 6  in third quarter 2017 on continued acceptance of FreeStyle Libre internationally Market PotentialAccording to a report by Mordor Intelligence  the global market for diabetes care devices is expected to reach a value of  30 25 billion by 2021  at a CAGR of 5 93   Considering the huge potential of the market  we believe the latest development will help Abbott gain traction in this space Share Price   Estimate Revision TrendAbbott has been gaining investor confidence on consistently positive results  Over the last six months  the stock has outperformed the broader   It has gained 17 6   in comparison with the broader industry s 3 5  The current estimate revision trend is favorable  For the current year  13 estimates moved north compared with no movement in the opposite direction over the last two months  As a result  the Zacks Consensus Estimate for the full year has risen 1 1  to  2 86 per share Zacks Rank   Key PicksAbbott carries a Zacks Rank  3  Hold  Some better ranked stocks in the broader medical sector are PerkinElmer   NYSE PKI    Bio Rad Laboratories   NYSE BIO   and Becton  Dickinson and Company   NYSE BDX   Bio Rad Laboratories has a Zacks Rank  2  Buy   You can see  The company has a long term expected earnings growth rate of 25  PerkinElmer has a long term expected earnings growth rate of 12 3   The stock carries a Zacks Rank  2 Becton  Dickinson and Company has a Zacks Rank  2  The company has a long term expected earnings growth rate of 13 3  Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-02-11,Zacks Investment Research,https://www.investing.com/analysis/abbotts-freestyle-librelink-app-now-available-in-europe-200289483,200289483
119992,341507,PKI,Haemonetics  HAE  Banks On Plasma Franchise  Competition Rife,opinion,On Feb 9  we issued an updated research report on Haemonetics Corporation   NYSE HAE    The stock carries a Zacks Rank  2  Buy  This leading provider of hematology products and solutions has been trading above the  over the last six months  The stock has rallied 61 5  compared with the industry s 3 5  gain  The stock has also outperformed the S P 500 s 7 4  gain Haemonetics exited third quarter fiscal 2018 on a promising note  with earnings and revenues beating the Zacks Consensus Estimate  Continued momentum in new business generation and geographical expansion has helped the company deliver strong results in the quarter  The expansion in gross and operating margin buoys optimism   We are upbeat about Haemonetics  growth in the Plasma franchise  Strong end market demand for plasma derived biopharmaceuticals continues to drive growth  Haemonetics is also confident about maintaining growth in the commercial Plasma collection business Further  the raised fiscal 2018 adjusted earnings guidance is encouraging  The company s strong cash position also boosts investors  confidence On the flip side  Haemonetics operates in a very competitive environment  for manual and automated systems  which includes the likes of MAK Systems Moreover  the company has been witnessing sluggish revenue growth at the Blood Center franchise  significantly affecting its results over the past few quarters  Management also doesn t expect any early recovery in Blood Center s outcome  which adds to our concerns Other Key PicksSome other top ranked stocks in the broader medical sector are PerkinElmer   NYSE PKI    Bio Rad Laboratories   NYSE BIO   and Becton  Dickinson and Company   NYSE BDX   Bio Rad Laboratories has a Zacks Rank  2  You can see  The company has a long term expected earnings growth rate of 25  PerkinElmer has a long term expected earnings growth rate of 12 3   The stock carries a Zacks Rank  2 Becton  Dickinson and Company has a Zacks Rank  2  The company has a long term expected earnings growth rate of 13 3  Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-02-11,Zacks Investment Research,https://www.investing.com/analysis/haemonetics-hae-banks-on-plasma-franchise-competition-rife-200289481,200289481
119993,341508,PKI,5 Reasons To Invest In PerkinElmer  PKI  Stock Right Now,opinion,"PerkinElmer  Inc    NYSE PKI   is one of the top performing stocks in the MedTech space  Improved price performance and strong fundamentals reflect the stock s bullish run  Thus  if you haven t taken advantage of the share price appreciation yet  it s time you add the stock to your portfolio The company has performed impressively in the fourth quarter of 2017 and is likely to sustain the momentum in the upcoming period Why an Attractive Pick Share Price AppreciationA glimpse of the company s price trend reveals that the stock has had an impressive run on the bourses over the last six months  PerkinElmer s shares have returned 16 5   which compares favorably with S P 500 index s rally of 7 9   The current return is also higher than the  s gain of 9 9    Northward Estimate RevisionNine estimates for current year earnings moved north in the last 30 days  versus no downward revision  indicating analysts  optimism  During the period  the Zacks Consensus Estimate rose from  3 40 per share to  3 52  The company holds a Zacks Rank  2  Buy   which indicates robust fundamentals and expectations of outperformance in the near term PerkinElmer  Inc  Price and Consensus
     Promising GuidanceRecently  the company has issued its adjusted earnings per share guidance of  3 50 for 2018  Furthermore  revenues are expected to be within the range of  2 72 to  2 74 billion  Organic growth projected for 2018 is 5 6  The Zacks Consensus Estimate for earnings of 62 cents for the current quarter which reflects year over year growth of 12 7   Moreover  earnings are expected to register growth of 12 9  in 2019 The Zacks Consensus Estimate for 2018 revenues is  2 74 billion for the current year  reflecting year over year growth of 21 3   Moreover  revenues are expected to grow 5 7  in 2019 Improving Operating MarginPerkinElmer s operating margin continues to improve on the back of productivity initiatives and volume leverage  A broad spectrum of products along with new product integrations is expected to improve product mix and also drive gross margin  Also  stringent cost control is expected to drive the operating margin further DevelopmentsPerkinElmer exited the fourth quarter of 2017 on a solid note  with the Discovery and Analytical solutions segment registering 6 5  organic growth  The upside can be attributed to product introductions and healthy growth across all major regions The company has also been benefitting from its latest acquisition of EUROIMMUN Laboratory Diagnostics AG  which majorly drove the Diagnostics segment sales in the reported quarter  The EUROIMMUN alliance has added autoimmune and allergy testing to the company s portfolio as well as additional infectious disease testing capabilities The addition of EUROIMMUN and Tulip diagnostics in 2017 increased the company s headcount in diagnostics by more than 3000 employees  significantly bolstering its research and development sales and clinical capabilities Other Key Picks
A few other top ranked stocks in the broader medical space are Amphastar Pharmaceuticals Inc    NASDAQ AMPH    HCA Healthcare  Inc    NYSE HCA   and athenahealth Inc    NASDAQ ATHN    Each of these stocks sports a Zacks Rank  1  Strong Buy   You can see  Amphastar has an impressive expected long term growth rate of 25   In the last six months  the stock has rallied 25 3  HCA Healthcare has a projected long term growth rate of 11 5   In the last three months  the stock has gained 29 2  athenahealth has a long term growth rate of 23 1   Over the last three months  the stock has gained 6 8  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-02-12,Zacks Investment Research,https://www.investing.com/analysis/5-reasons-to-invest-in-perkinelmer-pki-stock-right-now-200289914,200289914
120023,341538,PKI,Myriad Genetics  MYGN  Beats On Earnings   Revenues In Q2,opinion,Myriad Genetics  Inc    NASDAQ MYGN   reported adjusted earnings per share  EPS  of 31 cents in the second quarter of fiscal 2018  up 19 2  year over year  Moreover  adjusted EPS beat the Zacks Consensus Estimate by a solid margin of 29 2  and exceeded the company s guided range of 22 24 cents Reported earnings came in at 45 cents per share in the quarter  compared with net 9 cents in the year ago quarter RevenuesTotal revenues were down 1 3  year over year to  194 million in the quarter under review  The figure however outpaced the Zacks Consensus Estimate of  189 million and was above the company s guidance of  187  189 million  The year over year decline was however caused by a fall in Hereditary cancer testing revenues owing to price reductions in long term contracts Myriad Genetics  Inc  Price  Consensus and EPS Surprise     However  the decline was partially offset by growing new product volumes  expanded reimbursement for new products and increase in international RNA kit revenues  Moreover  this was the fourth consecutive quarter where the company witnessed year over year Hereditary cancer volume growth led by encouraging response to the newly launched riskScore test under its myRisk Hereditary Cancer testing portfolio Quarter in DetailsSegment wise  Molecular diagnostic tests  92 4  of total revenue  recorded total revenues of  179 2 million  down 2 6  year over year on account of a 11 8  decline in Hereditary cancer testing revenuesto  126 9 million  EndoPredict testing revenues grew 25  year over year to  2 million in the reported quarter  Moreover  Vectra DA testing revenues came in at  11 1 million  up 3 7  year over year  while other testing revenues declined 13 9  to  2 5 million In the Prolaris testing space  volumes maintained double digit growth in the fiscal first quarter as well as an increase in average selling price that benefited from the Medicare favorable intermediate LCD  which was put to effect on Sep 25  2017  Prolaris tests raked in revenues of  5 million in the quarter  up 61 3   Also  Hereditary Cancer testing revenues declined due to price reductions in the long term contracts  However  volume growth exceeded the company s 3  growth target on a year over year basis Pharmaceutical and clinical service revenues  accounting for the rest  in the quarter totaled  14 8 million  reflecting a year over year increase of 17 5  Margin TrendsGross margin in the quarter under review contracted 30 basis points  bps  to 77 1   According to management  the gross margin performance was affected by Hereditary Cancer test pricing issue  partially offset by improved efficiencies in Hereditary Cancer production process as a result of the Elevate 2020 initiatives and increasing new product reimbursement Operating expenses decreased 4 8  to  132 million as a 4 1  rise in selling  general and administrative  SG A  expenses  to  115 4 million  was offset by a 9 7  slash in  research and development  R D  expenses 9to  16 8 million  in the reported quarter Financial PositionMyriad Genetics exited the fiscal second quarter with cash  cash equivalents and marketable securities of  143 5 million  compared with  148 3 million at the end of the preceding quarter  Year to date  cash flow from operations totaled  56 5 million  compared with  28 5 million in the year ago period  Year to date the company registered free cash flow of  54 5 million  compared with  22 7 million in the year ago period GuidanceMyriad Genetics has raised the guidance for fiscal 2018 revenues to  760  770 million from  750  770 million provided earlier  The Zacks Consensus Estimate of  766 2 million lies within the guided range On the bottom line front  the company lifted the adjusted EPS range to  1 11  1 16 from the previous  1 00  1 05  The current Zacks Consensus Estimate of  1 06 is below the company s guided range Management has provided the guidance for the third quarter of fiscal 2018  The company estimates adjusted earnings per share of 26 28 cents on total revenues of  186  188 million  The Zacks Consensus Estimate for adjusted EPS is 26 cents and revenues is  191 6 million Our ViewMyriad Genetics registered a better than expected performance in its second quarter fiscal 2018  However  the year over year decline in revenues is disappointing  On a positive note  the company observed strong growth in both GeneSight and EndoPredict testing revenues  The recent FDA approvals and encouraging test results buoy optimism On the flip side  unfavorable foreign currency translation continues to pose a threat  With a considerable portion of its revenues coming from outside the United States  the company faces the risk of exchange rate fluctuations Zacks Rank   Key PicksMyriad Genetics has a Zacks Rank  3  Hold  A few better ranked stocks that reported solid results this earnings season are PetMed Express   NASDAQ PETS    PerkinElmer   NYSE PKI   and Becton  Dickinson and Company   NYSE BDX    While PetMed sports a Zacks Rank  1  Strong Buy   PerkinElmer and Becton  Dickinson carry a Zacks Rank  2  Buy   You can see PetMed recently reported third quarter fiscal 2018 results  Adjusted earnings per share were 44 cents  up 88 3  from the prior year quarter  Revenues rose 13 7  on a year over year basis to  60 1 million PerkinElmer reported fourth quarter 2017 adjusted earnings per share of 97 cents  Adjusted revenues were approximately  641 6 million  up from  567 million in the year ago quarter Becton  Dickinson reported first quarter 2018 adjusted earnings per share of  2 48  up 3 9  at constant currency  Revenues are  3 08 billion  up 3 7  at constant currency Zacks Top 10 Stocks for 2018In addition to the stocks discussed above  would you like to know about our 10 finest buy and hold tickers for the entirety of 2018 Last year s 2017 Zacks Top 10 Stocks portfolio produced double digit winners  including FMC Corp  NYSE FMC   and VMware which racked up stellar gains of  67 9  and  61   Now a brand new portfolio has been handpicked from over 4 000 companies covered by the Zacks Rank  Don t miss your chance to get in on these long term buys ,2018-02-06,Zacks Investment Research,https://www.investing.com/analysis/myriad-genetics-mygn-beats-on-earnings--revenues-in-q2-200288033,200288033
120024,341539,PKI,Haemonetics   HAE  Q3 Earnings Top Estimates  EPS View Up,opinion,Haemonetics Corporation   NYSE HAE   reported adjusted earnings per share  EPS  of 62 cents in the third quarter of fiscal 2018  a 44  surge year over year  The bottom line also beat the Zacks Consensus Estimate of 41 cents  The metric was favourably attributed by 10 cents of lower tax rate and 4 cents of currency translation  partly offset by a couple of cents  dilution on increased share count On a reported basis  Haemonetics posted net loss of 12 cents per share compared with earnings of 30 cents in the prior year quarter  The metric included  12 million of net transition tax on earnings from certain foreign subsidiaries  previously tax deferred  However  the same is partly offset by a  7 million benefit from the revaluation of deferred tax items using the lower corporate tax rates effective Jan 1  2018 Total RevenuesRevenues were up 2 7  year over year  up 1 1  at constant exchange rate or CER  to  234 million in the reported quarter  The top line also exceeded the Zacks Consensus Estimate of  227 million  The year over year growth was consistently backed by strong results in North America and improving international results in the key markets Haemonetics Corporation Price  Consensus and EPS Surprise    Revenues by Product CategoriesHaemonetics reports operating results under four business franchises  Plasma  Haemostasis Management  Cell Processing and Blood Center At Plasma  reported revenues of  113 1 million  48 3  of total revenues  were up 4 1  year over year  up 5  at CER  Revenues at BloodCenter  31 8  of total revenues  declined 2 8   down 5 1  at CER  to  74 2 million Hemostasis Management franchise revenues  8 5  of total revenues  rose 17 6   up 15 7  at CER  to  19 9 million  Revenues from Cell Processing were up 3 5   up 0 6  at CER  to  26 8 million  11 5  of total revenues  MarginsHaemonetics  third quarter adjusted gross margin was 47 6   up 310 basis points  bps  year over year  driven by favorable mix  productivity and currency Adjusted operating income was  41 8 million in the quarter  a 20 5  rally year over year  Adjusted operating margin expanded 270 bps year over year to 17 9  in the quarter under review  Favourable foreign currency translation contributed about 100 basis points to year over year operating margin improvement Financial PositionHaemonetics exited the third quarter of fiscal 2018 with cash and cash equivalents of  252 million compared with  203 6 million at the end of the preceding year  The company generated operating cash flow of  163 million year to date  Adjusted free cash flow  before transformation and restructuring costs  was  113 4 million this quarter  a 33  increase from the year ago period Fiscal 2018 GuidanceHaemonetics revised its fiscal 2018 revenue guidance  The company expects full year revenues to be in line with fiscal 2017 revenues  excludes currency impact of over 50 bps   The view for Plasma revenue growth has been raised to 5  from the 3 5  range  projected earlier  The outlook for hospital revenue rise has been updated to 6  from the earlier expectation of 7 10   Blood Center revenues are likely to decline in the 6 7  range  the previous guidance was a decrease of 7 10    The Zacks Consensus Estimate for 2018 revenues is pegged at  892 1 million The company raised its 2018 adjusted EPS guidance to  1 80  1 90 from the previous band of  1 65  1 75  The Zacks Consensus Estimate of  1 69 remains below the guided range Our TakeHaemonetics exited third quarter fiscal 2018 on a promising note with both earnings and revenues beating the Zacks Consensus Estimate  Continued momentum in new business generation and geographical expansions have helped the company deliver strong results of late  However  we are disappointed with the company s sluggish Blood Center business moderating its overall growth this reporting cycle despite encouraging progress noticed in the Plasma and Hospitals The company s strong cash position boosts investors  confidence  The increased fiscal 2018 adjusted earnings guidance is also impressive Zacks Rank   Key PicksHaemonetics has a Zacks Rank  3  Hold   A few better ranked stocks having reported solid results this earnings season are PetMed Express   NASDAQ PETS    PerkinElmer   NYSE PKI   and ResMed   NYSE RMD    While PetMed sports a Zacks Rank  1  Strong Buy   PerkinElmer and ResMed carry a Zacks Rank  2  Buy   You can see PetMed recently reported third quarter fiscal 2018 results  Adjusted earnings per share of 44 cents were up 88 3  from the prior year quarter  Revenues rose 13 7  on a year over year basis to  60 1 million PerkinElmer reported fourth quarter 2017 adjusted earnings per share of 97 cents  Adjusted revenues were approximately  641 6 million  up from  567 million in the year ago quarter ResMed posted second quarter fiscal 2018 adjusted earnings per share of  1  up 36 9  from the prior year quarter  Revenues increased 13 4  year over year  up 11  at constant exchange rate or CER  to  601 3 million Breaking News  Cryptocurrencies Now Bigger than VisaThe total market cap of all cryptos recently surpassed  700 billion   more than a 3 800  increase in the previous 12 months  They re now bigger than Morgan Stanley  NYSE MS   Goldman Sachs  NYSE GS  and even Visa  The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved Zacks  has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market ,2018-02-06,Zacks Investment Research,https://www.investing.com/analysis/haemonetics-hae-q3-earnings-top-estimates-eps-view-up-200288030,200288030
120025,341540,PKI,Cerner  CERN  Misses Q4 Earnings Estimates  Bookings Soar,opinion,"Cerner Corp    NASDAQ CERN   reported adjusted fourth quarter earnings of 58 cents per share  down from 61 cents in the year ago quarter  The figure also missed the Zacks Consensus Estimate by 3 cents Revenues of  1 314 billion rose above 4  year over year but marginally missed the Zacks Consensus Estimate of  1 33 billion Over the last six months  Cerner has had a favorable run on the bourses  The stock has returned 1 3  compared with the  s gain of 0 8   Cerner Corporation Price  Consensus and EPS Surprise
     Segment DetailsSystem Sales in the fourth quarter rose 3 2  to  363 5 million  on a year over year basis  It was driven primarily by growth in licensed software Support  Maintenance and Services accounted for revenues worth  922 million  up 4 7  on year over year basis and in line with management s expectations Reimbursement Travel sales amounted to  28 million  up 12 2  compared with the year ago quarter Bookings  An All time HighThe upside in revenues can be primarily attributed to an increase in bookings in the fourth quarter  Bookings were  2 329 billion  up 62  on year over year basis  The company reported full year bookings at a record of  6 325 billion  up 16  compared with the 2016 level MarginsGross margin in fourth quarter is 82 6   flat year over year Operating margin for the reported quarter is 20 5   which contracted 280 basis points  bps  on a year over year basis The downside was caused by surge in operating expenses  which rose 9  year over year  The growth is driven by personnel expense related to revenue generating associates and non cash items Financial PositionOperating cash flow in the fourth quarter was  384 9 million compared with  338 million from the year ago quarter Cerner exited the fourth quarter with cash and cash equivalents of  371 million Long term debt  including capital lease obligations  was  527 million  down slightly on a sequential basis 2017 At a GlanceIn 2017  domestic revenues grew 8  and non U S  revenues rose 3  Full year 2017 revenues were  5 142 billion  up 7  compared with 2016 Adjusted earnings per share were  2 38  compared with  2 30 in 2016 Gross margin was 83 4   which contracted 40 bps from 2016 In full year 2017  System Sales accounted for 26 4  of total revenues  while Support  Maintenance and Services contributed a whopping 71 7   The Reimbursement travel segment represented a mere 2  of total revenues GuidanceCerner expects first quarter 2018 revenues between  1 315 billion and  1 365 billion  The Zacks Consensus Estimate of  1 35 billion for the same  falls below the projected range For 2018  revenues are projected in the range of  5 450  5 650 billion  The Zacks Consensus Estimate of  5 59 billion for the same  lags the projected range First quarter 2018 adjusted earnings per share is projected in the range of 57 59 cents  The figure lags the Zacks Consensus Estimate of 64 cents Full year 2018 adjusted earnings per share is estimated in the range of  2 57  2 73  The figure is higher than the Zacks Consensus Estimate of  2 68 Further  the company expects first quarter 2018 new business bookings in the range of  1 250  1 450 billion Our TakeCerner ended the fourth quarter on a mixed note  The company saw significant surge in bookings and growing revenues  However  dwindling earnings is a concern  Moreover  sales margin was partially affected  thanks to lower margins on technology resale  resulting from higher mix of device resale Per management  large and complex opportunities in their pipeline  drove bookings in the reported quarter  This is likely to drive bookings in the quarters ahead Zacks Ranks   Other Stocks to ConsiderCerner carries a Zacks Rank  2  Buy  A few other top ranked stocks that reported solid results are PetMed Express   NASDAQ PETS    PerkinElmer   NYSE PKI   and Becton  Dickinson and Company   NYSE BDX    While PetMed sports a Zacks Rank  1  Strong Buy   PerkinElmer and Becton  Dickinson carry a Zacks Rank  2  You can see PetMed recently reported third quarter fiscal 2018 results  Adjusted earnings per share was 44 cents  up 88 3  from the prior year quarter  Revenues in the reported quarter rose 13 7  on a year over year basis to  60 1 million PerkinElmer reported fourth quarter 2017 adjusted earnings per share of 97 cents  Adjusted revenues were approximately  641 6 million  up from  567 million in the year ago quarter Becton  Dickinson reported first quarter 2018 adjusted earnings per share of  2 48  up 3 9  at constant currency  Revenues were  3 08 billion  up 3 7  at constant currency Zacks Top 10 Stocks for 2018In addition to the stocks discussed above  would you like to know about our 10 finest buy and hold tickers for the entirety of 2018 Last year s 2017 Zacks Top 10 Stocks portfolio produced double digit winners  including FMC Corp  NYSE FMC   and VMware which racked up stellar gains of  67 9  and  61   Now a brand new portfolio has been handpicked from over 4 000 companies covered by the Zacks Rank  Don t miss your chance to get in on these long term buys ",2018-02-06,Zacks Investment Research,https://www.investing.com/analysis/cerner-cern-misses-q4-earnings-estimates-bookings-soar-200288024,200288024
120026,341541,PKI,STERIS  STE  Q3 Earnings Beat   Revenues Miss  Margins Up,opinion,"STERIS plc   NYSE STE   reported third quarter fiscal 2018 adjusted earnings per share  EPS  of  1 12  excluding net tax benefit of  25 7 million or 30 cents as a result of the U S  tax reform  Reported EPS came in at  1 11 The adjusted EPS figure was up 14 3  year over year and was 4 7  above the Zacks Consensus Estimate of  1 07 Revenues in DetailSTERIS generated revenues of  661 9 million  up 2 3  year over year  Meanwhile  the top line missed the Zacks Consensus Estimate of  665 5 million  Organic revenue growth at constant currency was 5  year over year  mainly driven by high single digit or low double digit growth across majority of the segments The company operates through four segments  Healthcare Products  Healthcare Specialty Services  Applied Sterilization Technologies and Life Sciences Revenues at Healthcare Products remained relatively flat year over year at  324 9 million  This was largely due to a 9  decline in capital equipment revenues  offsetting a 9  rise in consumable revenues and a 6  increase in service revenues Revenues at the Healthcare Specialty Services segment fell 9 1  to  117 4 million on a reported basis due to linen divestitures  However  organic revenues grew 9   reflecting growth at IMS North America 
STERIS PLC Price  Consensus and EPS Surprise
     Revenues at Applied Sterilization Technologies rose 12 5  to  128 7 million  while organic revenues grew 9  on increased demand from core medical device customers Revenues at the Life Sciences segment grew 15 6  to  90 9 million on 8  growth in Service revenues  12  increase in consumable revenues and 33  rise in capital equipment revenues  On an organic basis  revenues increased 14  year over year  MarginsAdjusted gross margin improved 230 basis points  bps  year over year to 42 1  in the reported quarter on account of synergies from divested low margin businesses and a favorable product mix and pricing STERIS witnessed a 0 2  year over year rise in selling  general and administrative expenses to  159 1 million  Research and development expenses rose 4 1  to  15 2 million  Accordingly  adjusted operating margin expanded 280 bps on a year over year basis to 15 8  in the reported quarter Financial DetailsSTERIS exited third quarter fiscal 2018 with cash and cash equivalents of  283 8 million  compared with  295 6 million at the end of second quarter fiscal 2018  The company had long term debt of  1 42 billion at the end of third quarter fiscal 2018 compared with  1 45 billion at the end of second quarter fiscal 2018 Year to date  the company generated  327 9 million in cash flow from operations  up 13 3  from the year ago period  Free cash flow in this period was  216 4 million compared with  181 9 million in the prior year period 2018 GuidanceSTERIS continues to expect 4 5  of organic revenue growth in fiscal 2018 on a constant currency basis from the prior fiscal  The Zacks Consensus Estimate for fiscal 2018 revenues is pegged at  2 60 billion The company has raised it adjusted EPS outlook for fiscal 2018  The adjusted EPS is now projected in the range of  4 10  4 16 in comparison to the previously provided range of  3 96  4 09  The Zacks Consensus Estimate for fiscal 2018 adjusted EPS is pegged at  4 06  below the guided range Our TakeSTERIS exited third quarter fiscal 2018 on a mixed note  We are encouraged with the favorable underlying market trends along with new product and service offerings Further  growth in free cash flow reserve is indicative of the company s strong cash balance  The company has also made certain divestments and organizational changes  which are expected to better align with its operations Zacks Rank   Key PicksSTERIS has a Zacks Rank  3  Hold  A few better ranked stocks that reported solid results this earnings season are PetMed Express   NASDAQ PETS    PerkinElmer   NYSE PKI   and Becton  Dickinson and Company   NYSE BDX    While PetMed sports a Zacks Rank  1  Strong Buy   PerkinElmer and Becton  Dickinson carry a Zacks Rank  2  Buy   You can see   PetMed recently reported third quarter fiscal 2018 results  Adjusted earnings per share of 44 cents were up 88 3  from the prior year quarter  Revenues rose 13 7  on a year over year basis to  60 1 million PerkinElmer reported fourth quarter 2017 adjusted earnings per share of 97 cents  Adjusted revenues were approximately  641 6 million  up from  567 million in the year ago quarter Becton  Dickinson reported first quarter 2018 adjusted earnings per share of  2 48  up 3 9  at constant currency  Revenues were  3 08 billion  up 3 7  at constant currency Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2018-02-07,Zacks Investment Research,https://www.investing.com/analysis/steris-ste-q3-earnings-beat--revenues-miss-margins-up-200288399,200288399
120027,341542,PKI,Illumina Banks On Strategic Partnerships  Competition Rife,opinion,On Feb 7  we issued an updated research report on Illumina  Inc    NASDAQ ILMN     a Zacks Rank  3  Hold  stock Over the last three months  this San Diego  CA based company  providing tools and integrated systems for the analysis of genetic variation and function  has gained 4 7   higher than the broader  s 1 4  Illumina exited fourth quarter 2017 on a solid note  beating the Zacks Consensus Estimate on both the fronts  Additionally  revenues and earnings improved on a year over year basis  This apart  an improving margin scenario instilled investor confidence in the stock  We are also optimistic about Illumina s expansion strategy through the enhancement of its portfolio of sequencing products and the development of strategic partnerships with therapeutic and diagnostic service providers  In this regard  in January 2018  Illumina signed a commercial agreement for distributing Thermo Fisher Scientific s Ion AmpliSeq technology to researchers who conduct studies on Illumina s next generation sequencing platform  Currently  Illumina is focusing on product innovation through research and development as well  which is evident from the recent launch of iSeq 100 Sequencing System  Post a promising fourth quarter  we expect Illumina to maintain growth momentum on continued uptake of sequencing consumables  instruments and microarray portfolios Meanwhile  Illumina faces stiff competition in the sequencing  SNP genotyping  gene expression and molecular diagnostics markets with several large players already enjoying significant market share  intellectual property portfolios and regulatory expertise  Also  the National Institutes of Health  NIH  funding issue raises concern Key PicksSome better ranked stocks in the broader medical sector are Bio Rad Laboratories   NYSE BIO    Becton  Dickinson and Company   NYSE BDX   and PerkinElmer   NYSE PKI   Bio Rad Laboratories has a Zacks Rank  2  Buy   You can see The company has a long term expected earnings growth rate of 25  Becton  Dickinson and Company has a Zacks Rank  2  The company has a long term expected earnings growth rate of 12 8  PerkinElmer has a long term expected earnings growth rate of 12 3   The stock carries a Zacks Rank  2 Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2018-02-07,Zacks Investment Research,https://www.investing.com/analysis/illumina-banks-on-strategic-partnerships-competition-rife-200288642,200288642
120028,341543,PKI,Cardinal Health  CAH  Beats On Q2 Earnings  Raises  18 View ,opinion,Cardinal Health Inc    NYSE CAH   reported second quarter fiscal 2018 adjusted earnings of  1 51 per share  which beat the Zacks Consensus Estimate of  1 14 However  excluding 20 cents benefit from the legislated tax reform  adjusted earnings were  1 31 per share  Meanwhile  adjusted earnings in the year ago quarter were  1 34 per share Revenues increased 6 1  on a year over year basis to almost  35 19 billion and beat the Zacks Consensus Estimate of  34 69 billion Cardinal Health  Inc  Price  Consensus and EPS Surprise    The stock has a Zacks Rank  2  Buy  Segmental AnalysisPharmaceutical SegmentPharmaceutical revenues increased 4 7  to  31 15 billion on a year over year basis  The segment witnessed strong growth in the Specialty business and also gained a large number of Pharmaceutical Distribution customers However  the segment witnessed a 4  decline in profits to  514 million  thanks to generic pharmaceutical pricing  recent investments in Pharmaceutical IT platform and lackluster generics program performance However  solid performance by the Specialty Solutions business partially offset the negative impact in the segment Medical SegmentRevenues in the segment improved 18 6  to  4 04 billion  primarily on higher contributions from new and existing customers Medical segment profits increased 38  to  220 million  courtesy of higher contributions from new and existing customers and acquisition of the Patient Recovery business Share Repurchase ProgramThe company s board of directors approved a new authorization to repurchase up to  1 billion of the company s common shares  which will expire on Dec 31  2020 With the latest authorization  Cardinal Health is authorized to repurchase up to  1 3 billion of its common shares MarginsAs a percentage of revenues  gross margin contracted 50 basis points  bps  to 5 3  of net revenues  However  gross profit in the quarter was  1 86 billion  up 16  year over year Distribution  selling  general and administrative  SG A  expenses increased 24  on a year over year basis to  1313 billion GuidanceConsidering the benefit of 40 cents per share from the lower federal rate due to U S  tax reform  Cardinal Health raised fiscal 2018 outlook  The company expects adjusted earnings per share from continuing operations in the range of  5 25  5 50 per share  higher from the previous range of  4 85  5 10 Our TakeCardinal Health exited the quarter on a solid note  courtesy of encouraging performance in the Medical segment  The Pharmaceutical segment witnessed strong growth in the Specialty business and gained a large number of Pharmaceutical Distribution customers  Further  the company is banking on strategic buyouts  joint ventures and supply agreements to drive growth  A strong fiscal 2018 outlook buoys optimism On the flip side  despite growth in business  profits at the Pharmaceutical segment were hurt by generic pharmaceutical pricing  Huge investments in Pharmaceutical IT platform and lackluster generics performance are likely to mar Cardinal Health s operational efficiencies in the upcoming quarter  Intense competition and customer concentration are other bottlenecks  Recently  the company recently closed  divestiture of its Cardinal Health China distribution Other Key PicksA few other top ranked stocks that reported solid results this earnings season are PetMed Express   NASDAQ PETS    PerkinElmer   NYSE PKI   and Becton  Dickinson and Company   NYSE BDX    While PetMed sports a Zacks Rank  1  Strong Buy   PerkinElmer and Becton  Dickinson carry a Zacks Rank  2  You can see  PetMed r reported third quarter fiscal 2018 results  Adjusted earnings per share were 44 cents  up 88 3  from the prior year quarter  Revenues rose 13 7  on a year over year basis to  60 1 million PerkinElmer reported fourth quarter 2017 adjusted earnings per share of 97 cents  Adjusted revenues were approximately  641 6 million  up from  567 million in the year ago quarter Becton  Dickinson reported first quarter 2018 adjusted earnings per share of  2 48  up 3 9  at constant currency  Revenues totaled  3 08 billion  up 3 7  at constant currency Will You Make a Fortune on the Shift to Electric Cars  Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2018-02-07,Zacks Investment Research,https://www.investing.com/analysis/cardinal-health-cah-beats-on-q2-earnings-raises-18-view-200288606,200288606
120056,341571,PKI,Pacific Biosciences  PACB  Q4 Loss Narrows  Consumables Up,opinion,Pacific Biosciences of California Inc    NASDAQ PACB   reported a loss of 18 cents per share in the fourth quarter of 2017  a penny narrower than the Zacks Consensus Estimate  Also  the figure was 14 2  narrower than the year ago quarter s reported loss of 21 cents  Strength in China and Asia contributed to the company s bottom line improvement in the reported period For the full year  reported loss per share was 87 cents  4 8  wider than the year ago tally of 83 cents Fourth quarter revenues of  24 9 million exceeded the Zacks Consensus Estimate of  22 million but dipped 3 1  on a year over year basis  Notably  the DNA sequencing market is highly competitive due to presence of several established players  Cutthroat competition in the niche space is the primary reason for the year over year top line decline Segment DetailsProduct revenues rose 5 9  to almost  21 8 million  Service and Other revenues deteriorated 18 3  from the year earlier quarter to almost  3 1 million  Total  24 9 million of product  service and other revenues in the fourth quarter were 2  higher than the prior year number Pacific Biosciences of California  Inc  Price  Consensus and EPS Surprise    Consumable revenues in the quarter under review were  12 7 million  up 70  on a year over year basis  marking the metric s eighth consecutive quarter of growth on continued consumable sales momentum  This upside was driven by an increased utilization of the company s growing installed base of sequel systems Instrument revenues in the fourth quarter were  9 2 million  down from  13 1 million on a year over year basis as higher shipments of instruments took place in the latter part of 2016 and early 2017 The company has no record of contractual revenues in the quarter Margin DetailsIn the fourth quarter  Pacific Biosciences generated gross profit of  9 5 million  As a percentage of revenues  gross margin in the quarter was 38 1   down 610 basis points year over year Operating expenses in the fourth quarter of 2017 totaled  30 million compared with  29 2 million on a year over year basis  R D expenses in the quarter totaled  15 6 million  down from  16 3 million a year ago  Selling  general and administrative expenses in the period were  14 4 million compared with  12 9 million in the fourth quarter of 2016  The company incurred  20 5 million of operating loss in the quarter  wider than the loss of  17 8 million a year ago Financial UpdateCash and investments at the end of 2017 was  62 9 million compared with  71 9 million at 2016 end OutlookBanking on a better than expected fourth quarter show  Pacific Biosciences expects its 2018 revenues to grow 20  from the year ago figure  translating to approximately  112 million in total revenues  For the near term  the company anticipates first quarter 2018 revenues to be slightly lower than the reported count in fourth quarter 2017 due to seasonality Our ViewpointPacific Biosciences ended the fourth quarter of 2017 on a promising note  Consumable revenue platform acted as a significant positive for Pacific Biosciences in the quarter  Sales momentum in China continued to remain strong on the company s recent receipt of an order for 10 sequel systems from the premier sequencing service provider  BGI  The outlook for 2018 looks encouraging as well Of the major concerns  the DNA sequencing market breeds stiff competition with several established players dominating the market  Aggressive rivalry in this niche space is a headwind  Also  higher operating expenses are likely to mar prospects The company has a Zacks Rank  3  Hold  Companies Reporting Solid Earnings ResultsA few better ranked stocks that reported solid earnings this season are PetMed Express   NASDAQ PETS    PerkinElmer   NYSE PKI   and Accuray   NASDAQ ARAY    While PetMed sports a Zacks Rank  1  Strong Buy   PerkinElmer and Accuray carry a Zacks Rank  2  Buy   You can see PetMed recently announced third quarter fiscal 2018 results with adjusted earnings per share of 44 cents  The bottom line soared 88 3  year over year  Revenues in the reported quarter rose 13 7  on a year over year basis to  60 1 million PerkinElmer released fourth quarter 2017 adjusted earnings per share of 97 cents  Adjusted revenues were approximately  641 6 million  up from  567 million in the year ago quarter Accuray reported a loss of 6 cents per share in second quarter fiscal 2018  narrower than the year ago figure by 5 cents  The top line improved 15  year over year to  100 3 million Breaking News  Cryptocurrencies Now Bigger than VisaThe total market cap of all cryptos recently surpassed  700 billion   more than a 3 800  increase in the previous 12 months  They re now bigger than Morgan Stanley  NYSE MS   Goldman Sachs  NYSE GS  and even Visa  The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved Zacks has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market ,2018-02-01,Zacks Investment Research,https://www.investing.com/analysis/pacific-biosciences-pacb-q4-loss-narrows-consumables-up-200286475,200286475
120057,341572,PKI,Omnicell  OMCL  Earnings Beat  Revenues Miss Estimates In Q4,opinion,"Omnicell  Inc    NASDAQ OMCL   reported adjusted earnings  excluding the one time tax benefit from the tax reform  per share of 54 cents in fourth quarter 2017  beating the Zacks Consensus Estimate by a couple of cents  The figure is at the high end of the guided range of 49 55 cents 
Earnings improved from the year ago figure of 37 cents as well  Despite the revenue timing headwind for the fourth quarter  strong gross margin improvement  and solid control on operating expenses resulted in the upside in adjusted EPS 
Full year adjusted earnings came in at  1 33 compared with the year ago figure of  1 51  The figure surpassed the Zacks Consensus Estimate of  1 31 Omnicell  Inc  Price  Consensus and EPS Surprise

    
Revenues in Detail
Adjusted revenues in the fourth quarter increased 15 1  year over year to  198 3 million  but missed the Zacks Consensus Estimate of  204 2 million  Also  the figure was down from the earlier provided guidance of  201  207 million owing to the timing of two specific large install accounts delays 
Full year adjusted revenues came in at  717 4 million  up 2  from the year ago period  The figure missed the Zacks Consensus Estimate of  722 9 million 
On a segmental basis  Omnicell s Automation and Analytics revenues increased 13 6  year over year in the fourth quarter to  163 1 million 
However  revenues at the Medication Adherence segment rose 22 6  year over year to  34 8 million 
Operational Update
Omnicell s gross profit during the reported quarter increased 27 9  to  95 1 million  Gross margin expanded 480 basis points  bps  to 48   According to the company  adjusted gross margin as provided by the company in the fourth quarter was 50 1   reflecting an expansion of 200 bps year over year 
SG A expenses in the fourth quarter increased 6 5  year over year to  63 5 million  Research and development expenses rose 6 7  year over year to  15 9 million  Operating expenses were  79 4 million in the fourth quarter  up 6 5  year over year 
Adjusted operating expenses in the quarter totaled  71 2 million  up 8 9  from the year ago quarter 
Financial Update
Omnicell exited 2017 with cash and cash equivalents of  32 4 million  compared with  54 5 million at the end of 2016 
2017 Guidance
For the first quarter of 2018  Omnicell expects adjusted revenues in the band of  174  179 million  which includes the impact of reclassification of selling costs as a reduction of revenues  The company expects first quarter 2018 adjusted earnings in the range of 22 28 cents per share  The Zacks Consensus Estimate for first quarter revenues is pegged at  190 2 million and earnings per share at 42 cents 
For 2018  Omnicell expects product bookings in the range of  625  660 million  Also  the company expects adjusted revenues in the band of  780  800 million  which includes the impact of reclassification of selling costs as a reduction of revenue  The company also expects adjusted earnings to be in the band of  1 85  2 05 per share 
The Zacks Consensus Estimate for full year earnings per share is pegged at  1 29  below the company s guided range  The Zacks Consensus Estimate for full year revenues stands at  730 3 million  above the company s guided range 
Our Take
Omnicell s fourth quarter 2017 performance was impressive with year over year increase in earnings and revenues  Further  both of the company s segments witnessed year over year growth  We are encouraged to note that the company is working on product innovation through R D  Also  Omnicell is expected to gain from its recent launches and strategic partnerships 
Last December  the company announced the XR2 Automated Central Pharmacy System  In the same month  the company announced that the IVX Workflow  which operates on IVX Cloud  creating a significant technological advancement for sterile compounding workflow processes and enabling pharmacies to safely and efficiently compound and prepare IV doses The improvement in margin is also encouraging 
However  a tough competitive landscape acts as a dampener 
Zacks Rank   Key Picks
Omnicell has a Zacks Rank  3  Hold  
A few better ranked stocks that reported solid results this earnings season are PetMed Express   NASDAQ PETS    PerkinElmer   NYSE PKI   and ResMed   NYSE RMD    While PetMed sports a Zacks Rank  1  Strong Buy   PerkinElmer and ResMed carry a Zacks Rank  2  Buy   You can see 
PetMed reported third quarter fiscal 2018 results  Adjusted earnings per share were 44 cents  up 88 3  from the prior year quarter  Revenues rose 13 7  on a year over year basis to  60 1 million 
PerkinElmer reported fourth quarter 2017 adjusted earnings per share of 97 cents  Adjusted revenues were approximately  641 6 million  up from  567 million in the year ago quarter 
ResMed posted second quarter fiscal 2018 adjusted earnings per share of  1  up 36 9  from the prior year quarter  Revenues in the reported quarter increased 13 4  year over year  up 11  at constant exchange rate or CER  to  601 3 million 
Breaking News  Cryptocurrencies Now Bigger than VisaThe total market cap of all cryptos recently surpassed  700 billion   more than a 3 800  increase in the previous 12 months  They re now bigger than Morgan Stanley  NYSE MS   Goldman Sachs  NYSE GS  and even Visa  The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved Zacks  has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market ",2018-02-02,Zacks Investment Research,https://www.investing.com/analysis/omnicell-omcl-earnings-beat-revenues-miss-estimates-in-q4-200286553,200286553
120058,341573,PKI,Integra LifeSciences Global Prospects Solid  Competition Rife,opinion,"On Jan 29  we issued an updated research report on Integra LifeSciences Holdings Corporation   NASDAQ IART    The stock carries a Zacks Rank  3  Hold  
Over the past year  Integra LifeSciences has been trading above the broader   The stock has gained 26 4   compared with 4 6  gain of the industry  Integra LifeSciences has been witnessing key developments on the overseas front  International sales within specialty surgical increased in last reported quarter driven by strength in door repair and tissue ablation franchises in Asia Pacific and Europe 
According to the company  the acquisition of Codman will effectively double the company s international business within this segment  Within Orthopedics   Tissue Technologies  international sales increased double digits largely on incremental revenues from Derma Sciences 
Moreover  the consistently strong performance of its Orthopedics and Tissue Technologies  segment buoys optimism  Notably  the company s Regenerative Technologies is the largest franchise under Orthopedics and Tissue Technologies  In the last reported quarter  the company registered mid single digits growth in this franchise primarily on the addition of Derma Sciences and strong growth in inpatient skin portfolio  
Moreover  Integra LifeSciences introduced several products that have expanded its solutions portfolio in the United States hernia repair market and in the European breast reconstruction market  This should spur growth in 2018 

 
We are also encouraged by the company s three pillar strategy  optimize  execute and accelerate growth  According to management  this will help the company s optimize its infrastructure  deliver commitments through improved planning and communication  and grow through the launch of products  internal development  geographic expansion and strategic acquisitions  
However  Integra LifeSciences faces significant competition in the surgical implants and medical instruments market  The company needs to be innovative on the product front to fend off competition  Moreover  consolidation in the industry could lead to intense pricing pressure  Further  the company generates significant revenues from the international business  which increases its vulnerability to adverse currency movements 
Key Picks
A few better ranked stocks in the broader medical sector are PerkinElmer   NYSE PKI    Bio Rad Laboratories   NYSE BIO   and ResMed   NYSE RMD   
Bio Rad Laboratories has a Zacks Rank  2  Buy   You can see  The company has a long term expected earnings growth rate of 25  
PerkinElmer has a long term expected earnings growth rate of 12 3   The stock carries a Zacks Rank  2 
ResMed has a long term expected earnings growth rate of 13   The stock carries a Zacks Rank  2 
Breaking News  Cryptocurrencies Now Bigger than VisaThe total market cap of all cryptos recently surpassed  700 billion   more than a 3 800  increase in the previous 12 months  They re now bigger than Morgan Stanley  NYSE MS   Goldman Sachs  NYSE GS  and even Visa  The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved Zacks  has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market ",2018-02-02,Zacks Investment Research,https://www.investing.com/analysis/integra-lifesciences-global-prospects-solid-competition-rife-200286604,200286604
120059,341574,PKI,Hill Rom  HRC  Trades On Product Innovation  Competition Rife,opinion,"On Jan 31  we issued an updated research report on Hill Rom Holdings  Inc    NYSE HRC    The stock carries a Zacks Rank  2  Buy  
This Batesville  IN based company has been trading above the broader in the past year  The stock has so far gained 46 9  in comparison with the industry s 26 8   Hill Rom exited the first quarter of fiscal 2018 on a strong note with better than expected earnings and revenues  The company saw a solid year over year increase in revenues on strong international growth  primarily banking on the  One Hill Rom  approach 
The company is focusing on product innovation  the latest launch being Connex Cardio ECG  Hill Rom has updated its 2020 long range financial objectives and outlook considering gains from the new tax reform  Hill Rom now expects adjusted earnings growth of 12 14  on a compound annual basis through 2020  compared with the previous guidance of 10 12  

 
Moreover  an improvement in gross and adjusted operating margin buoys optimism  Further  according to management  Hill Rom expects the latest U S  tax regulations to have a positive impact on its adjusted effective tax rate and earnings beginning the first quarter of fiscal 2018 
Hill Rom s merger and acquisition activities are going strong  The company actively pursues buyouts to accelerate growth in five key clinical areas viz  patient mobility  wound care and prevention  surgical  safety and efficiency  clinical workflow solutions and respiratory help  Apart from Welch Allyn and Trumpf  the recent noteworthy acquisitions include that of Virtus  Aspen Surgical and Mortara Instrument 
On the flip side  a decline in revenues at the Patient Support Systems segment is quite disappointing  Hill Rom operates in a highly competitive space dominated by large as well as small and regional manufacturers  Also  unfavorable currency movement continues to be a threat as a large chunk of the company s revenues is generated from international operations 
Key Picks
Other top ranked stocks in the broader medical sector are PerkinElmer   NYSE PKI    Bio Rad Laboratories   NYSE BIO   and ResMed   NYSE RMD   
Bio Rad Laboratories has a Zacks Rank  2  The company has a long term expected earnings growth rate of 25   You can see 
PerkinElmer has a long term expected earnings growth rate of 12 3   The stock carries a Zacks Rank  2 
ResMed has a long term expected earnings growth rate of 13   The stock carries a Zacks Rank  2 
Breaking News  Cryptocurrencies Now Bigger than VisaThe total market cap of all cryptos recently surpassed  700 billion   more than a 3 800  increase in the previous 12 months  They re now bigger than Morgan Stanley  NYSE MS   Goldman Sachs  NYSE GS  and even Visa  The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved Zacks  has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market ",2018-02-02,Zacks Investment Research,https://www.investing.com/analysis/hillrom-hrc-trades-on-product-innovation-competition-rife-200286602,200286602
120060,341575,PKI,Athenahealth  ATHN  Tops Earnings   Revenue Estimates In Q4,opinion,Maintaining its streak of positive earnings surprises  athenahealth Inc    NASDAQ ATHN   reported adjusted earnings of  1 11 per share in the fourth quarter of 2017  which beat the Zacks Consensus Estimate of 64 cents  Further  earnings increased a whopping 79  on a year over year basis The Watertown  MA based maker of billing and medical practice management software posted revenues of  329 million  beating the Zacks Consensus Estimate of  323 million  Revenues increased 14 2  on a year over year basis athenahealth flaunts a Zacks Rank  1  Strong Buy  2017 at a GlanceIn 2017  total revenues of  1 220 3 million rose 13  year over year  Consolidated bookings were  293 million  down from  348 million in 2016 Business and Services segment registered revenues of  1 188 4 million  97 4  of net revenues   Implementation and Other segment reported revenues of  31 9 million  2 6  of net revenues  athenahealth  Inc  Price  Consensus and EPS Surprise     Q4 DetailsSegment Detailsathenahealth reported Business and Services revenues of  321 3 million  up 15 2  from the year ago quarter  However  the implementation and other segment reported revenues of  7 9 million  down 15 1  year over year Network ExpansionPer management  the company expanded its network across ambulatory  hospital and population health platforms  Recently  athenahealth surpassed the 100 million patient threshold and now serves more than 100 000 healthcare providers  The company s network has 110 648 Collector Providers  60342 Clinical Providers and 69 915 Communicator Providers  up 15   22  and 21  respectively on a year over year basis In the athenaOne  Hospital  platform  number of discharged beds increased a whopping 349  year over year In the Population Health platform  number of covered lives increased 48  year over year Buoyed by stellar network expansion  the company is expected to fortify its foothold in the Revenue Cycle Management  RCM  space and drive revenues and earnings over the long haul Margin DetailsA strong client base has been a major growth driver for the company  Adjusted gross margin in the fourth quarter was 68   compared with 66 2  in the year ago quarter The company saw an operating margin of 14 3  of total revenues  up 210 basis points year over year  Notably  adjusted operating income in the reported quarter increased 83  year over year to  78 million Guidanceathenahealth is expected to introduce fiscal 2018 guidance at the 2018 Investor Summit  which is scheduled to be held on Feb 15 Meanwhile  the Zacks Consensus estimate for 2018 earnings is pegged at  2 96  up 19 4  year over year  For 2018  the Zacks Consensus Estimate for revenues is pegged at  1 34 billion Bottom Lineathenahealth exited the fourth quarter of 2017 on a solid note  with earnings and revenues outpacing the Zacks Consensus Estimate  We believe applications like athenaClinicals  athenaClinicals Streamlined  athenaInsight  athenaCommunicator  athenaOne  athenaCollector for Hospital and Health Systems and the brand promise of  Unbreak Healthcare  are fortifying its market position in terms of exclusiveness of services provided in the respective markets  A strong client base has been a key catalyst Business and Services revenues witnessed year over year growth while the same in the implementation and other segment declined  Among major concerns  athenahealth s EHR solution faces significant competition from the likes of Allscripts Healthcare Solutions and others  Further  athenahealth fell short of its bookings goals in 2017  Deteriorated client retention rates also add to the company s woes Other Key PicksA few top ranked stocks that reported impressive earnings this season are PetMed Express   NASDAQ PETS    PerkinElmer   NYSE PKI   and Accuray   NASDAQ ARAY    While PetMed sports a Zacks Rank  1  PerkinElmer and Accuray carry a Zacks Rank  2  Buy   You can see PetMed recently announced third quarter fiscal 2018adjusted earnings per share of 44 cents  The bottom line soared 88 3  year over year  Revenues in the reported quarter rose 13 7  on a year over year basis to  60 1 million PerkinElmer reported fourth quarter 2017 adjusted earnings per share of 97 cents  Adjusted revenues were approximately  641 6 million  up from  567 million in the year ago quarter Accuray reported a loss of 6 cents per share in second quarter fiscal 2018  narrower by 5 cents than the year ago quarter s figure  The top line improved 15  year over year to  100 3 million Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-02-04,Zacks Investment Research,https://www.investing.com/analysis/athenahealth-athn-tops-earnings--revenue-estimates-in-q4-200287002,200287002
120083,341598,PKI,Stryker  SYK  Beats Earnings And Revenue Estimates In Q4,opinion,"Maintaining the streak of positive earnings surprises  Stryker Corporation   NYSE SYK   reported fourth quarter 2017 adjusted earnings per share of  1 96  beating the Zacks Consensus Estimate by a penny  Revenues of  3 47 billion outpaced the Zacks Consensus Estimate of  3 44 billion  Notably  revenues improved 9 9  year over year  Adjusted earnings per share increased 10 1  from the year ago quarter The upside can primarily be attributed to organic sales growth of 8 1  in the reported quarter  Organic growth in the United States was 8 6  on a year over year basis  while the same for OUS was 6 7  Per management  fourth quarter results were driven by research and development innovations as well as stellar performance by the company s Mako Total Knee Applications Stryker Corporation Price  Consensus and EPS Surprise
     Over the last year  Stryker had a favorable run on the bourses  The stock has returned 36 3  compared with the  s rally of 24   Segment DetailsOrthopaedic  Revenues in the segment totaled  1 3 billion  up 6 8  year over year at constant currency  cc   In 2017  revenues increased 6 5  at cc to  4 71 billion The segment delivered organic growth of 6 8  at cc  courtesy of strong performance in the United States  Notably  the region witnessed organic growth of 8 1  in the quarter  Such gains indicate robust demand for the company s 3 D printed products  Foot and Ankle portfolio and Mako platform MedSurg  Sales at the segment totaled  1 58 billion  up 9 8  on a year over year basis at cc  In 2017  revenues increased 13 4  at cc to  5 56 billion Internationally  MedSurg reported constant currency growth of 6 7  and organic sales growth of 5 7   which indicate strong performances in Europe and Australia Neurotechnology and Spine  The segment delivered sales worth  586 million  up 10 3  year over year at cc  In 2017  revenues improved 8 3  at cc to  2 2 billion Neurotechnology and Spine witnessed 10 3  growth at cc and organic growth of 10  on a year over year basis  This shows strong demand for products like Target coil  AIS and CMF among the company s neuropowered instruments Further  Spine business in the United States also posted positive numbers bolstered by high demand for IVS and 3 D printed interbody Tritanium products Quarter HighlightsMako Momentum Continues  In the fourth quarter  the Mako Total Knee platform drove Stryker s earnings  Mako robot installations totaled 35 globally  with 27 in the United States  Additionally  the company had its first robot sale in Japan  where the approval for Mako is expected by the end of 2018 About 200 surgeons have been trained during the reported quarter  since the integration of Mako  Moreover  Mako Total Knee procedures for 2017 were 15 778  with 20  more competitive surgeons using the Triathlon Total Knee implant for the first time Mako utilization rates have surged more than 40  on a year over year basis  The company exited the year with 372 Mako robots installed in U S  hospitals  representing 10  of its customer base R D Edge  During the fourth quarter  Stryker continued to invest in internal innovation  R D expenses totaled 5 9  of the sales in the reported quarter and 6 3  on a full year basis MarginsAdjusted gross margin in the fourth quarter is 66 4   flat year over year  Per management  gross margin was affected by productivity issues associated with the continued recovery of the Puerto Rico manufacturing facility  Operations in the facility were disrupted  thanks to natural calamities  Further  unfavorable pricing and integration risks dented margins Operating margin in the quarter is 27  of net sales  down 70 basis points from the year ago quarter 2017 At a GlanceOn a full year basis  revenues grew 9 9  to  12 44 billion  while adjusted earnings increased 11 9  to  6 49 Orthopedics segment reported 37 9  of net sales and MedSurg accounted for 45 2  of total sales  Neurotechnology   Spine contributed 17 7  of total revenues FY18 GuidanceStryker expects net sales to be positively impacted by 1  in 2018  courtesy of favorable foreign exchange rates Adjusted earnings are expected in the range of  7 07   7 17  For the first quarter of 2018  the earnings guidance is  1 57  1 62 The company anticipates organic sales growth in the range of 6 6 5  for 2018 Management announced capital expenditures in the range of  550  600 million compared with approximately  600 million in 2017 Financial PositionStryker continues to maintain a strong balance sheet with  2 8 billion of cash  Cash flow from operations was approximately  1 6 billion in 2017 Total debt at the end of the year amounted to  7 2 billion Our TakeStryker Corporation exited the fourth quarter and the full year of 2017 with impressive earnings and revenue figures  The company s solid product portfolio  outstanding Mako Total Knee performance and R D initiatives buoy optimism  However  high debt and the Sage product recall issues are concerns Zacks Ranks   Key PicksStryker carries a Zacks Rank  3  Hold  A few better ranked stocks in the broader medical sector are ResMed   NYSE RMD    PerkinElmer   NYSE PKI   and Accuray   NASDAQ ARAY    All the three companies carry a Zacks Rank  2  Buy   You can see ResMed posted second quarter fiscal 2018 adjusted earnings per share of  1  up 36 9  from the prior year quarter  Revenues in the reported quarter increased 13 4  year over year  up 11  at constant exchange  to  601 3 million PerkinElmer reported fourth quarter 2017 adjusted earnings per share of 97 cents  Adjusted revenues were approximately  641 6 million  up from  567 million in the year ago quarter Accuray reported a loss of 6 cents per share in second quarter fiscal 2018  5 cents narrower than the year ago figure  Total revenues in the second quarter improved 15  year over year to  100 3 million The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-01-30,Zacks Investment Research,https://www.investing.com/analysis/stryker-syk-beats-earnings-and-revenue-estimates-in-q4-200285374,200285374
120084,341599,PKI,Thermo Fisher  TMO  Q4 Earnings Beat On Growth In All Lines,opinion,Thermo Fisher Scientific Inc    NYSE TMO   reported better than expected performance in fourth quarter 2017  Adjusted EPS came in at  2 79  beating the Zacks Consensus Estimate by 4 9  and the year ago quarter figure by 15 8  On a reported basis  fourth quarter EPS of  1 30 marked an 18 2  decline year over year  The bottom line figure includes a one time tax provision associated with the recent enactment of tax reform legislation in the United States For the full year  adjusted EPS came in at  9 49  up 15  from the year ago period and ahead of the Zacks Consensus Estimate of  9 36 by 1 4   The quarter s EPS also exceeds the company provided guidance at a range of  9 29  9 38 Revenues in the quarter came in at  6 05 billion  up 22 1  year over year  The top line also outpaced the Zacks Consensus Estimate of  5 69 billion by 6 3  Full year revenues of  20 92 billion were up 14  from the year ago period  surpassing the Zacks Consensus Estimate of  20 59 billion  Moreover  the revenue count stands above the company s guided band of  20 50  20 66 billion Quarter in DetailOrganic revenues in the fourth quarter grew 8  year over year while acquisitions increased revenues by 11   Currency translation positively impacted total revenues by 3  Thermo Fisher Scientific Inc Price  Consensus and EPS Surprise    Thermo Fisher currently operates under four business segments  Life Sciences Solutions  Analytical Instruments  Specialty Diagnostics plus Laboratory Products and Services Revenues at the Life Sciences Solutions segment  28 6  of total revenues  improved 11  year over year to  1 58 billion while Analytical Instruments Segment sales  24 6   rose 16  to  1 41 billion  representing the acquisition of FEI Company Revenues at the Laboratory Products and Services segment  33 9   surged 43  to  1 40 billion  reflecting the buyout of Patheon in August 2017  The Specialty Diagnostics segment  16 8   recorded a 10  rise to  0 91 billion Gross margin of 46 3  during the fourth quarter was down 234 basis points  bps  year over year  despite a 16 2  improvement in gross profits  Adjusted operating margin contracted 59 bps to 23 2  on a 14 4  rise in selling  general and administrative expenses and a 9 4  increase in research and development expenses The company exited the year 2017 with cash and cash equivalents of  4 billion compared with  3 25 billion at the end of 2016  Full year net cash provided by operating activities was  2 13 billion compared with  3 25 billion in the year ago period 2018 GuidanceThe company will provide 2018 financial outlook on its earnings conference call Bottom LineThermo Fisher ended the fourth quarter on a promising note with both adjusted earnings and revenues beating the Zacks Consensus Estimate We are encouraged by the company s solid international performance with strong year over year growth in the Asia Pacific and the emerging markets like China  South Korea and the Middle East Also  a series of product launches along with major progress in precision medicine initiatives benefited the company s performance  Thermo Fisher s acquisition of FEI Company has already started to boost its analytical instruments portfolio  Also in 2017  the company deployed  7 8 billion on strategic acquisitions  adding leading biopharma contract development and manufacturing services through Patheon Significantly  enhancing the company s value proposition for biopharma customers  Patheon has started to contribute to the company s laboratory products and services segment Zacks Rank   Key PicksThermo Fisher has a Zacks Rank  3  Hold   Some better ranked stocks in the broader medical sector are ResMed   NYSE RMD    PerkinElmer   NYSE PKI   and Accuray   NASDAQ ARAY    all three carrying a Zacks Rank  2  Buy   You can see  ResMed posted second quarter fiscal 2018 adjusted earnings of  1  up 36 9  from the prior year quarter  Revenues in the reported quarter increased 13 4  year over year  up 11  at constant exchange rate or CER  to  601 3 million PerkinElmer released fourth quarter 2017 adjusted earnings of 97 cents  The company reported adjusted revenues of approximately  641 6 million  topping the year ago quarter s  567 million Accuray announced a loss of 6 cents in the second quarter of fiscal 2018  5 cents narrower than the year ago figure  Total revenues gained 15  year over year to  100 3 million The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-01-30,Zacks Investment Research,https://www.investing.com/analysis/thermo-fisher-tmo-q4-earnings-beat-on-growth-in-all-lines-200285585,200285585
120085,341600,PKI,QIAGEN  QGEN  Beats On Q4 Earnings And Revenues  Issues View,opinion,QIAGEN N V  s   NYSE QGEN   fourth quarter 2017 adjusted earnings per share  EPS  came in at 43 cents  excluding an after tax charge of  104 4 million or 45 cents per share as an impact of U S  tax reform  Notably  roughly  94 9 million or 41 cents per share of this charge included non cash items that were derived from the revaluation of deferred taxes and other tax provisions  Reported loss came in at 18 cents per share The adjusted EPS figure was up 10 3  year over year  The figure beat the Zacks Consensus Estimate by a penny  At constant exchange rate or CER  the company reported adjFull year adjusted EPS came in at  1 27 compared with  1 11 in the year ago quarter  The figure also surpassed the Zacks Consensus Estimate of  1 25 Revenues in DetailNet sales at actual rates in the fourth quarter grew 8 3  on a year over year basis to  396 9 million  5  at CER   Also  the top line surpassed the Zacks Consensus Estimate of  394 5 million  Qiagen N V  Price  Consensus and EPS Surprise     In the full year  net sales grew 6   same at CER  to  1 42 billion from the year ago quarter s  1 34 billion  The figure surpassed the Zacks Consensus Estimate of  1 41 billion Region wise  sales from the Americas  44  of revenues  grew 7  at CER  while revenues from Europe Middle East Africa  34   and Asia Pacific Japan  22   increased 6  and 1   respectively  Sales in the top seven emerging markets  18   exhibited growth of 9  year over year at CER in the quarter under review Segments in DetailQIAGEN primarily generates revenues from Molecular Diagnostics  Applied Testing  Pharma and Academia  which represented 49   10   18  and 23  of net sales  respectively  during the reported quarter Molecular diagnostics sales were up 4  at CER  Sales derived from Applied Testing rose 9  at CER  Pharma sales rose 9  at CER in the fourth quarter and Academia sales improved 5  backed by growing demand Operational UpdateAdjusted operating income  excluding restructuring charges  increased 8  year over year to  121 7 million in the fourth quarter  Also  adjusted operating margin expanded 230 basis points to 30 7   Financial UpdateQIAGEN exited full year 2017 with cash and cash equivalents of  657 7 million  down from  671 8 million in the preceding quarter  Net cash from operating activities in 2017 was  286 8 million  down from  341 6 million a year ago  Moreover  the company reported full year 2017 free cash flow of  196 7 million compared with  267 1 million in the year ago period QIAGEN has announced a new commitment to return  200 million to shareholders via open market repurchases  after returning  300 million to shareholders by the end of 2017  Notably  shares will be repurchased on the Frankfurt Stock Exchange 2018 GuidanceFor 2018  organic growth in net sales is expected to be 6 7  at CER  up from 5  in 2017   excluding business portfolio changes in as well as the acquisition of STAT Dx  launch planned for second half 2018   The company expects total 2018 adjusted net sales to be  1 42 billion  The Zacks Consensus Estimate for net sales is pegged at  1 52 billion  QIAGEN expects underlying growth in adjusted EPS to approximately  1 38  1 40 at CER  This is however expected to decline to  1 31  1 33 due to dilution of about 3 cents at CER owing to the U S  tax reform and an adjusted tax rate of about 20 21  for 2018  anticipated dilution of about 5 cents for commercialization and development of the QIAstat Dx system  and accretion of about a penny per share from the  200 million share repurchase plan  The Zacks Consensus Estimate for adjusted earnings is pegged at  1 37 For first quarter 2018  adjusted net sales growth is expected at  308 3 million  The Zacks Consensus Estimate for net sales stands at  339 million  which is above the guided range  Moreover  first quarter 2018 adjusted EPS is projected at 23 cents  The Zacks Consensus Estimate for adjusted earnings is pegged at 26 cents  above the guided range Our TakeQIAGEN ended the fourth quarter on a solid note  We are impressed with year over year growth across all segments  The company also delivered a strong performance with respect to operating margin  Meanwhile  its commitment to return more to shareholders through increased repurchases reflects its solid cash position  The market is also looking forward to the recently inked agreement of QIAGEN to buy a privately held developer of the next generation of multiplex diagnostics for fully integrated and one step molecular analysis of certain well known syndromes using a novel system based on real time proven QIAGEN chemistries and PCR technology On the flip side  a competitive landscape and strong reliance on collaborations remain major overhangs Zacks Rank   Key PicksQIAGEN has a Zacks Rank  4  Sell  A few better ranked stocks that reported solid results this earnings season are PetMed Express   NASDAQ PETS    PerkinElmer   NYSE PKI   and Accuray   NASDAQ ARAY    While PetMed sports a Zacks Rank  1  Strong Buy   PerkinElmer and Accuray carry a Zacks Rank  2  Buy   You can see PetMed recently reported third quarter fiscal 2018 results with adjusted earnings per share of 44 cents rising 88 3  year over year  Revenues in the reported quarter rose 13 7  on a year over year basis  to  60 1 million PerkinElmer reported fourth quarter 2017 adjusted earnings per share of 97 cents  Adjusted revenues were approximately  641 6 million  up from  567 million in the year ago quarter Accuray reported a loss of 6 cents per share in second quarter fiscal 2018  5 cents narrower than the year ago figure  Total revenues improved 15  year over year to  100 3 million Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-01-31,Zacks Investment Research,https://www.investing.com/analysis/qiagen-qgen-beats-on-q4-earnings-and-revenues-issues-view-200285908,200285908
120086,341601,PKI, IDEXX Laboratories  IDXX  Beats On Q4 Earnings And Revenues ,opinion,"IDEXX Laboratories  Inc    NASDAQ IDXX   reported fourth quarter 2017 adjusted earnings per share  EPS  of 77 cents  excluding the negative impact of 34 cents per share due to U S tax reform  The adjusted EPS figure surpassed the Zacks Consensus Estimate of 73 cents  Reported EPS came in at 43 cents Full year 2017 reported EPS came in at  2 94 per share  Moreover  reported earnings figure was up 21  on a comparable constant currency basis Revenues in DetailRevenues rose 14 2  year over year  up 11 7  on organic basis  to  506 1 million  surpassing the Zacks Consensus Estimate of  491 million by 3 1  Worldwide sales in the year came in at  1 97 billion  up 10 9  year over year on a reported basis  The figure also surpassed the Zacks Consensus Estimate of  1 95 billion The year over year upside was driven by strong global gains in Companion Animal Group   CAG   Diagnostics recurring revenues  including double digit organic revenue gains across consumable and reference lab as well as strong acceptance of rapid assays and veterinary software  services and diagnostic imaging systems 
IDEXX Laboratories  Inc  Price  Consensus and EPS Surprise    Segmental AnalysisIDEXX derives revenues from four operating segments  CAG  Water  Livestock  Poultry and Dairy   LPD    and Other In the fourth quarter  CAG revenues rose 14 2   up 11 8  organically  year over year to  433 5 million  Water segment s revenues were up 18 6  from the prior year quarter  up 16 1  organically  to  28 9 million  LPD revenues grew 12 8   up 8 4  organically  to  37 2 million  Revenues at the Other segment rose 6 3   up 5 8  organically  to  6 5 million MarginsGross profit increased 13 3  to  272 5 million in the reported quarter  However  gross margin contracted 50 basis points  bps  to 53 8  on a 15 4  rise in cost of revenues to  233 6 million Sales and marketing expenses rose 12 3  to  90 5 million  while general and administrative expenses increased 8 9  to  55 3 million  Research and development expenses rose 13 4  to  28 8 million  Operating margin in the quarter improved 40 bps to 19 3  Financial PositionIDEXX exited fiscal 2017 with cash and cash equivalents of  472 million  up from  391 8 million at the end of 2016  Net cash provided by operating activities in 2017 was  373 3 million  compared with  338 9 million in the year ago period 2018 GuidanceIDEXX raised its 2018 revenue outlook to  2 205  2 245 million from the previous  2 140  2 180 million  reflecting organic revenue growth expectations of 9 5  to 11 5  compared with 9 11  stated previously  The Zacks Consensus Estimate for 2018 revenues is pegged at  2 17 billion  below the guided range Management also raised its EPS guidance to  4 04  4 18 from the earlier  3 50  3 62  supported by continued operating margin expansion aligned with its long term goals  The updated outlook represents EPS growth of 37 42  on a reported basis compared with 8 12  stated previously  The Zacks Consensus Estimate for 2017 EPS is pegged at  3 75  below the guided range Our TakeIDEXX exited the fourth quarter on a solid note  Moreover  solid year over year growth in organic revenues and a raised EPS guidance for 2018 are encouraging The stellar performance was driven by strong sales at the CAG business  The companion animal market fundamentals remain solid with tremendous global runway for growth  Management s innovation based  multi modality global strategy  enabled by enhanced commercial capability  accelerated recurring CAG Diagnostics revenue growth  Moreover  the strong top line growth in the quarter was driven by considerable contributions from the rest of the business segments Zacks Rank   Other Key PicksIDEXX has a Zacks Rank  2  Buy   A few other top ranked stocks that reported solid results this earnings season are PetMed Express   NASDAQ PETS    PerkinElmer   NYSE PKI   and Accuray   NASDAQ ARAY    While PetMed sports a Zacks Rank  1  Strong Buy   PerkinElmer and Accuray carry a Zacks Rank of 2  You can see PetMed reported third quarter fiscal 2018 results with adjusted EPS of 44 cents  improving 88 3  from the prior year quarter  Revenues rose 13 7  on a year over year basis to  60 1 million PerkinElmer reported fourth quarter 2017 adjusted EPS of 97 cents  Adjusted revenues were approximately  641 6 million  up from  567 million in the year ago quarter Accuray reported a loss of 6 cents per share in second quarter fiscal 2018  5 cents narrower than the year ago figure  Total revenues improved 15  year over year to  100 3 million Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2018-01-31,Zacks Investment Research,https://www.investing.com/analysis/idexx-laboratories-idxx-beats-on-q4-earnings-and-revenues-200286108,200286108
120087,341602,PKI,Baxter  BAX  Beats On Q4 Earnings   Revenues   18 View Solid,opinion,Baxter International Inc    NYSE BAX   reported fourth quarter 2017 adjusted earnings per share of 64 cents  which beat the Zacks Consensus Estimate by 5 cents and improved from the year ago quarter s figure of 57 cents  Baxter has a Zacks Rank  3  Hold  The figure also came in above the company s guidance of 56 59 cents  Over the last four quarters  the company delivered positive earnings surprises  the average being 10 6  Baxter posted sales of  2 77 billion  marginally beating the Zacks Consensus Estimate of  2 76 billion  At constant currency  cc   revenues increased 3  on a year over year basis  U S  sales were up 1  year over year to  1 1 billion  International sales increased 4  at cc to almost  1 6 billion Baxter International Inc  Price  Consensus and EPS Surprise    Segmental DetailsHospital ProductsSales at the hospital products segment rose 3  at cc on a year over year basis to  1 7 billion  Hospital Products sales in the quarter were driven by solid sales in the U S  fluid systems and select anesthesia and critical care products Hospital Sales were also driven by solid demand for injectable pharmaceuticals and hospital pharmacy compounding services  Sales in the segment benefited from solid demand for the company s advanced surgery products and cytotoxic contract manufacturing services Renal ProductsSales in the segment increased 3  at cc to  1 1 billion  Renal products sales were supported by improved performance in all major product lines and therapies  globally  Notably  solid performance in chronic and acute renal therapies drove sales in the segment Consistent Efforts to Increase ProductionPer management  the company s Puerto Rico facilities  affected by the Hurricanes  are ramping up production  Additionally  Baxter has been working closely with FDA to support supply of certain products in the domestic market  which were cautioned for importation from Baxter s facilities in Ireland  Australia  Canada  Mexico  England  Italy and Brazil In the fourth quarter  Baxter launched the oXIRIS set for continuous renal replacement therapy  CRRT  and sepsis management protocols in select markets of Europe  Middle East and Africa  oXIRIS  which leverages on the company s flagship PRISMAFLEX system  is expected to lend the company a competitive edge in the global market Recently  the company upgraded the SIGMA Spectrum Infusion System with the launch of DeviceVue Advanced Asset Tracking System  Baxter is the first and only smart infusion pump manufacturer to offer a tagless  end to end acid tracking application designed in consultation with potential customers to drive operational efficiencies and maximize the clinical value of their pump investments GuidanceFor 2018  Baxter estimates sales growth of approximately 6 7  at cc  Adjusted earnings for the full year are expected in the band of  2 72 to  2 80 per share Baxter expects first quarter in the range of 60 62 cents  However  Baxter expects sales in the first quarter to be affected by approximately  25 million due to disruptions in the Puerto Rico facility 2017 at a GlanceIn 2017  Baxter registered revenues of  10 6 billion  up 4  at cc on a year over year basis  Sales of Hospital Products totaled  6 6 billion  62 3  of net sales   Baxter s Renal sales totaled more than  3 9 billion in the year  36 7  of net sales  Baxter increased the annual dividend rate by 23  and repurchased  564 million worth of shares  while also pursuing internal and external initiatives to augment growthOur TakeBaxter ended the fourth quarter on an encouraging note  beating the Zacks Consensus Estimate on both the counts  The company s impressive performance at the hospital products and renal segments hold promise  Recently  Baxter launched the oXIRIS set for continuous renal replacement therapy  CRRT  and sepsis management protocols in select markets of Europe  Middle East and Africa  Further  the recent launch of DeviceVue  a comprehensive asset tracking solution available exclusively to hospitals  boosts the company s product portfolio On the flip side  foreign currency headwinds  intense competition and lackluster sales growth have been dampening Baxter s performance since long  Generic competition for cyclophosphamide is a headwind  Further  the recent hurricanes are expected to dent the company s results in the near term Companies Reporting Solid Earnings ResultsA few better ranked stocks that reported decent results this earnings season are PetMed Express   NASDAQ PETS    PerkinElmer   NYSE PKI   and Accuray   NASDAQ ARAY    While PetMed sports a Zacks Rank  1  Strong Buy   PerkinElmer and Accuray carry a Zacks Rank  2  Buy   You can see PetMed recently reported third quarter fiscal 2018 results  Adjusted earnings per share was 44 cents  up 88 3  from the prior year quarter  Revenues rose 13 7  on a year over year basis to  60 1 million PerkinElmer reported fourth quarter 2017 adjusted earnings per share of 97 cents  Adjusted revenues were approximately  641 6 million  up from  567 million in the year ago quarter Accuray reported a loss of 6 cents per share in second quarter fiscal 2018  5 cents narrower than the year ago figure  Total revenues in the second quarter improved 15  year over year to  100 3 million Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-02-01,Zacks Investment Research,https://www.investing.com/analysis/baxter-bax-beats-on-q4-earnings--revenues-18-view-solid-200286089,200286089
120088,341603,PKI,McKesson  MCK  Beats On Q3 Earnings   Revenues  Ups  18 View,opinion,McKesson   NYSE MCK   reported third quarter fiscal 2018 earnings of  3 41 per share  beating the Zacks Consensus Estimate of  2 92  Earnings surpassed the year ago quarter s figure of  3 04 Notably  third quarter GAAP earnings per share included a net tax benefit of  1 78  driven by the Tax Cuts and Jobs Act of 2017 McKesson posted sales of  53 6 billion  beating the Zacks Consensus Estimate of  52 billion and up from  50 0 billion in the prior year quarter McKesson Corporation Price  Consensus and EPS Surprise    Quarter in DetailMcKesson operates through two segments   Distribution Solutions and Technology Solutions  All growth rates given below are on a year over year basis Distribution SolutionsDistribution Solutions revenues were  53 6 billion for the quarter  up 8  on a reported basis and 7  on a constant currency  cc  basis Revenues from North America pharmaceutical distribution and services were  44 9 billion for the quarter  up 8  on a reported basis and 7  at cc International pharmaceutical distribution and services revenues were  7 billion  up 13  on a reported basis and 4  at cc  The upside was driven by acquisitions and market growth Medical Surgical distribution and services revenues were  1 7 billion for the third quarter  up 9  Technology SolutionsTechnology Solutions adjusted operating profit was  53 million for the third quarter Per management  the segment witnessed lower profit  thanks to the divestment of Enterprise Information Solutions business and the negative impact of reduced reimbursement in the company s U K  retail pharmacy business MarginsAs a percentage of revenues  gross margin contracted 50 basis points to 5 1  in the quarter In the third quarter  adjusted operating profit was  991 million  up 22  at cc on a year over year basis  Adjusted operating margin for the Distribution Solutions segment was 1 85  of net revenues at cc Financial ConditionAs of Dec 31  2017  McKesson had  2 62 billion in cash and cash equivalents  Through the first nine months of the year  McKesson repaid  545 million in long term debt and paid  2 0 billion for acquisitions Notably  McKesson repurchased  900 million of its common stock  invested  392 million internally and paid  192 million in dividends Fiscal 2018 OutlookMcKesson expects GAAP earnings per share in the range of  7 65  9 00 for the fiscal 2018 As a result of the lower tax rate  adjusted earnings for the same are expected in the range of  12 50  12 80  up from the previous range of  11 80  12 50 Company Announces DividendMcKesson declared a regular dividend of 34 cents per share of common stock  The dividend will be payable on April 2  to stockholders of record on March 1  2018 Zacks Rank   Price MovementsMcKesson carries a Zacks Rank  3  Hold  Over the last three months  McKesson has been trading below the broader   The company s shares have gained 6 3  compared with the broader industry s rally of 6 7   The current level is lower than the S P 500 index s return of just 15 4  Pricing pressure in the independent retail pharmacy channel is a headwind  Further  intense competition  currency headwind and reimbursement issues are challenges  Adding to the woes  revenues from Technology Solutions are expected to deteriorate year over year Companies Reporting Impressive ResultsA few better ranked stocks which reported favorable results this earnings season are PetMed Express   NASDAQ PETS    PerkinElmer   NYSE PKI   and Accuray   NASDAQ ARAY    While PetMed sports a Zacks Rank  1  Strong Buy   PerkinElmer and Accuray carry a Zacks Rank  2  Buy   You can see PetMed recently reported third quarter fiscal 2018 results  Adjusted earnings per share was 44 cents  up 88 3  from the prior year quarter  Revenues rose 13 7  on a year over year basis to  60 1 million PerkinElmer reported fourth quarter 2017 adjusted earnings per share of 97 cents  Adjusted revenues were approximately  641 6 million  up from  567 million in the year ago quarter Accuray reported a loss of 6 cents per share in second quarter fiscal 2018  5 cents narrower than the year ago figure  Total revenues improved 15  year over year to  100 3 million Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-02-01,Zacks Investment Research,https://www.investing.com/analysis/mckesson-mck-beats-on-q3-earnings--revenues-ups-18-view-200286088,200286088
120090,341605,PKI,Boston Scientific  BSX  Q4 Earnings In Line  Revenues Top,opinion,"Boston Scientific Corporation   NYSE BSX   posted adjusted earnings per share  EPS  of 34 cents in the fourth quarter of 2017  up 13 3  from the year ago quarter  The figure remained in line with the Zacks Consensus Estimate and fell within the company s guided range of 32 35 cents for adjusted EPS 
The adjustments take into consideration the estimated net income tax charge related to the deemed repatriation of unremitted earnings of foreign subsidiaries  partially offset by the benefit related to the re measurement of the company s deferred taxes arising from a lower U S  corporate tax rate 
Without these adjustments  the company reported a loss of 45 cents per share compared with EPS of 9 cents in the year ago period 
For the full year  adjusted EPS came in at  1 26  a 13 5  increase from the year ago number  However  this was in line with the Zacks Consensus Estimate  The full year adjusted EPS also remains within the company s projected band of  1 24  1 27 
Revenues in Detail
Revenues in the fourth quarter were up 9 9  year over year on a reported basis and up 8 1  on operational basis  at constant exchange rate or CER  to  2 41 billion  The tally remained in line with the company s earlier announced preliminary sales result and exceeded the Zacks Consensus Estimate of  2 38 billion 
Revenues in 2017 were  9 05 billion  up 7 9  on reported basis and up 7 8  on operational basis from the 2016 count Boston Scientific Corporation Price  Consensus and EPS Surprise

   Organic revenue growth in the fourth quarter  excluding the impact of changes in foreign currency exchange rates and sales from the acquisitions of EndoChoice Holdings and Symetis SA  was 6 8  year over year 
Geographically  in the fourth quarter  the company achieved 8 5  operational growth in the United States  up 7 5  organically   up 8  in Europe  up 4 4    up 7 7  in the Asia  Middle East and Africa region  up 7 6   and up 13 1  in the emerging markets  up 12 9   
Segment Analysis
Boston Scientific currently has three global reportable segments  Cardiovascular  Rhythm Management and MedSurg 
The company generates maximum revenues from Cardiovascular  Sales from its subsegments   Interventional Cardiology and Peripheral Interventions   were  636 million  up 6 9  year over year at CER  and  277 million  up 6 7    respectively  during the fourth quarter 
The second largest contributor to Boston Scientific s top line was Rhythm Management  comprising Cardiac Rhythm Management  CRM  and Electrophysiology  CRM reflected a 1 2  year over year increase in sales to  488 million at CER in the reported quarter 
Worldwide  sales from pacemakers  within CRM  declined 7 1  to  143 million while defibrillators were up 8 5  to  346 million 
Electrophysiology sales went up 17 7  year over year at CER to  77 million 
Other segments like Endoscopy  Urology and Pelvic Health and Neuromodulation  under the MedSurg broader group  recorded sales of  436 million  up 13 1  at CER    308 million  up 11 3   and  186 million  up 14 6    respectively 
Margins
Gross margin in the fourth quarter expanded 30 basis points  bps  year over year to 72 1  on 8 7  rise in cost of products sold  Adjusted operating margin improved 232 bps to 23 5  in the reported quarter  During the quarter  selling  general and administrative expenses went up 6 6  to  886 million while research and development expenses rose 3 1  to  264 million  Royalty expenses decreased 10  to  18 million in the quarter 
Guidance
Boston Scientific has provided its 2018 guidance  The company projects current year earnings in the range of  9 650  9 800 billion  annualized growth of 7 8  on reported basis and 5 6  increase on an organic basis  at CER and including contribution of approximately 30 bps from Symetis   The Zacks Consensus Estimate for current year revenues is pegged at  9 1 billion  below the guided range 
Adjusted EPS guidance for 2018 is issued in the range of  1 35  1 39  The Zacks Consensus Estimate of  1 37 is within this guided band 
The company also provided its first quarter 2018 financial outlook  Adjusted earnings are expected in the band of 30 32 cents per share on revenues of  2 320  2 350 billion  The consensus mark for EPS stands at 31 cents while for revenues   2 29 billion 
Our Take
Boston Scientific posted a mixed fourth quarter performance with earnings in line with the Zacks Consensus Estimate and revenues  ahead of the mark  However  balanced growth across all business lines and geographies were impressive  Also  a gradually improving foreign exchange scenario has also started to contribute to the company s overall topline performance  The promising 2018 view is all the more encouraging and indicative of this overall bullish trend to continue in the near term 
Boston Scientific is leaving no stone unturned to strengthen its core businesses and invest in new technologies as well as global markets  accounting for higher sales across all its geographies in the fourth quarter  We are also optimistic about the company gaining a number of product approvals both in the domestic and overseas markets 
Among the recent developments  worth mentioning are the FDA approvals for the company s Vercise Deep Brain Stimulation System  to treat the symptoms of Parkinson s disease  and the Spectra WaveWriter Spinal Cord Stimulator System  to simultaneously provide paresthesia based and sub perception therapy   The company has also invested in Millipede  a privately held company having developed the IRIS Transcatheter Annuloplasty Ring System for treating severe mitral regurgitation 
Zacks Rank   Key Picks
Boston Scientific carries a Zacks Rank  3  Hold   A few better ranked stocks that reported solid earnings this season are PetMed Express   NASDAQ PETS    PerkinElmer   NYSE PKI   and Accuray   NASDAQ ARAY    While PetMed sports a Zacks Rank  1  Strong Buy   PerkinElmer and Accuray carry a Zacks Rank  2  Buy   You can see 
PetMed recently reported third quarter fiscal 2018 results with adjusted earnings per share of 44 cents  The bottom line soared 88 3  year over year  Revenues in the reported quarter rose 13 7  on a year over year basis to  60 1 million 
PerkinElmer released fourth quarter 2017 adjusted earnings per share of 97 cents  Adjusted revenues were approximately  641 6 million  up from  567 million in the year ago quarter 
Accuray reported a loss of 6 cents per share in second quarter fiscal 2018  narrower than the year ago figure by 5 cents  The top line improved 15  year over year to  100 3 million 
Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2018-02-01,Zacks Investment Research,https://www.investing.com/analysis/boston-scientific-bsx-q4-earnings-in-line-revenues-top-200286188,200286188
120095,341610,PKI,Quest Diagnostics  DGX  Tops Q4 Earnings  2018 View Strong,opinion,"Quest Diagnostics Inc  s   NYSE DGX   fourth quarter 2017 adjusted earnings per share  EPS  of  1 40 beat the Zacks Consensus Estimate by 3 cents and the year ago number by 6 9  
Adjusted EPS in the reported quarter excluded certain tax benefit recorded as a result of the Tax Cuts and Jobs Act  TCJA   The reported EPS came in at  1 82  a 67  surge from the year ago quarter figure 
Full year adjusted EPS came in at  5 67 per share  a 10 1  increase from the year ago adjusted number and 2 cents ahead of the Zacks Consensus Estimate 
Reported revenues in the fourth quarter inched up 4 1  year over year to  1 936 billion  marginally in line with the Zacks Consensus Estimate  According to the company  the year over year improvement came on the back of successful execution of its two point strategy of accelerating growth and driving operational excellence Quest Diagnostics Incorporated Price  Consensus and EPS Surprise

   Volume  measured by the number of requisitions  increased 2 4  year over year in the fourth quarter  Also  revenue per requisition increased 2 1   Diagnostic information services revenues in the quarter rose 4 5  on a year over year basis to  1 85 billion 
Cost of services during the reported quarter was  1 19 billion  up 2 9  year over year  Gross margin came in at 38 3   reflecting a 66 basis points  bps  expansion year over year 
Among the operating expenses  selling  general and administrative expenses increased 13 3  to  453 million in the reported quarter  Accordingly  adjusted operating margin showed a contraction of 125 bps to 14 9  
Quest Diagnostics exited the year 2017 with cash and cash equivalents of  137 million as compared to  359 million in the year ago quarter  Full year net cash provided by operating activities was  1 18 billion  compared with  1 07 billion in the year ago period 
In the fourth quarter  the company repurchased 1 million shares for  100 million  As of Dec 31  2017  Quest Diagnostics was left with  917 million of authorization under the previous share repurchase plan 
Outlook
Quest Diagnostics has provided its 2018 guidance  Excluding the impact of special items  amortization expense and ETB  excess tax benefit associated with stock based compensation   adjusted EPS for full year is projected in the range of  6 50 to  6 70  The Zacks Consensus Estimate of  6 10 falls below the guided range 
Revenues for 2018 are expected in the range of  7 7 billion to  7 77 billion  annualized growth of 4 5    The current Zacks Consensus Estimate for revenues is pegged at  7 94 billion  ahead of the company s projected range 
Operating cash flow for 2018 is expected at around  1 3 billion  The current estimates for capital expenditure are pegged at  350  400 million 
Our Take
Quest Diagnostics  fourth quarter earnings exceeded the Zacks Consensus Estimate  while revenues remained in line with the same  On a positive note  the company is currently refocusing on its core diagnostic information services business and working on disciplined capital deployment 
We are also highly optimistic about the company s focus on its two point strategy  The company s several new collaborations with hospitals and integrated delivery networks continue to act as major growth drivers 
On the flip side  in the last couple of years  Quest Diagnostics faced several reimbursement issues hurting its revenues  The company is concerned about the CMS  Centers for Medicare   Medicaid Services  proposal related to Protecting Access to Medicare Act 
Notably in December  the company as a key member of the American Clinical Laboratory Association   ACLA   has come forward to support a lawsuit filed by ACLA against the Acting Secretary of the US Department of Health and Human Services  HHS   The lawsuit charged that the CMS  operating under the purview of HHS  has failed to follow a congressional directive to implement a market based laboratory payment system 
The company has not positively taken the latest Centers for Medicare and Medicaid Services  CMS  publication of proposed 2018 Medicare reimbursement rates for clinical laboratory tests under the Clinical Lab Fee Schedule  CLFS   It is currently requesting CMS to delay the implementation of PAMA  Protecting Access to Medicare Act  
Zacks Rank   Key Picks
Currently  Quest Diagnostics carries a Zacks Rank  3  Hold   A few better ranked stocks that reported solid earnings this season are PetMed Express   NASDAQ PETS    PerkinElmer   NYSE PKI   and Accuray   NASDAQ ARAY    While PetMed sports a Zacks Rank  1  Strong Buy   PerkinElmer and Accuray carry a Zacks Rank  2  Buy   You can see 
PetMed recently reported third quarter fiscal 2018 results with adjusted earnings per share of 44 cents  The bottom line soared 88 3  year over year  Revenues in the reported quarter rose 13 7  on a year over year basis to  60 1 million 
PerkinElmer released fourth quarter 2017 adjusted earnings per share of 97 cents  Adjusted revenues were approximately  641 6 million  up from  567 million in the year ago quarter 
Accuray reported a loss of 6 cents per share in second quarter fiscal 2018  narrower than the year ago figure by 5 cents  The top line improved 15  year over year to  100 3 million 
Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2018-02-01,Zacks Investment Research,https://www.investing.com/analysis/quest-diagnostics-dgx-tops-q4-earnings-2018-view-strong-200286187,200286187
120096,341611,PKI,Edwards Lifesciences  EW  Beats On Q4 Earnings And Revenues,opinion,"Edwards Lifesciences Corporation s   NYSE EW   fourth quarter 2017 adjusted earnings per share  EPS  came in at 94 cents  excluding net expense of  223 5 million or  1 04 per share as an impact of U S  tax reform  Reported EPS came in at 17 cents The adjusted EPS figure beat the Zacks Consensus Estimate of 90 cents by 4 4   However  adjusted earnings improved 25 3  year over year  primarily driven by strong sales growth at the company s transcatheter heart valves business Full year 2017 adjusted EPS came in at  3 80  beating the Zacks Consensus Estimate of  3 76 by 1 1   Moreover  the figure beat the year ago number by 31  Sales DetailsFourth quarter sales improved 15 7  to  888 5 million  Moreover  the figure beat the Zacks Consensus Estimate of  862 9 million by 2 9   Underlying sales increased 15 9   including the impact of Germany stocking sales as customers in the nation chose to purchase additional inventory of the SAPIEN 3 valve in anticipation of a potential supply interruption resulting from recent intellectual property litigation  Net revenues in 2017 totaled  3 44 billion  outpacing the Zacks Consensus Estimate of  3 39 billion  The figure also improved 16 2  from the year ago number Revenues were primarily driven by considerable growth in transcatheter heart valve sales as well as strong performance by Surgical Heart Valve Therapy and Critical Care product lines too    
Edwards Lifesciences Corporation Price  Consensus and EPS Surprise
     Segments DetailsIn the fourth quarter  the company reported Transcatheter Heart Valve Therapy  THVT  sales of  519 3 million  reflecting 20 2  growth over the prior year quarter  In the United States  THVT sales totaled  326 7 million  up 22 3  year over year  Growth was driven by excellent clinical performance by SAPIEN 3 as well continued strong therapy implementation across all regions Surgical Heart Valve Therapy sales in the quarter were  204 9 million  up 8 2  from the prior year quarter  This was led by strong demand for the EDWARDS INTUITY Elite valve system and solid uptake of core products outside the United States Critical Care sales were  164 3 million in the reported quarter  representing an increase of 12 3  from fourth quarter 2016   Solid growth across all product categories was driven by strong growth in the company s core products  mainly in the United States and China MarginsIn the fourth quarter  gross margin expanded 130 basis points  bps  to 73 5  owing to a more profitable product mix led by growing sales of transcatheter valves  This was however partially offset by the shutdown of the company s manufacturing plant in Switzerland SG A expenses rose 14 2  year over year to  266 7 million on account of sales and personnel related expenses  primarily in the Transcatheter Valve  THV  segment  R D expenditures increased 27 6  year over year to  146 6 million owing to continued investments in the transcatheter aortic valve and mitral valve program  Adjusted operating margin in the quarter expanded 20 bps to 27  as the rise in revenues outweighed the increase in operating expenses Cash PositionEdwards Lifesciences exited 2017 with cash and cash equivalents and short term investments of  1 34 billion  compared with  1 27 billion at the end of 2016  Long term debt in 2017 totaled  438 4 million  compared with  822 3 million reported in the previous year Cash flow from operating activities was  1 billion in 2017  Excluding capital spending of  168 1 million  free cash flow was  831 9 million  During the quarter  average diluted shares outstanding were 215 4 million  2018 Guidance RaisedEdwards Lifesciences has raised its 2018 sales expectations to the high end of the previously projected range of  3 5  3 9 billion  The Zacks Consensus Estimate for full year revenues is  3 71 billion  well within the guided range  Adjusted EPS expectations have also been raised to  4 43  4 63 from the previous range of  4 10  4 30  The Zacks Consensus Estimate for full year adjusted EPS stands at  4 16  near the low end of the company s guided range For the first quarter of 2018  the company projects sales between  900 million and  950 million  The Zacks Consensus Estimate for revenues is  889 2 million  below the company s projected range  The company estimates adjusted EPS between  1 04 and  1 14  Meanwhile  the Zacks Consensus Estimate for adjusted EPS is  1 01  which is also below the company s forecasted range Our TakeEdwards Lifesciences exited the fourth quarter on a solid note  Strong transcatheter valve sales in the domestic market as well as overseas is a major positive  The company also performed well on its gross margin front Management expects to gain traction in the ever expanding TAVR market  based on increasing preference in favor of transcatheter aortic valve replacement as well as compelling clinical evidence  leading to strong adoption of THV therapy  However  tough competition in the cardiac devices market and reimbursement issues continue to pose challenges Zacks Rank   Key PicksEdwards Lifesciences has a Zacks Rank  3  Hold  A few better ranked stocks that reported solid results this earnings season are  PetMed Express   NASDAQ PETS    PerkinElmer   NYSE PKI   and ResMed   NYSE RMD    While PetMed sports a Zacks Rank  1  Strong Buy   PerkinElmer and ResMed carry a Zacks Rank  2  Buy   You can see PetMed recently reported third quarter fiscal 2018 results  Adjusted earnings per share was 44 cents  up 88 3  from the prior year quarter  Revenues in the reported quarter rose 13 7  on a year over year basis to  60 1 million PerkinElmer reported fourth quarter 2017 adjusted earnings per share of 97 cents  Adjusted revenues were approximately  641 6 million  up from  567 million in the year ago quarter ResMed posted second quarter fiscal 2018 adjusted earnings per share of  1  up 36 9  from the prior year quarter  Revenues in the reported quarter increased 13 4  year over year  up 11  at constant exchange rate or CER  to  601 3 million Breaking News  Cryptocurrencies Now Bigger than VisaThe total market cap of all cryptos recently surpassed  700 billion   more than a 3 800  increase in the previous 12 months  They re now bigger than Morgan Stanley  NYSE MS   Goldman Sachs  NYSE GS  and even Visa  The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved Zacks has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market ",2018-02-01,Zacks Investment Research,https://www.investing.com/analysis/edwards-lifesciences-ew-beats-on-q4-earnings-and-revenues-200286395,200286395
120123,341638,PKI,PerkinElmer  PKI  Closes EUROIMMUN Acquisition For  1 3B,opinion,PerkinElmer  Inc    NYSE PKI   recently announced the completion of the buyout of EUROIMMUN Medical Laboratory Diagnostics AG for approximately  1 3 billion in cash  The latter is an autoimmune testing company and an emerging player in infectious disease and allergy testing We feel the acquisition is a strategic move by PerkinElmer  Lubeck  Germany based EUROIMMUN has approximately 9 500 employees serving customers in more than 150 countries Financial ImpactThe acquisition of EUROIMMUN Medical Laboratory Diagnostics should expand PerkinElmer s reach into autoimmune and allergy diagnostic markets  The buyout will also enhance PerkinElmer s capabilities in China s new infectious disease market  Per management  the acquisition is expected to add about 28 cents to 30 cents per share to 2018 adjusted earnings Management expects the addition of EUROIMMUN to drive R D expense margin The company is consistently trying to drive inorganic growth through acquisitions  The company recently completed the buyout of Tulip Diagnostics Private Limited  a company based in Goa  India  for a total consideration of  127 3 million   Diagnostic Segment Gets a BoostPerkinElmer will now have advanced detection capabilities  and imaging and assay development prospects to deliver better and more complete solutions to customers In fact  post acquisition  PerkinElmer s complete global diagnostics portfolio will get a boost  The segment now includes solutions focused on reproductive health  autoimmune  infectious disease  allergy testing  gene analyses  and genomics offerings for oncology and other molecular tests through its wide range of instruments  reagents  assay platforms and software offerings In this regard  the company s Diagnostics segment grew 5  organically on a year over year basis to  168 9 million in the last quarter  We believe the latest development will further boost growth at the segment Stock PerformanceThe price performance of PerkinElmer has been favorable in the last year  The stock has gained 8 3   outperforming the broader  s gain of almost 6 8   The current level compares favorably with the S P 500 s return of 8  Zacks Rank   Key PicksPerkinElmer carries a Zacks Rank  3  Hold  A few better ranked medical stocks are athenahealth  Inc    NASDAQ ATHN    Align Technology  Inc    NASDAQ ALGN   and Luminex Corporation   NASDAQ LMNX    Notably  athenahealth and Align Technology sport a Zacks Rank  1  Strong Buy   while Luminex carries a Zacks Rank  2  Buy   You can see athenahealth has a long term expected earnings growth rate of 22 3   The stock has rallied roughly 17 1  over a year Align Technology has a long term expected earnings growth rate of 28 9   The stock has gained 134 5  in a year Luminex has a long term expected earnings growth rate of 16 3   The stock has gained 4 6  in the past three months 5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ,2017-12-19,Zacks Investment Research,https://www.investing.com/analysis/perkinelmer-pki-closes-euroimmun-acquisition-for-13b-200274722,200274722
120124,341639,PKI,Key Factors To Influence PerkinElmer s  PKI  Q4 Earnings,opinion,"PerkinElmer  Inc    NYSE PKI   is expected to release fourth quarter 2017 results on Jan 25  after the market closes  In the last quarter  the company registered adjusted earnings of 73 cents per share  which beat the Zacks Consensus Estimate of 72 cents  Further  adjusted revenues of approximately  554 million also beat the Zacks Consensus Estimate of  552 million 
Solid performances in the Discovery and Analytical Solutions unit as well as Diagnostics segment will drive PerkinElmer s top line in the fourth quarter  In fact  the Zacks Consensus Estimate for Discovery and Analytical Solutions revenues is currently pegged at  437 million  This reflects an improvement of 13 5  from the third quarter  Further  the Zacks Consensus Estimate for the Diagnostics segment revenues is pegged at  180 million  up 6 5  from the last quarter PerkinElmer  Inc  Price and Consensus

   Notably  PerkinElmer has also outperformed the  over the last year  The stock has gained 52  surpassing the industry s rally of 47 7  

 
Let s take a look at how things are shaping up prior to the fourth quarter earnings announcement 
Factors to Consider
View Upbeat  The Zacks Consensus Estimate for PerkinElmer s fourth quarter earnings is at 94 cents per share  reflecting year over year growth of 13 3   For revenues  the consensus estimate is pegged at  615 8 million  up 8 7  year over year 
Earlier  management confirmed that the company has been progressing favorably per the original guidance cited in the beginning of fiscal 2017  Expecting a better than expected financial result for the fourth quarter  the company revised its guidance of adjusted earnings per share for the full year 
In this regard  PerkinElmer now expects full year adjusted earnings per share in the band of  2 80  2 90  compared with the previous range of  2 75  2 85  Further  post the first quarter earnings  the company raised its revenue guidance as well 
Favorable Market Trends  PerkinElmer continues to witness favorable market conditions  For the first time in more than five years  the company experienced positive organic growth in every region of the world and end market in which it operates in the last quarter  We expect the company to maintain this momentum in the quarter to be reported  Looking specifically at the end markets  pharma biotech and diagnostics are expected to see strong sales in the fourth quarter 
Acquisition to Drive Growth  Acquisitions and strategic partnerships have proved to be key growth catalysts for PerkinElmer  Recently  the company completed its previously announced acquisition of EUROIMMUN Medical Laboratory Diagnostics AG  Through this acquisition  EUROIMMUN expanded PerkinElmer s reach in the autoimmune and allergy diagnostic markets  It also fortified the company s foothold in curing new infectious diseases  The management is optimistic about acquisition driven growth in fiscal 2018 
Solid Product Portfolio  PerkinElmer delivers a comprehensive suite of scientific informatics and software solutions to aggregate data into actionable insights in an automated and scalable way  The company launched its new mass spectrometry platform  QSight Triple Quad LC MS MS for the clinical market in the last quarter  While QSight has already received a very positive response in the niche space  this is expected to provide PerkinElmer a competitive edge in the MedTech space in the fourth quarter 
The company s products include the industry leading ChemDraw software  Electronic Lab Notebooks including cloud based Elements SaaS Offering and enterprise E Notebook Solutions  along with the TIBCO Spotfire platform for scientific data analytics 
PerkinElmer s expanding portfolio is helping the company win market share worldwide 
Thus  PerkinElmer is confident of improving growth trajectory in the fourth quarter 
Our quantitative model conclusively shows an earnings beat for PerkinElmer this quarter This is because a stock needs to have a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to be able to beat estimates 
Zacks ESP  Earnings ESP for PerkinElmer is  0 21   The Most Accurate estimate is  0 94  which is in line with the Zacks Consensus Estimate  You can uncover the best stocks to buy or sell before they re reported with our  
Zacks Rank  PerkinElmer carries a Zacks Rank  2  A favorable Zacks Rank increases the predictive power of ESP and the company s positive ESP makes surprise prediction feasible 
Stocks Worth a Look
Here are a few similar medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter 
Bio Rad Laboratories  Inc    NYSE BIO   has an Earnings ESP of  4 45  and a Zacks Rank  1  You can see  
BIOVERATIV Inc    NASDAQ BIVV   has an Earnings ESP of  2 56  and a Zacks Rank  1 
Baxter International Inc    NYSE BAX   has an Earnings ESP of  1 52  and a Zacks Rank  3 
Zacks Top 10 Stocks for 2018In addition to the stocks discussed above  would you like to know about our 10 finest buy and hold tickers for the entirety of 2018 Last year s 2017 Zacks Top 10 Stocks portfolio produced double digit winners  including FMC Corp  NYSE FMC   and VMware which racked up stellar gains of  67 9  and  61   Now a brand new portfolio has been handpicked from over 4 000 companies covered by the Zacks Rank  Don t miss your chance to get in on these long term buys ",2018-01-18,Zacks Investment Research,https://www.investing.com/analysis/key-factors-to-influence-perkinelmers-pki-q4-earnings-200281584,200281584
120125,341640,PKI,PerkinElmer Hits 52 Week High  What s Driving The Stock ,opinion,On Jan 18  2018  PerkinElmer Inc  s   NYSE PKI   shares hit a new 52 week high of  79 89  closing the session nominally lower at  79 54  On the same day  the company issued dividends of 7 cents to shareholders The company s shares have returned 52 6  over the last year  higher than the S P 500 index s gain of 24 2   Also  shares have outperformed the  s rally of 49 1   The stock has a market cap of  7 81 billion Considering this  one may expect PerkinElmer to scale new highs in the upcoming quarters  Further  the company has an impressive long term earnings growth rate of 12 62   which looks encouraging  Projected sales growth is 5 9  for the first quarter of 2018 PerkinElmer  Inc  Price and Consensus   5 Factors Driving PerkinElmerLet s find out what are the four possible growth propellers QSight Triple Quad LC MS MS to Drive Growth  PerkinElmer delivers a comprehensive suite of scientific informatics and software solutions to aggregate data into actionable insights in an automated and scalable way  The company launched its new mass spectrometry platform  QSight Triple Quad LC MS MS  for the clinical market in the third quarter and received a very positive response from customers Notably  QSight was also registered as a Class 1 instrument with the FDA  Further  the instrument s CE marking for the European market has also been accomplished  enabling it to be used in clinical applications  beyond newborn screening The company s other products include the industry leading ChemDraw software  Electronic Lab Notebooks including cloud based Elements SaaS Offering and enterprise E Notebook Solutions along with the TIBCO Spotfire platform for scientific data analytics  PerkinElmer s expanding portfolio is helping the company win market share worldwide Acquisitions  Recently  the company completed the previously announced acquisition of EUROIMMUN Medical Laboratory Diagnostics AG  for  1 3 billion in cash  The buyout is expected to extend PerkinElmer s reach in the autoimmune and allergy diagnostic markets  The acquisition is likely to enable the company cure new infectious diseases  Management is optimistic about the acquisition to drive the company s growth in fiscal 2018 Notably  the acquisition of Tulip Diagnostics in the recent past has been beneficial for the company s revenue growth Robust Fundamental Growth  In the last 9 years  the company has been witnessing high revenue growth  multiplying at a CAGR of 3 1   Adjusted earnings per share witnessed a CAGR of 8 2  PerkinElmer s Zacks Consensus Estimate for fourth quarter earnings is pegged at 94 cents  up 13 3  year over year  The Zacks Consensus Estimate for revenues is pegged at  615 8 million  up 8 7  on a year over year basis Meanwhile  the company also delivered a positive earnings surprise of 1 39  in the last quarter Solid Organic Growth  Dampening the continuing headwinds in its radionucleotide business  PerkinElmer continues to experience favorable market trends  For the first time in more than five years  PerkinElmer witnessed positive organic growth in every region of the world in the third quarter  Looking specifically at the end markets  pharma biotech and diagnostics are expected to see strong sales in the quarters ahead Guidance Raised  Earlier  management confirmed that the company has been advancing favorably per the original guidance cited in the beginning of fiscal 2017  In this regard  the company raised its adjusted earnings per share guidance to the band of  2 80  2 90  compared with the previous range of  2 75  2 85  This reflects that the company is upbeat about delivering positive financial results in the quarters to come Stocks Worth a LookPerkinElmer carries a Zacks Rank  2  Buy  Other top ranked stocks in the broader medical space are BIOVERATIV Inc    NASDAQ BIVV    Centene Corporation   NYSE CNC   and Molina Healthcare Inc    NYSE MOH    All these stocks sport a Zacks Rank  1  Strong Buy   You can see  BIOVERATIV has an impressive expected growth rate of 27 9  for the first quarter of 2018  The stock has gained 39 5  over the last year  above the industry s gain Centene has a projected long term growth rate of 14   In the last six months  the stock has rallied an impressive 30   surpassing the industry s rally of 23 4  Molina Healthcare expects a long term growth rate of 24 5   Over the last six months  the stock has gained 30 1   performing above the industry Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2018-01-18,Zacks Investment Research,https://www.investing.com/analysis/perkinelmer-hits-52week-high-whats-driving-the-stock-200281919,200281919
120126,341641,PKI,Abaxis  ABAX  Beats Earnings And Revenue Estimates In Q3,opinion,"Abaxis  Inc    NASDAQ ABAX   reported third quarter fiscal 2018 adjusted earnings per share of 31 cents  beating the Zacks Consensus Estimate by 6 9   Moreover  adjusted earnings rose 3 3  from the year ago 30 cents Total RevenueIn the fiscal third quarter  Abaxis recorded revenues of  59 7 million  reflecting an increase of 13 1  from a year ago  The top line also surpassed the Zacks Consensus Estimate of  58 million  Foreign currency exchange fluctuations had a favorable 1  impact on the top line Segments in DetailRevenues from North America  accounting for 77 7  of total revenues  rose 11 8  to  46 4 million in the reported   quarter  Revenues from the international markets  accounting for the rest  improved 17 9  to  13 2 million Abaxis operates through three main segments   Veterinary  Medical and Other  In the reported quarter  Veterinary sales accounted for 81 1  of total sales  Medical contributed 17 1  while the remaining 1 8  was generated from Other Veterinary market revenues improved 12  year over year to  48 4 million  driven by a 12  uptick in veterinary consumable revenues to  37 9 million  Veterinary instrument revenues were up 12  year over year to  8 7 million Revenues from the medical market were up from  8 7 million in the same quarter last year to  10 2 million led by strength in Piccolo instrument as well as medical rotors  Also  revenues at the North American medical division totaled  7 million  up 25  year over year  On a global basis  Abaxis sold 228 Piccolos in the quarter compared with 212 a year ago 
ABAXIS  Inc  Price  Consensus and EPS Surprise
     Abaxis exhibited strong consumable growth  up 13  year over year to  45 5 million in the quarter  Within the consumable product lines  total rotor revenues were  31 9 million  up 13  from  28 2 million in the year ago quarter  On a global basis  Abaxis sold 2 57 million rotor units in the quarter under review  up 13  from 2 28 million units in the year ago quarter  Hematology reagents  rapid assays  i STAT cartridges  coagulation cartridges and urine analysis strips also drove growth in veterinary consumable revenues With solid contributions from feline test and test for canine specific lipase  revenues from rapid assay were major contributors to the top line in the reported quarter Moreover  total instruments  sales rose 12  to  10 5 million on a rise in the sales of haematology  i STAT  coagulation and Piccolo instruments  Also  impressive revenues from VetScan UA  a hand held urine chemistry analyzer launched last September  contributed significantly to the top line Operational UpdatesGross profit in the third quarter rose 9 5  to  32 2 million  Gross margin contracted 180 basis points  bps  to 53 9  Research and development expenses increased 8 3  year over year to  5 2 million and sales and marketing expenses rose 29 2  to  13 7 million  General and administrative expenses also rose 50  to  4 8 million  The resultant operating income was down 20 4  to  8 6 million in the quarter and operating margin declined 610 bps to 14 4  Financial UpdateAbaxis exited the fiscal third quarter with cash  cash equivalents and short term investments of  161 6 million  compared with  148 8 million in the fiscal second quarter Our TakeAbaxis exited the fiscal third quarter on a promising note  However  a decline in gross and operating margin is a concern  Meanwhile  a year over year increase in revenues buoys optimism  We are upbeat about the company s solid consumable and instrument sales growth along with strength in the Medical and Veterinary market segments Meanwhile  we are encouraged to note that the company is initiating new sales and marketing strategies  In this regard  the company recently received approval from USDA  Center for Veterinary Biologics  for a combination test for heartworm  lyme  ehrlichia and anaplasma   VetScan FLEX4 Rapid Test  Moreover  the company plans to sell and introduce this product at the VMX conference in February  Abaxis plans additional launches in fiscal 2018  including the urine sediment analyzer  According to the company  these products will drive growth over the long haul Zacks Rank   Key PicksAbaxis has a Zacks Rank  3  Hold   A few better ranked stocks in the broader medical sector are ResMed   NYSE RMD    PerkinElmer   NYSE PKI   and Accuray   NASDAQ ARAY    All the three companies carry a Zacks Rank  2  Buy   You can see ResMed posted second quarter fiscal 2018 adjusted earnings of  1  up 36 9  from the prior year quarter  Revenues in the reported quarter increased 13 4  year over year  up 11  at constant exchange rate or CER  to  601 3 million PerkinElmerreported fourth quarter 2017 adjusted earnings of 97 cents  The company reported adjusted revenues of approximately  641 6 million  surpassing the year ago quarter s  567 million Accuray reported a loss of 6 cents in the second quarter of fiscal 2018  5 cents narrower than the year ago figure  Total revenues increased 15  year over year to  100 3 million Zacks Top 10 Stocks for 2018In addition to the stocks discussed above  would you like to know about our 10 finest buy and hold tickers for the entirety of 2018 Last year s 2017 Zacks Top 10 Stocks portfolio produced double digit winners  including FMC Corp  NYSE FMC   and VMware which racked up stellar gains of  67 9  and  61   Now a brand new portfolio has been handpicked from over 4 000 companies covered by the Zacks Rank  Don t miss your chance to get in on these long term buys ",2018-01-28,Zacks Investment Research,https://www.investing.com/analysis/abaxis-abax-beats-earnings-and-revenue-estimates-in-q3-200284488,200284488
120127,341642,PKI,Hill Rom  HRC  Beats Q1 Earnings And Revenues  Margins Up,opinion,Hill Rom Holdings  Inc    NYSE HRC   reported first quarter fiscal 2018 adjusted earnings per share  EPS  of 92 cents  reflecting a 21 7  increase from the year ago quarter  Adjusted earnings surpassed the Zacks Consensus Estimate by 15  and were well above the company s projected range of 77 79 cents The strong bottom line performance was backed by solid core revenue growth  continued margin expansion  strategic investments to drive growth and a 6 cent benefit related to U S  tax reform  This marked the 10th consecutive quarter of double digit earnings growth for the company Revenue DetailsRevenues in the first quarter increased 4 6  year over year to  669 7 million  up 3  at CER   The top line also exceeded the Zacks Consensus Estimate of  659 million on momentum in core business  Mortara acquisition and value added from new products Geographically  U S  revenues grew 2  to  453 million while revenues outside the United States increased 13   up 7  at CER  to  217 million  Core revenue growth was 2  at CER Hill Rom Holdings Inc Price  Consensus and EPS Surprise     Segmental PerformanceIn the first quarter  Patient Support Systems revenues dropped 0 2  year over year  down 1 9  at CER  to  334 4 million  The segment s domestic revenues declined 2   However  after adjusting for divestitures  U S  core revenues increased nominally from the prior year Revenues at the Front Line Care segment  which includes Welch Allyn  Respiratory Care and Mortara  increased 11 3  to  224 6 million  up 9 8  at CER   Apart from gains from Mortara  the performance was driven by contributions from new products  strong growth of thermometry and blood pressure monitoring devices plus double digit growth at respiratory care business The Surgical Solutions segment revenues increased 10 3   up 5 8  at CER  to  110 7 million on 10  international growth  driven by strong momentum in the Middle East and Europe  U S  revenues increased 2  despite the negative hurricane impact  The growth was backed by record placement of Integrated Table Motion and contribution from products like the iLED7 and the new TS 3000 Mobile Operating Table MarginsReported gross margin in the fiscal first quarter was 47 7   up 20 bps year over year  Despite 4 6  increase in cost of revenue  the company witnessed gross margin expansion on account of a 4 6  increase in revenues  Adjusted gross margin grew 20 bps to 47 7  on the back of the company s consistent initiative with portfolio diversification  benefits from cost and sourcing efficiencies  product launches and gains from Mortara  Adjusted operating margin improved 10 bps to 14 7  OutlookIn view of a promising first quarter performance  Hill Rom has raised its fiscal 2018 guidance and has also provided the second quarter estimates For the full year  the company continues to expect revenue growth of 3 4  on a reported basis  up 2  to 3  at CER   Excluding foreign currency  Mortara  divestitures and other non strategic assets  the company continues to expect core revenue growth of 3   Hill Rom expects adjusted earnings per share in the range of  4 22  4 30  The Zacks Consensus Estimate for fiscal 2018 earnings is pegged at  4 38 on revenues of  2 84 billion For the second quarter  Hill Rom expects revenue growth of around 4  on a reported basis  or approximately 2  at CER   Core revenues are expected to increase 2  year over year   The company expects adjusted earnings per share of  1  1 02  The Zacks Consensus Estimate for second quarter earnings stands at  1 on revenues of  704 1 million Our TakeHill Rom exited the fiscal first quarter on a strong note with earnings and revenues beating the Zacks Consensus Estimate  The company saw a solid year over year increase in revenues on strong international growth  The company is also focusing on product innovation through research and development  Hill Rom has updated its 2020 long range financial objectives and outlook  The company expects a positive impact on adjusted effective tax rate  Hill Rom now expects to drive adjusted earnings by 12 14  on a compound annual basis through 2020 from the previous guidance of 10 12  However  a decline in revenues at the Patient Support Systems segment is quite disappointing  Also  foreign exchange remains a concern Zacks Rank   Key PicksHill Rom has a Zacks Rank  3  Hold   A few better ranked stocks in the broader medical sector are ResMed   NYSE RMD    PerkinElmer   NYSE PKI   and Accuray   NASDAQ ARAY    All the three companies carry a Zacks Rank  2  Buy   You can see ResMed posted second quarter fiscal 2018 adjusted earnings of  1  up 36 9  from the prior year quarter  Revenues in the quarter increased 13 4  year over year  up 11  at constant exchange rate or CER  to  601 3 million PerkinElmer reported fourth quarter 2017 adjusted earnings of 97 cents  Adjusted revenues of approximately  641 6 million surpassed the year ago quarter s  567 million Accuray reported a loss of 6 cents per share in the second quarter of fiscal 2018  5 cents narrower than the year ago figure  Total revenues in the second quarter increased 15  year over year to  100 3 million Zacks Top 10 Stocks for 2018In addition to the stocks discussed above  would you like to know about our 10 finest buy and hold tickers for the entirety of 2018 Last year s 2017 Zacks Top 10 Stocks portfolio produced double digit winners  including FMC Corp  NYSE FMC   and VMware which racked up stellar gains of  67 9  and  61   Now a brand new portfolio has been handpicked from over 4 000 companies covered by the Zacks Rank  Don t miss your chance to get in on these long term buys ,2018-01-28,Zacks Investment Research,https://www.investing.com/analysis/hillrom-hrc-beats-q1-earnings-and-revenues-margins-up-200284467,200284467
120131,341646,PKI,Zimmer Biomet  ZBH  Q4 Earnings Meet Estimates  Sales Beat  Revised ,opinion,"Zimmer Biomet Holdings  Inc    NYSE ZBH   reported fourth quarter 2017 adjusted earnings per share of  2 10  down 1 9  year over year but in line with the Zacks Consensus Estimate  Reportedly  net earnings came in at  6 16 compared with the year ago quarter s 34 cents  Notably  reported net earnings include a one time tax benefit of approximately  6 40 from the recently enacted U S  tax reform legislation 
Full year 2017 adjusted earnings per share came in at  8 03  in line with the Zacks Consensus Estimate  However  the figure beat the year ago number by 0 9  
Revenue Details
Fourth quarter net sales came in at  2 07 billion  marking a 3  increase  up 1 5  at constant exchange rate or CER  year over year  Net sales also surpassed the Zacks Consensus Estimate of  2 03 billion 
Net sales in 2017 totaled  7 82 billion  surpassing the Zacks Consensus Estimate of  7 78 billion  The figure also beat the year ago number by 1 8  Full year sales increased 0 5  over the prior year at CER  excluding approximately 130 basis points of contribution from the LDR Holding Corporation acquisition 
During the quarter  sales generated in the Americas were  1 28 billion  up 0 8  year over year at CER   while the same in EMEA  Europe  the Middle East and Africa  grossed  473 million  down 0 3    Asia Pacific  however  registered 7 2  growth at CER to  321 million 
Segments
Sales at Knees were down 0 1  year over year at CER to  731 million  Hips recorded an increase of 1 6  at CER from the prior year quarter to  499 million  Revenues from S E T   Surgical  Sports Medicine  Foot and Ankle  Extremities and Trauma  were up 4 6  year over year to  454 million 
Among the other segments  Spine   CMF recorded a marginal improvement of 0 5  at CER to  194 million  while Dental was down 0 4  to  108 million in the quarter  Other revenues increased 2 9  to  88 million 
Margins
Gross margin came in at 71 5   reflecting an expansion of 238 bps in the fourth quarter  Selling  general and administrative expenses were up 1 9  to  770 6 million  However  research and development expenses declined 0 7  to  95 million  Adjusted operating margin expanded 297 bps to 29 8  during the quarter 
Cash Position
Zimmer Biomet exited the year 2017 with cash and cash equivalents of  524 4 million  as compared with  480 8 million at the end of the third quarter  Total long term debt was  10 1 billion  compared with  10 4 billion at the end of the preceding quarter 
For the full year  operating cash flow was  1 58 billion  compared with  1 63 billion in the year ago period  The company also paid  48 6 million in dividends during the fourth quarter 
2017 Outlook
The company has issued first quarter 2018 guidance  Sales are projected in the range of  1 955 billion to  1 995 billion  representing a change of negative 1  to positive 1   and negative 4  to negative 2  on a constant currency basis compared to the prior year quarter  This is inclusive of the negative impact related to approximately one less billing day as compared to the year earlier quarter  The current Zacks Consensus Estimate of  2 billion lies above the guided range 
Adjusted EPS for the quarter is expected to remain in the band of  1 84 to  1 91  The Zacks Consensus Estimate of  2 01 remains above the guided range 
Our Take
Zimmer Biomet ended the quarter on a positive note  We are also encouraged by the company s consistent efforts in product and renovation through research and development  We are optimistic about synergies from the LDR Holding acquisition  which should broaden and complement the company s musculoskeletal range  We are also impressed by the strong strategic and financial goals which the combined entity expects to reach 
However  we are disappointed by the company s declining sales at its Knees segment at CER 
Zacks Rank   Key Picks
Zimmer Biomet has a Zacks Rank  4  Sell   A few better ranked stocks in the broader medical sector are ResMed   NYSE RMD    PerkinElmer   NYSE PKI   and Accuray   NASDAQ ARAY    All the three companies carry a Zacks Rank  2  Buy   You can see 
ResMed posted second quarter fiscal 2018 adjusted earnings per share of  1  up 36 9  from the prior year quarter  Revenues in the reported quarter increased 13 4  year over year  up 11  at constant exchange rate or CER  to  601 3 million 
PerkinElmer reported fourth quarter 2017 adjusted earnings per share of 97 cents  Adjusted revenues were approximately  641 6 million  surpassing the year ago quarter s  567 million 
Accuray reported a loss of 6 cents per share in the second quarter of fiscal 2018  5 cents narrower than the year ago figure  Total revenues in the second quarter increased 15  year over year to  100 3 million 
Don t Even Think About Buying Bitcoin Until You Read ThisThe most popular cryptocurrency skyrocketed last year  giving some investors the chance to bank 20x returns or even more  Those gains  however  came with serious volatility and risk  Bitcoin sank 25  or more 3 times in 2017 Zacks  has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly 
 We are reissuing this article to correct a mistake  The original version  published earliertoday  should no longerbe relied upon  ",2018-01-30,Zacks Investment Research,https://www.investing.com/analysis/zimmer-biomet-zbh-q4-earnings-meet-estimates-sales-beat-revised-200285088,200285088
120132,341647,PKI,Align Technology  ALGN  Q4 Earnings Top On Invisalign Sales,opinion,"Align Technology  Inc  s   NASDAQ ALGN   fourth quarter 2017 adjusted earnings per share  EPS  came in at  1 19  excluding net expense of  86 6 million or  1 06 per share as an impact of U S  tax reform  Reported EPS came in at 13 cents The adjusted EPS figure was up 77 6  year over year  Earnings were also higher than the company s guided range of 92 95 cents  The figure beat the Zacks Consensus Estimate of 96 cents by 23 9  Full year 2017 adjusted EPS came in at  3 89  beating the Zacks Consensus Estimate of  3 67 by 5 9   Moreover  the figure beat the year ago number by 66 9  RevenuesRevenues grew 43 7  year over year to  421 3 million in the quarter  surpassing the Zacks Consensus Estimate of  395 5 million  Revenues were well ahead of the company s guided range of  391  398 million Net revenues in 2017 totaled  1 47 billion  outpacing the Zacks Consensus Estimate of  1 45 billion  The figure also improved from the year ago number by 36 4  
Align Technology  Inc  Price  Consensus and EPS Surprise
     Per management  the top line was driven by a 34 2  year over year increase in Invisalign case shipments to 255 000 in the fourth quarter  The upside was driven by growth in North America and international regions from expanded customer base and increased utilization  Moreover  increased revenues from iTero scanner contributed to the top line Segments in DetailRevenues at the Clear Aligner segment  86 4  of total revenues  soared 44 8  year over year to  364 2 million in the reported quarter  primarily driven by continued strong Invisalign case volume growth across all customer channels and geographical regions In the fourth quarter  Invisalign case shipments amounted to 255 000  up 34 2  year over year  aided by growth across all regions as well as the expansion of customer base  During the quarter  Align Technology Invisalign cases were shipped to 44 985 doctors worldwide  of which 25 365 were to North America and 19 620 to international regions Revenues from Scanner and Service  13 6   improved a significant 37  to  57 1 million MarginsGross margin in the quarter under review was up 40 basis points  bps  year over year to 75 5  in spite of a 41 8  rise in cost of net revenues During the quarter  Align Technology witnessed a 39 8  year over year increase in selling  general and administrative expenses to  182 1 million and a 21 3  rise in research and development  R D  expenses to  26 2 million  The operating margin expanded 270 bps to 26  Financial DetailsAlign Technology exited 2017 with cash and cash equivalents and short term marketable securities of  721 5 million  which marked a 12 7  rise from 2016 In the reported quarter  Align Technology repurchased 0 2 million shares of stock for  50 million under the April 2016 stock repurchase program  The company currently has approximately  200 0 million left under the buy back program GuidanceFor the first quarter of 2018  the company projects EPS of 94 98 cents on revenues of  400  410 million  The company projects Invisalign case shipments in the band of 264 000 269 000  up 26 9 29 3  from a year ago  Meanwhile  the current Zacks Consensus Estimate for first quarter 2018 EPS is 90 cents on revenues of  395 9 million  Both the estimates are falling below the projected range Our TakeAlign Technology ended the fourth quarter on a solid note  We are upbeat about the continued strength in Invisalign volumes  While GP dentists saw higher demand in North America following the summer holidays season  orthodontists witnessed increased adult patient footfall after a busy teen season in the preceding quarter  Internationally  we are encouraged by strength in the EMEA and Asia Pacific markets Within Scanners and Service  the company witnessed strong uptake of iTero scanners by GP dentists along with record contracts coming from the GP summit last September  Moreover  increased uptake due to the recent deal with Patterson Dental for Align s iTero Element intraoral scanning system also contributed to the top line  The company witnessed solid demand for the iTero scanners in EMEA and Asia Pacific as well Align Technology has a strong cash balance that enables it to carry out share repurchases and in turn provide solid returns to investors On the flip side  the company is exposed to foreign exchange fluctuations  seasonal demand fluctuations  higher operating expenses pertaining to increased head count along with higher investments targeted toward expansion of geographical presence and portfolio Zacks Rank   Other Key PicksAlign Technology carries a Zacks Rank  2  Buy  Some other top ranked stocks in the broader medical sector are ResMed   NYSE RMD    PerkinElmer   NYSE PKI   and Accuray   NASDAQ ARAY    All the three companies carry a Zacks Rank  2  You can see  ResMed posted second quarter fiscal 2018 adjusted earnings of  1  up 36 9  from the prior year quarter  Revenues in the reported quarter increased 13 4  year over year  up 11  at constant exchange rate or CER  to  601 3 million PerkinElmer  reported fourth quarter 2017 adjusted earnings of 97 cents  The company reported adjusted revenues of approximately  641 6 million  surpassing the year ago quarter s  567 million Accuray reported a loss of 6 cents in the second quarter of fiscal 2018  5 cents narrower than the year ago figure  Total revenues increased 15  year over year to  100 3 million The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-01-30,Zacks Investment Research,https://www.investing.com/analysis/align-technology-algn-q4-earnings-top-on-invisalign-sales-200285392,200285392
120135,341650,PKI,Illumina  ILMN  Tops Q4 Earnings   Revenues  Issues Guidance,opinion,Illumina  Inc    NASDAQ ILMN   reported adjusted earnings per share  EPS  of  1 44 in the fourth quarter of 2017  which beat the Zacks Consensus Estimate of  1 22 by 18   Adjusted earnings surpassed the year ago number by 69 4  Including one time items  the company reported EPS of 46 cents  compared with 84 cents a year ago  This includes the provisional estimate of the one time transition tax impact from the U S  tax reform Full year 2017 adjusted EPS came in at  4  beating the Zacks Consensus Estimate of  3 80 by 5 3   Moreover  the figure beat the year ago number by 20 1  RevenuesIn the quarter under review  Illumina s revenues grew 25 7  year over year to  778 million  The top line beat the Zacks Consensus Estimate by 3 3  Net revenues in 2017 totaled  2 75 billion  outpacing the Zacks Consensus Estimate of  2 72 billion  The figure also improved 15 1  from the year ago number Per management  top line growth in the fourth quarter can be attributed to strong uptake of sequencing consumables and instruments as well as microarray portfolios  Moreover  the NovaSeq platform continued to drive growth with close to 285 NovaSeq systems currently at customers  hands since the launch in January 2017 Product revenues  84 7  of total revenue  increased 25 5  year over year to  659 million  Service and Other  15 3   revenues were up 26 6  year over year to  119 million Illumina  Inc  Price  Consensus and EPS Surprise   Operational UpdateAdjusted gross margin came in at 69 7   reflecting an expansion of 200 basis points  bps  year over year owing to favorable product mix within sequencing consumables  Excluding amortization of acquired intangible assets and including stock based compensation expenses  adjusted gross margin was 70 9   highlighting an expansion of 140 bps from a year ago Research and development expenses were up 5 4  year over year to  137 million and selling  general   administrative expenses rose 19 9  to  175 million  However  the adjusted operating margin of 31 4  reflected a rise of 630 bps from the year ago quarter Financial UpdateIllumina exited 2017 with cash and cash equivalents and short term investments of  2 15 billion  up from  1 56 billion in 2016  Net cash provided by operating activities in 2017 was  875 million  compared with  779 million a year ago 2018 GuidanceIllumina projects full year 2018 revenue growth in the 13 14  range  Meanwhile  the Zacks Consensus Estimate for 2018 revenues is pegged at  3 10 billion Adjusting for certain net specified items for the full year  adjusted earnings per share from continuing operations are expected in the band of  4 50  4 60  The Zacks Consensus Estimate for earnings stands at  4 53  near the low end of the projected range Our TakeIllumina exited the fourth quarter on a solid note  We are encouraged by the year over year increase in both the fronts  Management is hopeful that products like NovaSeq  recently launched iSeq and a broad clinical portfolio comprising the VeriSeq NIPT Solution  NextSeqDx and MiSeqDx will drive the top line Moreover  improving margins buoy optimism  Meanwhile  the company is operating in a tough competitive landscape which is a concern Zacks Rank   Key PicksIllumina has a Zacks Rank  3  Hold  A few better ranked stocks in the broader medical sector are ResMed   NYSE RMD    PerkinElmer   NYSE PKI   and Accuray   NASDAQ ARAY    All the three companies carry a Zacks Rank  2  Buy   You can see  ResMed posted second quarter fiscal 2018 adjusted earnings of  1  up 36 9  from the prior year quarter  Revenues increased 13 4  year over year  up 11  at constant exchange rate or CER  to  601 3 million PerkinElmer reported fourth quarter 2017 adjusted earnings of 97 cents  The company reported adjusted revenues of approximately  641 6 million  surpassing the year ago quarter s  567 million Accuray reported a loss of 6 cents in the second quarter of fiscal 2018  5 cents narrower than the year ago figure  Total revenues increased 15  year over year to  100 3 million The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-01-30,Zacks Investment Research,https://www.investing.com/analysis/illumina-ilmn-tops-q4-earnings--revenues-issues-guidance-200285379,200285379
120172,341687,PKI,PerkinElmer  PKI  To Acquire German Firm EUROIMMUN For  1 3B,opinion,Waltham  MA based PerkinElmer Inc    NYSE PKI    a worldwide provider of products  services and solutions to the diagnostics  research  and laboratory service markets  recently announced that it would acquire EUROIMMUN Medical Laboratory Diagnostics AG for approximately  1 3 billion in cash  The latter is an autoimmune testing company and an emerging player in infectious disease and allergy testing Stock PerformanceThe price performance of PerkinElmer has been unfavorable in the last three months  The stock gained 19 08   underperforming the Zacks classified  sub industry s gain of almost 19 31   The current level compares favorably with the S P 500 s return of 5 16  over the same time frame The estimate revision trend for the current year was favorable in the last two months  Ten estimates moved north against no movements in the opposite direction   Notably  the current year estimate for the stock increased by 5 cents to  2 86 per share over the same time frame We feel the acquisition is a sound move on the part of PerkinElmer   Lubeck  Germany based EUROIMMUN  which has about 2 400 employees  has an annual turnover of about  310 million  In 2016  the latter generated sales in more than 130 countries worldwide  with approximately 45  of revenues coming from China  30  from Europe  Middle East   Africa  5  from the Americas and 20  from Rest of the World  The deal is expected to close in the fourth quarter of 2017 The acquisition of EUROIMMUN Medical Laboratory Diagnostics would expand PerkinElmer s reach into autoimmune and allergy diagnostic markets   The acquisition would also reinforce PerkinElmer s capabilities toward new infectious disease in the Chinese market  Per management the acquisition is expected to add about 28 cents to 30 cents per share to its 2018 adjusted earnings PerkinElmer offers a global diagnostics portfolio focused on  reproductive health  infectious disease screening and genomics offerings for oncology and other molecular tests  It has approximately 9 500 employees serving customers in more than 150 countries In recent times  PerkinElmer delivered a solid first quarter  beating the Zacks Consensus Estimate on both counts  The quarter witnessed solid organic revenue growth across all the business segments  Furthermore  a positive guidance instills our confidence on the stock  The company continues to offer a global diagnostics portfolio focused on reproductive health  infectious disease screening and genomics offerings for oncology and other molecular tests  Despite having a solid portfolio  unfavorable foreign exchange is a primary concern for PerkinElmer Zacks Rank   Key PicksCurrently  PerkinElmer carries a Zacks Rank  3  Hold  Some better ranked medical stocks are Align Technology  Inc    NASDAQ ALGN    Inogen  Inc    NASDAQ INGN   and Accelerate Diagnostics  Inc    NASDAQ AXDX    Both Align Technology and Inogen sport a Zacks Rank  1  Strong Buy   while Accelerate Diagnostics carries a Zacks Rank  2  Buy   You can see  You can see     See more at   can see     See more at   Technology has an expected long term adjusted earnings growth of almost 24 1   The stock has added roughly 21  in the last three months Inogen has a long term expected earnings growth rate of 17 5   The stock has a solid one year return of around 96  Accelerate Diagnostics has an expected long term adjusted earnings growth of 30   The stock has added roughly 17  in the last three months Zacks  Hidden TradesWhile we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors  Zacks  Hidden TradesWhile we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors   See more at    Hidden TradesWhile we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors   See more at   we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors   See more at    Hidden TradesWhile we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors   See more at    Hidden TradesWhile we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors   See more at  ,2017-06-20,Zacks Investment Research,https://www.investing.com/analysis/perkinelmer-(pki)-to-acquire-german-firm-euroimmun-for-$1.3b-200196643,200196643
120173,341688,PKI,PerkinElmer Strong On Product Lineup Amid Integration Risks,opinion,On Aug 22  we issued an updated research report on Waltham  MA based PerkinElmer  Inc    NYSE PKI    The company provides scientific instruments  consumables  and services to pharmaceutical  biomedical  environmental testing  chemical  and general industrial markets worldwide  The company currently has a Zacks Rank  3  Hold  PerkinElmer s expanding product portfolio is helping the company win market share worldwide  Within a short span of time  its new products have gained significant traction among consumers  We believe the products will continue to boost the company s market share in areas like diagnostics  research and environment Moreover  PerkinElmer is well positioned to benefit from investments in the area of cancer immunotherapy as well as the rising trend of outsourcing instrument maintenance and scientific services over the long term Acquisitions and strategic partnerships have been key catalysts for PerkinElmer over the years  Earlier this year  the company announced plans to acquire EUROIMMUN Medical Laboratory Diagnostics AG for approximately  1 3 billion in cash  The deal is expected to close in the fourth quarter of 2017 The acquisition of EUROIMMUN Medical Laboratory Diagnostics will expand PerkinElmer s reach in the autoimmune and allergy diagnostic markets  The acquisition will also reinforce the company s capabilities pertaining to new infectious diseases in the Chinese market  Per management  the acquisition is expected to add about 28 cents to 30 cents to 2018 adjusted earnings PerkinElmer continues to acquire a large number of companies  While this improves revenue opportunities  it adds to integration risks  The frequent acquisitions can also negatively impact its balance sheet in the form of a high level of goodwill and intangible assets  Frequent acquisitions are also a distraction for management and impacts organic growth Stock Performance at a GlancePerkinElmer s share price movement in the past one year has been unsatisfactory  The company represented a return of almost 16   a bit lower than the  industry s return of almost 22 1   The company has been witnessing weakness in academic markets outside the United States  Furthermore  lackluster performance in Europe impacted the company s third party logistics in the second quarter The estimate revision trend has been favorable for PerkinElmer over the last two months  For the current quarter  five estimates moved north compared to one movement in the opposite direction  while for the full year eight estimates moved north over the same time frame This has had a significant impact on the magnitude of the estimates as the current quarter estimates increased 2 8   while full year estimates inched 1  up over the same time frame Key PicksA few better ranked stocks in the broader medical sector are Edwards Lifesciences Corp    NYSE EW    IDEXX Laboratories  Inc    NASDAQ IDXX   and Cogentix Medical  Inc    NASDAQ CGNT    Notably  Edwards Lifesciences sports a Zacks Rank  1  Strong Buy   while IDEXX Laboratories and Cogentix Medical have a Zacks Rank  2  Buy   You can see  Edwards Lifesciences delivered an average earnings beat of 10 8  over the trailing four quarters  The company has a long term expected earnings growth rate of 15 2  Cogentix Medical registered a positive earnings surprise of 200  in the last reported quarter  The stock represented a stellar return of 100 9  over the last one year IDEXX Laboratories delivered an average earnings beat of 9 3  over the trailing four quarters  It has a long term expected earnings growth rate of 19 8 4 Surprising Tech Stocks to Keep an Eye onTech stocks have been a major force behind the market s record highs  but picking the best ones to buy can be tough  There s a simple way to invest in the success of the entire sector  Zacks has just released a Special Report revealing one thing tech companies literally cannot function without  More importantly  it reveals 4 top stocks set to skyrocket on increasing demand for these devices  I encourage you to get the report now   before the next wave of innovations really takes off ,2017-08-22,Zacks Investment Research,https://www.investing.com/analysis/perkinelmer-strong-on-product-lineup-amid-integration-risks-200208979,200208979
120174,341689,PKI,PerkinElmer Hits A 52 Week High  What s Driving The Stock ,opinion,"Shares of PerkinElmer  Inc    NYSE PKI   rallied to a new 52 week high of  70 59 on Oct 5  closing a tad lower at  70 44  This represents a strong year to date return of approximately 35 1   better than the S P 500 s 13 1  over the same time frame PerkinElmer provides scientific instruments  consumables  and services to pharmaceutical  biomedical  environmental testing  chemical  and general industrial markets worldwide  The company currently has a Zacks Rank  3  Hold  For the majority of the last month  the company s share price has considerably outperformed the  industry  The stock has rallied 3 9  over the month  slightly higher than the industry s gain of just 3 1    Notably  PerkinElmer has a market cap of  7 6 billion  Taking the stable performance of the stock into consideration  we expect PerkinElmer to scale higher in the coming quarters  The company s long term growth of 12 1  also holds promise CatalystsProduct Spectrum Broad  PerkinElmer s expanding product portfolio is helping it win market share and boost organic growth  Through the first half of the year  organic growth has been about 3  for the company on a year over year basis  Within a short span of time  PerkinElmer s new products gained significant traction among consumers  We believe the products will continue to boost the company s market share in areas like diagnostics  research and environment Estimate Revision Trend Solid  The estimate revision trend for PerkinElmer is favorable at the moment  For the full year  eight analysts moved north compared to no movement in the opposite direction over the last two months  As a result  full year estimates inched up 0 3  to  2 89 per share For the current quarter  five analysts moved north  compared to one movement in the opposite direction in the last two months  The Zacks Consensus Estimate for current quarter earnings rose 1 4  to 73 cents per share over the same time frame PerkinElmer  Inc  Price and Consensus
    Acquisitions Drive Growth  Acquisitions and strategic partnerships have been key catalysts for PerkinElmer over the years  Earlier this year  the company announced plans to acquire EUROIMMUN Medical Laboratory Diagnostics AG for approximately  1 3 billion in cash  The deal is expected to close in the fourth quarter of 2017 The buyout will expand PerkinElmer s reach in the autoimmune and allergy diagnostic markets  The acquisition will also reinforce the company s capabilities pertaining to new infectious diseases in the Chinese market  Per management  the acquisition is expected to add about 28 cents to 30 cents to 2018 adjusted earnings Guidance Raised  PerkinElmer revised its adjusted earnings guidance for full year 2017  The company now expects adjusted earnings per share in the band of  2 84 to  2 92  up from the previously provided range of  2 80 to  2 90 Key PicksA few better ranked stocks in the broader medical sector are SONOVA HOLDING   OTC SONVY    IDEXX Laboratories  Inc    NASDAQ IDXX   and Luminex Corporation   NASDAQ LMNX    SONOVA and Luminex have a Zacks Rank  1  Strong Buy   while IDEXX Laboratories has a Zacks Rank  2  Buy   You can see  SONOVA represented a solid return of 35  over the last year  The company has a long term expected earnings growth rate of 7  IDEXX Laboratories has an average earnings beat of 9 3  over the trailing four quarters  It has a long term expected earnings growth rate of 19 8  Luminex came up with a positive earnings surprise of 188 9  in the last quarter  The stock has a long term expected earnings growth rate of 16 3  5 Trades Could Profit   Big League   from Trump PoliciesIf the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ",2017-10-05,Zacks Investment Research,https://www.investing.com/analysis/perkinelmer-hits-a-52week-high-whats-driving-the-stock-200217463,200217463
120175,341690,PKI,6 Selected Shorts  Ccl  CR  CSX  HDB  JCI  PKI,opinion,"Preface to chart posts for this weekend  Instead of doing a bunch of videos  I decided to show static charts created  of course  with   which you should use     hint  hint   I am allocating most of these ideas to my  subscribers  The Slope Plus bonus charts for Sunday are  
What the charts below all have in common is  1  they are all  live  short positions in my portfolio  2  the patterns should be fairly self explanatory  What s unique about this particular set is that they are all based on prices that are near the tops of long term pattern ranges 
Carnival PLC  NYSE CCL  Chart 

Crane Company  NYSE CR  Cart 

CSX Corporation  NASDAQ CSX  Chart 

HDFC Bank Limited ADR  NYSE HDB  Chart 

Johnson Controls International PLC  NYSE JCI  Chart 

PerkinElmer Inc  NYSE PKI  Chart ",2017-11-06,Tim Knight,https://www.investing.com/analysis/selected-shorts-tops-of-the-range-200258304,200258304
120210,341725,PKI,Can PerkinElmer  PKI  Pull A Surprise This Earnings Season ,opinion,PerkinElmer Inc    NYSE PKI   is expected to report second quarter 2016 results on Aug 4  Last quarter  the company reported earnings of 56 cents per share which surpassed the Zacks Consensus Estimate by 5 cents Notably  on an average  PerkinElmer beat the Zacks Consensus Estimate by 5 09  over the last four quarters Let s see how things are shaping up for this quarter Factors at PlayAn expanding product portfolio  margin expansion and accretive acquisitions open up growth opportunities for PerkinElmer  Meanwhile  the acquisitions of Vanadis Diagnostics  Perten Instruments and Ceiba Solutions have fortified the company s market position Moreover  partnerships with the likes of Sophie BioSciences  Monash Institute of Pharmacutical Sciences  Good Start Genetics and others are anticipated to drive top line growth PERKINELMER INC Price and EPS Surprise   New product launches and expansion into emerging markets like China  India  Indonesia  Thailand  Mexico and Brazil are expected to be key catalysts  going forward For the second quarter of 2016  revenues are forecasted to grow organically by almost 4   The current revenue guidance is pegged at the range of  570 million to  575 million  Adjusted earnings are projected in the band of 65 cents to 66 cents per share However  sluggish European macro environment  the risk of foreign exchange volatility  integration risks  high debt level  restrained spending on research and challenges in Japan are expected to impede top line growth in the near term Earnings WhispersOur proven model does not conclusively show that PerkinElmer is likely to beat earnings this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here as you will see below Zacks ESP  The Earnings ESP for PerkinElmer is 0 00   This is because both the Most Accurate estimate and the Zacks Consensus Estimate stand at 66 cents Zacks Rank  PerkinElmer carries a Zacks Rank  2  which when combined with 0 00  ESP makes surprise prediction difficult Meanwhile  we caution against stocks with a Zacks Ranks  4 and  5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderHere are a few stocks worth considering that  as per our model  have the right combination of elements to post an earnings beat this quarter ANI Pharmaceuticals Inc   NASDAQ ANIP    with an Earnings ESP of  2 63  and a Zacks Rank  1 Glycomimetics Inc   NASDAQ GLYC    with an Earnings ESP of  13 64  and a Zacks Rank  1 Humana Inc   NYSE HUM    with an Earnings ESP of  0 44  and a Zacks Rank  1 ,2016-07-28,Zacks Investment Research,https://www.investing.com/analysis/can-perkinelmer-(pki)-pull-a-surprise-this-earnings-season-200145011,200145011
120211,341726,PKI,PerkinElmer  PKI  Beats Q2 Earnings  FY16 View Maintained,opinion,"PerkinElmer Inc   NYSE PKI   reported second quarter 2016 earnings of 67 cents per share  which beat the Zacks Consensus Estimate by a penny  Additionally  the figure was better than the management s guided range of 65 66 cents  Earnings also increased 11 7  year over year driven by modest top line growth and margin expansion Revenues increased 1 5  on a year over year basis to  572 8 million  which lagged the Zacks Consensus Estimate of  573 million  but was within the management s guided range of  570  575 million  The year over year upside was primarily attributed to growth across both segments Organically  revenues grew 3  in the quarter  but missed the company s expectations of 4  growth  Management stated that organic revenue for four of its focus areas grew by more than 10  in the reported quarter  The focus areas are food quality and safety  pharma services and solutions  reproductive health  and emerging market diagnostics  Per PerkinElmer  these focus areas represent 40  of its total revenues In terms of end market  PerkinElmer witnessed accelerating diagnostic demand  healthy pharma and biotech as well as a strong demand for food applications during the quarter  This was partially offset by weakness in industrial markets as well as soft academic and government demand  primarily in the U S  during the quarter Region wise  PerkinElmer achieved double digit organic revenue growth in Asia and low single digit growth in Europe  while revenues declined in low single digit in the Americas  Emerging markets organic revenues increased mid teens  driven by a strong performance in China  which more than offset weak demand in Brazil   
Organic revenue growth in China grew double digit in the quarter  with broad based strength across both Human and Environmental Health segments  Within Environmental Health  Haoyuan blood screening business reported robust revenue performance  with strength expected to continue into the second half 2016  On the Environmental side  food and environmental testing solutions were the key growth drivers in China Segment DetailsHuman Health  61 7  of total revenues  segment revenues increased 3 5  year over year to  353 7 million  while Environmental health  38 3  of total revenues  revenues decreased 1 4  year over year to  219 2 million in the quarter  Environmental Health organic revenues declined 1  in the quarter  while Human health increased 6  On an organic basis  diagnostics business  29  of Human Health revenues  revenue growth was driven by double digit growth in the company s core diagnostics franchises  Both China and India were up more than 25  in the quarter  The company also won a number of neonatal wins in Pakistan  Jordan and Poland Medical imaging declined high single digits due to continued weak hospital demand  However  an increased demand for a number of new CMOS applications was witnessed as diversification efforts within the portfolio gain traction Life Science Solutions  33  of Human Health revenues  organic revenues increased in low single digits Margin DetailsAdjusted gross margin was 47 9   up 90 basis points  bps  year over year  driven by successful cost cutting  Lean  initiatives  volume leverage and favorable product mix  PERKINELMER INC Price  Consensus and EPS Surprise
   Adjusted selling  general   administrative  SG A  as percentage of revenues were 24 3   flat over the year ago quarter  Research and Development  R D  spending was  2 million higher in the quarter driven by continuing investments on the four focused areas Adjusted operating margin expanded approximately 50 bps in the reported quarter  Environmental Health margin expanded 160 bps on the back of strong mix  benefits from year ago restructuring actions and solid operational execution Human Health margins were essentially flat  largely due to planned growth investments and mix  partially mitigated by the positive impact of pricing initiatives implemented at the end of 2015 Product Clinical Partnership UpdatesPerkinElemer recently entered into collaboration with the Genome Institute of Singapore  The institute aims to develop a high throughput screening platform to predict therapeutic sensitivity in tumor models in real time  with the ultimate goal of translating precision oncology research results into the clinic  In order to do this  the institute is using a number of PerkinElmer products  including automation and liquid handling solutions  as well as tissue and cellular imaging platforms PerkinElmer s solutions are now used by a major dairy company in China to verify nutrients  test vitamin content  and detect heavy metals in their products  The customer win reflects the company s expanding footprint and the strength in its product portfolio which includes solutions like Perten and Delta In the fast growing area of reproductive health  PerkinElemer is partnering a number of states in the U S  to facilitate the screening of lysosomal storage diseases  LSDs   Management noted that early detection of these rare inherited metabolic disorders is in compliance with the HRSA recommended newborn screening panel PerkinElemer continues to introduce number of new products like the latest Avio 200 ICP spectrometer  which is the smallest analyzer of its kind on the market  The company also launched more than 25 new biochemical and immunoassays that support drug discovery applications During the quarter  PerkinElmer launched a NGS 3K assay  which runs on its LabChip Touch microfluidic platform  Per company  this assay delivers the highest sensitivity at the lowest DNA sample concentration  providing customers with improved sample quality control for their sequencing experiments  Acquisitions DivestituresPerkinElmer expanded its next generation sequencing  NGS  capabilities with the recent acquisition of BioScientific  a company based in Austin  TX  BioScientific provides biotechnology solutions for food and feed safety testing along with life science research  The company stated that BioScientific s laboratory preparation offering broadens Perkin Elemer s NGS workflow solutions GuidanceManagement at PerkinElmer expects challenging global economic conditions to persist  with no immediate relief at sight  However  the company is well poised to continue investments in its focus areas throughout 2016 For the second half  PerkinElmer continues to see accelerating growth for its diagnostic business with expanding market share as well as addressable market  The company s OneSource business continues to benefit from the growth in spending in pharmaceutical and growing outsourcing Management states that food analysis business is gaining from increased synergies across the company s product portfolio as well as the overall growth of the market However  growth concerns in the industrial end markets are a headwind  Medical imaging continues to face declining market demand  which is also hurting growth For the third quarter of 2016  revenues are forecasted to grow organically by almost 2  to 3   The current revenue guidance is pegged at the range of  570 million to  575 million  Adjusted earnings are expected in the range of 65 cents to 67 cents per share For full year 2016  PerkinElmer expects organic revenue growth of 4   Research   Development expenses are forecasted to increase 50 bps owing to continuing investments Adjusted earnings are still projected in the band of  2 75 to  2 85 per share Zacks Rank   Other Stocks to ConsiderCurrently  PerkinElmer has a Zacks Rank  2  Buy  Better ranked stocks in the same space include Halyard Health   NYSE HYH    Merit Medical   NASDAQ MMSI   and Masimo Corp   NASDAQ MASI    All the three stocks sport a Zacks Rank  1  Strong Buy  ",2016-08-05,Zacks Investment Research,"https://www.investing.com/analysis/perkinelmer-(pki)-beats-q2-earnings,-fy16-view-maintained-200146445",200146445
120212,341727,PKI,Is It Over Yet ,opinion,Tuesday  November 8  2016The South and the Farm Belt are solidly red  The Northeast and West Coast are solidly blue  Great Lakes are mixed  Today lays plain the U S  s political landscape  as it always does the first Tuesday after the first Monday in November every four years We ve had old presidents  young ish  presidents  fat presidents  thin presidents  tall and short presidents  presidents of Irish descent  Dutch descent and even our first African American  Now we stand to elect either our first female president or our first non politician president  Whichever way the scales tip  it will be an historic occasion  Which leaves me with one question Is it  bleep ing over yet A year and a half of insults  half truths  outright lies  rumors  intrigue  passions and   every once in awhile   policy matters  It s a multi billion dollar industry  this business of electing a president in this country  and those involved mean to squeeze every last dime out of it  Personally  I m still getting emails imploring me to donate to various campaigns  what good would an extra  100 or  1000 do for candidates now that the polls are already open Barring the three ring circus that was Election 2000  by this time tomorrow we will have a new president   either Donald Trump or Hillary Clinton  Market analysts have priced in a 4  bump for stocks if Clinton wins  though yesterday s big up day has likely priced in nearly half of this already  while a Trump win means the market will likely take a 7  hit Trump s policies  where they are concrete  represent a dramatic shift from current policy  which means greater uncertainty  The stock market does not like uncertainty  Wall Street s preference would be for a Clinton victory  provided she keeps most economic policies in place  but the Republican Party to retain both houses of Congress   the better to keep gridlock with Small Business sentiment this morning came out with a read of 94 9 in October  an improvement from 94 1 in September but off the historic highs Valeant Pharma   NYSE VRX   has tumbled 16  in the pre market following a top  and bottom line miss in quarterly earnings  The company has also cut full year forecasts  and now trades at a multi year low CVS   NYSE CVS   is also down 16  in early trading  The company beat earnings estimates but missed on revenues  as did PerkinElmer   NYSE PKI    D R  Horton   NYSE DHI   fell short of expectations but bumped up its dividend yield 25   Wayfair   NYSE W   beat estimates and expressed optimism for the long term Mark VickerySenior Editor,2016-11-07,Zacks Investment Research,https://www.investing.com/analysis/is-it-over-yet-200163489,200163489
120213,341728,PKI,Will Clinton Or Trump Win The US Election ,opinion,"The South and the Farm Belt are solidly red  The Northeast and West Coast are solidly blue  Great Lakes are mixed  Today lays plain the U S  s political landscape  as it always does the first Tuesday after the first Monday in November every four years 
We ve had old presidents  young ish  presidents  fat presidents  thin presidents  tall and short presidents  presidents of Irish descent  Dutch descent and even our first African American  Now we stand to elect either our first female president or our first non politician president  Whichever way the scales tip  it will be an historic occasion  Which leaves me with one question 
Is it  bleep ing over yet 
A year and a half of insults  half truths  outright lies  rumors  intrigue  passions and   every once in awhile   policy matters  It s a multi billion dollar industry  this business of electing a president in this country  and those involved mean to squeeze every last dime out of it  Personally  I m still getting emails imploring me to donate to various campaigns  what good would an extra  100 or  1000 do for candidates now that the polls are already open 
Barring the three ring circus that was Election 2000  by this time tomorrow we will have a new president   either Donald Trump or Hillary Clinton  Market analysts have priced in a 4  bump for stocks if Clinton wins  though yesterday s big up day has likely priced in nearly half of this already  while a Trump win means the market will likely take a 7  hit 
Trump s policies  where they are concrete  represent a dramatic shift from current policy  which means greater uncertainty  The stock market does not like uncertainty  Wall Street s preference would be for a Clinton victory  provided she keeps most economic policies in place  but the Republican Party to retain both houses of Congress   the better to keep gridlock with 
Small Business sentiment this morning came out with a read of 94 9 in October  an improvement from 94 1 in September but off the historic highs 
Valeant Pharma  has tumbled 16  in the pre market following a top  and bottom line miss in quarterly earnings  The company has also cut full year forecasts  and now trades at a multi year low 
CVS  is also down 16  in early trading  The company beat earnings estimates but missed on revenues  as did PerkinElmer  NYSE PKI    D R  Horton  fell short of expectations but bumped up its dividend yield 25   Wayfair  beat estimates and expressed optimism for the long term ",2016-11-07,Zacks Investment Research,https://www.investing.com/analysis/will-clinton-or-trump-win-the-us-election-200163488,200163488
120214,341729,PKI,PerkinElmer  Human Health And Environmental Sales A Drag,opinion,On Nov 18  we issued an updated research report on Waltham  MA based PerkinElmer  Inc    NYSE PKI     a leading global provider of scientific instruments  consumables  and services to pharmaceutical  biomedical and environmental testing markets  The company currently carries a Zacks Rank  4  Sell  Over the last 30 days  the Zacks Consensus Estimate for full year 2016 earnings fell by 4 cents to  2 76 per share  The stock recorded an earnings surprise of 3 03  in the last reported quarter and has a long term expected earnings growth rate of almost 11 3  PerkinElmer ended the third quarter on a mixed note wherein adjusted earnings surpassed management s guided range and the Zacks Consensus Estimate  However  revenues lagged the guided range and also deteriorated on a year over year basis Human Health and Environmental revenues declined massively on a year over year basis in the just reported quarter  due to softer capital equipment end markets  Additionally  lower than estimated sales in the U S  and Europe caused a drag on Environmental sales The decline in sales at the Medical Imaging segment raises concern  PerkinElmer faced significant headwinds in the radiochemical and capital intensive businesses as well Additionally  management s decision to eliminate certain slower growth segments from the priority list has marred the short term prospects for PerkinElmer We believe a sluggish European macro economic environment and restrained spending and challenges in Japan are also likely to hurt the top line in the near term Nevertheless  with an enhanced focus on product innovation and expansion into emerging markets like China  PerkinElmer holds considerable promise for the coming quarters Key PicksBetter ranked stocks in the broader medical space include Cogentix Medical  Inc    NASDAQ CGNT    CryoLife Inc    NYSE CRY   and IDEXX Laboratories  Inc    NASDAQ IDXX    Notably  IDEXX Laboratories and Cogentix sport a Zacks Rank  1  Strong Buy  while CryoLife has a Zacks Rank  2  Buy   You can see  Cogentix Medical registered a positive earnings surprise of 100  in the last reported quarter  Notably  the company has a solid one year return of roughly 73 7  CryoLife has a stellar one year return of roughly 90 7   In the last reported quarter  the company registered an impressive earnings surprise of 225  IDEXX Laboratories represents a solid one year return of almost 67 8   The company has a long term expected growth rate of roughly 14 96  Zacks  Best Private Investment Ideas In addition to the recommendations that are available to the public on our website  how would you like to follow all Zacks  private buys and sells in real time Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors  Starting today  for the next month  you can have unrestricted access ,2016-11-20,Zacks Investment Research,https://www.investing.com/analysis/perkinelmer:-human-health-and-environmental-sales-a-drag-200165822,200165822
120215,341730,PKI,Tech Stocks To Watch For Earnings On May 4  MTD  PKI   More,opinion,The first quarter earnings season is past the halfway mark  In fact  the majority of the S P 500 members will complete reporting by the end of this week  82 8  of the index s total membership  Picture Emerging Thus FarAs per the latest   as of Apr 28  288 S P 500 members  representing 63 8  of the index s total market capitalization  have already reported quarterly numbers  Total earnings of these companies are up 13 7  on a year over year basis  76 4  of the companies beat EPS estimates  while total revenue is up 8 2   68 1  of the companies beat top line estimates  Notably  earnings and revenue growth numbers have been significantly better than investors  expectations so far  primarily due to robust results from technology  industrial products  basic materials and energy sectors Overall first quarter earnings for S P 500 companies are anticipated to be up 11 2  from the year ago quarter on revenues that are estimated to increase 6 2   This would be better than 7 4  growth in fourth quarter earnings on 4 8  higher revenues Technology Earnings SoarInvestors seem to be rejoicing as most of the companies in the technology sector surpassed estimates last week  particularly revenue estimates  Also  growth rate is up from the preceding quarter and is on track to reach its highest level in almost three years  Continuation of these trends through the rest of this earnings season should serve as a reassuring development for the market We note that almost 57 4  of the total market capitalization in the technology sector has reported till now  Total earnings are up 17 7  on a year over year basis  80  of the companies beat EPS estimates  while total revenue is up 6 2  on a year over year basis  73 3  of the companies beat top line estimates  Earnings for the technology sector are anticipated to be up 13 9  on the back of 6 1  higher revenues  driven by strong broad based growth Earnings Releases on May 4Let s take a sneak peek into four technology companies that are set to report their quarterly earnings on May 4 Worldwide analytical instruments provider Mettler Toledo International Inc    NYSE MTD   looks likely to beat first quarter 2017 estimates as it has a favorable combination of a Zacks Rank  2  Buy  and an  of  0 33   You can uncover the best stocks to buy or sell before they re reported with our  This is because  as per our proven model  a stock needs to have both a positive Earnings ESP and a Zacks Rank  1  Strong Buy   2 or 3  Hold  to beat earnings  You can see Interestingly  Mettler Toledo s results compared favorably with the Zacks Consensus Estimate in all of the last four quarters with an average positive surprise of 3 4  Mettler Toledo International  Inc  Price and EPS Surprise   Similarly  global technology company PerkinElmer  Inc  s   NYSE PKI   Zacks Rank  3 and an Earnings ESP of  1 85  increases its odds of an earnings surprise when it reports first quarter 2017 PerkinElmer s track record has been quite impressive  with the company comfortably beating estimates in three of the trailing four quarters  at an average of 2 7  PerkinElmer  Inc  Price and EPS Surprise   However  we don t expect manufacturer of innovative optical and photonic products Lumentum Holdings Inc    NASDAQ LITE   to post a surprise when it reports third quarter fiscal 2017 results This is because the company s Earnings ESP of 0 00  complicates our surprise prediction in spite of its favorable Zacks Rank  3 The company s surprise history  however  is impressive as it beat estimates in three of the last four quarters with an average positive beat of 17 27  Lumentum Holdings Inc  Price and EPS Surprise   We caution against provider of water quality and water regulation and control products Watts Water Technologies  Inc    NYSE WTS   when it reports first quarter 2017  This is because it has a unfavorable combination of a Zacks Rank  4  Sell  and Earnings ESP of  1 64 We actually don t recommend Zacks Rank  4 or 5  Strong Sell  stocks going into the earnings announcement especially when the company is seeing negative estimate revisions Watts Water Technologies  Inc  Price and EPS Surprise   Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge  With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2017-05-02,Zacks Investment Research,"https://www.investing.com/analysis/tech-stocks-to-watch-for-earnings-on-may-4:-mtd,-pki---more-200186843",200186843
120244,341759,PKI,PerkinsElmer  Selling Has Abated  Time To Own The Stock ,opinion,"Being a Market Technician has a lot of freedom  Because my trades are based off of price action I can look at any company in any sector any day for a possible trade  No boundaries  I know that is hard for many to understand  They think we are detached floating through space or something 
I hear things like  these are the clean ones   How can you buy that stock  it has a forward P E of 60 and the industry average is only 33  plus its margins are sinking   or  The economic environment shows a slowing in consumer spending so it is time to pump the brakes on stocks   I have been around the sun a few times and also hold a CFA designation so I know what these people are talking about  And their thoughts and comment may play out eventually over time  But day to day they just do not matter 
One of the quirky things about being a Technician is that sometimes I have no idea what a company does when I am looking at a chart  Here is a good example  PerkinElmer  NYSE PKI   This stock could be the holding company for Perkin s Pancake House  Elmer s Glue  or anything else  So I often look them up to find out what they do  Here is what Yahoo Finance YHOO says about PerkinElmer 

Well that clears things up  So no pancakes or glue  but huh  Whatever  It is the price action that catches my attention anyway 

The chart above shows the price action over the last year  3 things are prominent in this chart  First  the pullback from the July high in a rounded bottoming format  It is clearly heading higher now since the October low  Second  is the red zone just under 46 that was important for buyers in June and July and sellers in August and November is now important for buyers again  acting as a support level 
The third is the short term red line that has acted important for sellers  a resistance level  until Tuesday  With the move over that level the selling has abated and it is time to own the stock for a move higher  It may encounter another area of selling at the prior high near 48  but history shows there is not much inventory of holders at that level to work through to continue higher 
How high could it go  Who knows  But one measure is to look at the move into the range between support and resistance and add that back to the break out  This suggests that a move to 50 50 is possible  Technicians will point out other patterns that could move the stock higher as well  But a quick 7 5  would not be anything to snarl at  Unless you don t like the earnings multiple  or sales to book ratio or something else 
Disclaimer  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my Disclaimer page for my full disclaimer ",2015-02-24,Gregory W. Harmon,"https://www.investing.com/analysis/pancakes,-glue-and-technicals--the-story-of-perkinselmer-242985",242985
120245,341760,PKI,Top Trade Ideas For Week Of August 3  2015  CAG  FL  FMER  PKG  PKI,opinion,"Here are the Rest of the Top 10 
ConAgra Foods  NYSE CAG 
ConAgra Foods had been trending higher through 2014 and took a break in 2015  Then it got an activist investor involved and gapped higher in June  Since then  it has consolidated with the Bollinger Bands  tightening  often a precursor to a move  The MACD has slowed its decent and is turning as the RSI falls  but in the bullish zone  Watch for a break of the consolidation either way 
Foot Locker  NYSE FL 
Foot Locker is one way to avoid a decision between Nike  NYSE NKE  and Under Armour  NYSE UA  altogether  It has been moving higher in long steps for quite some time  Now it sits under resistance at 71 with tightening Bollinger Bands  The RSI is bullish and rising while the MACD has been pulling back  but is stabilizing  Watch for a break over 71 to enter 
FirstMerit  NASDAQ FMER 
First Merit stock fell hard following its earnings report last week  But notice that the level it is holding has been an important one in the past  as both support in the second quarter and resistance at the end of 2014  It is also holding at the 200 day SMA  The RSI is oversold and kinking back higher  but the MACD is falling  Look for a potential bounce in this stock 
Packaging Corporation of America  NYSE PKG 
Packaging Corporation of America had a strong move up off of the October 2014 bottom in the market to a peak in February  Since then  though  it pulled back  making a low as a double bottom in July  Now it is rising again and testing resistance at the gap down from April  It has support for a move higher from the rising and bullish RSI and MACD 
PerkinElmer  NYSE PKI 
PerkinElmer has been a strong stock  rising through most of 2015 until the June and July pullback  There are signs that the pullback is over though and the stock is ready to reverse back higher  The RSI moved up off of the oversold level again and is making a higher high into the bullish zone  The MACD is turned and crossing up as well  Finally  the price is breaking above a falling wedge and pushing the Bollinger Bands higher 
After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad Market Macro picture reviewed Friday which  heading into the dog days of August  sees the Equity markets having weathered another storm  but not showing strength to push higher yet 
Elsewhere  look for gold to consolidate or continue lower  while crude oil moves to the downside  The US dollar index looks to move sideways with an upward bias  while US Treasuries are biased to continue higher  The Shanghai Composite and Emerging Markets both are biased to the downside  but trying to consolidate 
Volatility looks to remain subdued keeping the bias higher for the equity index ETF s ARCA SPY  ARCA IWM and NASDAQ QQQ  Their charts suggest that there is potential for some weakness in the current move short term though  On the longer timeframe  the QQQ looks strong and may be ready for new all time highs  while the SPY is on consolidation and the IWM a retrenching consolidation  Use this information as you prepare for the coming week and trad em well 
Disclaimer  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  Please see my Disclaimer page for my full disclaimer ",2015-08-03,Gregory W. Harmon,"https://www.investing.com/analysis/top-trade-ideas-for-the-week-of-august-3,-2015:-the-rest-260258",260258
120246,341761,PKI,Top Trade Ideas For Week Of November 30  FITB  HBAN  ODFL  PKI  ZTS,opinion,"Here are the Rest of the Top 10 
Fifth Third Bancorp  O FITB 
Fifth Third Bancorp  FITB  dropped hard in August from a consolidation zone  The next few months saw a failed attempt higher and then some consolidation before a move higher in mid October  That found resistance at the prior zone of importance and pulled back  It made a higher low and moved back up through the zone last week  The RSI is rising and bullish and the MACD is rising  both supporting further upside 
Huntington Bancshares  O HBAN 
Huntington Bancshares  HBAN  also dropped hard with the market in August and then consolidated for a couple of months  The rise that began in October met resistance at the pre drop level and pulled back to a higher low at the 20 day SMA  before rising to test it again  The RSI is bullish and rising and the MACD is flat but positive  A new high is an entry signal 
Old Dominion Freight Line Inc  O ODFL 
Old Dominion Freight Line  ODFL  has been in a downward channel since March  with the exception of a small period riding the top of the channel as support in August  The price action may have changed in September though as it has been moving sideways since then  Into the new week the price is pressing against resistance with the RSI pressing against the bullish zone  The MACD is bullish and rising  Look for a move over that resistance to participate 
PerkinElmer  N PKI 
PerkinElmer  PKI  fell lower with the market in August then took a second leg down in September  A 25  drop in all  before a strong run higher to the prior resistance zone  After a small pullback the price reversed back up and is testing that resistance again  The RSI is bullish and rising and the MACD is crossing up after a short pullback of its own  Look for a push through the resistance as a signal to participate 
Zoetis Inc  N ZTS 
Zoetis  ZTS  spiked 10  higher in June only to reverse and more the very next day  It then embarked on a downward journey finding a double bottom near 40 in October  Since then it has been slowly rising and looks ready for more  The RSI is in the bullish zone while the MACD is rising  both supporting more upward price action  Look for a break of consolidation to participate higher 
After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad  picture reviewed Friday which  heading into December sees the equity markets looking solid and maybe with new leadership 
Elsewhere look for gold to continue lower while Crude Oil builds a bear flag in its longer downtrend  The US Dollar Index is breaking out to multi year highs while US Treasuries consolidate with a short term bias higher  The Shanghai Composite broke consolidation to the downside and may be resuming the downtrend  while Emerging Markets are moving lower after failing at resistance 
Volatility looks to remain subdued and possibly fall keeping the bias higher for the equity index ETF s N SPY  N IWM and O QQQ  The SPY and QQQ paused this week and the IWM has taken over leadership in the short term  All look positive on the intermediate term chart  Use this information as you prepare for the coming week and trad em well 
DISCLAIMER  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ",2015-11-29,Gregory W. Harmon,"https://www.investing.com/analysis/top-trade-ideas-for-the-week-of-november-30,-2015:-the-rest-272813",272813
120247,341762,PKI,5 Stocks To Watch  AMTD  DHR  ETN  PKI  RHT,opinion,"TD Ameritrade  NASDAQ AMTD 
TD Ameritrade fell hard with the market to start the year  It found support into early February as volume ramped up and them fell back  Since mid February it has been rising  reaching resistance at the January bounce level and consolidating through March  Friday saw a bullish engulfing candle break over that range and the 100 day SMA  With the RSI bullish and the MACD about to cross up and rise again look for continuation to participate to the upside   
Danaher  NYSE DHR 
Danaher ended 2015 with a strong run higher stopping just short of 100 at the end of November  The pullback that followed was deep  retracing the entire move higher  bottoming in late January  That was followed by another sharp leg higher  What was that about the Efficient Market Hypothesis  It is now consolidating and Friday saw a bullish engulfing candle  This shifted the MACD from a possible cross down to flat with the RSI strong in the bullish zone  Look for a continuation to participate to the upside   
Eaton  NYSE ETN 
Eaton also had a long run lower over the summer of 2015  There was some bouncing around then from October through to a final low in mid January  Since then there has been no doubt the trend is up  with the stock rising for nearly 3 months  The last two weeks it has consolidated and Friday s bullish engulfing candle looks for continuation higher  The RSI is bullish and the MACD pulling back slightly  Look for continuation higher Monday to participate to the upside   
PerkinElmer  NYSE PKI 
PerkinElmer started the year with a quick move lower followed by consolidation  Then a second move lower ran to the lower in early February on a spike in volume  The following move higher has stalled at the prior resistance  until Friday saw a break higher  It has support for more upside from a rising and bullish RSI and MACD  Look for follow through to participate to the upside   
Red Hat  NYSE RHT 
Red Hat started the year off to the downside as well  bottoming nearly 30  lower in early February  But since then it has risen steadily  It touched the 200 day SMA 2 weeks ago and pulled back  The reversal back higher made a higher low and it is now back at the prior high  The RSI is in the bullish zone and rising while the MACD avoided a cross down  These support more upside  and if it pushes to a higher high look to participate on the upside  
After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad Market Macro picture reviewed Friday which heading into the first full week of April sees the equity indexes looking strong and ready to make another leg higher 
Elsewhere look for gold to continue its pullback along with crude oil  The US dollar also looks to continue lower  possibly testing key 12 month support while US Treasuries are breaking to the upside and look to continue  The Shanghai Composite looks poised to move higher in its downtrend as Emerging Markets continue to trend higher 
Volatility looks to remain low and biased lower keeping the bias higher for the equity index ETFs NYSE SPY  NYSE IWM and NASDAQ QQQ  despite the moves the past week  Their charts also look strong on both the daily and weekly timeframe with the only slight warnings coming from slowing momentum indications  Use this information as you prepare for the coming week and trad em well 
The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  Please see my Disclaimer page for my full disclaimer ",2016-04-04,Gregory W. Harmon,"https://www.investing.com/analysis/top-trade-ideas-for-the-week-of-april-4,-2016:-the-rest-200123771",200123771
120248,341763,PKI,Moving Average Crossover Alert  PerkinElmer  PKI   ,opinion,"PerkinElmer Inc    NYSE PKI   is looking like an interesting pick from a technical perspective  as the company is seeing favorable trends on the moving average crossover front  Recently  the 50 Day Moving Average for PKI broke out above the 200 Day Simple Moving Average  suggesting a short term bullish trend 
This has already started to take place  as the stock has moved higher by 8 4  in the past four weeks  Plus  the company currently has a Zacks Rank  2  Buy  suggesting that now could definitely be the time for this breakout candidate 
More bullishness may especially be the case when investors consider what has been happening for PKI on the earnings estimate revision front lately  No estimate has gone lower in the past two months  compared to 8 higher  while the consensus estimate has also moved higher too 
So given this move in estimates  and the positive technical factors  investors may want to watch this breakout candidate closely for more gains in the near future ",2016-05-09,Zacks Investment Research,https://www.investing.com/analysis/moving-average-crossover-alert:-perkinelmer-(pki)-200129108,200129108
